WO2011079327A1 - Analogues for the treatment or prevention of flavivirus infections - Google Patents

Analogues for the treatment or prevention of flavivirus infections Download PDF

Info

Publication number
WO2011079327A1
WO2011079327A1 PCT/US2010/062168 US2010062168W WO2011079327A1 WO 2011079327 A1 WO2011079327 A1 WO 2011079327A1 US 2010062168 W US2010062168 W US 2010062168W WO 2011079327 A1 WO2011079327 A1 WO 2011079327A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
compound
substituted
unsubstituted
independently
Prior art date
Application number
PCT/US2010/062168
Other languages
French (fr)
Inventor
Bingcan Liu
Carl Poisson
Laval Chan Chun Kong
Sanjoy Kumar Das
Constantin Yannopoulos
Caroline Cadilhac
T. Jagadeerswar Reddy
Louis Vaiillancourt
Guy Falardeau
Oswy W. Pereira
Monica Bubenik
John Maxwell
Original Assignee
Vertex Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN2010800642874A priority Critical patent/CN102883718A/en
Priority to SG2012042610A priority patent/SG181614A1/en
Priority to MX2012007420A priority patent/MX2012007420A/en
Priority to US13/518,059 priority patent/US20130072523A1/en
Priority to JP2012546254A priority patent/JP2013515746A/en
Priority to CA2784036A priority patent/CA2784036A1/en
Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated
Priority to EP10801348A priority patent/EP2515902A1/en
Priority to AU2010336355A priority patent/AU2010336355A1/en
Priority to KR1020127019619A priority patent/KR20120130173A/en
Publication of WO2011079327A1 publication Critical patent/WO2011079327A1/en
Priority to IL220215A priority patent/IL220215A0/en
Priority to ZA2012/04625A priority patent/ZA201204625B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Definitions

  • the present invention relates to novel compounds and a method for the treatment 10 or prevention of Flavivirus infections using novel compounds.
  • Hepatitis is a disease occurring throughout the world. It is generally of viral nature, although there are other causes known. Viral hepatitis is by far the most common form of hepatitis. Nearly 750,000 Americans are affected by hepatitis each year, and out of those, more than 150,000 are infected with the hepatitis C virus ("HCV").
  • HCV hepatitis C virus
  • HCV is a positive-stranded RNA virus belonging to the Flaviviridae family and has close relationship to the pestiviruses that include hog cholera virus and bovine viral diarrhea virus (BVDV). HCV is believed to replicate through the production of a complementary RNA virus belonging to the Flaviviridae family and has close relationship to the pestiviruses that include hog cholera virus and bovine viral diarrhea virus (BVDV). HCV is believed to replicate through the production of a complementary RNA virus belonging to the Flaviviridae family and has close relationship to the pestiviruses that include hog cholera virus and bovine viral diarrhea virus (BVDV). HCV is believed to replicate through the production of a complementary BVDV.
  • BVDV bovine viral diarrhea virus
  • HCV particles were isolated from pooled human plasma and shown, by electron microscopy, to have a diameter of about 50-60 nm.
  • the HCV genome is a single-stranded, positive-sense RNA of about 9,600 bp coding for a polyprotein of 3009-3030 amino-acids, which is cleaved co- and post-translationally into mature viral proteins (core, E1 , E2, p7, NS2, NS3, NS4A, NS4B, NS5A, NS5B). It is believed that the structural glycoproteins, E1 and E2, are embedded into a viral lipid envelope and form stable heterodimers. It is also believed that the structural core protein interacts with the viral RNA genome to form the nucleocapsid.
  • the nonstructural proteins designated NS2 to NS5 include proteins with enzymatic functions involved in virus replication and protein processing including a
  • the main source of contamination with HCV is blood.
  • the magnitude of the HCV infection as a health problem is illustrated by the prevalence among high-risk groups. For example, 60% to 90% of hemophiliacs and more than 80% of intravenous drug abusers in western countries are chronically infected with HCV. For intravenous drug abusers, the prevalence varies from about 28% to 70% depending on the population studied.
  • Combination of pegylated interferon plus ribavirin is the treatment of choice for chronic HCV infection.
  • This treatment does not provide sustained viral response (SVR) in a majority of patients infected with the most prevalent genotype (1 a and 1 b).
  • SVR sustained viral response
  • significant side effects prevent compliance to the current regimen and may require dose reduction or discontinuation in some patients.
  • the present invention provides a compound of formula (I):
  • A is C 6 -14 aryl, 4-12 membered heterocycle, C 3 . 10 cycloalkyl, 5-12 membered heteroaryl, or a bond;
  • B and B' are each independently d- 6 alkyl, C 2 - 6 alkenyl, or C 2 . 6 alkynyl;
  • C and C are each independently a 4-7 membered heterocycle
  • R a , R b , R c , and R d are each independently H, d. 12 alkyl, C 2 _i 2 alkenyl, C 2 -i 2 alkynyl, d-12 aryl, C 7 . 16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
  • R 3 and R 3 ' are each independently H, d-6 alkyl, C 2 . 6 alkenyl, or C 2 . 6 alkynyl;
  • R 4 and R 4 ' are each independently H, halogen, d-6 alkyl, hydroxyl, C 6 -14 aryl, or d- 4 alkoxy;
  • R 4 can be taken together with the atoms to which they are attached to form a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R 10 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R 12 ;
  • R 4 ' can be taken together with the atoms to which they are 20 attached to form a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R 10 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R 12 ;
  • X and Y are each independently --- , or a bond
  • R 5 and R 5 ' are each independently H, d-12 alkyl which is unsubstituted or substituted one 30 or more times by R 10 , C 2 . 12 alkenyl which is unsubstituted or substituted one or more times by R 10 , C 2 .
  • BOST 1803930.1 3 substituted one or more times by R 12 , or 4-18 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R 12 ;
  • R 6 is H, C1-6 alkyl, or halogenated d. 6 alkyl, or can be merged with R 6 or R 6 ' to form a 3-12 membered heterocycle; m and n, are each independently 0, 1 , 2, 3 or 4; p is 0, 1 , 2, 3 or 4;
  • R a , R b , R c , and R d are each independently H , CM 2 alkyl, C 2 _i 2 alkenyl, C 2 _i 2 alkynyl, C 6 -i 2 aryl, C 7 _i 6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
  • R a ., R b ., R c ., and R d > are each independently H or C-i-12 alkyl; or a pharmaceutically acceptable salt thereof.
  • the present invention provides a compound of formula (IA):
  • each A is independently C 6 -i 4 aryl, 4-12 membered heterocycle, C3-10 cycloalkyl, or 5-12 membered heteroaryl containing at least one heteroatom selected from the group consisting of O and S; wherein when q is 2 then both A rings are not phenyl;
  • B and B' are each independently absent, d. 6 alkyl, C 2 -6 alkenyl, or C 2 -6 alkynyl; wherein when q is 1 then at least one of B and B' is absent;
  • C and C are each independently a 4-7 membered heterocycle
  • R a , R b , Ro and R d are each independently H, d-12 alkyl, C 2 . 12 alkenyl, C 2 . 12 alkynyl, d-12 aryl, C 7 .i 6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
  • R 2 > and R 2 are independently halogen, d. 10 alkyl, d-6 halogenated alkyl, -(CH 2 ) 1 .
  • R 3 and R 3 ' are each independently H, d-6 alkyl, -(CH 2 )i-60H , C 2 -6 alkenyl, or C 2 -6 alkynyl;
  • R 4 and R 4 ' are each independently halogen, -NR a R b , -C(0)NR a R bj -(CH 2 )i- 6 0H, d-6 alkyl, d-6 halogenated alkyl, hydroxyl, -14 aryl, or d.
  • R 4 can be taken together with the atoms to which they are attached to form a d 6 alkenyl which is unsubstituted or substituted one or more times by R 10 , a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R 11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R 12 ; wherein two occurrence of R 4 ' can be taken together with the atoms to which they are attached to form a d-6 alkenyl which is unsubstituted or 30 substituted one or more times by R 10 , a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R 11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R 12 ;
  • X and Y are each independently
  • R 5 ' are each independently H, CMS alkyl which is unsubstituted or substituted one or more times by R 10 , C2-12 alkenyl which is unsubstituted or substituted one or more times by R 10 , C2-12 alkynyl which is unsubstituted or substituted one or more times by R 10 , C 6 -i 4 aryl which is unsubstituted or substituted one or more times by R 11 , C7.16 aralkyl which is unsubstituted or substituted one or more times by R 1 1 , 5-12 membered heteroaryl which is unsubstituted or substituted one or more times by R 1 1 , 6-18 membered heteroaralkyl which is unsubstituted or substituted one or more times by R 11 , 3-12 membered heterocycle which is unsubstituted or substituted one or more times by R 12
  • R 6 is H , C1-6 alkyl, or halogenated Ci- 6 alkyl; m and n, are each independently 0, 1 , 2, 3 or 4; p is 0, 1 , 2, 3 or 4;
  • the distance between C and C is between about 16 A and about 24 A in length.
  • a method for treating or preventing a Flaviviridae viral infection in a patient comprising administering to the patient a 20 therapeutically effective amount of a compound, composition or combination of the invention.
  • composition comprising at least one compound of the invention and at least one pharmaceutically acceptable carrier or excipient.
  • a combination comprising a compound of the invention and one or more additional agents chosen from viral serine protease inhibitors, viral polymerase inhibitors, viral helicase inhibitors, immunomudulating agents, 30 antioxidant agents, antibacterial agents, therapeutic vaccines, hepatoprotectant agents, antisense agent, inhibitors of HCV NS2/3 protease and inhibitors of internal ribosome entry site (IRES).
  • additional agents chosen from viral serine protease inhibitors, viral polymerase inhibitors, viral helicase inhibitors, immunomudulating agents, 30 antioxidant agents, antibacterial agents, therapeutic vaccines, hepatoprotectant agents, antisense agent, inhibitors of HCV NS2/3 protease and inhibitors of internal ribosome entry site (IRES).
  • BOST 1803930.1 8 in still another aspect, there is provided the use of a compound, composition or combination of the invention for the manufacture of a medicament for treating or preventing a viral Flaviviridae infection in a human.
  • compounds of the present invention comprise those wherein the following embodiments are present, either independently or in combination.
  • the compounds of the present invention are re resented by formula (IIA):
  • each A is independently C 6 -14 aryl, 4-12 membered heterocycle, C3-10 cycloalkyl, or 10 5-12 membered heteroaryl;
  • B and B' are each independently absent, d. 6 alkyl, C 2 . 6 alkenyl, or C 2 . 6 alkynyl; wherein when q is 1 then at least one of B and B' is absent;
  • R a , R b , Rc, and R d R a -R d are each independently H, d- 12 alkyl, C 2 . 12 alkenyl, C 2 . 12 alkynyl, C 6 . n aryl, C 7 . 16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle- alkyl;
  • R 2 > and R 2 are independently H, halogen, CMO alkyl, Ci- 6 halogenated alkyl, -(CH 2 ) 1 .
  • R 3 and R 3 ' are each independently H, d. 6 alkyl, -(CH 2 )i- 6 0H, C 2 -6 alkenyl, or C 2 -6 alkynyl;
  • R 4 and R 4 ' are each independently -NR a R b , -C(0)NR a R b , -(CH 2 )i- 6 0H, Ci_ 6 alkyl, Ci_ 6 10 halogenated alkyl, C 6 -14 aryl, or Ci- 6 alkoxy; wherein two occurrence of R 4
  • R 10 can be taken together with the atoms to which they are attached to form a d-6 alkenyl which is unsubstituted or substituted one or more times by R 10 , a 4-7 cycloalkyl which is unsubstituted or substituted one or more times by R 11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R 12 ; wherein two occurrence of R 4 ' can be taken together with the atoms to which they are attached to form a Ci_ 6 alkenyl which is unsubstituted or substituted one or more times by R 10 , a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R 11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R 12 ; 20 wherein R a -R b are each independently H, CM 2 alkyl, C 2 _i 2 alkenyl, C 2
  • alkynyl C 6 -i 2 aryl, C 7 _i 6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle- alkyl;
  • X and Y are each independently — , or a bond
  • R 5 and R 5 ' are each independently H , CMS alkyl which is unsubstituted or substituted one or more times by R 10 , C 2 . 12 alkenyl which is unsubstituted or substituted one or more times by R 10 , C 2 . 12 alkynyl which is unsubstituted or substituted one or more times by R 10 , C 6 -i 4 aryl which is unsubstituted or substituted one or more times by R 11 , C 7 _i 6 aralkyl which is unsubstituted or substituted one or more times by R 11 , 5-12 membered heteroaryl which is unsubstituted or substituted one or more times by R 1 1 , 6-18 membered
  • R 6 is H, C1-6 alkyl, or halogenated C 1 6 alkyl
  • n and n are a positive integer and when combined are 1 , 2, 3, or 4;, provided that each of m and n are not 3 or 4;
  • p 0, 1 , 2, 3 or 4;
  • q 1 or 2;
  • u is 0 or 1 ;
  • s is 0 or 1 ;
  • NEB formula (NIB):
  • BOST 1803930.1 12 pharmaceutically acceptable salt thereof wherein each A is independently C 6 -14 aryl, 4-12 membered heterocycle, C3-10 cycloalkyl, or 5-12 membered heteroaryl wherein when q is 2 then both A rings are not phenyl;
  • B and B' are each independently absent, d. 6 alkyl, C 2 -6 alkenyl, or C 2 . 6 alkynyl; wherein q is 1 then at least one of B and B' is absent;
  • R a , R b , Ro and R d are each independently H, d. 12 alkyl, C 2 . 12 alkenyl, C 2 . 12 alkynyl, C 6 -12 aryl, C 7 . 16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle- alkyl;
  • R 2 > and R 2 are independently H, halogen, d- 10 alkyl, d-6 halogenated alkyl, -(CH 2 ) 1 .
  • R 3 and R 3 ' are each independently H, d-6 alkyl, -(CH 2 )i- 6 0H, C 2 -6 alkenyl, or C 2 -6 alkynyl;
  • R 4 and R 4 ' are each independently halogen, -NR a R b , -C(0)NR a R bj -(CH 2 )i- 6 0H, d-6 alkyl, d-6 halogenated alkyl, hydroxyl, or d-6 alkoxy; wherein two occurrence of R 4 can be taken together with the atoms to which they are attached to form a d-6 alkenyl which is unsubstituted or substituted one or more times by R 10 , a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R 11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R 12 ; wherein two occurrence of R 4 ' can be taken together with the atoms to which they are attached to form a d-6 alkenyl which is unsubstituted or substituted one or more times by R 10 , a 3-7 cycloalky
  • X and Y are each independently
  • R 5 and R 5 ' are each independently H, -ie alkyl which is unsubstituted or substituted one or more times by R 10 , C 2 -i 2 alkenyl which is unsubstituted or 30 substituted one or more times by R 10 , C 2 -i 2 alkynyl which is unsubstituted or substituted one or more times by R 10 , C 6 -i 4 aryl which is unsubstituted or substituted one or more times by R 11 , -16 aralkyl which is unsubstituted or substituted one or more times by R 11 , 5-12 membered heteroaryl which is
  • BOST 1803930.1 14 unsubstituted or substituted one or more times by R 11 , 6-18 membered heteroaralkyl which is unsubstituted or substituted one or more times by R 11 , 3-12 membered heterocycle which is unsubstituted or substituted one or more times by R 12 , or 4-18 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R 12 ;
  • R 6 is H, C 1 -6 alkyl, or halogenated Ci -6 alkyl; m and n combined are each independently 1 , 2, 3, or 4; p is 0, 1 , 2, 3 or 4; q is 1 or 2; u is 0 or 1 ; s is 0 or 1 ;
  • BOST 1803930.1 15 or -P( 0)OR a OR b , C 1 -12 alkyl, C 2 -i 2 alkenyl, C 2 . 12 alkynyl, C 6 . n aryl, C 7 . 16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
  • each of the further embodiments disclosed herein for the variables A, B, B', R 1 ; p, q, R 2 , R 2 ., s, u, R 3 , R 3 >, R 4 , R 4 >, m, n, R 5 , R 5 ., X, Y, R a , R b , R c , R d , R 10 , Rn , and R 12 applies to any and all of the structural formulas in which the variable apprears.
  • each A is independently cyclopropyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, piperazinyl, piperadinyl, phenyl, naphthalenyl, thienyl, furanyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, oxazolyl, oxadiazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, indolyl, indazolyl, benzimidazolyl, benzoxazolyl, benzodioxolyl, benzothiazolyl, benzothiadiazolyl, dihydrobenzodioxine, thienofuranyl, thienothienyl, thienopyrrolyl, quin
  • each A is independently cyclopropyl, 20 cyclohexyl, phenyl, or naphthalenyl, wherein each A is independently substituted with
  • A is independently selected from the consisting of:
  • A is independently selected from the consisting of:
  • each A is independently a 5-12 membered heteroaryl wherein the heteroatom(s) are selected from the group consisting of oxygen and sulphur; wherein each A is independently substituted with (Ri ) p .
  • A is independently piperazinyl, piperadinyl, thienyl, furanyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, thiadiazolyl, pyrrolidinyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzoxazolyl, benzodioxolyl, benzothiazolyl, benzothiadiazolyl, dihydrobenzodioxinyl, thienofuranyl, thienothienyl, quinolinyl, or triazolyl.
  • A is phenyl, thiophene, pyridine, pyrimidine, triazole, naphthalene, thieno[3,2-b]thiophene, benzo[c][1 ,2,5]thiadiazole, quinoline, or benzo[b]thiophene.
  • A is phenyl, thiophene, thieno[3,2- b]thiophene, pyridine, pyrimidine, naphthyl, benzo[1 ,3]dioxole, benzooxazole, or triazole.
  • A is phenyl, thiophene, thieno[3,2- b]thiophene, naphtyl, benzo[1 ,3]dioxole, or benzooxazole.
  • A is phenyl, thiophene, pyridine, pyrimidine, or triazole.
  • A is phenyl or thieno[3,2-b]thiophene.
  • A is phenyl or thioph
  • A is
  • A is
  • A is
  • a in formula (I), (II), (III), (IV) or (V) is a bond.
  • B and B' in formula (IA), (IIA), (IIIA), (1MB), (IVA), or (VA) are independently absent, d. 6 alkyl or C 2 -6 alkynyl.
  • B and B' in formula (IA), (IIA), (IIIA), (1MB), (IVA), or (VA) are independently absent, -(CH 2 ) 2 - or -(C ⁇ C)-.
  • B and B' in formula (IA), (IIA), (IIIA), (1MB), 20 (IVA), or (VA) are independently absent or -(C ⁇ C)-.
  • (IIA), (IIIA), (IIIB), (IVA), or (VA) is selected from the group consisting of:
  • (IIA), (IIIA), (IIIB), (IVA), or (VA) is selected from the group consisting of:
  • (IIA), (IIIA), (IIIB), (IVA), or (VA) is selected from the group consisting of:
  • (IIA), (IIIA), (IIIB), (IVA), or (VA) is selected from the group consisting of:
  • B and B' are each independently C 2 -6 alkynyl
  • B and B' are each independently -(C ⁇ C)- or
  • B and B' are each -(CH 2 ) 2 -.
  • B and B' are each -(C ⁇ C)-.
  • m or n is 2.
  • m or n is 1.
  • m and n are 1 .
  • one of m or n is 1 and the other of m and n are independently 1 or 2.
  • p is 2.
  • p is 1 .
  • X and Y are
  • R 4 and R 4 ' in formula (I ), (IA), (II ), (I IA), or (1 M B) are each independently halogen, -NR a R b , -C(0)NR a R b , -(CH 2 )i- 6 0H, Ci_ 6 alkyl, Ci_ 6 halogenated alkyl, hydroxyl, C 6 -14 aryl, or d- 6 alkoxy; wherein two occurrence of R 4 can be taken together with the atoms to which they are attached to form a d.
  • R 4 and R 4 ' in formula (I), (IA), (II), or (I I A) are each independently halogen, methyl, ethyl, isopropyl, di-fluoromethyl, di-fluoroethyl, trifluoromethyl, tri-fluoroethyl, -CH 2 OH, -NR a N b , t-butoxy-, or hydroxyl; or two R 4 groups together with the atoms to which they are attached form fused cyclopropyl, spiro
  • R 4 and R 4 ' in formula (I), (IA), (II), (IIA), or (1MB) are each independently halogen, methyl, ethyl, isopropyl, di-fluoromethyl, di- 10 fluoroethyl, trifluoromethyl, tri-fluoroethyl, -CH 2 OH, -NR a N b , t-butoxy-, or hydroxyl; or s together with the atoms to which they are attached form spiro cyclopropyl two R 4 ' groups together with the atoms to which they are attached form
  • R 4 and R 4 ' in formula (I), (IA), (II), (IIA), or (1MB) are each independently methyl, ethyl, isopropyl, di-fluoromethyl, di-fluoroethyl, trifluoromethyl, tri-fluoroethyl, -CH 2 OH, -NR a N b or t-butoxy-; or two together
  • R 4 and R 4 ' in formula (I), (IA), (II), (IIA), (IIIA), (1MB), (IVA), or (VA) are each independently methyl, ethyl, isopropyl, di-fluoromethyl, di- fluoroethyl, trifluoromethyl, tri-fluoroethyl, -CH 2 OH, -NR a N b or t-butoxy-; or two R 4
  • BOST 1803930.1 30 groups together with the atoms to which they are attached fo , or two R 4 '
  • R 4 and R 4 ' in formula (I), (IA), (II), or (IIA) are
  • R 4 and R 4 ' in formula (I), (IA), (II), (IIA), or (1MB) are each independently methyl, ethyl, methoxy, di-fluoromethyl, trifluoromethyl, or two R 4 groups together with the atoms to which they are attached form spiro cyclopropyl or two R 4 ' groups together with the atoms to which they are attached form spiro cyclopropyl.
  • R 4 and R 4 ' are each independently H, halogen, d- 6 alkyl, hydroxyl, phenyl, or d-4 alkoxy.
  • R 4 and R 4 ' are each independently - -NR a R b , -C(0)NR a R b> -(CH 2 )i- 6 0H, d-6 alkyl, d-6 halogenated alkyl, C 6 -i 4 aryl, or d-6 alkoxy.
  • R 4 and R 4 ' are each independently halogen, methyl, ethyl, isopropyl, di-fluoromethyl, di-fluoroethyl, trifluoromethyl, tri- fluoroethyl, -CH 2 OH, -NR a N b , t-butoxy-, or hydroxyl.
  • R 4 and R 4 ' are each independently halogen, methyl, ethyl, isopropyl, di-fluoromethyl, di-fluoroethyl, trifluoromethyl, tri- fluoroethyl, -CH 2 OH, t-butoxy-, or hydroxyl.
  • R 4 and R 4 ' are each independently methyl, ethyl, isopropyl, di-fluoromethyl, di-fluoroethyl, trifluoromethyl, tri-fluoroethyl, - CH 2 OH, -NR a N b , or t-butoxy.
  • R 4 and R 4 ' are each independently methyl, 10 ethyl, isopropyl, di-fluoromethyl, di-fluoroethyl, trifluoromethyl, tri-fluoroethyl, or - CH 2 OH.
  • R 4 and R 4 ' are each independently methyl, ethyl, methoxy, di-fluoromethyl, or trifluoromethyl.
  • R 4 and R 4 ' are each independently H, halogen, methyl, ethyl, t-butoxy-, or hydroxyl.
  • R 4 and R 4 ' are each H.
  • R 4 and R 4 ' are each fluoro. According to a further embodiment, R 4 and R 4 ' are C 1-6 alkyl. According to a further embodiment, R 4 and R 4 ' are each Ci- 6 haloalkyl. According to a further embodiment, R 4 and R 4 ' are methyl or ethyl. According to a further embodiment, R 4 and R 4 ' are each methyl.
  • R 4 and R 4 ' are each ethyl.
  • R 4 and R 4 ' are each methoxy.
  • R 4 and R 4 ' are each independently halogen, Ci-6 alkyl, or d- 6 alkoxy.
  • one of R 4 and R 4 ' is hydrogen and the other of R 4 and R 4 ' is C 1 6 alkyl.
  • R 3 and R 3 ' are H or methyl.
  • R 3 and R 3 ' are each H.
  • R and R ' are methyl.
  • Ci- 6 alkenyl, C 2 . 6 alkynyl, or Ci- 6 halogenated alkyl or any two occurrences of can be taken together with the atoms to which they are attached to form a 5-7 cycloalkyl which is unsubstituted or substituted one or more times by R 10 or a 5-7 membered heterocycle which is unsubstituted or substituted one or more times by R 12 .
  • R ⁇ is halogen, d. alkyl, hydroxyl, cyano, or C 1 -3 alkoxy, or methoxycarbonyl.
  • R ⁇ is chloro, fluoro, bromo, methyl, ethyl, propyl, butyl, -CH 2 OH, difluoromethyl, trifluoromethyl, hydroxyl, cyano, methoxy, or methoxycarbonyl.
  • R ⁇ is chloro, fluoro, methyl, hydroxyl, cyano, trifluoromethyl, methoxy, or methoxycarbonyl.
  • R ⁇ is halogen, d-3 alkyl, hydroxyl, cyano, or C 1 -3 alkoxy.
  • R 2 and R 2 ' are each independently H, iodo, methyl, hydroxy methyl, trifluoromethyl, or thienothienyl.
  • R 2 ' is independently methyl, trifluoromethyl, iodo, CH 2 OH, or NHC(0)CH 3 .
  • R 2 and R 2 ' are each methyl.
  • R 2 and R 2 ' are each iodo.
  • s is 0.
  • R 2 and R 2 ' are each H.
  • R 6 is H or C 1 -3 alkyl.
  • R 5 and R 5 ' are each independently Ci- 8 alkyl which is unsubstituted or substituted one or more times by R 10 , C 2 . 8 alkenyl which is unsubstituted or substituted one or more times by R 10 , C 2 . 8 alkynyl which is unsubstituted or substituted one or more times by R 10 , phenyl which is unsubstituted or substituted one or more times by R 11 , C 7 .
  • aralkyl which is unsubstituted or substituted one or more times 10 by R 11 , 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R 11 , 6-8 membered heteroaralkyl which is unsubstituted or substituted one or more times by R 11 , 3-6 membered heterocycle which is unsubstituted or substituted one or more times by R 12 , or 4-8 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R 12 .
  • R 5 and R 5 ' are each independently Ci- 6 alkyl which is unsubstituted or substituted one or more times by R 10 , C 2 . 6 alkenyl which is unsubstituted or substituted one or more times by R 10 , C 2 .
  • R 5 and R 5 ' are each independently Ci- 6 alkyl which is unsubstituted or substituted one or more times by R 10 , C 2 . 6 alkenyl which is unsubstituted or substituted one or more times by R 10 , or C 2 . 6 alkynyl which is 30 unsubstituted or substituted one or more times by R 10 .
  • R 5 and R 5 ' are each independently Ci_ 12 alkyl which is unsubstituted or substituted one or more times by R 10 .
  • R 5 and R 5 ' are each independently methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, 2-methylbutane, 3-
  • R 5 and R 5 ' are each independently methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, 2-methylbutane, 3- methylbutane, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cyclohexyl(CH 2 )-.
  • R 5 and R 5 ' are each independently isopropyl which is unsubstituted or substituted one or more times by R 10 .
  • R 5 and R 5 ' are each independently isopropyl which is unsubstituted or substituted one or more times by -OCH 3 .
  • R 5 and R 5 ' are each isopropyl.
  • R 5 and R 5 ' are each H or tert-butyl.
  • R 5 and R 5 ' are each independently phenyl which is unsubstituted or substituted one or more times by R 11 .
  • R 5 and R 5 ' are each independently benzyl which is unsubstituted or substituted one or more times by R 11 .
  • R 10 is halogen, d- 6 alkoxy, hydroxyl, or NH 2 .
  • R 10 is halogen, hydroxyl, or NH 2 .
  • R 10 is halogen
  • R a , R b , and R d are each independently are each independently H, d-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, d-12 aryl, C 7 . 16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
  • R 11 is halogen, -OR a , -NR a R b , -C(0)NR a R b , -
  • R a , R b , and R d are each independently H, d-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C 6 -12 aryl, -16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
  • R 11 is halogen, -OR a , -NR a R b , hydroxyl, cyano, or d-6 alkyl, wherein R a -R b are each independently H, d-12 alkyl, d-12 alkenyl, d-12 30 alkynyl, d-12 aryl, C 7 _i 6 aralkyl, 5-12 membered heteroaryl, 6-18 membered
  • heteroaralkyl 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
  • R 11 is halogen, hydroxyl, cyano, or NH 2 .
  • R 11 is halogen
  • R a , R b , and R d are each independently H, d-12 alkyl, d-12 alkenyl, d-12 alkynyl, C 6 -i 2 aryl, C 7 . 16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
  • R 12 is halogen, -OR a , oxo, -NR a R b , -C(0)NR a R b ,
  • R a , R b , and R d are each independently H, d-12 alkyl, C 2 . 12 alkenyl, d-12 alkynyl, C 6 -i 2 aryl, d-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
  • R 12 is halogen, -OR a , oxo, -NR a R b , hydroxyl, cyano, or d-6 alkyl, wherein R a -R b are each independently H, d-12 alkyl, C 2 . 12 alkenyl, C 2 - 12 30 alkynyl, C 6 -i 2 aryl, -16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
  • R 12 is halogen
  • R a , R b , R c , and R d are each independently H, d-6 alkyl, C 2 . 6 alkenyl, C 2 . 6 alkynyl, phenyl, C 7 . 8 aralkyl, 5-6 membered heteroaryl, 6-8
  • R a and R c are each independently H, Ci- 6 alkyl, C 2 -6 alkenyl, C 2 . 6 alkynyl, phenyl, C 7 . 8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle- alkyl, and R b , and R d are each independently H or C 1 -3 alkyl.
  • R a and R c are each independently H, Ci- 6 10 alkyl, C 2 . 6 alkenyl, C 2 . 6 alkynyl, phenyl, benzyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl, and R b , and R d are each independently H or d- 3 alkyl.
  • R a , R b , R c , and R d are each independently H or Ci-3 alkyl.
  • A, B, B', R 1 ; p, R 2 , R 2 >, R 3 , R >, R 4 , and R 4 > are as defined for formula (I ), and
  • R 7 and R 7 ' are each independently Ci_ 8 alkyl which is unsubstituted or substituted one or more times by R 10 , C 2 . 8 alkenyl which is unsubstituted or substituted one or more times by R 10 , C 2 . 8 alkynyl which is unsubstituted or substituted one or more times by R 10 , phenyl which is unsubstituted or substituted one or more times by R 11 , benzyl which is unsubstituted or substituted one or more times by R 11 , 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R 11 , 6-7
  • R 7 and R 7 ' are each independently d- 8 alkyl which is unsubstituted or substituted one or more times by R 10 , C 2 s alkenyl which is unsubstituted or substituted one or more times by R 10 , C 2 s alkynyl which is unsubstituted or substituted one or more times by R 10 , phenyl which is unsubstituted or substituted one or more times by R 11 , benzyl which is unsubstituted or substituted one or more times by R 11 , 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R 11 , 6-7 membered heteroaralkyl which is unsubstituted or substituted one or more times by R 11 , 3-6 membered heterocycle which is unsubstituted or substituted one or more times by R 12 , or 4-7 membered heterocycle-alkyl which is unsubstituted or substituted one or more times
  • n and n combined are 0, 1 , 2, 3 or 4.
  • R 7 and R 7 ' are each independently d- 8 alkyl, C 2 -8 alkenyl, C 2 s alkynyl, phenyl, benzyl, 5-6 membered heteroaryl, 6-7 membered heteroaralkyl, 3-6 membered heterocycle, or 4-7 membered heterocycle-alkyl;
  • R 7 and R 7 ' are each independently phenyl.
  • R 7 and R 7 ' are each independently d. 6 alkyl.
  • R 7 and R 7 ' are each independently Ci_ 6 alkyl 10 which is unsubstituted or substituted one or more times by R 10 .
  • R 7 and R 7 ' are each independently methyl, ethyl, propyl, isopropyl, methoxyisopropyl, butyl, sec-butyl, tert-butyl, pentyl, 2- methylbutane, 3-methylbutane, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
  • R 7 and R 7 ' are each independently methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, 2-methylbutane, 3- methylbutane, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
  • R 7 and R 8 or R 7 > and R 8 > together with the carbon to which they are attached are each independently:
  • R 7 and R 7 ' are each isopropyl.
  • each of A, B, B' , R 1 , p, R 2 , R 2 >, R , R >, R 4 , R 4 >, R 7 , R 7 >, R 8 , and R 8 ., are as defined for formula (I ).
  • the compounds of the present invention are represented by formula (VA):
  • valency allows in B, B', R a , R b , R c , and R d , Ri , R 2 , R 2 ' , R3, R3' , R4, R4 , R 10 , R 11 and R 12 each of alkyl, alkenyl, alkynyl, alkoxy, aryl, 20 aralkyl, heteroaryl, heteroaralkyl, heterocycle, or heterocycle-alkyl is independently unsubstituted or substituted one time by halogen.
  • BOST 1803930.1 44 According to a further embodiment, as valency allows in B, B' , R a , R b , R c , and R d , Ri , R 2 , R 2 ' , R3, R3' , R4, R4 , R 10 , R 11 and R 12 each of alkyl, alkenyl, alkynyl, alkoxy, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocycle, or heterocycle-alkyl is independently unsubstituted or substituted one time by fluoro.
  • the compounds are selected from compounds as defined in the formulas wherein:
  • A is C 6 -14 aryl, 5-12 membered heteroaryl, or a bond
  • 10 B and B' are each independently -(C ⁇ C)- or -(CH 2 ) 2 -;
  • R 2 and R 2 ' are each independently H, methyl, or iodo
  • n are each independently 0, 1 or 2;
  • p 0, 1 or 2;
  • R 3 and R 3 ' are H
  • R 4 and R 4 ' are each independently H, halogen, d. 6 alkyl, hydroxyl, phenyl, or d. 4 alkoxy;
  • R 5 and R 5 ' are each independently d. 12 alkyl which is unsubstituted or substituted one or more times by R 10 .
  • the compounds are selected from compounds as defined in the formulas wherein:
  • 30 A is C 6 -14 aryl, 5-12 membered heteroaryl, or a bond
  • B and B' are each independently -(C ⁇ C)- or -(CH 2 ) 2 -;
  • RT is H or methyl
  • R 2 and R 2 ' are each independently H, methyl or iodo
  • n are each independently 0, 1 or 2;
  • p 0, 1 or 2;
  • R 3 and R 3 ' are H
  • R 4 and R 4 ' are each independently H, halogen, d. 6 alkyl, hydroxyl, phenyl, or d. 4 alkoxy; X and Y are
  • R 5 and R 5 ' are each independently d-12 alkyl which is unsubstituted or substituted one or more times by R 10 .
  • the compounds are selected from compounds as defined in the formulas wherein:
  • 10 A is phenyl, thiophene, thieno[3,2-b]thiophene, pyridine, pyrimidine, naphthyl, benzo[1 ,3]dioxole, benzooxazole, or triazole;
  • B and B' are each independently -(C ⁇ C)- or -(CH 2 )2- ;
  • R 2 and R 2 ' are each independently H, methyl or iodo
  • n are each independently 0, 1 or 2;
  • p 0, 1 or 2;
  • R 3 and R 3 ' are H
  • R 4 and R 4 ' are each independently H, halogen, d-6 alkyl, hydroxyl, phenyl, or Ci_ 4 alkoxy; 20 X and Y are
  • R 5 and R 5 ' are each independently d-12 alkyl which is unsubstituted or substituted one or more times by R 10 .
  • the compounds are selected from compounds as defined in the formulas wherein:
  • A is phenyl, thiophene, thieno[3,2-b]thiophene, naphthyl, benzo[1 ,3]dioxole, or benzooxazole;
  • 30 B and B' are each independently -(C ⁇ C)- or -(CH 2 ) 2 -;
  • R 2 and R 2 ' are each independently H, methyl or iodo
  • n are each independently 0, 1 or 2;
  • BOST 1803930.1 46 p is 0, 1 or 2;
  • R 3 and R 3 ' are H
  • R 4 and R 4 ' are each independently H, halogen, Ci- 6 alkyl, hydroxyl, phenyl, or d- 4 alkoxy;
  • X and Y are each
  • R 5 and R 5 ' are each independently d. 12 alkyl which is unsubstituted or substituted one or more times by R 10 ;
  • R 7 and R 7 ' are each independently Ci- 8 alkyl which is unsubstituted or substituted one or more times by R 10 , C 2 . 8 alkenyl which is unsubstituted or substituted one or more times by R 10 , C 2 .
  • the compounds of this invention are represented in Table 1 A. In some embodiments, the compounds of this invention are represented in Table 1 B. In certain embodiments, the variables used herein are as defined in the specific
  • BOST 1803930.1 47 one or more times by R 10 , C 2 -6 alkenyl which is unsubstituted or substituted one or more times by R 10 , C 2 . 6 alkynyl which is unsubstituted or substituted one or more times by R 10 ;
  • p is 0, 1 or 2.
  • p is 0 or 1 .
  • p 0.
  • p is 2.
  • R 4 and R 4 ' are H .
  • halogen In one embodiment in the compounds of the present invention is halogen, Ci_ alkyl, hydroxyl, cyano, or d. alkoxy.
  • n is H.
  • R a ,R b , and R d are each independently are each independently H, C-i-12 alkyl, C 2 -i 2 alkenyl, C 2 -i 2 alkynyl, C 6 -i 2 aryl, C 7 . 16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
  • R 11 is halogen, -
  • R a , R b , and R d are each independently H , CM 2 alkyl, C 2 -i 2 alkenyl, C 2 -i 2 alkynyl, C 6 -i 2 aryl, C 7 _i 6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4- 18 membered heterocycle-alkyl.
  • R 11 is halogen, - OR a , -NR a R b , hydroxyl, cyano, Ci_ 6 alkyl, wherein R a -R b are each independently H, CM 2
  • alkyl C 2 -i 2 alkenyl, C 2 -i 2 alkynyl, C 6 -i 2 aryl, C 7 _i 6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle- alkyl.
  • R 12 is halogen, - OR a , oxo, -NR a R b , hydroxyl, cyano, Ci_ 6 alkyl, wherein R a -R b are are each independently H, C1-12 alkyl, CM 2 alkenyl, C2-12 alkynyl, C 6 -12 aryl, C 6 aralkyl, 5-12 membered heteroaryl, 6- 18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
  • valency 20 allows in B, B', R a , R b , R c , and R d , R 1 ; R 2 , R 2 ' , R 3 , R3' , R 4 , R 4 ' , R 10 , R 11 and R 12 each of alkyl, alkenyl, alkynyl, alkoxy, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocycle, or heterocycle-alkyl is independently unsubstituted or substituted one or more times by halogen, -OR a . -NR a .R b .
  • each of alkyl, alkenyl, alkynyl, alkoxy, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocycle, or heterocycle-alkyl is independently unsubstituted or substituted one time by halogen.
  • each of alkyl, alkenyl, alkynyl, alkoxy, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocycle, or heterocycle-alkyl is independently unsubstituted or substituted one time by fluoro.
  • a compound of the present invention for treating an Hepatitis C viral infection in a human.
  • the use of a compound of the present invention further comprising administering at least one additional agent.
  • the use of a compound of the present invention wherein said at least one additional agent is selected from viral serine protease
  • IRES internal ribosome entry site
  • a pharmaceutical formulation comprising at least one compound of the present 10 invention and at least one pharmaceutically acceptable carrier or excipient.
  • the use of a compound of the present invention further comprising administering at least one additional agent.
  • said at least one additional agent is selected from viral serine protease inhibitors, viral polymerase inhibitors, viral helicase inhibitors, immunomudulating agents, antioxidant agents, antibacterial agents, therapeutic vaccines, hepatoprotectant agents, antisense agents, inhibitors of HCV NS2/3 protease and inhibitors of internal ribosome entry site (IRES).
  • the use of a compound of the present invention wherein said at least one additional agent is selected from ribavirin and interferon-a.
  • a pharmaceutical formulation comprising at least one compound of the present invention and at least one pharmaceutically acceptable carrier or excipient.
  • the compounds of the invention are selected from Table 1A:
  • the compounds of the invention are selected from Table 1 B:
  • the present invention provides a method for preparing a compound of formula (IV):
  • the present invention provides a method for preparing a compound of formula (IV):
  • the coupling conditions comprise bis(triphenylphosphine) palladiumchloride, copper iodide, and triethylamine.
  • the present invention provides a method for preparing a compound of formula (XXXII):
  • R 2 , R3, R 4 , R 7 , and R 8 are as defined herein,
  • the oxidizing of step g) comprises 2,2,6,6-tetramethyl- piperidin-1 -oxyl (TEMPO).
  • TEMPO 2,2,6,6-tetramethyl- piperidin-1 -oxyl
  • the present invention provides a method for preparing a compound of formula (XXVI):
  • R 4 is as defined herein, and each R is each independently an alkyl group, wherein said method comprises the steps of:
  • the present invention provides a method for preparing a compound of formula (XXXI):
  • R 2 >, R3' , R 4 >, R 7 >, and R 8 > are as defined herein,
  • said method comprises the steps as disclosed for preparing a compound of formula (XXXII), wherein each of R 2 ., R 3 >, R 4 ., R 7 ., and R 8 ., are as defined for R 2 , R 3 , R 4 , and R 8 , respectively
  • the present invention provides a method for preparing ((S)-1 - ⁇ (2S,4S)-2-[5-(4- ⁇ 2-[(2S,4S)-1 -((S)-2-Methoxycarbonylamino-3-methyl-butyryl)-4-methyl- pyrrolidin-2-yl]-3H-imidazol-4-ylethynyl ⁇ -phenylethynyl)-1 H-imidazol-2-yl]-4-methyl- pyrrolidine-1 -carbonyl ⁇ - -methylpropyl)-carbamic acid methyl ester:
  • BOST 1803930.1 68 wherein said method comprises:
  • the coupling conditions comprise bis(triphenylphosphine) palladiumchloride, copper iodide, and triethylamine.
  • the present invention provides a method for preparing a compound of formula (X):
  • the coupling conditions of step b) comprise first contacting a compound of formula (XII) with 0-(7-azabenzotriazol-1 -yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU) and diisopropypyethylamine (DIPEA).
  • HATU 0-(7-azabenzotriazol-1 -yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate
  • DIPEA diisopropypyethylamine
  • the deprotection conditions of step a) comprise a mineral acid.
  • the present invention provides a method for preparing a compound of formula (XIII):
  • reaction conditions comprise methyl magnesium bromide.
  • present invention provides a method for preparing a
  • the separating of step f) comprises silica gel chromatography.
  • reaction conditions of step e) comprise 1 -iodopyrrolidine- 2,5-dione.
  • the oxidizing of step c) comprises 2,2,6,6-tetramethyl- 10 piperidin-1 -oxyl (TEMPO).
  • the reducing of step b) comprises borane.
  • the hydrogenating of step a) comprises platinum oxide and hydrogen gas.
  • the present invention provides a method for preparing a compound of formula (XIV) having
  • reaction conditions of step d) comprise the steps of: a) reacting a compound of formula (XXIV) under reaction conditions sufficient to provide a compound of formula (XXV); and:
  • the present invention provides a method for preparing a compound of formula (III)
  • the present invention provides a method for preparing compound of formula (XXXIV)
  • each of A, B, B', R 1 , p, R 2 , R 2 ., R 3 , R 3 ., R 4 , R 4 ., R 7 , R 7 ., R 8 , and R 8 . are as defined herein and each of B and B', R 2 and R 2 >, R and R >, R 4 and R 4 >, R 7 and R T , and R 8 , and R 8 > are the same respectively,
  • the coupling conditions comprise bis(triphenylphosphine palladiumchloride, copper iodide, and triethylamine.
  • the present invention provides a method for preparing ((S)-1 ⁇ (2S,4S)-2-[5-(4- ⁇ 2-[(2S,4S)-1 -((S)-2-Methoxycarbonylamino-3-methyl-butyryl)-4-methyl- pyrrolidin-2-yl]-3H-imidazol-4-ylethynyl ⁇ -phenylethynyl)-1 H-imidazol-2-yl]-4-methyl- pyrrolidine-1 -carbonyl -2-methylpropyl)-carbamic acid methyl ester:
  • the coupling conditions of step a) comprise bis(triphenylphosphine) palladiumchloride, copper iodide, and triethylamine.
  • the present invention provides a compound according to the invention described herein for treating or preventing a Flaviviridae viral infection in a host.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising at least one compound according to the invention described herein and at least one pharmaceutically acceptable carrier or excipient.
  • the present invention provides a pharmaceutical composition comprising at least one compound according to the invention described herein and at 20 least one pharmaceutically acceptable carrier or excipient, for treating or preventing a Flaviviridae viral infection in a host.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising at least one compound according to the invention described herein ,and further comprising administering at least one additional agent chosen from viral serine protease inhibitors, viral polymerase inhibitors, viral helicase inhibitors, immunomudulating agents, antioxidant agents, antibacterial agents, therapeutic vaccines, hepatoprotectant agents, antisense agents, inhibitors of HCV NS2/3 protease and inhibitors of internal ribosome entry site (IRES).
  • at least one additional agent chosen from viral serine protease inhibitors, viral polymerase inhibitors, viral helicase inhibitors, immunomudulating agents, antioxidant agents, antibacterial agents, therapeutic vaccines, hepatoprotectant agents, antisense agents, inhibitors of HCV NS2/3 protease and inhibitors of internal ribosome entry site (IRES).
  • a combination comprising a least one compound according to the invention described herein and one or more additional agents.
  • BOST 1803930.1 77 chosen from viral serine protease inhibitors, viral polymerase inhibitors, viral helicase inhibitors, immunomudulating agents, antioxidant agents, antibacterial agents, therapeutic vaccines, hepatoprotectant agents, antisense agent, inhibitors of HCV NS2/3 protease and inhibitors of internal ribosome entry site (IRES).
  • the compound and additional agent are administered sequentially.
  • the compound and additional agent are 10 administered simultaneously.
  • compositions comprising a combination as defined above together with a pharmaceutically acceptable carrier therefore comprise a further aspect of the invention.
  • compositions and combinations include, for example, ribavirin, amantadine, merimepodib, Levovirin, Viramidine, and maxamine.
  • viral serine protease inhibitor means an agent that is effective to inhibit the function of the viral serine protease including HCV serine protease in a mammal.
  • Inhibitors of HCV serine protease include, for example, those compounds described in WO 99/07733 (Boehringer Ingelheim), WO 99/07734 (Boehringer Ingelheim), WO 00/09558 (Boehringer Ingelheim), WO 00/09543 (Boehringer Ingelheim), WO 00/59929 (Boehringer Ingelheim), WO 02/060926 (BMS), WO 2006039488 (Vertex), WO 2005077969 (Vertex), WO 2005035525 (Vertex), WO 2005028502 (Vertex) WO 2005007681 (Vertex), WO 2004092162 (Vertex), WO 2004092161 (Vertex), WO 2003035060 (Vertex), of WO 03/087092
  • viral serine protease inhibitors include Telaprevir (VX-950,
  • Vertex Vertex
  • VX-500 Vertex
  • TMC435350 Tebotec/Medivir
  • MK-7009 Merck
  • ITMN-191 R7227, InterMune/Roche
  • Boceprevir SCH503034, Schering
  • viral polymerase inhibitors means an agent that is effective to inhibit the function of a viral polymerase including an HCV polymerase in a
  • Inhibitors of HCV polymerase include non-nucleosides, for example, those compounds described in:
  • WO 03/010140 Boehringer Ingelheim
  • WO 03/026587 Bristol Myers Squibb
  • WO 02/100846 A1 WO 02/100851 A2, WO 01 /85172 A1 (GSK), WO 02/098424 A1 (GSK), WO 00/06529 (Merck), WO 02/06246 A1 (Merck), WO 01 /47883 (Japan Tobacco), WO 03/000254 (Japan Tobacco) and EP 1 256 628 A2 (Agouron).
  • inhibitors of HCV polymerase also include nucleoside analogs, 10 for example, those compounds described in: WO 01 /90121 A2 (Idenix), WO 02/069903 A2 (Biocryst Pharmaceuticals Inc.), and WO 02/057287 A2(Merck/lsis) and WO 02/057425 A2 (Merck/lsis).
  • inhibitors of an HCV polymerase include VCH-759 (ViroChem Pharma), VCH-916 (ViroChem Pharma), VCH-222 (ViroChem Pharma), R1626 (Roche), R7128 (Roche/Pharmasset), PF-868554 (Pfizer), MK-0608 (Merck/lsis), MK-3281 (Merck), A-837093 (Abbott), GS 9190 (Gilead), ana598 (Anadys), HCV-796 (Viropharma) and GSK625433 (GlaxoSmithKline).
  • viral helicase inhibitors as used herein means an agent that is effective to inhibit the function of a viral helicase including a Flaviviridae helicase in a mammal.
  • Immunomodulatory agent as used herein means those agents that are effective to enhance or potentiate the immune system response in a mammal.
  • Immunomodulatory agents include, for example, class I interferons (such as ⁇ -, ⁇ -, ⁇ - and ⁇ - interferons, ⁇ - interferons, consensus interferons and asialo-interferons), class II interferons (such as ⁇ - interferons) and pegylated interferons.
  • Immunomodulatory agent as used herein include IL-29 (PEG-
  • class I interferon means an interferon selected from a group of interferons that all bind to receptor type 1. This includes both naturally and synthetically produced class I interferons. Examples of class I interferons include ⁇ -, ⁇ - , ⁇ - and ⁇ - interferons, ⁇ -interferons, consensus interferons and asialo-interferons.
  • class II interferon means an interferon selected from a group of interferons that all bind to receptor type II. Examples of class II interferons include ⁇ - 10 interferons.
  • Antisense agents include, for example, ISIS-14803.
  • ISIS-1 803 ISIS Pharmaceuticals
  • PTC therapeutics PTC therapeutics
  • the additional agent is interferon a, ribavirin, silybum marianum, interleukine-12, amantadine, ribozyme, thymosin, N-acetyl cysteine or cyclosporin.
  • the additional agent is interferon a, or ribavirin.
  • the additional agent is interferon a 1A, interferon a 1 B, interferon a 2A, or interferon a 2B.
  • Interferon is available in pegylated and non pegylated forms.
  • Pegylated interferons include PEGASYS tm and Peg-intron tm .
  • the additional agent is interferon a 1A, interferon a 1 B, 30 interferon a 2A (Roferon), PEG -interferon a 2A (Pegasys), interferon a 2B (Intron A) or PEG- interferon a 2B (Peg-lntron).
  • the additional agent is standard or pegylated interferon a (Roferon, Pegasys, Intron A, Peg-lntron) in combination with ribavirin.
  • the additional agent is chosen from A-831 (AZD0530, Arrow Therapeutics acquired by AstraZeneca), TLR9 agonist : IMO-2125 (Idera Pharmaceuticals), PYN17 (Phynova), Vavituximab (Tarvacin, Peregrine), DEBIO-025 (DEBIO), NIM-811 (Novartis), SCY635 (Scynexis), PF-03491390 (IDN-6556, Pfizer), Suvus (formerly BIVN-401 , Virostat, Bioenvision), MX-3253 (Celgosivir, Migenix), Viramidine (Taribavirin, Valeant Pharmaceuticals), Hepaconda (Giaconda), TT033 (Benitec/Tacere Bio/Pfizer), SIRNA-034 (Sirna Therapeutics aquired by Merck) and EHC-18 (Enzo Biochem), ACH-1095 (A-831 (AZD0530, Arrow
  • the additional agent is a therapeutic vaccine chosen from CSL123 (Chiron/CSL), IC41 (Intercell Novartis), Gl 5005 (Glo situmune), TG4040 (Transgene), Chronvac C (Tripep/lnovio), GNI-103 (GENimmune), HCV/MF59 (Chiron/Novartis), PeviPROTM (Pevion biotect).
  • the recommended dose of PEGASYS tm monotherapy for chronic hepatitis C is 180 mg (1.0 mL vial or 0.5 mL prefilled syringe) once weekly for 48 weeks by subcutaneous administration in the abdomen or thigh.
  • the recommended dose of PEGASYS tm when used in combination with ribavirin for chronic hepatitis C is 180 mg (1.0 mL vial or 0.5 mL prefilled syringe) once weekly.
  • the daily dose of Ribavirin is 800 mg to 1200 mg administered orally in two divided doses.
  • the dose should be individualized to the patient depending on baseline disease characteristics (e.g., genotype), response to therapy, and tolerability of the regimen.
  • the recommended dose of PEG-lntron tm regimen is 1.0 mg/kg/week 30 subcutaneously for one year.
  • the dose should be administered on the same day of the week.
  • the recommended dose of PEG- Intron is 1.5 micrograms/kg/week.
  • viral serine protease inhibitor is a flaviviridae serine protease inhibitor.
  • viral polymerase inhibitor is a flaviviridae polymerase inhibitor.
  • viral helicase inhibitor is a flaviviridae helicase inhibitor. In further embodiments:
  • viral serine protease inhibitor is HCV serine protease inhibitor
  • viral polymerase inhibitor is HCV polymerase inhibitor
  • viral helicase inhibitor is HCV helicase inhibitor.
  • the present invention provides a method for treating or preventing a Flaviviridae viral infection in a host comprising administering to the host a therapeutically effective amount of at least one compound according to formula (I ), (I I ), (I II ), or (IV).
  • the viral infection is chosen from Flavivirus infections.
  • the Flavivirus infection is Hepatitis C virus (HCV), bovine viral diarrhea virus (BVDV), hog cholera virus, dengue fever virus, Japanese encephalitis virus or yellow fever virus.
  • HCV Hepatitis C virus
  • BVDV bovine viral diarrhea virus
  • hog cholera virus dengue fever virus
  • Japanese encephalitis virus yellow fever virus.
  • the Flaviviridea viral infection is hepatitis C viral infection
  • the host is human.
  • the present invention provides a method for treating or 30 preventing a Flaviviridae viral infection in a host comprising administering to the host a therapeutically effective amount of at least one compound according to the invention described herein, and further comprising administering at least one additional agent.
  • the present invention provides a method for treating or preventing a Flaviviridae viral infection in a host comprising administering to the host a therapeutically effective amount of at least one compound according to the invention
  • at least one additional agent chosen from viral serine protease inhibitors, viral polymerase inhibitors, viral helicase inhibitors, immunomudulating agents, antioxidant agents, antibacterial agents, therapeutic vaccines, hepatoprotectant agents, antisense agents, inhibitors of HCV NS2/3 protease and inhibitors of internal ribosome entry site (IRES).
  • compositions comprising a combination as defined above together with a pharmaceutically acceptable carrier 10 therefore comprise a further aspect of the invention.
  • the individual components for use in the method of the present invention or combinations of the present invention may be administered either sequentially or simultaneously in separate or combined pharmaceutical formulations.
  • the present invention provides the use of a compound according to the invention described herein for treating or preventing Flaviviridae viral infection in a host.
  • the present invention provides the use of a compound according to the invention described herein and further comprising at least one additional agent chosen from viral serine protease inhibitors, viral polymerase inhibitors, viral helicase inhibitors, immunomudulating agents, antioxidant agents, antibacterial agents, therapeutic vaccines, hepatoprotectant agents, antisense agents, inhibitors of HCV NS2/3 protease and inhibitors of internal ribosome entry site (I RES). for treating or preventing Flaviviridae viral infection in a host.
  • at least one additional agent chosen from viral serine protease inhibitors, viral polymerase inhibitors, viral helicase inhibitors, immunomudulating agents, antioxidant agents, antibacterial agents, therapeutic vaccines, hepatoprotectant agents, antisense agents, inhibitors of HCV NS2/3 protease and inhibitors of internal ribosome entry site (I RES).
  • the present invention provides the use of a compound according to the invention described herein for the manufacture of a medicament.
  • the present invention provides the use of a compound according to the invention described herein for the manufacture of a medicament for treating or preventing a viral Flaviviridae infection in a host.
  • the present invention provides the use of a compound according to the invention described herein and further comprising at least one
  • additional agent chosen from viral serine protease inhibitors, viral polymerase inhibitors, viral helicase inhibitors, immunomudulating agents, antioxidant agents, antibacterial agents, therapeutic vaccines, hepatoprotectant agents, antisense agents, inhibitors of HCV NS2/3 protease and inhibitors of internal ribosome entry site (I RES).
  • structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms 10 of the structure; for example, the R and S configurations for each asymmetric center, (Z) and (E) double bond isomers, and (Z) and (E) conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the invention.
  • the single optical isomer or enantiomer can be obtained by method well known in the art, such as chiral HPLC, enzymatic resolution and chiral auxiliary.
  • the compounds of the present invention are provided in the form of a single stereoisomer at least 95%, at least 97% and at least 99% free of the corresponding stereoisomers.
  • the compound of the present invention are in the form of a single stereoisomer at least 95% free of the corresponding stereoisomers.
  • the compound of the present invention are in the form of a single stereoisomer at least 97% free of the corresponding stereoisomers.
  • the compound of the present invention are in the form of a single stereoisomer at least 99% free of the corresponding stereoisomers.
  • pharmaceutically acceptable salts of the compounds of the present invention are meant those derived from pharmaceutically acceptable inorganic and organic acids and
  • BOST 1803930.1 84 bases examples include hydrochloric, hydrobromic, sulphuric, nitric, perchloric, fumaric, maleic, phosphoric, glycollic, lactic, salicylic, succinic, toleune-p-sulphonic, tartaric, acetic, trifluoroacetic, citric, methanesulphonic, formic, benzoic, malonic, naphthalene-2-sulphonic and benzenesulphonic acids.
  • Other acids such as oxalic, while not themselves pharmaceutically acceptable, may be useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts.
  • Salts derived from amino acids are also included (e.g. L-arginine, L-Lysine).
  • Salts derived from appropriate bases include alkali metals (e.g. sodium, lithium, potassium) and alkaline earth metals (e.g. calcium, magnesium).
  • alkali metals e.g. sodium, lithium, potassium
  • alkaline earth metals e.g. calcium, magnesium
  • a reference hereinafter to a compound according to the invention includes that compound and its pharmaceutically acceptable salts.
  • polymorphism is an ability of a compound to crystallize as more than one distinct crystalline or "polymorphic" species.
  • a polymorph is a solid crystalline phase of a compound with at least two different arrangements or polymorphic forms of that compound molecule in the solid state.
  • Polymorphic forms of any given compound are defined by the same chemical formula or composition and are as distinct in chemical structure as crystalline structures of two different chemical compounds.
  • compositions to treat or prevent the herein identified disorders.
  • Solvates of the compounds of the invention may also form when solvent molecules are incorporated into the crystalline lattice structure of the compound molecule during the crystallization process.
  • alkyl represents a linear, branched or cyclic hydrocarbon moiety.
  • alkenyl and alkynyl represent a linear, branched or cyclic hydrocarbon moiety which has one or more double bonds or triple bonds in the chain.
  • alkyl, alkenyl, and alkynyl groups include but are not limited to methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, hexyl, isohexyl, neohexyl, allyl, vinyl, acetylenyl, ethylenyl, propenyl, isopropenyl, butenyl, isobutenyl, hexenyl, butadienyl, pentenyl, pentadienyl, hexenyl, heptenyl, heptadienyl, heptatrienyl, octenyl, propynyl, butynyl, pentynyl, hexynyl
  • alkyl, alkenyl, and alkynyl also include combinations of linear and branched groups, e.g., cyclopropylmethyl, cyclohexylethyl, etc.
  • alkenyl also includes C1 alkenyl where the one carbon atom is attached to the remainder of the molecule via a double bond.
  • alkyl, alkenyl, and alkynyl can be optionally substituted such as in the case of haloalkyls in which one or more hydrogen atom is replaced by a halogen, e.g., an alkylhalide.
  • haloalkyls include but are not limited to trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, dichloromethyl, chloromethyl, trifluoroethyl, difluoroethyl, fluoroethyl, trichloroethyl, dichloroethyl, chloroethyl, chlorofluoromethyl, chlorodifluoromethyl, dichlorofluoroethyl.
  • R a , -S0 2 NR a R b , -NR b S0 2 R a , -NR b S0 2 NR a R b , or -P( 0)OR a OR b , wherein R a , R b , Ro and R d are each independently H, d_ 12 alkyl, C 2 . 12 alkenyl, C 2 . 12 alkynyl, C 6 -i 2 aryl, C 7 .i 6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
  • cycloalkyl and “cycloalkenyl” represent a cyclic hydrocarbon alkyl or alkenyl, respectively, and are meant to include monocyclic (e.g., cyclopropyl, cyclobutyl, cyclohexyl), spiro (e.g., spiro [2.3]hexanyl), fused (e.g., bicyclo[4.4.0]decanyl), and bridged (e.g., bicyclo[2.2.1 ]heptanyl) hydrocarbon moieties.
  • monocyclic e.g., cyclopropyl, cyclobutyl, cyclohexyl
  • spiro e.g., spiro [2.3]hexanyl
  • fused e.g., bicyclo[4.4.0]decanyl
  • bridged e.g., bicyclo[2.2.1 ]heptanyl
  • alkoxy represents an alkyl, alkenyl or alkynyl moiety, respectively, which is covalently bonded to the adjacent atom ??? through an oxygen atom. Examples include but are not limited to methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy,
  • BOST 1803930.1 87 pentyloxy, isopentyloxy, neopentyloxy, tert-pentyloxy, hexyloxy, isohexyloxy, trifluoromethoxy and neohexyloxy.
  • R a , -S0 2 NR a R b , -NR b S0 2 R a , - NR b S0 2 NR a R b , or -P( 0)OR a OR b , wherein R a , R b , R c , and R d are each independently H, C1 -12 alkyl, C 2 -i 2 alkenyl, C2-12 alkynyl, C 6 -i 2 aryl, C 7 .i 6 aralkyl, 5-12 membered 10 heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
  • aryl represents a carbocyclic moiety containing at least one benzenoid-type ring (i.e. , may be monocyclic or polycyclic), and which where indicated may be optionally substituted with one or more substituents. Examples include but are not limited to phenyl, tolyl, dimethylphenyl, aminophenyl, anilinyl, naphthyl, anthryl, phenanthryl or biphenyl.
  • R 16 16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, wherein R a , R b , R,-, and R d are each independently H, Ci _ 1 2 alkyl, C 2 _i 2 alkenyl, C 2 _i 2 alkynyl, C 6 -i 2 aryl, C 7 _i 6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
  • aralkyl represents an aryl group attached to the adjacent atom 30 by an alkyl, alkenyl or alkynyl. Like the aryl groups, where indicated the aralkyl groups can also be optionally substituted. Examples include but are not limited to benzyl, benzhydryl, trityl, phenethyl, 3-phenylpropyl, 2-phenylpropyl, 4- phenylbutyl and naphthylmethyl.
  • R a , R b , R c , and R d are each independently H , CM 2 alkyl, C 2 _i 2 alkenyl, C 2 _i 2 alkynyl, C 6 -i 2 aryl, C 7 . 1 6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
  • heterocycle represents a non aromatic, saturated or partially 10 saturated cyclic moiety wherein said cyclic moiety is interrupted by at least one heteroatom selected from oxygen (O), sulfur (S) or nitrogen (N). Heterocycles may be monocyclic or polycyclic rings.
  • Examples include but are not limited to azetidinyl, dioxolanyl, morpholinyl, morpholino, oxetanyl, piperazinyl, piperidyl, piperidinyl, cyclopentapyrazolyl, cyclopentaoxazinyl, cyclopentafuranyl, tetrahydrofuranyl, thiazolinyl, oxazolinyl, pyranyl, aziridinyl, azepinyl, dioxazepinyl, diazepinyl, oxyranyl, oxazinyl, pyrrolidinyl, thiopyranyl, thiolanyl, pyrazolidinyl, dioxanyl, and imidazolidinyl.
  • R a , R b , R c , and R d are each independently H , CM 2 alkyl, C 2 _i 2 alkenyl, C 2 _i 2 alkynyl, C 6 -i 2 aryl, C 7 _i 6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
  • heterocycle-alkyl represents a heterocycle group attached to 30 the adjacent atom by an alkyl, alkenyl or alkynyl group. It is understood that in, for example, a 4-18 member heterocycle-alkyl moiety, the 4-18 member represent the total of the ring atoms present in the heterocycle moiety and the carbon atoms present in the alkyl, alkenyl or alkynyl group. For example, the following groups are encompassed by a 7 member heterocycle-alkyl (* represents the attachment point):
  • R a , R b , R c , and R d are each independently H , Ci_ 12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C 6 -i 2 aryl, C 7 .i 6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
  • heteroaryl represents an aromatic cyclic moiety wherein said cyclic moiety is interrupted by at least one heteroatom selected from oxygen (0), sulfur (S) or nitrogen (N).
  • Heteroaryls may be monocyclic or polycyclic rings wherein at least one ring in the polycyclic ring system is aromatic and at least one ring (not necessarily the same ring contains a heteroatom.
  • Examples include but are not limited to dithiadiazinyl, furanyl, isooxazolyl, isothiazolyl, imidazolyl, oxadiazolyl, oxazolyl, pyrazinyl, pyridazinyl, pyrimidinyl, pyridyl, pyrazolyl, pyrrolyl, thiatriazolyl, tetrazolyl, thiadiazolyl, triazolyl, thiazolyl, thienyl, tetrazinyl, thiadiazinyl, triazinyl, thiazinyl, furoisoxazolyl, imidazothiazolyl, thienoisothiazolyl, thienothiazolyl, imidazopyrazolyl, pyrrolopyrrolyl, thienothienyl, thiadiazolopyrimidinyl, thiazolothiazinyl, thiazolopyr
  • R A , R B , R C , and R D are each independently H , CM 2 alkyl, C 2 _i 2 alkenyl, C 2 _i 2 alkynyl, C 6 -i 2 aryl, C 7 .
  • thienothienyl encompasses all connectivites, including but not limited to, thieno[3,2-b]thiophene.
  • heteroaralkyl represents an optionally substituted heteroaryl group attached to the adjacent atom by an alkyl, alkenyl or alkynyl group.
  • R A , R B , R C , and R D are each independently H, d. 12 alkyl, C 2 -i 2 alkenyl, C 2 _i 2 alkynyl, C 6 -i 2 aryl, C 7 _i 6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl. It is understood that in, for example, a 6-18 member heteroaralkyl moiety, the 6-18 member represents the total of the ring atoms present in the heterocycle moiety and the carbon atoms in the alkyl, alkenyl or
  • Halogen atom or halo is specifically a fluorine atom, chlorine atom, bromine atom or iodine atom.
  • a dash (“-") that is not between two letters or symbols is used to indicate a point of attachement for a substitutent.
  • -CONR d R e is attached through the carbon of the amide.
  • a dash line (“ ") is used to indicate the point of attachment for the group.
  • A is attached through the carbon at position 1 and 4 in the following representation:
  • the sulfur atom can be at different oxidation levels, i.e., S, SO, or S0 2 . All such oxidation levels are within the scope of the present invention.
  • substituted refers to the replacement of hydrogen radicals on a carbon or nitrogen atom in a given structure with the radical of a specified substituent.
  • substituents are described above in the definitions and below in the description of compounds and examples thereof.
  • an optionally substituted group can have a substituent at each substitutable position of the group, and when more than one 30 position in any given structure can be substituted with more than one substituent selected from a specified group, the substituent can be either the same or different at every position.
  • the language, "which is unsubstituted or substituted one or more times by R 10 " means that when the group is substituted with more than one R 10 group, the R 10 groups can be different from each other.
  • a ring substituent such as a
  • BOST 1803930.1 92 heterocycle can be bound to another ring, such as a cycloalkyl, to form a spiro-bicyclic ring system, e.g., both rings share one common atom.
  • a stable compound or 10 chemically feasible compound is one that is not substantially altered when kept at a temperature of 40°C or less, in the absence of moisture or other chemically reactive conditions, for at least a week.
  • a compound represented by: also includes where the R group replaces the H on the nitrogen atom.
  • structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms.
  • compounds of this invention wherein one or more hydrogen atoms are replaced deuterium or tritium, or one or more carbon atoms are replaced by a 13 C- or 14 C-enriched carbon are within the scope of this invention.
  • Such compounds are useful, for example, as analytical tools, probes in biological assays, or antiviral compounds with improved therapeutic profile.
  • host or "patient” mean human male or female, for example child, adolescent or adult.
  • BOST 1803930.1 93 It will be appreciated that the amount of a compound of the invention required for use in treatment will vary not only with the particular compound selected but also with the route of administration, the nature of the condition for which treatment is required and the age and condition of the patient and will be ultimately at the discretion of the attendant physician or veterinarian. In general however a suitable dose will be in the range of from about 0.1 to about 750 mg/kg of body weight per day, for example, in the range of 0.5 to 60 mg/kg/day, or, for example, in the range of 1 to 20 mg/kg/day.
  • the desired dose may conveniently be presented in a single dose or as divided 10 dose administered at appropriate intervals, for example as two, three, four or more doses per day.
  • the compound is conveniently administered in unit dosage form; for example containing 10 to 1500 mg, conveniently 20 to 1000 mg, most conveniently 50 to 700 mg of active ingredient per unit dosage form.
  • the active ingredient should be administered to achieve peak plasma concentrations of the active compound of from about 1 to about 75 ⁇ , about 2 to 50 ⁇ , about 3 to about 30 ⁇ . This may be achieved, for example, by the intravenous injection 20 of a 0.1 to 5% solution of the active ingredient, optionally in saline, or orally administered as a bolus containing about 1 to about 500 mg of the active ingredient. Desirable blood levels may be maintained by a continuous infusion to provide about 0.01 to about 5.0 mg/kg/hour or by intermittent infusions containing about 0.4 to about 15 mg/kg of the active ingredient.
  • each compound may be either the same as or differ from that when the compound is used alone. Appropriate doses will be readily appreciated by 30 those skilled in the art.
  • a compound of the invention may be administered as the raw chemical it is preferable to present the active ingredient as a pharmaceutical composition.
  • the invention thus further provides a pharmaceutical composition comprising compounds of the present invention or a pharmaceutically acceptable derivative thereof together with one or more pharmaceutically acceptable
  • BOST 1803930.1 94 carriers therefore and, optionally, other therapeutic and/or prophylactic ingredients.
  • the carrier(s) must be "acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • compositions include those suitable for oral, rectal, nasal, topical (including buccal and sub-lingual), transdermal, vaginal or parenteral (including intramuscular, sub-cutaneous and intravenous) administration or in a form suitable for administration by inhalation or insufflation.
  • the formulations may, where appropriate, be conveniently presented in discrete dosage units and may be prepared by any of the 10 methods well known in the art of pharmacy. All methods include the step of bringing into association the active compound with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.
  • compositions suitable for oral administration may conveniently be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution, a suspension or as an emulsion.
  • the active ingredient may also be presented as a bolus, electuary or paste.
  • Tablets and capsules for oral administration may contain conventional excipients such as binding agents, fillers, lubricants, disintegrants, or 20 wetting agents.
  • the tablets may be coated according to methods well known in the art.
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for constitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, nonaqueous vehicles (which may include edible oils), or preservatives.
  • the compounds according to the invention may also be formulated for parenteral administration (e.g. by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume 30 infusion or in multi-dose containers with an added preservative.
  • the compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution, for constitution with a suitable vehicle, e.g. sterile, pyrogen -free water, before use.
  • the compounds according to the invention may be formulated as ointments, creams or lotions, or as a transdermal patch.
  • Such transdermal patches may contain penetration enhancers such as linalool, carvacrol, thymol, citral, menthol and t-anethole.
  • Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents.
  • Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, or colouring agents.
  • compositions suitable for topical administration in the mouth include lozenges comprising active ingredient in a flavoured base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerin or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
  • compositions suitable for rectal administration wherein the carrier is a solid are for example presented as unit dose suppositories.
  • suitable carriers include cocoa butter and other materials commonly used in the art, and the suppositories may be conveniently formed by admixture of the active compound with the softened or 20 melted carrier(s) followed by chilling and shaping in moulds.
  • compositions suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
  • the compounds of the invention may be used as a liquid spray or dispersible powder or in the form of drops.
  • Drops may be formulated with an aqueous or non-aqueous base also comprising one more dispersing agents, solubilizing agents or suspending agents.
  • Liquid sprays are conveniently delivered from pressurized 30 packs.
  • the compounds according to the invention are conveniently delivered from an insufflator, nebulizer or a pressurized pack or other convenient means of delivering an aerosol spray.
  • Pressurized packs may comprise a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • the dosage unit may be determined by providing a valve to deliver a metered amount.
  • the compounds according to the invention may take the form of a dry powder composition, for example a powder mix of the compound and a suitable powder base such as lactose or starch.
  • the powder composition may be presented in unit dosage form in, for example, capsules or cartridges or e.g. gelatin or blister packs from which the powder may be administered with the aid of an inhalator or insufflator.
  • the compounds of this invention may be prepared in light of the specification 10 using steps generally known to those of ordinary skill in the art. Those compounds may be analyzed by known methods, including but not limited to LCMS (liquid chromatography mass spectrometry) HPLC (high performance liquid chromatography) and NMR (nuclear magnetic resonance). It should be understood that the specific conditions shown below are only examples, and are not meant to limit the scope of the conditions that can be used for making compounds of this invention. Instead, this invention also includes conditions that would be apparent to those skilled in that art in light of this specification for making the compounds of this invention. Unless otherwise indicated, all variables in the following schemes are as defined herein. General Schemes:
  • Mass spec samples were analyzed on a MicroMass Quattro Micro of MicroMass LCZ 20 mass spectrometer operated in single MS mode with electrospray ionization. Samples were introduced into the mass spectrometer using chromatography. Mobile phase for all mass spec, analyses consisted of 10mM pH 7 ammonium acetate and a 1 :1 acetonitrile- methanol mixture.
  • Method A Column gradient conditions were 5%-100% acetonitrile- methanol over 3.5 mins gradient time and 4.8 mins run time on an ACE5C8 3.0 x 75mm column. Flow rate was 1.2 ml/min. Method B: Column gradient were 5%-100%
  • Rt(min) refers to the LCMS retention time, in minutes, associated with the compound. Unless otherwise indicated, the LCMS method utilized to obtain the reported retention time is as detailed 30 above. If the Rt(min) is ⁇ 5 min method A was used, if the Rt(min) is >5 min then method B was used.
  • BOST 1803930.1 98 performed using a linear gradient 20 to 90 % (CH 3 CN in water or CH 3 CN in water with 0.02%HCl) with a flow rate of 5.0 mL/minute.
  • the diethynyl intermediate is prepared in 2 steps from the commercially available bis-halogenated aryl or heterocycle.
  • a Sonogashira coupling with bis(trimethylsilyl)acetylene using Cul and palladium catalysts in solvent such as DMF in presence of base such as TEA or DIPEA give the bis-trimethyl ethynyl silane intermediate.
  • the silyl groups are hydrolyzed in presence of a base such as K 2 C0 3 in MeOH to give the expected diethynyl intermediate.
  • the Sonogashira coupling reaction is a well established method for producing acetylene containing compounds. Conditions for such coupling are well known in the art and can be found for example in the examples of the present application, in Yamagushi et al. (Synlett 1999, No.5, 549-550), or in Tykwinski et al. Angew. Chem.. Inte. Ed. 2003, 42, 1566-1568.
  • the compound is formed from the diethynyl intermediate and the iodo or bromo imidazole intermediate by a Sonogoshira coupling using Cul and palladium catalysts in solvents such as DMF in presence of base such as TEA or DIPEA.
  • the halogen is iodo or bromo. In one embodiment, the halogen is iodo.
  • Reduction of the triple bond is done under standard hydrogenation procedure as known by those of ordinary skill in the art.
  • the compound having triple bonds is dissolved in a suitable solvent such as methanol and a catalytic amount of a 1M solution 10 of HCl is added followed by a catalytic amount of 10% Pd/C.
  • the reaction mixture is stirred at RT under 1 atmosphere of hydrogen until completion of the reaction, filtered and the filtrate concentrated to dryness to afford the alkyl derivatives.
  • PG is a protecting group
  • the compound is formed from the diethynyl intermediate and the protected iodo or bromo imidazole intermediate by a Sonogoshira coupling using Cul and palladium catalysts in solvents such as DMF in presence of base such as TEA or DIPEA. Removal of the protecting group optionally followed by coupling with the complimentary functionalized X-R5' or Y-R5 group can be accomplished under standard reactioj conditions known in the art.
  • the halogen is iodo or bromo.
  • the halogen is iodo.
  • the protecting group is tert-butoxycarbonyl.
  • Mass spec samples were analyzed on a Micromass Platform LCZ mass spectrometer operated in single MS mode with electrospray ionization. Samples were introduced into the mass spectrometer using chromatography. Mobile phase for all mass spec, analyses consisted of H 2 O+0.01%TFA and CH 3 CN+0.01%TFA. Method: Column gradient conditions were 5%-85%CH 3 CN+0.01%TFA in 20 minutes gradient time on a 20 SymmetryShield RP18 3.5um, 2.1x50mm column. Flow rate was 0.5mL/minute. As used herein, the term "Rt(minute)" refers to the LCMS retention time, in minutes, associated with the compound. Unless otherwise indicated, the LCMS method utilized to obtain the reported retention time is detailed above.
  • (2S)-3-Methyl-2-methylamino-butanoic acid (5 g, 38.12 mmol) is added to a stirring solution of sodium hydroxide (76.2 mL of 1 M, 76.24 mmol). After complete dissolution, disodium carbonate (2.1 g, 19.82 mmol) is added followed by methyl chloroformate (3.18 mL, 41.17 mmol) at 0°C over 40 minutes. The reaction mixture is stirred at RT for 4 20 hours, then washed with diethyl ether (2x 75 ml). The aqueous layer is cooled to 0°C, acidified to pH 1 -2 and extracted with CH 2 Cl 2 .
  • reaction mixture is stirred 2 hours at 0°C, concentrated to dryness, and the residue is purified by flash column chromatography on silica gel (25% EtOAc in Hexanes) to give tert-butyl(2S)-2-(4,5 diiodo-1 H-imidazol-2-yl)pyrrolidine-1 - carboxylate(8.6g, 83%).
  • reaction mixture is extracted by EtOAc, washed with H 2 0, dried over Na 2 S0 4 , filtered, concentrated to dryness, and purified by flash column chromatography on silica gel (0 to 10 50% EtOAc in Hexanes) to give tert-butyl (2S)-2-(5-iodo-1 H-imidazol-2-yl)pyrrolidine-1 - carboxylate (2.93g, 60%).
  • reaction mixture is stirred at -78°C for 2 hours and is allowed to warm to RT over 2 hours.
  • To this mixture is added slowly 800 mL of 1 N HCl. After stirring, the organic phase is separated, dried over Na 2 S0 4 , filtered and concentrated to dryness. The residue is purified by flash column chromatography on silica gel (0 to 20% EtOAc in Hexanes) to give tert-butyl (2S)-2-formyl-4-methyl-pyrrolidine-1 -carboxylate (48.5 g, 227.4 mmol, 85%) as a brown oil (mixture cis/trans 77/23).
  • aqueous phase is extracted a second time with CH 2 Cl 2 and the combined organic layers are washed with H 2 0, dried over Na 2 S0 4 , filtered and evaporated to dryness.
  • the residue is purified by recrystallization in EtOAc, to give 24 g of the title compound.
  • the filtrate is evaporated to dryness and the residue is purified by flash 30 column chromatography on silica gel (25 to 100% EtOAc in Hexanes) to give 9.67 g of title compound.
  • the two isolated solids are combined to give tert-butyl (2S)-2-(1 H-imidazol- 2-yl)-4-methyl-pyrrolidine-1 -carboxylate (33.67 g, 63.5%).
  • Another additional amount of isopropyl magnesium chloride in THF (423.1 ⁇ _ of 1.3 M, 0.5500 mmol) is added, and the mixture is stirred at RT for 2 hours.
  • An additional amount of isopropyl magnesium chloride in THF (423.1 ⁇ _ of 1.3 M, 0.5500 mmol) is added, and the mixture is stirred for
  • Rf 0.5 (EA:Hex, 1 :1 ).
  • reaction mixture is slowly warmed up to RT, stirred overnight, diluted with water (5 mL), and extracted with ethyl acetate (3 x 10 mL). The combined extracts are washed with a saturated aqueous sodium bicarbonate solution, brine, dried over Na 2 S0 4 , and concentrated to dryness.
  • the reaction mixture is slowly warmed up to RT, stirred overnight, diluted with water (5 mL), and extracted with EtOAc (3 x 10 mL). The combined extracts are washed with saturated aqueous sodium bicarbonate solution, brine, dried over Na 2 S0 4 , and concentrated to dryness. The residue is purified by flash column chromatography on 20 silica gel (50 to 100% EtOAc / hexanes).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Compounds represented by Formula I: (I) or pharmaceutically acceptable salts thereof, wherein A, B, B', X, Y, R1, R2, R2', R3, R3', R4 , R4', R5 , R5'm, n, or p are as defined herein, are useful for treating flaviviridae viral infections.

Description

ANALOGUES FOR THE TREATMENT OR
PREVENTION OF FLAVIVIRUS INFECTIONS
The present application claims the benefit under 35 U.S.C. § 1 19(e) of United States Provisional Application No. 61 /290,030, filed December 24, 2009, and United States Provisional Application No. 61 /316,998, filed March 24, 2010, both of which are hereby incorporated by reference in their entirety.
The present invention relates to novel compounds and a method for the treatment 10 or prevention of Flavivirus infections using novel compounds.
Hepatitis is a disease occurring throughout the world. It is generally of viral nature, although there are other causes known. Viral hepatitis is by far the most common form of hepatitis. Nearly 750,000 Americans are affected by hepatitis each year, and out of those, more than 150,000 are infected with the hepatitis C virus ("HCV").
HCV is a positive-stranded RNA virus belonging to the Flaviviridae family and has close relationship to the pestiviruses that include hog cholera virus and bovine viral diarrhea virus (BVDV). HCV is believed to replicate through the production of a complementary
20 negative-strand RNA template. Due to the lack of efficient culture replication system for the virus, HCV particles were isolated from pooled human plasma and shown, by electron microscopy, to have a diameter of about 50-60 nm. The HCV genome is a single-stranded, positive-sense RNA of about 9,600 bp coding for a polyprotein of 3009-3030 amino-acids, which is cleaved co- and post-translationally into mature viral proteins (core, E1 , E2, p7, NS2, NS3, NS4A, NS4B, NS5A, NS5B). It is believed that the structural glycoproteins, E1 and E2, are embedded into a viral lipid envelope and form stable heterodimers. It is also believed that the structural core protein interacts with the viral RNA genome to form the nucleocapsid. The nonstructural proteins designated NS2 to NS5 include proteins with enzymatic functions involved in virus replication and protein processing including a
30 polymerase, protease and helicase.
The main source of contamination with HCV is blood. The magnitude of the HCV infection as a health problem is illustrated by the prevalence among high-risk groups. For example, 60% to 90% of hemophiliacs and more than 80% of intravenous drug abusers in western countries are chronically infected with HCV. For intravenous drug abusers, the prevalence varies from about 28% to 70% depending on the population studied. The
BOST 1803930.1 1 proportion of new HCV infections associated with post-transfusion has been markedly reduced lately due to advances in diagnostic tools used to screen blood donors.
Combination of pegylated interferon plus ribavirin is the treatment of choice for chronic HCV infection. This treatment does not provide sustained viral response (SVR) in a majority of patients infected with the most prevalent genotype (1 a and 1 b). Furthermore, significant side effects prevent compliance to the current regimen and may require dose reduction or discontinuation in some patients.
10 There is therefore a great need for the development of anti-viral agents for use in treating or preventing Flavivirus infections.
In one aspect, the present invention provides a compound of formula (I):
Figure imgf000003_0001
wherein
A is C6-14 aryl, 4-12 membered heterocycle, C3.10 cycloalkyl, 5-12 membered heteroaryl, or a bond;
B and B' are each independently d-6 alkyl, C2-6 alkenyl, or C2.6 alkynyl;
C and C are each independently a 4-7 membered heterocycle;
is H, halogen, -ORa, -NRaRb, -C(=0)ORa, -C(0)NRaRb, -C(=0)OH, -C(=0)Ra, -C(=NORc)Ra, - C(=NRc)NRaRb, -NRdC(=0)NRaRb, -NRbC(=0)Ra, -NRdC(=NRc)NRaRb, -NRbC(=0)ORa, - OC(=0)NRaRb, -OC(=0)Ra, -OC(=0)ORa, hydroxyl, nitro, azido, cyano, -S(0)o-3Ra, - S02NRaRb, -NRbS02Ra, -NRbS02NRaRb, -P(=0)ORaORb, Ci-6 alkyl, C2.6 alkenyl, C2.6 alkynyl, or d.6 halogenated alkyl, or any two occurrences of can be taken together with the atoms to which they are attached to form a 5-7 cycloalkyl which is unsubstituted or substituted one or more times by R10 or a 5-7 membered heterocycle which is unsubstituted or substituted one or more times by R12,
BOST 1803930.1 2 wherein Ra, Rb, Rc, and Rd are each independently H, d.12 alkyl, C2_i2 alkenyl, C2-i2 alkynyl, d-12 aryl, C7.16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
R2 and R2' are each independently H, halogen, d-6 alkyl, -(CH2)i-3OH, -ORa, -C(=0)ORa, - C(0)NRaRb, -C(=0)OH, C6-12 aryl, or 5-12 membered heteroaryl, wherein Ra, Rb, Rc, and Rd are each independently H, d-12 alkyl, d-12 alkenyl, d-12 alkynyl, C6-i2 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
10
R3 and R3' are each independently H, d-6 alkyl, C2.6 alkenyl, or C2.6 alkynyl;
R4 and R4' are each independently H, halogen, d-6 alkyl, hydroxyl, C6-14 aryl, or d-4 alkoxy;
wherein two occurrence of R4 can be taken together with the atoms to which they are attached to form a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R10 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R12 ;
wherein two occurrence of R4' can be taken together with the atoms to which they are 20 attached to form a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R10 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R12 ;
X and Y are each independently --- , or a bond;
Figure imgf000004_0001
wherein the bond marked with an asterisk (*) indicates the attachment to the nitrogen of ring C or C ;
R5 and R5' are each independently H, d-12 alkyl which is unsubstituted or substituted one 30 or more times by R10, C2.12 alkenyl which is unsubstituted or substituted one or more times by R10, C2.12 alkynyl which is unsubstituted or substituted one or more times by R10, C6-i4 aryl which is unsubstituted or substituted one or more times by R11 , C7-16 aralkyl which is unsubstituted or substituted one or more times by R11 , 5- 12 membered heteroaryl which is unsubstituted or substituted one or more times by R11 , 6-18 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11 , 3-12 membered heterocycle which is unsubstituted or
BOST 1803930.1 3 substituted one or more times by R12, or 4-18 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12;
R6 is H, C1-6 alkyl, or halogenated d.6 alkyl, or can be merged with R6 or R6' to form a 3-12 membered heterocycle; m and n, are each independently 0, 1 , 2, 3 or 4; p is 0, 1 , 2, 3 or 4;
10
R10 is halogen, -ORa, oxo, -NRaRb, =NO-Rc , -C(=0)ORa, -C(0)NRaRb, -C(=0)OH, -C(=0)Ra, - C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=0)NRaRb, -NRbC(=0)Ra, -NRdC(=NRc)NRaRb, - NRbC(=0)ORa, -OC(=0)NRaRb, -OC(=0)Ra, -OC(=0)ORa, hydroxyl, nitro, azido, cyano, -S(0)o-3Ra, -S02NRaRb, -NRbS02Ra, -NRbS02NRaRb, or -P(=0)ORaORb, wherein Ra, Rb, Rc, and Rd are each independently H, Ci_12 alkyl, C2_i2 alkenyl, C2_i2 alkynyl, C6-i2 aryl, C7.16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
R11 is halogen, -ORa, -NRaRb, -C(=0)ORa, -C(0)NRaRb, -C(=0)OH, -C(=0)Ra, -C(=NORc)Ra, - 20 C(=NRc)NRaRb, -NRdC(=0)NRaRb, -NRbC(=0)Ra, -NRdC(=NRc)NRaRb, -NRbC(=0)ORa, -
OC(=0)NRaRb, -OC(=0)Ra, -OC(=0)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, - S02NRaRb, -NRbS02Ra, -NRbS02NRaRb, or -P(=0)ORaORb, C1 -12 alkyl, C2.12 alkenyl, C2.12 alkynyl, C6-i2 aryl, C7.16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, wherein Ra, Rb, Rc, and Rd are each independently H , CM2 alkyl, C2_i2 alkenyl, C2_i2 alkynyl, C6-i2 aryl, C7_i6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
R12 is halogen, -ORa, oxo, -NRaRb, =NO-Rc , -C(=0)ORa, -C(0)NRaRb, -C(=0)OH, -C(=0)Ra, - 30 C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=0)NRaRb, -NRbC(=0)Ra, -NRdC(=NRc)NRaRb, -
NRbC(=0)ORa, -OC(=0)NRaRb, -OC(=0)Ra, -OC(=0)ORa, hydroxyl, nitro, azido, cyano, -S(0)o-3Ra, -S02NRaRb, -NRbS02Ra, -NRbS02NRaRb, or -P(=0)ORaORb, C1 -12 alkyl, C2-n alkenyl, C2_i2 alkynyl, C6-i2 aryl, C7_i6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, wherein Ra, Rb, Rc, and Rd are each independently H, d.12 alkyl, C2.12 alkenyl, C2.12 alkynyl, C6-i2 aryl, C7.16 aralkyl, 5-12 membered heteroaryl, 6-18
BOST 1803930.1 4 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl; wherein as valency allows in B, B', Ra-Rd, R R2, R2', R3, R3', R4, R4 ', R10, R11 and R12 each of alkyl, alkenyl, alkynyl, alkoxy, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocycle, or heterocycle-alkyl is independently unsubstituted or substituted one or more times by halogen, -ORa', oxo, -NRa.Rb., =NO-RC', -C(=0)ORa>, - C(0)NRa.Rb., -C(=0)OH, -C(=0)Ra., -C(=NORc.)Ra', -C(=NRc.)NRa.Rb., -
Figure imgf000006_0001
10 OC(=0)NRa.Rb., -OC(=0)Ra., -OC(=0)ORa., hydroxyl, nitro, azido, cyano, -S(0)o-3Ra', -
S02NRa.Rb., or -NRb.S02Ra'; wherein Ra., Rb., Rc., and Rd> are each independently H or C-i-12 alkyl; or a pharmaceutically acceptable salt thereof.
In one as ect, the present invention provides a compound of formula (IA):
Figure imgf000006_0002
or a pharmaceutically acceptable salt thereof, wherein
20
each A is independently C6-i4 aryl, 4-12 membered heterocycle, C3-10 cycloalkyl, or 5-12 membered heteroaryl containing at least one heteroatom selected from the group consisting of O and S; wherein when q is 2 then both A rings are not phenyl;
B and B' are each independently absent, d.6 alkyl, C2-6 alkenyl, or C2-6 alkynyl; wherein when q is 1 then at least one of B and B' is absent;
C and C are each independently a 4-7 membered heterocycle;
BOST 1803930.1 5 is halogen, -ORa, -NRaRb, -C(=0)ORa, -C(0)NRaRb, -C(=0)OH, -C(=0)Ra, -C(=NORc)Ra, - C(=NRc)NRaRb, -NRdC(=0)NRaRb, -NRbC(=0)Ra, -NRdC(=NRc)NRaRb, -NRbC(=0)ORa, - OC(=0)NRaRb, -OC(=0)Ra, -OC(=0)ORa, hydroxyl, nitro, azido, cyano, -S(O)0- 3Ra, -S02NRaRb, -NRbS02Ra, -NRbS02NRaRb, -P(=0)ORaORb, d-6 alkyl which is unsubstituted or substituted one or more times by R10, C2.6 alkenyl which is unsubstituted or substituted one or more times by R10, C2.6 alkynyl which is unsubstituted or substituted one or more times by R10, or any two occurrences of can be taken together with the atoms to which they are attached to form a 5-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 5-7 10 membered heterocycle which is unsubstituted or substituted one or more times by R12;
Ra, Rb, Ro and Rd are each independently H, d-12 alkyl, C2.12 alkenyl, C2.12 alkynyl, d-12 aryl, C7.i6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
R2> and R2 are independently halogen, d.10 alkyl, d-6 halogenated alkyl, -(CH2)1.
6OH, -NRbC(=0)Ra, C6-12 aryl, or 5-12 membered heteroaryl;
20 R3 and R3' are each independently H, d-6 alkyl, -(CH2)i-60H , C2-6 alkenyl, or C2-6 alkynyl;
R4 and R4' are each independently halogen, -NRaRb, -C(0)NRaRbj -(CH2)i-60H, d-6 alkyl, d-6 halogenated alkyl, hydroxyl, -14 aryl, or d.6 alkoxy; wherein two occurrence of R4 can be taken together with the atoms to which they are attached to form a d 6 alkenyl which is unsubstituted or substituted one or more times by R10, a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R12; wherein two occurrence of R4' can be taken together with the atoms to which they are attached to form a d-6 alkenyl which is unsubstituted or 30 substituted one or more times by R10, a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R12 ;
X and Y are each independently
BOST 1803930.1 6 — , or a bond;
Figure imgf000008_0001
wherein the asterisk (*) indicates the point of attachment to the nitrogen of ring C or C; and R5' are each independently H, CMS alkyl which is unsubstituted or substituted one or more times by R10, C2-12 alkenyl which is unsubstituted or substituted one or more times by R10, C2-12 alkynyl which is unsubstituted or substituted one or more times by R10, C6-i4 aryl which is unsubstituted or substituted one or more times by R11 , C7.16 aralkyl which is unsubstituted or substituted one or more times by R1 1 , 5-12 membered heteroaryl which is unsubstituted or substituted one or more times by R1 1 , 6-18 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11 , 3-12 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-18 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12;
R6 is H , C1-6 alkyl, or halogenated Ci-6 alkyl; m and n, are each independently 0, 1 , 2, 3 or 4; p is 0, 1 , 2, 3 or 4;
20
q is 1 or 2; u is 0 or 1 ; s is 0 or 1 ;
R10 is halogen, -ORa, oxo, -NRaRb, =NO-Rc , -C(=0)ORa, -C(0)NRaRb, -C(=0)OH, -C(=0)R,
C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=0)NRaRb, -NRbC(=0)Ra, -NRdC(=NRc)NRaRb, - NRbC(=0)ORa, -OC(=0)NRaRb, -OC(=0)Ra, -OC(=0)ORa, hydroxy I, nitro, azido, 30 cyano, -S(O)0.3Ra, -S02NRaRb, -NRbS02Ra, -NRbS02NRaRb, or -P(=0)ORaORb,;
R11 is halogen, -ORa, -NRaRb, -C(=0)ORa, -C(0)NRaRb, -C(=0)OH, -C(=0)Ra, -C(=NORc)Ra, - C(=NRc)NRaRb, -NRdC(=0)NRaRb, -NRbC(=0)Ra, -NRdC(=NRc)NRaRb, -NRbC(=0)ORa, -
BOST 1803930.1 7 OC(=0)NRaRb, -OC(=0)Ra, -OC(=0)ORa, hydroxyl, nitro, azido, cyano, -S(0)o-3Ra, - S02NRaRb, -NRbS02Ra, -NRbS02NRaRb, or -P(=0)ORaORb, C1-12 alkyl, C2.12 alkenyl, C2.12 alkynyl, C6-i2 aryl, C7.i 6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl; and
R12 is halogen, -ORa, oxo, -NRaRb, =NO-Rc , -C(=0)ORa, -C(0)NRaRb, -C(=0)OH, -C(=0)Ra, - C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=0)NRaRb, -NRbC(=0)Ra, -NRdC(=NRc)NRaRb, - NRbC(=0)ORa, -OC(=0)NRaRb, -OC(=0)Ra, -OC(=0)ORa, hydroxyl, nitro, azido, 10 cyano, -S(0)o-3Ra, -S02NRaRb, -NRbS02Ra, -NRbS02NRaRb, or -P(=0)ORaORb, C1-12 alkyl, C2.12 alkenyl, C2.12 alkynyl, C6-i2 aryl, C7.16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
According to a further embodiment for formula (I) or (IA), the distance between C and C is between about 16 A and about 24 A in length.
In another aspect, there is provided a method for treating or preventing a Flaviviridae viral infection in a patient comprising administering to the patient a 20 therapeutically effective amount of a compound, composition or combination of the invention.
In another aspect, there is provided a pharmaceutical composition comprising at least one compound of the invention and at least one pharmaceutically acceptable carrier or excipient.
In another aspect, there is provided a combination comprising a compound of the invention and one or more additional agents chosen from viral serine protease inhibitors, viral polymerase inhibitors, viral helicase inhibitors, immunomudulating agents, 30 antioxidant agents, antibacterial agents, therapeutic vaccines, hepatoprotectant agents, antisense agent, inhibitors of HCV NS2/3 protease and inhibitors of internal ribosome entry site (IRES).
In a further aspect, there is provided the use of a compound, composition or combination of the invention for treating or preventing a Flaviviridae viral infection in a human.
BOST 1803930.1 8 In still another aspect, there is provided the use of a compound, composition or combination of the invention for the manufacture of a medicament for treating or preventing a viral Flaviviridae infection in a human.
In one embodiment, compounds of the present invention comprise those wherein the following embodiments are present, either independently or in combination.
In accordance with a further embodiment, the compounds of the present 10 invention are represented by formula (II):
Figure imgf000010_0001
or a pharmaceutically acceptable salt thereof, wherein each of A, B, B', R1, p, R2, R2>, R , R3', R4, R4', R5, R5', X, and Y, are as defined for formula (I).
In accordance with a further embodiment, the compounds of the present invention are re resented by formula (IIA):
Figure imgf000010_0002
or a pharmaceutically acceptable salt thereof, wherein each of q, u, s, A, B, B', R1, p, R2, R2., R3, R3., R4, R4., R5, R5., m, n, X, and Y, are as defined for formula 20 (IA).
In accordance with a further embodiment, the compounds of the present invention are represented by formula (III):
BOST 1803930.1 9
Figure imgf000011_0001
or a pharmaceutically acceptable salt thereof, wherein each of A, B, B', R1, p, R2, R2>, R3, R3>, R4, R4', R5, R5>, X, and Y, are as defined for formula (I).
In accordance with a further embodiment, the compounds of the present invention are represented by formula (IIIA):
Figure imgf000011_0002
or a pharmaceutically acceptable salt thereof, wherein
each A is independently C6-14 aryl, 4-12 membered heterocycle, C3-10 cycloalkyl, or 10 5-12 membered heteroaryl;
B and B' are each independently absent, d.6 alkyl, C2.6 alkenyl, or C2.6 alkynyl; wherein when q is 1 then at least one of B and B' is absent;
R1 is halogen, -ORa, -NRaRb, -C(=0)ORa, -C(0)NRaRb,
Figure imgf000011_0003
NRdC(=0)NRaRb, -NRbC(=0)Ra, -NRdC(=NRc)NRaRb, -NRbC(=0)ORa, - OC(=0)NRaRb, -OC(=0)Ra, -OC(=0)ORa, hydroxyl, nitro, azido, cyano, -S(O)0- 3Ra, -S02NRaRb, -NRbS02Ra, -NRbS02NRaRb, -P(=0)ORaORb, C1-6 alkyl which is unsubstituted or substituted one or more times by R10, C2.6 alkenyl which is unsubstituted or substituted one or more times by R10, C2.6 alkynyl which is 20 unsubstituted or substituted one or more times by R10, or any two occurrences of can be taken together with the atoms to which they are attached to form a 5-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 5-7 membered heterocycle which is unsubstituted or substituted one or more times by R12;
BOST 1803930.1 i n Ra, Rb, Rc, and RdRa-Rd are each independently H, d-12 alkyl, C2.12 alkenyl, C2.12 alkynyl, C6.n aryl, C7.16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle- alkyl;
R2> and R2 are independently H, halogen, CMO alkyl, Ci-6 halogenated alkyl, -(CH2)1.
6OH, -NRbC(=0)Ra C6-12 aryl, or 5-12 membered heteroaryl;
R3 and R3' are each independently H, d.6 alkyl, -(CH2)i-60H, C2-6 alkenyl, or C2-6 alkynyl;
R4 and R4' are each independently -NRaRb, -C(0)NRaRb, -(CH2)i-60H, Ci_6 alkyl, Ci_6 10 halogenated alkyl, C6-14 aryl, or Ci-6 alkoxy; wherein two occurrence of R4
can be taken together with the atoms to which they are attached to form a d-6 alkenyl which is unsubstituted or substituted one or more times by R10, a 4-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R12 ; wherein two occurrence of R4' can be taken together with the atoms to which they are attached to form a Ci_6 alkenyl which is unsubstituted or substituted one or more times by R10, a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R12 ; 20 wherein Ra-Rb are each independently H, CM2 alkyl, C2_i2 alkenyl, C2_i2
alkynyl, C6-i2 aryl, C7_i6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle- alkyl;
X and Y are each independently — , or a bond;
Figure imgf000012_0001
wherein the asterisk (*) indicates the point of attachment to the nitrogen of ring C or C;
R5 and R5' are each independently H , CMS alkyl which is unsubstituted or substituted one or more times by R10, C2.12 alkenyl which is unsubstituted or substituted one or more times by R10, C2.12 alkynyl which is unsubstituted or substituted one or more times by R10, C6-i4 aryl which is unsubstituted or substituted one or more times by R11 , C7_i6 aralkyl which is unsubstituted or substituted one or more times by R11 , 5-12 membered heteroaryl which is unsubstituted or substituted one or more times by R1 1 , 6-18 membered
BOST 1803930.1 1 1 heteroaralkyl which is unsubstituted or substituted one or more times by R11 ,
3- 12 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-18 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12;
R6 is H, C1-6 alkyl, or halogenated C1 6 alkyl;
m and n are a positive integer and when combined are 1 , 2, 3, or 4;, provided that each of m and n are not 3 or 4;
p is 0, 1 , 2, 3 or 4;
q is 1 or 2;
u is 0 or 1 ;
s is 0 or 1 ;
R10 is halogen, -ORa, oxo, -NRaRb, =NO-Rc , -C(=0)ORa, -C(0)NRaRb, C(=0)OH, - C(=0)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=0)NRaRb, - NRbC(=0)Ra, - N RdC(=NRc)NRaRb, - NRbC(=0)ORa, -OC(=0)NRaRb, -OC(=0)Ra, -OC(=0)ORa, hydroxyl, nitro, azido, cyano, -S(0)o-3Ra, -S02NRaRb, - NRbS02Ra, -NRbS02NRaRb, or - P(=0)ORaORb, ;
R11 is halogen, -ORa, -NRaRb, -C(=0)ORa, -C(0)NRaRb, -C(=0)OH, -C(=0)Ra, - C(=NORc)Ra, -C(=NRc)NRaRb, -N RdC(=0)NRaRb, -N RbC(=0)Ra, -NRdC(=NRc)NRaRb, -NRbC(=0)ORa, -OC(=0)NRaRb, -OC(=0)Ra, -OC(=0)ORa, hydroxyl, nitro, azido, cyano, -S(0)o-3Ra, -S02NRaRb, - NRbS02Ra, - NRbS02NRaRb, or - P(=0)ORaORb, C1 -12 alkyl, C2_i 2 alkenyl, C2_i2 alkynyl, C6-i2 aryl, C7.i6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or
4- 18 membered heterocycle-alkyl; and
R12 is halogen, -ORa, oxo, -NRaRb, =NO- Rc , -C(=0)ORa, -C(0)NRaRb, -C(=0)OH, - C(=0)Ra, -C(=NORc)Ra, -C(=NRc)N RaRb, -NRdC(=0)NRaRb, -N RbC(=0)Ra, - NRdC(=N Rc)NRaRb, - NRbC(=0)ORa, -OC(=0)NRaRb, -OC(=0)Ra, -OC(=0)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -S02NRaRb, - NRbS02Ra, - NRbS02NRaRb, or -P(=0)ORaORb, d.12 alkyl, C2.12 alkenyl, C2.12 alkynyl, C6-i2 aryl, C7.16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
In accordance with a further embodiment, the compounds of the present invention are represented by formula (NIB):
BOST 1803930.1 12
Figure imgf000014_0001
pharmaceutically acceptable salt thereof, wherein each A is independently C6-14 aryl, 4-12 membered heterocycle, C3-10 cycloalkyl, or 5-12 membered heteroaryl wherein when q is 2 then both A rings are not phenyl;
B and B' are each independently absent, d.6 alkyl, C2-6 alkenyl, or C2.6 alkynyl; wherein q is 1 then at least one of B and B' is absent;
Ri is halogen, -ORa, -NRaRb, -C(=0)ORa, -C(0)NRaRb,
C(=0)OH, -C(=0)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb,
NRdC(=0)NRaRb, -NRbC(=0)Ra, -NRdC(=NRc)NRaRb, -NRbC(=0)ORa, - OC(=0)NRaRb, -OC(=0)Ra, -OC(=0)ORa, hydroxyl, nitro, azido, cyano, -S(O)0. 3Ra, -S02NRaRb, -NRbS02Ra, -NRbS02NRaRb, -P(=0)ORaORb, Ci-6 alkyl which is unsubstituted or substituted one or more times by R10, C2.6 alkenyl which is unsubstituted or substituted one or more times by R10, C2.6 alkynyl which is unsubstituted or substituted one or more times by R10, or any two occurrences of can be taken together with the atoms to which they are attached to form a 5-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 5-7 membered heterocycle which is unsubstituted or substituted one or more times by R12;
Ra, Rb, Ro and Rd are each independently H, d.12 alkyl, C2.12 alkenyl, C2.12 alkynyl, C6-12 aryl, C7.16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle- alkyl;
BOST 1803930.1 13 R2> and R2 are independently H, halogen, d-10 alkyl, d-6 halogenated alkyl, -(CH2)1.
6OH, -NRbC(=0)Ra C6-12 aryl, or 5-12 membered heteroaryl;
R3 and R3' are each independently H, d-6 alkyl, -(CH2)i-60H, C2-6 alkenyl, or C2-6 alkynyl;
R4 and R4' are each independently halogen, -NRaRb, -C(0)NRaRbj -(CH2)i-60H, d-6 alkyl, d-6 halogenated alkyl, hydroxyl, or d-6 alkoxy; wherein two occurrence of R4 can be taken together with the atoms to which they are attached to form a d-6 alkenyl which is unsubstituted or substituted one or more times by R10, a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R12 ; wherein two occurrence of R4' can be taken together with the atoms to which they are attached to form a d-6 alkenyl which is unsubstituted or substituted one or more times by R10, a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R12 ; wherein Ra-Rb are each independently H, d-12 alkyl, C2-i2 alkenyl, C2-i2 alkynyl, C6-i2 aryl, C7.i6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
X and Y are each independently
or a bond;
Figure imgf000015_0001
wherein the asterisk (*) indicates the point of attachment to the nitrogen of ring C or C;
R5 and R5' are each independently H, -ie alkyl which is unsubstituted or substituted one or more times by R10, C2-i2 alkenyl which is unsubstituted or 30 substituted one or more times by R10, C2-i2 alkynyl which is unsubstituted or substituted one or more times by R10, C6-i4 aryl which is unsubstituted or substituted one or more times by R11, -16 aralkyl which is unsubstituted or substituted one or more times by R11, 5-12 membered heteroaryl which is
BOST 1803930.1 14 unsubstituted or substituted one or more times by R11 , 6-18 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11 , 3-12 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-18 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12;
R6 is H, C1 -6 alkyl, or halogenated Ci-6 alkyl; m and n combined are each independently 1 , 2, 3, or 4; p is 0, 1 , 2, 3 or 4; q is 1 or 2; u is 0 or 1 ; s is 0 or 1 ;
R10 is halogen, -ORa, oxo, -NRaRb, =NO-Rc , -C(=0)ORa, -C(0)NRaRb, -C(=0)OH, -
Figure imgf000016_0001
NRdC(=NRc)NRaRb, -NRbC(=0)ORa, -OC(=0)NRaRb, -OC(=0)Ra, -OC(=0)ORa, hydroxyl, nitro, azido, cyano, -S(O)0.3Ra, -S02NRaRb, -NRbS02Ra, -NRbS02NRaRb, or -P(=0)ORaORb, ;
R11 is halogen, -ORa, -NRaRb, -C(=0)ORa, -C(0)NRaRb, -C(=0)OH, -C(=0)Ra, - C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=0)NRaRb, -NRbC(=0)Ra, -NRdC(=NRc)NRaRb, - NRbC(=0)ORa, -OC(=0)NRaRb, -OC(=0)Ra, -OC(=0)ORa, hydroxyl, nitro, azido, cyano, -S(O)0.3Ra, -S02NRaRb, -NRbS02Ra, -NRbS02NRaRb, or -P(=0)ORaORb, d.12 alkyl, C2.12 alkenyl, C2.12 alkynyl, C6-i2 aryl, C7.16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4- 18 membered heterocycle-alkyl; and
R12 is halogen, -ORa, oxo, -NRaRb, =NO-Rc , -C(=0)ORa, -C(0)NRaRb, -C(=0)OH, - C(=0)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=0)NRaRb, -NRbC(=0)Ra, - NRdC(=NRc)NRaRb, -NRbC(=0)ORa, -OC(=0)NRaRb, -OC(=0)Ra, -OC(=0)ORa, hydroxyl, nitro, azido, cyano, -S(O)0.3Ra, -S02NRaRb, -NRbS02Ra, -NRbS02NRaRb,
BOST 1803930.1 15 or -P(=0)ORaORb, C1 -12 alkyl, C2-i2 alkenyl, C2.12 alkynyl, C6.n aryl, C7.16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
It is to be understood that unless sepcifcally stated otherwise, each of the further embodiments disclosed herein for the variables A, B, B', R1 ; p, q, R2, R2., s, u, R3, R3>, R4, R4>, m, n, R5, R5., X, Y, Ra, Rb, Rc, Rd, R10, Rn , and R12, applies to any and all of the structural formulas in which the variable apprears.
10 In accordance with a further embodiment, each A is independently cyclopropyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, piperazinyl, piperadinyl, phenyl, naphthalenyl, thienyl, furanyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, oxazolyl, oxadiazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, indolyl, indazolyl, benzimidazolyl, benzoxazolyl, benzodioxolyl, benzothiazolyl, benzothiadiazolyl, dihydrobenzodioxine, thienofuranyl, thienothienyl, thienopyrrolyl, quinolinyl, quinoxalinyl, quinazolinyl, cinnolinyl, or triazolyl; and wherein each A is independently substituted with (Ri )p.
In accordance with a further embodiment, each A is independently cyclopropyl, 20 cyclohexyl, phenyl, or naphthalenyl, wherein each A is independently substituted with
In accordance with a further embodiment, A is independently selected from the consisting of:
BOST 1803930.1 16
Figure imgf000018_0001
t1 + t2 = p.
In accordance with a further embodiment, A is independently selected from the consisting of:
BOST 1803930.1 17
Figure imgf000019_0001
Figure imgf000020_0001
and
t1 + t2 = p.
In accordance with a further embodiment, each A is independently a 5-12 membered heteroaryl wherein the heteroatom(s) are selected from the group consisting of oxygen and sulphur; wherein each A is independently substituted with (Ri )p.
BOST 1803930.1 19 In accordance with a further embodiment, A is independently piperazinyl, piperadinyl, thienyl, furanyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, thiadiazolyl, pyrrolidinyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzoxazolyl, benzodioxolyl, benzothiazolyl, benzothiadiazolyl, dihydrobenzodioxinyl, thienofuranyl, thienothienyl, quinolinyl, or triazolyl.
According to a further embodiment, A is phenyl, thiophene, pyridine, pyrimidine, triazole, naphthalene, thieno[3,2-b]thiophene, benzo[c][1 ,2,5]thiadiazole, quinoline, or benzo[b]thiophene.
10
According to a further embodiment, A is phenyl, thiophene, thieno[3,2- b]thiophene, pyridine, pyrimidine, naphthyl, benzo[1 ,3]dioxole, benzooxazole, or triazole.
According to a further embodiment, A is phenyl, thiophene, thieno[3,2- b]thiophene, naphtyl, benzo[1 ,3]dioxole, or benzooxazole.
According to a further embodiment, A is phenyl, thiophene, pyridine, pyrimidine, or triazole.
20
According to a further embodiment, A is phenyl or thieno[3,2-b]thiophene.
According to a further embodiment, A is phenyl or thioph
In accordance with a further em
Figure imgf000021_0001
According to a further embo
Figure imgf000021_0002
30
According to a further embodiment, A is
BOST 1803930.1 20
Figure imgf000022_0001
According to a further embodiment, A is
Figure imgf000022_0002
According to a further embodiment, A is
Figure imgf000022_0003
10 According to a further embodiment, A in formula (I), (II), (III), (IV) or (V) is a bond.
According to a further embodiment, B and B' in formula (IA), (IIA), (IIIA), (1MB), (IVA), or (VA) are independently absent, d.6 alkyl or C2-6 alkynyl.
According to a further embodiment, B and B' in formula (IA), (IIA), (IIIA), (1MB), (IVA), or (VA) are independently absent, -(CH2)2- or -(C≡C)-.
According to a further embodiment, B and B' in formula (IA), (IIA), (IIIA), (1MB), 20 (IVA), or (VA) are independently absent or -(C≡C)-.
According to a further embodiment,
Figure imgf000022_0004
in formula (I),
(II), (III), (IV) or (V) is selected from the group consisting of:
BOST 1803930.1 21
Figure imgf000023_0001
Figure imgf000023_0002
— B'
According to a further embodiment, (^i )p ' 9 in formula (IA),
(IIA), (IIIA), (IIIB), (IVA), or (VA) is selected from the group consisting of:
Figure imgf000023_0003
(RI)P · (Ri)P ' and (Ri)p
BOST 1803930.1 22 — B'
According to a further embodiment, (Ri )p 9 in formula (IA),
(IIA), (IIIA), (IIIB), (IVA), or (VA) is selected from the group consisting of:
Figure imgf000024_0001
BOST 1803930.1 23
Figure imgf000025_0001
Figure imgf000025_0002
BOST 1803930.1 24
Figure imgf000026_0001
-N N-
(Rl)p and t1 + t2 = p.
According to a further embodiment,
Figure imgf000026_0002
in formula (IA),
(IIA), (IIIA), (IIIB), (IVA), or (VA) is selected from the group consisting of:
BOST 1803930.1 25
Figure imgf000027_0001
BOST 1803930.1 26 — B'
According to a further embodiment, (^i )p ' 9 in formula (IA),
(IIA), (IIIA), (IIIB), (IVA), or (VA) is selected from the group consisting of:
Figure imgf000028_0001
t1 + t2 = p.
According to a further embodiment,
Figure imgf000028_0002
in formula (IA), (IIA), (IIIA), (1MB), (IVA), or (VA
Figure imgf000028_0003
10
t1 + t2 = p.
According to a further embodiment,
Figure imgf000028_0004
in formula (IA), (IIA), (IIIA), (IIIB), (IVA), or (VA) is:
Figure imgf000028_0005
BOST 1803930.1 27 According to a further embodiment,
Figure imgf000029_0001
in formula (IA), (MA), (IMA), (1MB), (IVA), or (VA) is:
Figure imgf000029_0002
t1 + t2 = p.
According to a further embodiment,
Figure imgf000029_0003
in formula (IA), (MA), (IMA), (1MB), (IVA), or (VA) is:
Figure imgf000029_0004
According to a further embodiment, B and B' are each independently C2-6 alkynyl
10 or d-6 alkyl.
According to a further embodiment, B and B' are each independently -(C≡C)- or
(CH2)2-.
According to a further embodiment, B and B' are each -(CH2)2-.
According to a further embodiment, B and B' are each -(C≡C)-.
According to a further embodiment, m or n is 2.
20
According to a further embodiment, m or n is 1.
BOST 1803930.1 28 According to a further embodiment, m and n are 1 .
According to a further embodiment, one of m or n is 1 and the other of m and n are independently 1 or 2.
According to a further embodiment, p is 2.
According to a further embodiment, p is 1 .
10 According to a further embodiment, X and Y are
, or a bond.
Figure imgf000030_0001
According to a further embodime d Y are each
Figure imgf000030_0002
According to a further embodime are each
wherein the bond marked with an asterisk (*) indicates the attachment to the nitrogen.
20
According to a further embodiment, R4 and R4' in formula (I ), (IA), (II ), (I IA), or (1 M B) are each independently halogen, -NRaRb, -C(0)NRaRb, -(CH2)i-60H, Ci_6 alkyl, Ci_6 halogenated alkyl, hydroxyl, C6-14 aryl, or d-6 alkoxy; wherein two occurrence of R4 can be taken together with the atoms to which they are attached to form a d.6 alkenyl which is unsubstituted or substituted one or more times by R10, a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R12 ; wherein two occurrence of R4' can be taken together with the atoms to which they are attached to form a Ci_6 alkenyl which is unsubstituted or substituted one or more times by R10, a 3-7 cycloalkyl 30 which is unsubstituted or substituted one or more times by R11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R12.
BOST 1803930.1 29 According to a further embodiment, R4 and R4' in formula (I), (IA), (II), or (I I A) are each independently halogen, methyl, ethyl, isopropyl, di-fluoromethyl, di-fluoroethyl, trifluoromethyl, tri-fluoroethyl, -CH2OH, -NRaNb, t-butoxy-, or hydroxyl; or two R4 groups together with the atoms to which they are attached form fused cyclopropyl, spiro
cyclopropyl or , two R4' groups together atoms to which they are
attached form f
Figure imgf000031_0001
used cyclopropyl, spiro cyclopropyl o .
According to a further embodiment, R4 and R4' in formula (I), (IA), (II), (IIA), or (1MB) are each independently halogen, methyl, ethyl, isopropyl, di-fluoromethyl, di- 10 fluoroethyl, trifluoromethyl, tri-fluoroethyl, -CH2OH, -NRaNb, t-butoxy-, or hydroxyl; or s together with the atoms to which they are attached form spiro cyclopropyl
Figure imgf000031_0002
two R4' groups together with the atoms to which they are attached form
spiro cyclopropyl or
Figure imgf000031_0003
.
According to a further embodiment, R4 and R4' in formula (I), (IA), (II), (IIA), or (1MB) are each independently methyl, ethyl, isopropyl, di-fluoromethyl, di-fluoroethyl, trifluoromethyl, tri-fluoroethyl, -CH2OH, -NRaNb or t-butoxy-; or two together
with the atoms to which they are attached form spiro cyclopropyl or
Figure imgf000031_0004
, two R4' roups together with the atoms to which they are attached form spiro cyclopropyl or
Figure imgf000031_0005
According to a further embodiment, R4 and R4' in formula (I), (IA), (II), (IIA), (IIIA), (1MB), (IVA), or (VA) are each independently methyl, ethyl, isopropyl, di-fluoromethyl, di- fluoroethyl, trifluoromethyl, tri-fluoroethyl, -CH2OH, -NRaNb or t-butoxy-; or two R4
BOST 1803930.1 30 groups together with the atoms to which they are attached fo , or two R4'
groups together with the atoms to which they are attached form
Figure imgf000032_0001
According to a further embodiment, in formula (I), (IA), (II), (IIA), (MIA), (1MB), IVA), or (VA) two R4 groups together with the atoms to which they are attached form
and two R4' groups together with the atoms to which they are attached form
Figure imgf000032_0002
According to a further embodiment, R4 and R4' in formula (I), (IA), (II), or (IIA) are
10 each independently methyl, ethyl, methoxy, di-fluoromethyl, trifluoromethyl, or two R4 groups together with the atoms to which they are attached form fused cyclopropyl or spiro cyclopropyl or two R4' groups together with the atoms to which they are attached form fused cyclopropyl or spiro cyclopropyl.
According to a further embodiment, R4 and R4' in formula (I), (IA), (II), (IIA), or (1MB) are each independently methyl, ethyl, methoxy, di-fluoromethyl, trifluoromethyl, or two R4 groups together with the atoms to which they are attached form spiro cyclopropyl or two R4' groups together with the atoms to which they are attached form spiro cyclopropyl.
20
According to a further embodiment, R4 and R4' are each independently H, halogen, d-6 alkyl, hydroxyl, phenyl, or d-4 alkoxy.
According to a further embodiment, R4 and R4' are each independently - -NRaRb, -C(0)NRaRb> -(CH2)i-60H, d-6 alkyl, d-6 halogenated alkyl, C6-i4 aryl, or d-6 alkoxy.
According to a further embodiment, R4 and R4' are each independently halogen, methyl, ethyl, isopropyl, di-fluoromethyl, di-fluoroethyl, trifluoromethyl, tri- fluoroethyl, -CH2OH, -NRaNb, t-butoxy-, or hydroxyl.
30
BOST 1803930.1 31 According to a further embodiment, R4 and R4' are each independently halogen, methyl, ethyl, isopropyl, di-fluoromethyl, di-fluoroethyl, trifluoromethyl, tri- fluoroethyl, -CH2OH, t-butoxy-, or hydroxyl.
According to a further embodiment, R4 and R4' are each independently methyl, ethyl, isopropyl, di-fluoromethyl, di-fluoroethyl, trifluoromethyl, tri-fluoroethyl, - CH2OH, -NRaNb, or t-butoxy.
According to a further embodiment, R4 and R4' are each independently methyl, 10 ethyl, isopropyl, di-fluoromethyl, di-fluoroethyl, trifluoromethyl, tri-fluoroethyl, or - CH2OH.
According to a further embodiment, R4 and R4' are each independently methyl, ethyl, methoxy, di-fluoromethyl, or trifluoromethyl.
According to a further embodiment, R4 and R4' are each independently H, halogen, methyl, ethyl, t-butoxy-, or hydroxyl.
According to a further embodiment, R4 and R4' are each H.
20
According to a further embodiment, R4 and R4' are each fluoro. According to a further embodiment, R4 and R4' are C1-6 alkyl. According to a further embodiment, R4 and R4' are each Ci-6 haloalkyl. According to a further embodiment, R4 and R4' are methyl or ethyl. According to a further embodiment, R4 and R4' are each methyl.
30
According to a further embodiment, R4 and R4' are each ethyl.
According to a further embodiment, R4 and R4' are each methoxy.
According to a further embodiment, R4 and R4' are each independently halogen, Ci-6 alkyl, or d-6 alkoxy.
BOST 1803930.1 32 According to a further embodiment, one of R4 and R4' is hydrogen and the other of R4 and R4' is C1 6 alkyl.
According to a further embodiment, R3 and R3' are H or methyl.
According to a further embodiment, R3 and R3' are each H.
According to a further embodiment, R and R ' are methyl.
According to a further embodiment, R^ is H, halogen, -ORa, -NRaRb, -C(=0)ORa, - C(0)NRaRb, -C(=0)OH, -C(=0)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=0)NRaRb, - NRbC(=0)Ra, -NRdC(=NRc)NRaRb, -NRbC(=0)ORa, -OC(=0)NRaRb, -OC(=0)Ra, -OC(=0)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -S02NRaRb, -NRbS02Ra, -NRbS02NRaRb, - P(=0)ORaORb, C1-6 alkyl, C2.6 alkenyl, C2.6 alkynyl, or Ci-6 halogenated alkyl or any two occurrences of can be taken together with the atoms to which they are attached to form a 5-7 cycloalkyl which is unsubstituted or substituted one or more times by R10 or a 5-7 membered heterocycle which is unsubstituted or substituted one or more times by R12.
According to a further embodiment, is H, halogen, -ORa, -NRaRb, -C(=0)ORa, - C(0)NRaRb, -C(=0)OH, -NRbC(=0)Ra, -hydroxyl, nitro, cyano, -S(O)0.3Ra, C1-6 alkyl, C2.6 alkenyl, C2.6 alkynyl, or d.6 halogenated alkyl.
According to a further embodiment, R^ is halogen, d. alkyl, hydroxyl, cyano, or C1-3 alkoxy, or methoxycarbonyl.
According to a further embodiment, R^ is halogen, Ci_4 alkyl which is unsubstituted or substituted one or more times by R10, -C(=0)ORa, -C(0)NRaRb, hydroxyl, cyano, or d.3 alkoxy.
According to a further embodiment, R^ is chloro, fluoro, bromo, methyl, ethyl, propyl, butyl, -CH2OH, difluoromethyl, trifluoromethyl, hydroxyl, cyano, methoxy, or methoxycarbonyl.
According to a further embodiment, R^ is chloro, fluoro, methyl, hydroxyl, cyano, trifluoromethyl, methoxy, or methoxycarbonyl.
BOST 1803930.1 33 According to a further embodiment, R^ is halogen, d-3 alkyl, hydroxyl, cyano, or C 1 -3 alkoxy.
According to a further embodiment, is chloro, fluoro, methyl, hydroxyl, cyano, or methoxy.
According to a further embodiment, is methyl
10 According to a further embodiment, is H.
According to a further embodiment, R2 and R2' are each independently H, halogen, d-6 alkyl, -(CH2)i -3OH, -ORa, -C(=0)ORa, -C(0)NRaRb, -C(=0)OH , C6.12 aryl, or 5-12 membered heteroaryl, wherein Ra, Rb, Rc, and Rd are each independently H, d.12 alkyl, C6. 12 aryl, C7.16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
According to a further embodiment, R2 and R2' are each independently H, halogen, d-6 alkyl, -(CH^OH, -ORa, -C(=0)ORa, -C(0)NRaRb, -C(=0)OH, phenyl, or 5-6 20 membered heteroaryl, wherein Ra, Rb, Rc, and Rd are each independently H, d_12 alkyl, C6.
12 aryl, C7.16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
According to a further embodiment, R2 and R2' are each independently H, iodo, methyl, hydroxy methyl, trifluoromethyl, or thienothienyl.
According to a further embodiment, R2' is independently methyl, trifluoromethyl, iodo, CH2OH, or NHC(0)CH3.
30 According to a further embodiment, R2 and R2' are each methyl.
According to a further embodiment, R2 and R2' are each iodo.
According to a further embodiment, s is 0.
According to a further embodiment,
BOST 1803930.1 34 According to a further embodiment, R2 and R2' are each H. According to a further embodiment, R6 is H or C1-3 alkyl.
According to a further embodiment, R5 and R5' are each independently Ci-8 alkyl which is unsubstituted or substituted one or more times by R10, C2.8 alkenyl which is unsubstituted or substituted one or more times by R10, C2.8 alkynyl which is unsubstituted or substituted one or more times by R10, phenyl which is unsubstituted or substituted one or more times by R11 , C7.8 aralkyl which is unsubstituted or substituted one or more times 10 by R11 , 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R11 , 6-8 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11 , 3-6 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-8 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12.
According to a further embodiment, R5 and R5' are each independently Ci-6 alkyl which is unsubstituted or substituted one or more times by R10, C2.6 alkenyl which is unsubstituted or substituted one or more times by R10, C2.6 alkynyl which is unsubstituted or substituted one or more times by R10, phenyl which is unsubstituted or substituted one 20 or more times by R11 , benzyl which is unsubstituted or substituted one or more times by R11 , 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R11 , 6-7 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11 , 5-6 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 6-7 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12.
According to a further embodiment, R5 and R5' are each independently Ci-6 alkyl which is unsubstituted or substituted one or more times by R10, C2.6 alkenyl which is unsubstituted or substituted one or more times by R10, or C2.6 alkynyl which is 30 unsubstituted or substituted one or more times by R10.
According to a further embodiment, R5 and R5' are each independently Ci_12 alkyl which is unsubstituted or substituted one or more times by R10.
According to a further embodiment, R5 and R5' are each independently methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, 2-methylbutane, 3-
BOST 1803930.1 35 methylbutane, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cyclohexyl(CH2)-, which in each case is unsubstituted or substituted one or more times by R10.
According to a further embodiment, R5 and R5' are each independently methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, 2-methylbutane, 3- methylbutane, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cyclohexyl(CH2)-.
According to a further embodiment, R5 and R5' are each independently isopropyl which is unsubstituted or substituted one or more times by R10.
10
According to a further embodiment, R5 and R5' are each independently isopropyl which is unsubstituted or substituted one or more times by -OCH3.
According to a further embodiment, R5 and R5' are each isopropyl.
According to a further embodiment, R5 and R5' are each H or tert-butyl.
According to a further embodiment, R5 and R5' are each independently phenyl which is unsubstituted or substituted one or more times by R11.
20
According to a further embodiment, R5 and R5' are each independently benzyl which is unsubstituted or substituted one or more times by R11.
According to a further embodiment, R10 is halogen, -ORa, oxo, -NRaRb, =NO-Rc , - C(=0)ORa, -C(0)NRaRb, -C(=0)OH, -C(=0)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=0)NRaRb, -NRbC(=0)Ra, -NRdC(=NRc)NRaRb, -NRbC(=0)ORa, -OC(=0)NRaRb, -OC(=0)Ra, -OC(=0)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3 Ra, -S02NRaRb, -NRbS02Ra, or -NRbS02NRaRb, wherein Ra -Rd are each independently H, d.12 alkyl, C2-i2 alkenyl, C2-i 2 alkynyl, Cb.n aryl, C7.16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered 30 heterocycle, or 4-18 membered heterocycle-alkyl.
According to a further embodiment, R10 is -NRaRb, -NRdC(=0)NRaRb, -NRbC(=0)Ra, - NRdC(=NRc)NRaRb, -NRbC(=0)ORa, -NRbS02Ra, or -NRbS02NRaRb, wherein Ra, Rb, Rc, and Rd are each independently H, d.12 alkyl, C2-i2 alkenyl, C2-i2 alkynyl, Cb.n aryl, C7.16 aralkyl, 5- 12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
BOST 1803930.1 According to a further embodiment, R10 is -NRaRb, -NRdC(=0)NRaRb, -NRbC(=0)Ra, - NRbC(=0)ORa, or -NRbS02Ra, wherein Ra,Rb, and Rd are each independently H, Ci-i2 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-i2 aryl, C7.i6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle- alkyl.
According to a further embodiment, R10 is -NRaRb or -NRdC(=0)NRaRb, wherein Ra and Rb are each independently H, Ci_12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-i2 aryl, C7_i6 10 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
According to a further embodiment, R10 is -NRdC(=0)NRaRb, wherein Ra,Rb, are each independently H, Ci_12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-i2 aryl, C7_i6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4- 18 membered heterocycle-alkyl.
According to a further embodiment, R10 is halogen, -ORa, oxo, -C(=0)ORa, - C(0)NRaRb, -C(=0)OH, -C(=0)Ra, -OC(=0)NRaRb, -OC(=0)Ra, -OC(=0)ORa, hydroxy I, cyano, 20 wherein Ra-Rb are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-i2 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
According to a further embodiment, R10 is halogen, -ORa, oxo, -C(=0)ORa, - C(0)NRaRb, -C(=0)OH, -OC(=0)NRaRb, hydroxyl, or cyano, wherein Ra-Rb are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-i2 aryl, C7_i6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4- 18 membered heterocycle-alkyl.
30 According to a further embodiment, R10 is halogen, d-6 alkoxy, hydroxyl, or NH2.
According to a further embodiment, R10 is halogen, hydroxyl, or NH2.
According to a further embodiment, R10 is halogen.
BOST 1803930.1 37 According to a further embodiment, R11 is halogen, -ORa, -NRaRb, -C(=0)ORa, - C(0)NRaRb, -C(=0)OH, -C(=0)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=0)NRaRb, - NRbC(=0)Ra, -NRdC(=NRc)NRaRb, -NRbC(=0)ORa, -OC(=0)NRaRb, -OC(=0)Ra, -OC(=0)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -S02NRaRb, -NRbS02Ra, or -NRbS02NRaRb, d-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-i2 aryl, C7.i6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle- alkyl, wherein Ra, Rb, Rc, and Rd are each independently H, d-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, d-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
10
According to a further embodiment, R11 is halogen, -ORa, -NRaRb, -C(=0)ORa, - C(0)NRaRb, -C(=0)OH, -C(=0)Ra, -NRdC(=0)NRaRb, -NRbC(=0)Ra, -NRbC(=0)ORa, - OC(=0)NRaRb, -OC(=0)Ra, -OC(=0)ORa, hydroxyl, cyano, -S02NRaRb, -NRbS02Ra, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7.8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl, wherein Ra, Rb, and Rd are each independently are each independently H, d-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, d-12 aryl, C7.16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
20 According to a further embodiment, R11 is halogen, -ORa, -NRaRb, -C(0)NRaRb, -
C(=0)OH, -C(=0)Ra, -NRdC(=0)NRaRb, -NRbC(=0)Ra, -NRbC(=0)ORa, -OC(=0)NRaRb, hydroxyl, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7.8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle- alkyl, wherein Ra, Rb, and Rd are each independently H, d-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, -16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
According to a further embodiment, R11 is halogen, -ORa, -NRaRb, hydroxyl, cyano, or d-6 alkyl, wherein Ra-Rb are each independently H, d-12 alkyl, d-12 alkenyl, d-12 30 alkynyl, d-12 aryl, C7_i6 aralkyl, 5-12 membered heteroaryl, 6-18 membered
heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
According to a further embodiment, R11 is halogen, hydroxyl, cyano, or NH2.
According to a further embodiment, R11 is halogen.
BOST 1803930.1 According to a further embodiment, R12 is halogen, -ORa, oxo, -NRaRb, =NO-Rc , - C(=0)ORa, -C(0)NRaRb, -C(=0)OH, -C(=0)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=0)NRaRb, -NRbC(=0)Ra, -NRdC(=NRc)NRaRb, -NRbC(=0)ORa, -OC(=0)NRaRb, -OC(=0)Ra, -OC(=0)ORa, hydroxyl, nitro, azido, cyano, -S(0)o-3Ra, -S02NRaRb, -NRbS02Ra, -NRbS02NRaRb, d-12 alkyl, C2-i2 alkenyl, d-12 alkynyl, C6-i 2 aryl, C7.i6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle- alkyl, wherein Ra, Rb, Rc, and Rd are each independently H, d-12 alkyl, C2.12 alkenyl, C2.12 alkynyl, C6-i2 aryl, -16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
10
According to a further embodiment, R12 is halogen, -ORa, oxo, -NRaRb, -C(=0)ORa, - C(0)NRaRb, -C(=0)OH, -C(=0)Ra, -NRdC(=0)NRaRb, -NRbC(=0)Ra, -NRbC(=0)ORa, - OC(=0)NRaRb, -OC(=0)Ra, -OC(=0)ORa, hydroxyl, cyano, -S02NRaRb, -NRbS02Ra, C1 -6 alkyl, C2-6 alkenyl, C2.6 alkynyl, phenyl, C7.8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl, wherein Ra, Rb, and Rd are each independently H, d-12 alkyl, d-12 alkenyl, d-12 alkynyl, C6-i2 aryl, C7.16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
20 According to a further embodiment, R12 is halogen, -ORa, oxo, -NRaRb, -C(0)NRaRb,
-C(=0)OH, -C(=0)Ra, -NRdC(=0)NRaRb, -NRbC(=0)Ra, -NRbC(=0)ORa, -OC(=0)NRaRb, hydroxyl, cyano, d-6 alkyl, C2.6 alkenyl, C2.6 alkynyl, phenyl, C7.8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl, wherein Ra, Rb, and Rd are each independently H, d-12 alkyl, C2.12 alkenyl, d-12 alkynyl, C6-i2 aryl, d-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
According to a further embodiment, R12 is halogen, -ORa, oxo, -NRaRb, hydroxyl, cyano, or d-6 alkyl, wherein Ra-Rb are each independently H, d-12 alkyl, C2.12 alkenyl, C2-12 30 alkynyl, C6-i2 aryl, -16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
According to a further embodiment, R12 is halogen.
According to a further embodiment, Ra, Rb, Rc, and Rd are each independently H, d-6 alkyl, C2.6 alkenyl, C2.6 alkynyl, phenyl, C7.8 aralkyl, 5-6 membered heteroaryl, 6-8
BOST 1803930.1 39 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle- alkyl.
According to a further embodiment, Ra and Rc are each independently H, Ci-6 alkyl, C2-6 alkenyl, C2.6 alkynyl, phenyl, C7.8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle- alkyl, and Rb, and Rd are each independently H or C1 -3 alkyl.
According to a further embodiment, Ra and Rc are each independently H, Ci-6 10 alkyl, C2.6 alkenyl, C2.6 alkynyl, phenyl, benzyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl, and Rb, and Rd are each independently H or d-3 alkyl.
According to a further embodiment, Ra, Rb, Rc, and Rd are each independently H or Ci-3 alkyl.
In accordance with a further embodiment, the compounds of the present invention are represented by formula (IV):
Figure imgf000041_0001
20 or a pharmaceutically acceptable salt thereof, wherein A, B, B', R1 ; p, R2, R2>, R3, R >, R4, and R4> are as defined for formula (I ), and
R7 and R7' are each independently Ci_8 alkyl which is unsubstituted or substituted one or more times by R10, C2.8 alkenyl which is unsubstituted or substituted one or more times by R10, C2.8 alkynyl which is unsubstituted or substituted one or more times by R10, phenyl which is unsubstituted or substituted one or more times by R11 , benzyl which is unsubstituted or substituted one or more times by R11 , 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R11 , 6-7
BOST 1803930.1 40 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11 , 3-6 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-7 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12; and
R8 and R8' are each independently -NRaRb, -NRdC(=0)NRaRb, -NRbC(=0)Ra, - NRdC(=NRc)NRaRb, -NRbC(=0)ORa, -NRBS02Ra, -NRBS02NRaRb, wherein Ra, Rb, Rc, and Rd are each independently H , CM2 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7.i 6 aralkyl, 5- 1 2 membered heteroaryl, 6- 1 8 membered heteroaralkyl, 3- 1 2 membered 10 heterocycle, or 4- 1 8 membered heterocycle-alkyl.
In accordance with a further embodiment, the compounds of the present invention are represented by formula (IVA):
Figure imgf000042_0001
or a pharmaceutically acceptable salt thereof, wherein q, u, s, A, B, B' , R1 , p, R2, R2', R3, R3' , R4, R4>, m, and n, are as defined for formula (MIA)
R7 and R7' are each independently d-8 alkyl which is unsubstituted or substituted one or more times by R10, C2s alkenyl which is unsubstituted or substituted one or more times by R10, C2s alkynyl which is unsubstituted or substituted one or more times by R10, phenyl which is unsubstituted or substituted one or more times by R11 , benzyl which is unsubstituted or substituted one or more times by R11 , 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R11 , 6-7 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11 , 3-6 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-7 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12;
BOST 1803930.1 41 R8 and R8' are each independently -NRaRb, -NRdC(=0)NRaRb, -NRbC(=0)Ra, - NRdC(=NRc)NRaRb, -NRbC(=0)ORa, -NRbS02Ra, or -NRbS02NRaRb, wherein Ra, Rb, Rc, and Rd are each independently H, Ci-12 alkyl, C2_i2 alkenyl, C2_i2 alkynyl, C6-i2 aryl, C7. 16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl; and
m and n combined are 0, 1 , 2, 3 or 4.
According to a further embodiment, R8 and R8' are each independently -NRaRb, - 10 NRbC(=0)Ra, or -NRbC(=0)ORa, wherein Ra-Rb are each independently H, Ci-6 alkyl, phenyl, benzyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
According to a further embodiment, R8 and R8' are each independently -NRaRb or - NRbC(=0)ORa, wherein Ra-Rb are each independently H, Ci-6 alkyl, phenyl, benzyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
According to a further embodiment, R8 and R8' are each independently - 20 NRbC(=0)ORa, wherein Ra-Rb are each independently H, Ci-6 alkyl, phenyl, benzyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
According to a further embodiment, R8 and R8' are each independently - NRbC(=0)ORa, wherein Ra-Rb are each independently H, Ci-6 alkyl, phenyl, tetrahydrofuran, or benzyl.
According to a further embodiment, R8 and R8' are each independently - NRbC(=0)ORa> wherein Ra is d.6 alkyl and Rb is H or methyl.
30
According to a further embodiment, R8 and R8' are each independently - NRbC(=0)ORa, wherein Ra is Ci_6 alkyl and Rb is H.
According to a further embodiment, R8 and R8' are each independently NRbC(=0)ORa, wherein Ra is methyl and Rb is H.
BOST 1803930.1 42 According to a further embodiment, R7 and R7' are each independently d-8 alkyl, C2-8 alkenyl, C2s alkynyl, phenyl, benzyl, 5-6 membered heteroaryl, 6-7 membered heteroaralkyl, 3-6 membered heterocycle, or 4-7 membered heterocycle-alkyl;
According to a further embodiment, R7 and R7' are each independently phenyl.
According to a further embodiment, R7 and R7' are each independently d.6 alkyl.
According to a further embodiment, R7 and R7' are each independently Ci_6 alkyl 10 which is unsubstituted or substituted one or more times by R10.
According to a further embodiment, R7 and R7' are each independently methyl, ethyl, propyl, isopropyl, methoxyisopropyl, butyl, sec-butyl, tert-butyl, pentyl, 2- methylbutane, 3-methylbutane, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
According to a further embodiment, R7 and R7' are each independently methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, 2-methylbutane, 3- methylbutane, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
20 According to a further embodiment, R7 and R8 or R7> and R8> together with the carbon to which they are attached are each independently:
Figure imgf000044_0001
According to a further embodiment, R7 and R7' are each isopropyl.
In accordance with a further embodiment, the compounds of the present invention are represented by formula (V):
BOST 1803930.1 43
Figure imgf000045_0001
or a pharmaceutically acceptable salt thereof, wherein each of A, B, B' , R1 , p, R2, R2>, R , R >, R4, R4>, R7, R7>, R8, and R8., are as defined for formula (I ).
In accordance with a further embodiment, the compounds of the present invention are represented by formula (VA):
Figure imgf000045_0002
or a pharmaceutically acceptable salt thereof, wherein each of q, u, s, A, B, B' , R1 , p, R2, R2', R3, R3', R4, R4', R7, R7>, R8, and R8., are as defined for formula (I IIA).
10
According to a further embodiment, as valency allows in B, B', Ra, Rb, Rc, and Rd, Ri , R2, R2 ', R3, R3', R4, R4 ', R10, R11 and R12 each of alkyl, alkenyl, alkynyl, alkoxy, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocycle, or heterocycle-alkyl is independently unsubstituted or substituted one or more times by halogen, -ORa' -NRa.Rb., C(=0)ORa>, - C(0)NRa.Rb., -C(=0)OH, hydroxyl, nitro, azido, or cyano, wherein Ra., Rb., Rc., and Rd. are each independently H , CM2 alkyl.
According to a further embodiment, as valency allows in B, B', Ra, Rb, Rc, and Rd, Ri , R2, R2 ', R3, R3' , R4, R4 , R10, R11 and R12 each of alkyl, alkenyl, alkynyl, alkoxy, aryl, 20 aralkyl, heteroaryl, heteroaralkyl, heterocycle, or heterocycle-alkyl is independently unsubstituted or substituted one time by halogen.
BOST 1803930.1 44 According to a further embodiment, as valency allows in B, B', Ra, Rb, Rc, and Rd, Ri , R2, R2 ', R3, R3' , R4, R4 , R10, R11 and R12 each of alkyl, alkenyl, alkynyl, alkoxy, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocycle, or heterocycle-alkyl is independently unsubstituted or substituted one time by fluoro.
In accordance with the present invention, the compounds are selected from compounds as defined in the formulas wherein:
A is C6-14 aryl, 5-12 membered heteroaryl, or a bond;
10 B and B' are each independently -(C≡C)- or -(CH2)2-;
is H, halogen, -ORa, -NRaRb, -C(=0)ORa, -C(0)NRaRb, -C(=0)OH, -NRbC(=0)Ra, hydroxy I, nitro, cyano, -S(O)0- Ra, - Ci_6 alkyl, C2.6 alkenyl, C2.6 alkynyl, or Ci-6 halogenated alkyl;
R2 and R2' are each independently H, methyl, or iodo;
m and n are each independently 0, 1 or 2;
p is 0, 1 or 2;
R3 and R3' are H;
20 R4 and R4' are each independently H, halogen, d.6 alkyl, hydroxyl, phenyl, or d.4 alkoxy;
X and Y are
Figure imgf000046_0001
R5 and R5' are each independently d.12 alkyl which is unsubstituted or substituted one or more times by R10.
In accordance with the present invention, the compounds are selected from compounds as defined in the formulas wherein:
30 A is C6-14 aryl, 5-12 membered heteroaryl, or a bond;
B and B' are each independently -(C≡C)- or -(CH2)2-;
RT is H or methyl;
R2 and R2' are each independently H, methyl or iodo;
m and n are each independently 0, 1 or 2;
p is 0, 1 or 2;
R3 and R3' are H;
BOST 1803930.1 45 R4 and R4' are each independently H, halogen, d.6 alkyl, hydroxyl, phenyl, or d.4 alkoxy; X and Y are
Figure imgf000047_0001
R5 and R5' are each independently d-12 alkyl which is unsubstituted or substituted one or more times by R10.
In accordance with the present invention, the compounds are selected from compounds as defined in the formulas wherein:
10 A is phenyl, thiophene, thieno[3,2-b]thiophene, pyridine, pyrimidine, naphthyl, benzo[1 ,3]dioxole, benzooxazole, or triazole;
B and B' are each independently -(C≡C)- or -(CH2)2- ;
is H or methyl;
R2 and R2' are each independently H, methyl or iodo;
m and n are each independently 0, 1 or 2;
p is 0, 1 or 2;
R3 and R3' are H;
R4 and R4' are each independently H, halogen, d-6 alkyl, hydroxyl, phenyl, or Ci_4 alkoxy; 20 X and Y are
Figure imgf000047_0002
R5 and R5' are each independently d-12 alkyl which is unsubstituted or substituted one or more times by R10.
In accordance with the present invention, the compounds are selected from compounds as defined in the formulas wherein:
A is phenyl, thiophene, thieno[3,2-b]thiophene, naphthyl, benzo[1 ,3]dioxole, or benzooxazole;
30 B and B' are each independently -(C≡C)- or -(CH2)2-;
is H, halogen, -ORa, -NRaRb, -C(=0)ORa, -C(0)NRaRb, -C(=0)OH, -NRbC(=0)Ra, hydroxyl, nitro, cyano, -S(O)0-3Ra, - d-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, or d-6 halogenated alkyl;
R2 and R2' are each independently H, methyl or iodo;
m and n are each independently 0, 1 or 2;
BOST 1803930.1 46 p is 0, 1 or 2;
R3 and R3' are H;
R4 and R4' are each independently H, halogen, Ci-6 alkyl, hydroxyl, phenyl, or d-4 alkoxy; X and Y are each
Figure imgf000048_0001
R5 and R5' are each independently d.12 alkyl which is unsubstituted or substituted one or more times by R10;
10 R7 and R7' are each independently Ci-8 alkyl which is unsubstituted or substituted one or more times by R10, C2.8 alkenyl which is unsubstituted or substituted one or more times by R10, C2.8 alkynyl which is unsubstituted or substituted one or more times by R10, phenyl which is unsubstituted or substituted one or more times by R11 , benzyl which is unsubstituted or substituted one or more times by R11 , 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R11 , 6-7 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11 , 3-6 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-7 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12; and
20
R8 and R8' are each independently -NRaRb, -NRdC(=0)NRaRb, -NRbC(=0)Ra, - NRdC(=NRc)NRaRb, -NRbC(=0)ORa, -NRbS02Ra, -NRbS02NRaRb, wherein Ra, Rb, Rc, and Rd are each independently H, d.12 alkyl, C2.12 alkenyl, C2.12 alkynyl, C6-i2 aryl, C7.16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
In some embodiments, the compounds of this invention are represented in Table 1 A. In some embodiments, the compounds of this invention are represented in Table 1 B. In certain embodiments, the variables used herein are as defined in the specific
30 embodiments as shown in the tables below.
In one embodiment in the compounds of the present invention is halogen, -ORa, -NRaRb, -C(=0)ORa, -C(0)NRaRb, -C(=0)OH , -C(=0)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, - NRdC(=0)NRaRb, -NRbC(=0)Ra, -NRdC(=NRc)NRaRb, -NRbC(=0)ORa, -OC(=0)NRaRb, -OC(=0)Ra, -OC(=0)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -S02NRaRb, NRbS02Ra, -NRbS02NRaRb, -P(=0)ORaORb, Ci_6 alkyl which is unsubstituted or substituted
BOST 1803930.1 47 one or more times by R10, C2-6 alkenyl which is unsubstituted or substituted one or more times by R10, C2.6 alkynyl which is unsubstituted or substituted one or more times by R10;
In one embodiment in the compounds of the present invention, herein as valency allows in B, B' , Ra, Rb, Rc, and Rd, R1 ; R2, R2' , R3, R3' , R4, R4 ', R10, R11 and R12 each of alkyl, alkenyl, alkynyl, alkoxy, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocycle, or heterocycle-alkyl is independently unsubstituted or substituted one or more times by halogen, -ORa., oxo, -NRa.Rb., =NO-Rc., -C(=0)ORa., -C(0)NRa.Rb., -C(=0)OH , -C(=0)Ra., -
Figure imgf000049_0001
NRb.C(=0)ORa., -OC(=0)NRa.Rb., -OC(=0)Ra., -OC(=0)ORa., hydroxyl, nitro, azido, cyano, - 10 S(O)0-3Ra', -S02NRa.Rb., -NRb'S02Ra'; wherein Ra.-Rd' are each independently H, Ci_12 alkyl.
In one embodiment in the compounds of the present invention p is 0, 1 or 2.
In one embodiment in the compounds of the present invention p is 0 or 1 .
In one embodiment in the compounds of the present invention p is 0.
In one embodiment in the compounds of the present invention p is 2.
In one embodiment in the compounds of the present invention R4 and R4' are H .
In one embodiment in the compounds of the present invention is halogen, Ci_ alkyl, hydroxyl, cyano, or d. alkoxy.
In one embodiment in the compounds of the present invention is chloro, fluoro, methyl, hydroxyl, cyano, or methoxy.
20 In one embodiment in the compounds of the present invention n is H.
In one embodiment R10 is halogen, -ORa, oxo, -C(=0)ORa, -C(0)NRaRb, -C(=0)OH, - C(=0)Ra, -OC(=0)NRaRb, -OC(=0)Ra, -OC(=0)ORa, hydroxyl, cyano, wherein Ra-Rb are each independently H, d.12 alkyl, C2.12 alkenyl, C2.12 alkynyl, C6-i2 aryl, C7.16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4- 18 membered heterocycle-alkyl.
In one embodiment in the compounds of the present invention R11 is halogen, - ORa, -NRaRb, -C(=0)ORa, -C(0)NRaRb, -C(=0)OH, -C(=0)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, - NRdC(=0)NRaRb, -NRbC(=0)Ra, -NRdC(=NRc)NRaRb, -NRbC(=0)ORa, -OC(=0)NRaRb, -OC(=0)Ra, -OC(=0)ORa, hydroxyl, nitro, azido, cyano, -S(O)0. Ra, -S02NRaRb, -NRbS02Ra, or - 30 NRbS02NRaRb, Ci-i2 alkyl, C2_i2 alkenyl, C2_i2 alkynyl, C6-i2 aryl, C7_i6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, wherein Ra, Rb, Rc, and Rd are each independently H, CM2 alkyl, C2.12 alkenyl, C2.12 alkynyl, C6-i2 aryl, C7.16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle- alkyl.
BOST 1803930.1 48 In one embodiment in the compounds of the present invention R11 is halogen, - ORa, -NRaRb, -C(=0)ORa, -C(0)NRaRb, -C(=0)OH, -C(=0)Ra, -NRdC(=0)NRaRb, -NRbC(=0)Ra, - NRbC(=0)ORa, -OC(=0)NRaRb, -OC(=0)Ra, -OC(=0)ORa, hydroxyl, cyano, -S02NRaRb, - NRbS02Ra, C1-6 alkyl, C2.6 alkenyl, C2.6 alkynyl, phenyl, C7.8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl, wherein Ra,Rb, and Rd are each independently are each independently H, C-i-12 alkyl, C2-i2 alkenyl, C2-i2 alkynyl, C6-i2 aryl, C7.16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
10 In one embodiment in the compounds of the present invention R11 is halogen, -
ORa, -NRaRb, -C(0)NRaRb, -C(=0)OH, -C(=0)Ra, -NRdC(=0)NRaRb, -NRbC(=0)Ra, - NRbC(=0)ORa> -OC(=0)NRaRb, hydroxyl, cyano, d.6 alkyl, C2.6 alkenyl, C2.6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl, wherein Ra, Rb, and Rd are each independently H , CM2 alkyl, C2-i2 alkenyl, C2-i2 alkynyl, C6-i2 aryl, C7_i6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4- 18 membered heterocycle-alkyl.
In one embodiment in the compounds of the present invention R11 is halogen, - ORa, -NRaRb, hydroxyl, cyano, Ci_6 alkyl, wherein Ra-Rb are each independently H, CM2
20 alkyl, C2-i2 alkenyl, C2-i2 alkynyl, C6-i2 aryl, C7_i6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle- alkyl.
In one embodiment in the compounds of the present invention R12 is halogen, - ORa, oxo, -NRaRb, =NO-Rc , -C(=0)ORa, -C(0)NRaRb, -C(=0)OH, -C(=0)Ra, -C(=NORc)Ra, - C(=NRc)NRaRb, -NRdC(=0)NRaRb, -NRbC(=0)Ra, -NRdC(=NRc)NRaRb, -NRbC(=0)ORa, - OC(=0)NRaRb, -OC(=0)Ra, -OC(=0)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -S02NRaRb, -NRbS02Ra, -NRbS02NRaRb, Ci-12 alkyl, C2-i2 alkenyl, C2-i2 alkynyl, C6-i2 aryl, C7.i6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4- 18 membered heterocycle-alkyl, wherein Ra, Rb, Rc, and Rd are each independently H, d. 30 12 alkyl, C2-i2 alkenyl, C2-i2 alkynyl, C6-i2 aryl, C7_i6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle- alkyl.
In one embodiment in the compounds of the present invention R12 is halogen, - ORa, oxo, -NRaRb, -C(=0)ORa, -C(0)NRaRb, -C(=0)OH, -C(=0)Ra, -NRdC(=0)NRaRb, - NRbC(=0)Ra, -NRbC(=0)ORa, -OC(=0)NRaRb, -OC(=0)Ra, -OC(=0)ORa, hydroxyl, cyano, - S02NRaRb, -NRbS02Ra, Ci-6 alkyl, C2-& alkenyl, C2-& alkynyl, phenyl, C7.8 aralkyl, 5-6
BOST 1803930.1 49 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl, wherein Ra, Rb, and Rd are each independently H, d-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-i2 aryl, C7.i6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle- alkyl.
In one embodiment in the compounds of the present invention R12 is halogen, - ORa, oxo, -NRaRb, -C(0)NRaRb, -C(=0)OH, -C(=0)Ra, -NRdC(=0)NRaRb, -NRbC(=0)Ra, - NRbC(=0)ORa, -OC(=0)NRaRb, hydroxyl, cyano, Ci-6 alkyl, C2-& alkenyl, C2-& alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered 10 heterocycle, or 6-8 membered heterocycle-alkyl, wherein Ra, Rb, and Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, Cb.n aryl, C7.16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4- 18 membered heterocycle-alkyl.
In one embodiment in the compounds of the present invention R12 is halogen, - ORa, oxo, -NRaRb, hydroxyl, cyano, Ci_6 alkyl, wherein Ra-Rb are are each independently H, C1-12 alkyl, CM 2 alkenyl, C2-12 alkynyl, C6-12 aryl, C 6 aralkyl, 5-12 membered heteroaryl, 6- 18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
In one embodiment in the compounds of the present invention wherein as valency 20 allows in B, B', Ra, Rb, Rc, and Rd, R1 ; R2, R2' , R3, R3' , R4, R4 ', R10, R11 and R12 each of alkyl, alkenyl, alkynyl, alkoxy, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocycle, or heterocycle-alkyl is independently unsubstituted or substituted one or more times by halogen, -ORa. -NRa.Rb. , C(=0)ORa., -C(0)NRa.Rb., -C(=0)OH, hydroxyl, nitro, azido, cyano,'; wherein Ra°-Rd> are each independently H, d.12 alkyl.
In one embodiment in the compounds of the present invention wherein as valency allows in B, B', Ra, Rb, Rc, and Rd, R1 ; R2, R2' , R3, R3' , R4, R4 ', R10, R11 and R12 each of alkyl, alkenyl, alkynyl, alkoxy, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocycle, or heterocycle-alkyl is independently unsubstituted or substituted one time by halogen.
In one embodiment in the compounds of the present invention wherein as 30 valency allows in B, B' , Ra, Rb, Rc, and Rd, R1 ; R2, R2', R3, R3' , R4, R4 ', R10, R11 and R12 each of alkyl, alkenyl, alkynyl, alkoxy, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocycle, or heterocycle-alkyl is independently unsubstituted or substituted one time by fluoro.
The use of a compound of the present invention for treating an Hepatitis C viral infection in a human. The use of a compound of the present invention further comprising administering at least one additional agent. The use of a compound of the present invention wherein said at least one additional agent is selected from viral serine protease
BOST 1803930.1 50 inhibitors, viral polymerase inhibitors, viral helicase inhibitors, immunomudulating agents, antioxidant agents, antibacterial agents, therapeutic vaccines, hepatoprotectant agents, antisense agents, inhibitors of HCV NS2/3 protease and inhibitors of internal ribosome entry site (IRES).
The use of a compound of the present invention, wherein said at least one additional agent is selected from ribavirin and interferon-a.
The use of a compound of the present invention for the manufacture of a medicament.
A pharmaceutical formulation comprising at least one compound of the present 10 invention and at least one pharmaceutically acceptable carrier or excipient.
The use of a compound of the present invention for treating an Hepatitis C viral infection in a human. The use of a compound of the present invention further comprising administering at least one additional agent. The use of a compound of the present invention wherein said at least one additional agent is selected from viral serine protease inhibitors, viral polymerase inhibitors, viral helicase inhibitors, immunomudulating agents, antioxidant agents, antibacterial agents, therapeutic vaccines, hepatoprotectant agents, antisense agents, inhibitors of HCV NS2/3 protease and inhibitors of internal ribosome entry site (IRES). The use of a compound of the present invention wherein said at least one additional agent is selected from ribavirin and interferon-a.
20 The use of a compound of the present invention for the manufacture of a medicament.
A pharmaceutical formulation comprising at least one compound of the present invention and at least one pharmaceutically acceptable carrier or excipient.
According to an aspect of the invention, the compounds of the invention are selected from Table 1A:
Table 1A
30
Figure imgf000052_0001
BOST 1803930.1 51
Figure imgf000053_0001
BOST 1803930.1 52
Figure imgf000054_0001
BOST 1803930.1 53
Figure imgf000055_0001
BOST 1803930.1 54
Figure imgf000056_0001
BOST 1803930.1 55
Figure imgf000057_0001
BOST 1803930.1 56
Figure imgf000058_0001
BOST 1803930.1 57
Figure imgf000059_0001
BOST 1803930.1 58
Figure imgf000060_0001
BOST 1803930.1 59
Figure imgf000061_0001
BOST 1803930.1 60
Figure imgf000062_0001
or a pharmaceutically acceptable salt thereof.
According to another aspect of the invention, the compounds of the invention are selected from Table 1 B:
BOST 1803930.1 61 Table 1B
Figure imgf000063_0001
BOST 1803930.1 62
Figure imgf000064_0001
In one embodiment, the present invention provides a method for preparing a compound of formula (IV):
BOST 1803930.1 63
Figure imgf000065_0001
or a pharmaceutically acceptable salt thereof, wherein each of A, B, B', R1, p, R2, R2>, R3, R3>, R4, R4', R7, R7>, R8, and R8., are as defined herein,
wherein said method comprises the steps of:
a) contacting a compound of formula (XXX):
Figure imgf000065_0002
(XXX)
under coupling conditions with a compound of formula (XXXI) and a compound of formula (XXXII); and
Figure imgf000065_0003
(XXXI) (XXXII)
10 b) optionally hydrogenating the alkyne groups to provide a compound of formula
(IV).
In one embodiment, the present invention provides a method for preparing a compound of formula (IV):
BOST 1803930.1 64
Figure imgf000066_0001
or a pharmaceutically acceptable salt thereof, wherein each of A, B, B', R1, p, R2, I R3, R3>, R4, R4>, R7, R7>, R8, and R8., are as defined herein,
wherein said method comprises the steps of:
a) contacting a compound of formula (XXXA) where LG is a leaving group, such halo:
Figure imgf000066_0002
(XXXA)
under coupling conditions with a compound of formula (XXXIA) and a compound formula XXXI IA); and
10
Figure imgf000066_0003
(XXXIA) (XXXI I A)
b) optionally hydrogenating the alkyne groups to provide a compound of formula (IV).
In one embodiment, the coupling conditions comprise bis(triphenylphosphine) palladiumchloride, copper iodide, and triethylamine.
In one embodiment, the present invention provides a method for preparing a compound of formula (XXXII):
BOST 1803930.1 65
Figure imgf000067_0001
(XXXII)
wherein each of R2, R3, R4, R7, and R8, are as defined herein,
wherein said method comprises the steps of:
a) reducing a compound of formula (XXVI) to provide a compound of formula (XXVII), where each R is each independently an alkyl group:
Figure imgf000067_0002
(XXVI) (XXVII)
g) oxidizing a compound of formula (XXVII) to provide a compound of formula (XVI):
Figure imgf000067_0003
h) contacting a compound of formula (XVI) with a compound of formula (XVII) and
10 optionally a compound of formula R3-LG, where LG is a leaving group, under reaction conditions sufficient to provide a compound of formula (XV):
Figure imgf000067_0004
e) halogenating a compound of formula (XV) under reaction conditions sufficient to provide a compound of formula (XIII):
Figure imgf000067_0005
BOST 1803930.1 66 f) reacting a compound of formula (XIII) under deprotection conditions to provide a compound of formula (XI); and:
Figure imgf000068_0001
g) contacting a compound of formula (XI) under coupling conditions with a compound of formula (XII) to provide a compound of formula (XXXII):
to provide a compound of formula (XXXII).
In one embodiment, the oxidizing of step g) comprises 2,2,6,6-tetramethyl- piperidin-1 -oxyl (TEMPO).
10
In one embodiment, the present invention provides a method for preparing a compound of formula (XXVI):
Figure imgf000068_0002
wherein R4 is as defined herein, and each R is each independently an alkyl group, wherein said method comprises the steps of:
a) contacting a compound of formula (XXI) under reaction conditions sufficient to provide a compound of formula (XXII):
Figure imgf000068_0003
b) contacting a compound of formula (XXII) under reaction conditions sufficient to
20 provide a compound of formula (XXIII), and:
Figure imgf000068_0004
c) contacting a compound of formula (XXIII) under reaction conditions sufficient to provide a compound of formula (XXVI):
BOST 1803930.1 67
Figure imgf000069_0001
to provide a compound of formula (XXVI).
In one embodiment, the present invention provides a method for preparing a compound of formula (XXXI):
Figure imgf000069_0002
each of R2>, R3' , R4>, R7>, and R8>, are as defined herein,
wherein said method comprises the steps as disclosed for preparing a compound of formula (XXXII), wherein each of R2., R3>, R4., R7., and R8., are as defined for R2, R3, R4, and R8, respectively
Figure imgf000069_0003
(XXXII).
In one embodiment, the present invention provides a method for preparing ((S)-1 - {(2S,4S)-2-[5-(4-{2-[(2S,4S)-1 -((S)-2-Methoxycarbonylamino-3-methyl-butyryl)-4-methyl- pyrrolidin-2-yl]-3H-imidazol-4-ylethynyl}-phenylethynyl)-1 H-imidazol-2-yl]-4-methyl- pyrrolidine-1 -carbonyl}- -methylpropyl)-carbamic acid methyl ester:
Figure imgf000069_0004
BOST 1803930.1 68 wherein said method comprises:
contacting a compound of formula (X) under coupling conditions with a compound of formula (XXX):
Figure imgf000070_0001
to provide ((S)-1 -{(2S,4S)-2-[5-(4-{2-[(2S,4S)-1 -((S)-2-Methoxycarbonylamino-3- methyl-butyryl)-4-methyl-pyrrolidin-2-yl]-3H-imidazol-4-ylethynyl}-phenylethynyl)- 1 H-imidazol-2-yl]-4-methyl-pyrrolidine-1 -carbonyl}-2-methylpropyl)-carbamic acid methyl ester.
10 In one embodiment, the coupling conditions comprise bis(triphenylphosphine) palladiumchloride, copper iodide, and triethylamine.
In one embodiment, the present invention provides a method for preparing a compound of formula (X):
Figure imgf000070_0002
wherein said method comprises
a) reacting a compound of formula (XIII) under deprotection conditions to provide a compound of formula (XI); and:
Figure imgf000070_0003
20 b) contacting a compound of formula (XI) under coupling conditions with a compound of formula (XII):
Figure imgf000070_0004
BOST 1803930.1 69 to provide a compound of formula (X).
In one embodiment, the coupling conditions of step b) comprise first contacting a compound of formula (XII) with 0-(7-azabenzotriazol-1 -yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU) and diisopropypyethylamine (DIPEA).
In one embodiment, the deprotection conditions of step a) comprise a mineral acid.
10 In one embodiment, the present invention provides a method for preparing a compound of formula (XIII):
Figure imgf000071_0001
wherein said method comprises reacting a compound of formula (XIV):
Figure imgf000071_0002
under reaction conditions sufficient to provide a compound of formula (XIII).
In one embodiment, the reaction conditions comprise methyl magnesium bromide. In one embodiment, the present invention provides a method for preparing a
20 compound of formula (XIV) having
Figure imgf000071_0003
wherein said method comprises the steps of:
BOST 1803930.1 70 a) hydrogenating a compound of formula (XX) to provide a compound of formula (XIX):
Figure imgf000072_0001
b) reducing a compound of formula (XIX) to provide a compound of formula (XIII):
Figure imgf000072_0002
c) oxidizing a compound of formula (XIII) to provide a compound of formula (XVI):
Figure imgf000072_0003
d) contacting a compound of formula (XVI) with a compound of formula (XVII) reaction conditions sufficient to provide a compound of formula (XV):
10
Figure imgf000072_0004
(XV)
e) halogenating a compound of formula (XV) under reaction conditions sufficient to provide a compound of formula (XV), and:
Figure imgf000072_0005
BOST 1803930.1 71 f) separating the mixture of (2S,4S) and (2S,4R) diastereomers to provide a compound of formula (XIV) having a (2S,4S) configuration.
In one embodiment, the separating of step f) comprises silica gel chromatography.
In one embodiment, the reaction conditions of step e) comprise 1 -iodopyrrolidine- 2,5-dione.
In one embodiment, the oxidizing of step c) comprises 2,2,6,6-tetramethyl- 10 piperidin-1 -oxyl (TEMPO).
In one embodiment, the reducing of step b) comprises borane.
In one embodiment, the hydrogenating of step a) comprises platinum oxide and hydrogen gas.
In one embodiment the present invention provides a method for preparing a compound of formula (XIV) having
Figure imgf000073_0001
20 wherein said method comprises the steps of:
a) contacting a compound of formula (XXI) under reaction conditions sufficient to provide a compound of formula (XXII):
Figure imgf000073_0002
I)
b) contacting a compound of formula (XXII) under reaction conditions sufficient to provide a compound of formula (XXIII):
BOST 1803930.1 72 O 0
(XXIII)
c) contacting a compound of formula (XXIII) with 1 -t-butoxy-N,N,N',N'- tetramethylmethanediamine under reaction conditions sufficient to provide a compound of formula (XXIV):
Figure imgf000074_0001
d) reacting a compound of formula (XXIV) under reaction conditions sufficient to provide a compound of formula (XXVI):
Figure imgf000074_0002
e) reducing a compound of formula (XXVI) to provide a compound of formula (XXVII):
10
Figure imgf000074_0003
(xxvii)
f) oxidizing a compound of formula (XXVII) to provide a compound of formula (XVI):
Figure imgf000074_0004
BOST 1803930.1 73 g) contacting a compound of formula (XVI) with a compound of formula (XVII) under reaction conditions sufficient to provide a compound of formula (XV); and:
Figure imgf000075_0001
h) halogenating a compound of formula (XV) under reaction conditions sufficient to provide a compound of formula (XIV) having a (2S,4S) configuration.
In one embodiment, the reaction conditions of step d) comprise the steps of: a) reacting a compound of formula (XXIV) under reaction conditions sufficient to provide a compound of formula (XXV); and:
Figure imgf000075_0002
b) hydrogenating a compound of formula (XXV) to provide a compound of formula (XXVI):
Figure imgf000075_0003
In one embodiment the present invention provides a method for preparing a compound of formula (III)
Figure imgf000075_0004
BOST 1803930.1 74 or a pharmaceutically acceptable salt thereof, wherein each of A, B, B', R1, p, R2, R2>, R3, R >, R4, R4', R7, R7>, R8, and R8., are as defined herein,
wherein said method comprises the steps of:
a) contacting the compound of formula (XXXIV) with a compound of formula R -X-OH and/or R -Y-
Figure imgf000076_0001
(XXXIV)
under reaction conditions to provide a compound of formula (III).
In one embodiment the present invention provides a method for preparing compound of formula (XXXIV)
Figure imgf000076_0002
(XXXIV)
wherein each of A, B, B', R1, p, R2, R2., R3, R3., R4, R4., R7, R7., R8, and R8., are as defined herein and each of B and B', R2 and R2>, R and R >, R4 and R4>, R7 and RT, and R8, and R8> are the same respectively,
wherein said method comprises the steps of:
a) contacting a compound of formula (XXX) with a compound of formula (XIII) where R is an alkyl group:
Figure imgf000076_0003
20 under coupling conditions to provide a compound of formula (XXXIII):
Figure imgf000076_0004
(XXXIII)
BOST 1803930.1 75 b) contacting the compound of formula (XXXIII) under conditions to provide compound of formula (XXXIV).
In one embodiment, the coupling conditions comprise bis(triphenylphosphine palladiumchloride, copper iodide, and triethylamine.
In one embodiment the present invention provides a method for preparing ((S)-1 {(2S,4S)-2-[5-(4-{2-[(2S,4S)-1 -((S)-2-Methoxycarbonylamino-3-methyl-butyryl)-4-methyl- pyrrolidin-2-yl]-3H-imidazol-4-ylethynyl}-phenylethynyl)-1 H-imidazol-2-yl]-4-methyl- pyrrolidine-1 -carbonyl -2-methylpropyl)-carbamic acid methyl ester:
Figure imgf000077_0001
wherein said method comprises the steps of:
a) contacting a compound of formula (X) under coupling conditions with a compound of formula (XXX):
Figure imgf000077_0002
to provide a compound of formula (XXXV):
Figure imgf000077_0003
(XXXV)
b) contacting the compound of formula (XXXV) under conditions to provide a compound of formula (XXXVI); and
20
Figure imgf000077_0004
BOST 1803930.1 76 c) contacting the compound of formula (XXXVI) with N-methoxycarbonyl valine under reaction conditions to provide ((S)-1 -{(2S,4S)-2-[5-(4-{2-[(2S,4S)-1 -((S)-2- Methoxycarbonylamino-3-methyl-butyryl)-4-methyl-pyrrolidin-2-yl]-3H-imidazol-4- ylethynyl}-phenylethynyl)-1 H-imidazol-2-yl]-4-methyl-pyrrolidine-1 -carbonyl}-2- methylpropyl)-carbamic acid methyl ester.
In one embodiment the coupling conditions of step a) comprise bis(triphenylphosphine) palladiumchloride, copper iodide, and triethylamine.
10 In one embodiment, the present invention provides a compound according to the invention described herein for treating or preventing a Flaviviridae viral infection in a host.
In one embodiment, the present invention provides a pharmaceutical composition comprising at least one compound according to the invention described herein and at least one pharmaceutically acceptable carrier or excipient.
In one embodiment, the present invention provides a pharmaceutical composition comprising at least one compound according to the invention described herein and at 20 least one pharmaceutically acceptable carrier or excipient, for treating or preventing a Flaviviridae viral infection in a host.
In one embodiment, the present invention provides a pharmaceutical composition comprising at least one compound according to the invention described herein ,and further comprising administering at least one additional agent chosen from viral serine protease inhibitors, viral polymerase inhibitors, viral helicase inhibitors, immunomudulating agents, antioxidant agents, antibacterial agents, therapeutic vaccines, hepatoprotectant agents, antisense agents, inhibitors of HCV NS2/3 protease and inhibitors of internal ribosome entry site (IRES).
30
In another embodiment, there is provided a combination comprising a least one compound according to the invention described herein and one or more additional agents.
In another embodiment, there is provided a combination comprising a least one compound according to the invention described herein and one or more additional agents
BOST 1803930.1 77 chosen from viral serine protease inhibitors, viral polymerase inhibitors, viral helicase inhibitors, immunomudulating agents, antioxidant agents, antibacterial agents, therapeutic vaccines, hepatoprotectant agents, antisense agent, inhibitors of HCV NS2/3 protease and inhibitors of internal ribosome entry site (IRES).
In one combination embodiment, the compound and additional agent are administered sequentially.
In another combination embodiment, the compound and additional agent are 10 administered simultaneously.
The combinations referred to above may conveniently be presented for use in the form of a pharmaceutical formulation and thus pharmaceutical formulations comprising a combination as defined above together with a pharmaceutically acceptable carrier therefore comprise a further aspect of the invention.
The additional agents for the compositions and combinations include, for example, ribavirin, amantadine, merimepodib, Levovirin, Viramidine, and maxamine.
20 The term "viral serine protease inhibitor" as used herein means an agent that is effective to inhibit the function of the viral serine protease including HCV serine protease in a mammal. Inhibitors of HCV serine protease include, for example, those compounds described in WO 99/07733 (Boehringer Ingelheim), WO 99/07734 (Boehringer Ingelheim), WO 00/09558 (Boehringer Ingelheim), WO 00/09543 (Boehringer Ingelheim), WO 00/59929 (Boehringer Ingelheim), WO 02/060926 (BMS), WO 2006039488 (Vertex), WO 2005077969 (Vertex), WO 2005035525 (Vertex), WO 2005028502 (Vertex) WO 2005007681 (Vertex), WO 2004092162 (Vertex), WO 2004092161 (Vertex), WO 2003035060 (Vertex), of WO 03/087092 (Vertex), WO 02/18369 (Vertex), or W098/17679 (Vertex).
30 Specific examples of viral serine protease inhibitors include Telaprevir (VX-950,
Vertex), VX-500 (Vertex), TMC435350 (Tibotec/Medivir), MK-7009 (Merck), ITMN-191 (R7227, InterMune/Roche) and Boceprevir (SCH503034, Schering).
The term "viral polymerase inhibitors" as used herein means an agent that is effective to inhibit the function of a viral polymerase including an HCV polymerase in a
BOST 1803930.1 mammal. Inhibitors of HCV polymerase include non-nucleosides, for example, those compounds described in:
WO 03/010140 (Boehringer Ingelheim), WO 03/026587 (Bristol Myers Squibb); WO 02/100846 A1 , WO 02/100851 A2, WO 01 /85172 A1 (GSK), WO 02/098424 A1 (GSK), WO 00/06529 (Merck), WO 02/06246 A1 (Merck), WO 01 /47883 (Japan Tobacco), WO 03/000254 (Japan Tobacco) and EP 1 256 628 A2 (Agouron).
Furthermore other inhibitors of HCV polymerase also include nucleoside analogs, 10 for example, those compounds described in: WO 01 /90121 A2 (Idenix), WO 02/069903 A2 (Biocryst Pharmaceuticals Inc.), and WO 02/057287 A2(Merck/lsis) and WO 02/057425 A2 (Merck/lsis).
Specific examples of inhibitors of an HCV polymerase, include VCH-759 (ViroChem Pharma), VCH-916 (ViroChem Pharma), VCH-222 (ViroChem Pharma), R1626 (Roche), R7128 (Roche/Pharmasset), PF-868554 (Pfizer), MK-0608 (Merck/lsis), MK-3281 (Merck), A-837093 (Abbott), GS 9190 (Gilead), ana598 (Anadys), HCV-796 (Viropharma) and GSK625433 (GlaxoSmithKline).
20 The term "viral helicase inhibitors" as used herein means an agent that is effective to inhibit the function of a viral helicase including a Flaviviridae helicase in a mammal.
"Immunomodulatory agent" as used herein means those agents that are effective to enhance or potentiate the immune system response in a mammal. Immunomodulatory agents include, for example, class I interferons (such as α-, β-, δ- and Ω- interferons, τ- interferons, consensus interferons and asialo-interferons), class II interferons (such as γ- interferons) and pegylated interferons.
30 Specific examples of Immunomodulatory agent as used herein include IL-29 (PEG-
Interferon Lambda, ZymoGenetics), Belerofon (Nautilus Biotech) injectable or oral, Oral Interferon alpha (Amarillo Biosciences), BLX-883 (Locteron, Biolex Therapeutics/Octoplus), Omega Interferon (Intarcia Therapeutics), multiferon (Viragen), Albuferon (Human Genome Sciences), consensus Interferon (Infergen, Three Rivers Pharmaceuticals), Medusa Interferon (Flamel Technologies), NOV-205 (Novelos
BOST 1803930.1 79 Therapeutics), Oglufanide disodium (Implicit Bioscience), SCV-07 (SciClone), Zadaxin® (thymalfasin, SciClone/Sigma-Tau), AB68 (XTL bio) and Civacir (NABI).
The term "class I interferon" as used herein means an interferon selected from a group of interferons that all bind to receptor type 1. This includes both naturally and synthetically produced class I interferons. Examples of class I interferons include α-, β- ,δ- and Ω- interferons, τ-interferons, consensus interferons and asialo-interferons. The term "class II interferon" as used herein means an interferon selected from a group of interferons that all bind to receptor type II. Examples of class II interferons include γ- 10 interferons.
Antisense agents include, for example, ISIS-14803.
Inhibitors of internal ribosome entry site (IRES) include ISIS-1 803 (ISIS Pharmaceuticals) and those compounds described in WO 2006019831 (PTC therapeutics).
In one embodiment, the additional agent is interferon a, ribavirin, silybum marianum, interleukine-12, amantadine, ribozyme, thymosin, N-acetyl cysteine or cyclosporin.
20
In one embodiment, the additional agent is interferon a, or ribavirin.
In one embodiment, the additional agent is interferon a 1A, interferon a 1 B, interferon a 2A, or interferon a 2B.
Interferon is available in pegylated and non pegylated forms. Pegylated interferons include PEGASYStm and Peg-introntm.
In one embodiment, the additional agent is interferon a 1A, interferon a 1 B, 30 interferon a 2A (Roferon), PEG -interferon a 2A (Pegasys), interferon a 2B (Intron A) or PEG- interferon a 2B (Peg-lntron).
In one embodiment, the additional agent is standard or pegylated interferon a (Roferon, Pegasys, Intron A, Peg-lntron) in combination with ribavirin.
BOST 1803930.1 80 In one embodiment, the additional agent is chosen from A-831 (AZD0530, Arrow Therapeutics acquired by AstraZeneca), TLR9 agonist : IMO-2125 (Idera Pharmaceuticals), PYN17 (Phynova), Vavituximab (Tarvacin, Peregrine), DEBIO-025 (DEBIO), NIM-811 (Novartis), SCY635 (Scynexis), PF-03491390 (IDN-6556, Pfizer), Suvus (formerly BIVN-401 , Virostat, Bioenvision), MX-3253 (Celgosivir, Migenix), Viramidine (Taribavirin, Valeant Pharmaceuticals), Hepaconda (Giaconda), TT033 (Benitec/Tacere Bio/Pfizer), SIRNA-034 (Sirna Therapeutics aquired by Merck) and EHC-18 (Enzo Biochem), ACH-1095 (Achillion/Gilead), JKB-022 (Jenkin), CTS-1027 (Conatus), MitoQ (mitoquinone, Antipodean Pharmaceuticals), Alinia (nitazoxanide, Romark Laboratories) 10 and Bavituximab (Peregrine Pharm).
In one embodiment, the additional agent is a therapeutic vaccine chosen from CSL123 (Chiron/CSL), IC41 (Intercell Novartis), Gl 5005 (Globeimmune), TG4040 (Transgene), Chronvac C (Tripep/lnovio), GNI-103 (GENimmune), HCV/MF59 (Chiron/Novartis), PeviPRO™ (Pevion biotect).
The recommended dose of PEGASYStm monotherapy for chronic hepatitis C is 180 mg (1.0 mL vial or 0.5 mL prefilled syringe) once weekly for 48 weeks by subcutaneous administration in the abdomen or thigh.
20
The recommended dose of PEGASYStm when used in combination with ribavirin for chronic hepatitis C is 180 mg (1.0 mL vial or 0.5 mL prefilled syringe) once weekly.
The daily dose of Ribavirin is 800 mg to 1200 mg administered orally in two divided doses. The dose should be individualized to the patient depending on baseline disease characteristics (e.g., genotype), response to therapy, and tolerability of the regimen.
The recommended dose of PEG-lntrontm regimen is 1.0 mg/kg/week 30 subcutaneously for one year. The dose should be administered on the same day of the week.
When administered in combination with ribavirin, the recommended dose of PEG- Intron is 1.5 micrograms/kg/week.
BOST 1803930.1 81 In one embodiment, viral serine protease inhibitor is a flaviviridae serine protease inhibitor.
In one embodiment, viral polymerase inhibitor is a flaviviridae polymerase inhibitor.
In one embodiment, viral helicase inhibitor is a flaviviridae helicase inhibitor. In further embodiments:
viral serine protease inhibitor is HCV serine protease inhibitor;
10 viral polymerase inhibitor is HCV polymerase inhibitor;
viral helicase inhibitor is HCV helicase inhibitor.
In one embodiment, the present invention provides a method for treating or preventing a Flaviviridae viral infection in a host comprising administering to the host a therapeutically effective amount of at least one compound according to formula (I ), (I I ), (I II ), or (IV).
In one embodiment, the viral infection is chosen from Flavivirus infections.
20 In one embodiment, the Flavivirus infection is Hepatitis C virus (HCV), bovine viral diarrhea virus (BVDV), hog cholera virus, dengue fever virus, Japanese encephalitis virus or yellow fever virus.
In one embodiment, the Flaviviridea viral infection is hepatitis C viral infection
(HCV).
In one embodiment, the host is human.
In one embodiment, the present invention provides a method for treating or 30 preventing a Flaviviridae viral infection in a host comprising administering to the host a therapeutically effective amount of at least one compound according to the invention described herein, and further comprising administering at least one additional agent.
In one embodiment, the present invention provides a method for treating or preventing a Flaviviridae viral infection in a host comprising administering to the host a therapeutically effective amount of at least one compound according to the invention
BOST 1803930.1 82 described herein, and further comprising administering at least one additional agent chosen from viral serine protease inhibitors, viral polymerase inhibitors, viral helicase inhibitors, immunomudulating agents, antioxidant agents, antibacterial agents, therapeutic vaccines, hepatoprotectant agents, antisense agents, inhibitors of HCV NS2/3 protease and inhibitors of internal ribosome entry site (IRES).
The combinations referred to above may conveniently be presented for use in the form of a pharmaceutical formulation and thus pharmaceutical formulations comprising a combination as defined above together with a pharmaceutically acceptable carrier 10 therefore comprise a further aspect of the invention.
The individual components for use in the method of the present invention or combinations of the present invention may be administered either sequentially or simultaneously in separate or combined pharmaceutical formulations.
In one embodiment, the present invention provides the use of a compound according to the invention described herein for treating or preventing Flaviviridae viral infection in a host.
20 In one embodiment, the present invention provides the use of a compound according to the invention described herein and further comprising at least one additional agent chosen from viral serine protease inhibitors, viral polymerase inhibitors, viral helicase inhibitors, immunomudulating agents, antioxidant agents, antibacterial agents, therapeutic vaccines, hepatoprotectant agents, antisense agents, inhibitors of HCV NS2/3 protease and inhibitors of internal ribosome entry site (I RES). for treating or preventing Flaviviridae viral infection in a host.
In one embodiment, the present invention provides the use of a compound according to the invention described herein for the manufacture of a medicament.
30
In one embodiment, the present invention provides the use of a compound according to the invention described herein for the manufacture of a medicament for treating or preventing a viral Flaviviridae infection in a host.
In one embodiment, the present invention provides the use of a compound according to the invention described herein and further comprising at least one
BOST 1803930.1 83 additional agent chosen from viral serine protease inhibitors, viral polymerase inhibitors, viral helicase inhibitors, immunomudulating agents, antioxidant agents, antibacterial agents, therapeutic vaccines, hepatoprotectant agents, antisense agents, inhibitors of HCV NS2/3 protease and inhibitors of internal ribosome entry site (I RES). for the manufacture of a medicament for treating or preventing a viral Flaviviridae infection in a host.
Unless otherwise stated, structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms 10 of the structure; for example, the R and S configurations for each asymmetric center, (Z) and (E) double bond isomers, and (Z) and (E) conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the invention. The single optical isomer or enantiomer can be obtained by method well known in the art, such as chiral HPLC, enzymatic resolution and chiral auxiliary.
Unless otherwise stated, all tautomeric forms of the compounds of the invention are within the scope of the invention.
20
In one embodiment, the compounds of the present invention are provided in the form of a single stereoisomer at least 95%, at least 97% and at least 99% free of the corresponding stereoisomers.
In a further embodiment the compound of the present invention are in the form of a single stereoisomer at least 95% free of the corresponding stereoisomers.
In a further embodiment the compound of the present invention are in the form of a single stereoisomer at least 97% free of the corresponding stereoisomers.
30
In a further embodiment the compound of the present invention are in the form of a single stereoisomer at least 99% free of the corresponding stereoisomers.
There is also provided pharmaceutically acceptable salts of the compounds of the present invention. By the term pharmaceutically acceptable salts of compounds are meant those derived from pharmaceutically acceptable inorganic and organic acids and
BOST 1803930.1 84 bases. Examples of suitable acids include hydrochloric, hydrobromic, sulphuric, nitric, perchloric, fumaric, maleic, phosphoric, glycollic, lactic, salicylic, succinic, toleune-p-sulphonic, tartaric, acetic, trifluoroacetic, citric, methanesulphonic, formic, benzoic, malonic, naphthalene-2-sulphonic and benzenesulphonic acids. Other acids such as oxalic, while not themselves pharmaceutically acceptable, may be useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts.
Salts derived from amino acids are also included (e.g. L-arginine, L-Lysine).
10
Salts derived from appropriate bases include alkali metals (e.g. sodium, lithium, potassium) and alkaline earth metals (e.g. calcium, magnesium).
A reference hereinafter to a compound according to the invention includes that compound and its pharmaceutically acceptable salts.
With regards to pharmaceutically acceptable salts, see also the list of FDA approved commercially marketed salts listed in Table I of Berge et al., Pharmaceutical Salts, J. of Phar. Sci., vol. 66, no. 1 , January 1977, pp. 1 -19, the disclosure of which is 20 incorporated herein by reference.
It will be appreciated by those skilled in the art that the compounds in accordance with the present invention can exist in different polymorphic forms. As known in the art, polymorphism is an ability of a compound to crystallize as more than one distinct crystalline or "polymorphic" species. A polymorph is a solid crystalline phase of a compound with at least two different arrangements or polymorphic forms of that compound molecule in the solid state. Polymorphic forms of any given compound are defined by the same chemical formula or composition and are as distinct in chemical structure as crystalline structures of two different chemical compounds.
30
In addition to the compounds of this invention, pharmaceutically acceptable derivatives or prodrugs, and esters, of the compounds of this invention may also be employed in compositions to treat or prevent the herein identified disorders.
It will further be appreciated by those skilled in the art that the compounds in accordance with the present invention can exist in different solvate forms, for example
BOST 1803930.1 85 hydrates. Solvates of the compounds of the invention may also form when solvent molecules are incorporated into the crystalline lattice structure of the compound molecule during the crystallization process.
Pro-drugs
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this 10 invention belongs. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.
For purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th Ed. Additionally, general principles of organic chemistry are described in "Organic Chemistry", Thomas Sorrell, University Science Books, Sausalito: 1999, and "March's Advanced Organic Chemistry", 5th Ed., Ed.: Smith, M.B. and March, J., John 20 Wiley & Sons, New York: 2001 , the entire contents of which are hereby incorporated by reference.
In the formulas and drawings, a line transversing a ring and bonded to a group such as B, B', R1 ; R4 or R4'in formula (I)
Figure imgf000087_0001
means that the group can be bonded to any carbon, or if applicable, heteroatom such as N, of that ring as valency allows.
BOST 1803930.1 86 The term "alkyl" represents a linear, branched or cyclic hydrocarbon moiety. The terms "alkenyl" and "alkynyl" represent a linear, branched or cyclic hydrocarbon moiety which has one or more double bonds or triple bonds in the chain. Examples of alkyl, alkenyl, and alkynyl groups include but are not limited to methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, hexyl, isohexyl, neohexyl, allyl, vinyl, acetylenyl, ethylenyl, propenyl, isopropenyl, butenyl, isobutenyl, hexenyl, butadienyl, pentenyl, pentadienyl, hexenyl, heptenyl, heptadienyl, heptatrienyl, octenyl, propynyl, butynyl, pentynyl, hexynyl, cyclopropyl, cyclobutyl, cyclohexenyl, cyclohexdienyl and cyclohexyl. The terms alkyl, alkenyl, and alkynyl, also include combinations of linear and branched groups, e.g., cyclopropylmethyl, cyclohexylethyl, etc. The term alkenyl also includes C1 alkenyl where the one carbon atom is attached to the remainder of the molecule via a double bond. Where indicated the "alkyl," "alkenyl," and "alkynyl" can be optionally substituted such as in the case of haloalkyls in which one or more hydrogen atom is replaced by a halogen, e.g., an alkylhalide. Examples of haloalkyls include but are not limited to trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, dichloromethyl, chloromethyl, trifluoroethyl, difluoroethyl, fluoroethyl, trichloroethyl, dichloroethyl, chloroethyl, chlorofluoromethyl, chlorodifluoromethyl, dichlorofluoroethyl. Aside from halogens, where indicated, the alkyl, alkenyl or alkynyl groups can also be optionally substituted by, for example, halogen, -ORa, oxo, -NRaRb, =NO-Rc , -C(=0)ORa, -C(0)NRaRb, -C(=0)OH, -C(=0)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=0)NRaRb, -NRbC(=0)Ra, - NRdC(=NRc)NRaRb, -NRbC(=0)ORa, -OC(=0)NRaRb, -OC(=0)Ra, -OC(=0)ORa, hydroxyl, nitro, azido, cyano, -S(O)0.3Ra, -S02NRaRb, -NRbS02Ra, -NRbS02NRaRb, or -P(=0)ORaORb, wherein Ra, Rb, Ro and Rd are each independently H, d_12 alkyl, C2.12 alkenyl, C2.12 alkynyl, C6-i2 aryl, C7.i6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
The terms "cycloalkyl", and "cycloalkenyl" represent a cyclic hydrocarbon alkyl or alkenyl, respectively, and are meant to include monocyclic (e.g., cyclopropyl, cyclobutyl, cyclohexyl), spiro (e.g., spiro [2.3]hexanyl), fused (e.g., bicyclo[4.4.0]decanyl), and bridged (e.g., bicyclo[2.2.1 ]heptanyl) hydrocarbon moieties.
The terms "alkoxy," "alkenyloxy," and "alkynyloxy" represent an alkyl, alkenyl or alkynyl moiety, respectively, which is covalently bonded to the adjacent atom ??? through an oxygen atom. Examples include but are not limited to methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy,
BOST 1803930.1 87 pentyloxy, isopentyloxy, neopentyloxy, tert-pentyloxy, hexyloxy, isohexyloxy, trifluoromethoxy and neohexyloxy. Like the alkyl, alkenyl and alkynyl groups, where indicated the alkoxy, alkenyloxy, and alkynyloxy groups can be optionally substituted by, for example, halogen, -ORa, oxo, -NRaRb, =NO-Rc , -C(=0)ORa, - C(0)NRaRb, -C(=0)OH, -C(=0)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=0)NRaRb, - NRbC(=0)Ra, -NRdC(=NRc)NRaRb, -NRbC(=0)ORa, -OC(=0)NRaRb, -OC(=0)Ra, - OC(=0)ORa, hydroxy., nitro, azido, cyano, -S(O)0.3Ra, -S02NRaRb, -NRbS02Ra, - NRbS02NRaRb, or -P(=0)ORaORb, wherein Ra, Rb, Rc, and Rd are each independently H, C1 -12 alkyl, C2-i2 alkenyl, C2-12 alkynyl, C6-i 2 aryl, C7.i6 aralkyl, 5-12 membered 10 heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
The term "aryl" represents a carbocyclic moiety containing at least one benzenoid-type ring (i.e. , may be monocyclic or polycyclic), and which where indicated may be optionally substituted with one or more substituents. Examples include but are not limited to phenyl, tolyl, dimethylphenyl, aminophenyl, anilinyl, naphthyl, anthryl, phenanthryl or biphenyl. The aryl groups can be optionally substituted where indicated by, for example, halogen, -ORa, -NRaRb, -C(=0)ORa, - C(0)NRaRb, -C(=0)OH, -C(=0)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=0)NRaRb, - 20 NRbC(=0)Ra, -NRdC(=NRc)NRaRb, -NRbC(=0)ORa, -OC(=0)NRaRb, -OC(=0)Ra, - OC(=0)ORa, hydroxyl, nitro, azido, cyano, -S(O)0.3Ra, -S02NRaRb, -NRbS02Ra, - NRbS02NRaRb, or -P(=0)ORaORb, d.12 alkyl, C2.12 alkenyl, C2.12 alkynyl, C6.12 aryl, C7.16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, wherein Ra, Rb, R,-, and Rd are each independently H, Ci _1 2 alkyl, C2_i 2 alkenyl, C2_i 2 alkynyl, C6-i2 aryl, C7_i 6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
The term "aralkyl" represents an aryl group attached to the adjacent atom 30 by an alkyl, alkenyl or alkynyl. Like the aryl groups, where indicated the aralkyl groups can also be optionally substituted. Examples include but are not limited to benzyl, benzhydryl, trityl, phenethyl, 3-phenylpropyl, 2-phenylpropyl, 4- phenylbutyl and naphthylmethyl. Where indicated, the aralkyl groups can be optionally substituted one or more times by, for example, halogen, -ORa, -NRaRb, - C(=0)ORa, -C(0)NRaRb, -C(=0)OH, -C(=0)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, - NRdC(=0)NRaRb, -NRbC(=0)Ra, -NRdC(=NRc)NRaRb, -NRbC(=0)ORa, -OC(=0)NRaRb, -
BOST 1803930.1 OC(=0)Ra, -OC(=0)ORa, hydroxyl, nitro, azido, cyano, -S(0)o-3Ra, -S02NRaRb, - NRbS02Ra, -NRbS02NRaRb, or -P(=0)ORaORb, C1 -12 alkyl, C2.12 alkenyl, C2.12 alkynyl, C6.12 aryl, C7.i6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, wherein Ra, Rb, Rc, and Rd are each independently H , CM2 alkyl, C2_i2 alkenyl, C2_i2 alkynyl, C6-i2 aryl, C7. 16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
The term "heterocycle" represents a non aromatic, saturated or partially 10 saturated cyclic moiety wherein said cyclic moiety is interrupted by at least one heteroatom selected from oxygen (O), sulfur (S) or nitrogen (N). Heterocycles may be monocyclic or polycyclic rings. Examples include but are not limited to azetidinyl, dioxolanyl, morpholinyl, morpholino, oxetanyl, piperazinyl, piperidyl, piperidinyl, cyclopentapyrazolyl, cyclopentaoxazinyl, cyclopentafuranyl, tetrahydrofuranyl, thiazolinyl, oxazolinyl, pyranyl, aziridinyl, azepinyl, dioxazepinyl, diazepinyl, oxyranyl, oxazinyl, pyrrolidinyl, thiopyranyl, thiolanyl, pyrazolidinyl, dioxanyl, and imidazolidinyl. Where indicated, the heterocyclic groups can be optionally substituted one or more times by, for example, halogen, - ORa, oxo, -NRaRb, =NO-Rc , -C(=0)ORa, -C(0)NRaRb, -C(=0)OH , -C(=0)Ra, -C(=NORc)Ra, 20 -C(=NRc)NRaRb, -NRdC(=0)NRaRb, -NRbC(=0)Ra, -NRdC(=NRc)NRaRb, -NRbC(=0)ORa, - OC(=0)NRaRb, -OC(=0)Ra, -OC(=0)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, - S02NRaRb, -NRbS02Ra, -NRbS02NRaRb, or -P(=0)ORaORb, C1 -12 alkyl, C2.12 alkenyl, C2.12 alkynyl, C6-i2 aryl, C7.16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, wherein Ra, Rb, Rc, and Rd are each independently H , CM2 alkyl, C2_i2 alkenyl, C2_i2 alkynyl, C6-i2 aryl, C7_i6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
The term "heterocycle-alkyl" represents a heterocycle group attached to 30 the adjacent atom by an alkyl, alkenyl or alkynyl group. It is understood that in, for example, a 4-18 member heterocycle-alkyl moiety, the 4-18 member represent the total of the ring atoms present in the heterocycle moiety and the carbon atoms present in the alkyl, alkenyl or alkynyl group. For example, the following groups are encompassed by a 7 member heterocycle-alkyl (* represents the attachment point):
BOST 1803930.1 89
Figure imgf000091_0001
Where indicated the heterocycle-alkyl groups can be optionally substituted one or more times by, for example, halogen, -ORa, oxo, -NRaRb, =NO-Rc , -C(=0)ORa, -C(0)NRaRb, -C(=0)OH, -C(=0)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=0)NRaRb, - NRbC(=0)Ra, -NRdC(=NRc)NRaRb, -NRbC(=0)ORa, -OC(=0)NRaRb, -OC(=0)Ra, - OC(=0)ORa, hydroxyl, nitro, azido, cyano, -S(0)o-3Ra, -S02NRaRb, -NRbS02Ra, - NRbS02NRaRb, or -P(=0)ORaORb, Ci_12 alkyl, C2-12 alkenyl, C2-n alkynyl, Cb.n aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, wherein Ra, Rb, Rc, and Rd are each independently H , Ci_12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-i2 aryl, C7.i6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
The term "heteroaryl" represents an aromatic cyclic moiety wherein said cyclic moiety is interrupted by at least one heteroatom selected from oxygen (0), sulfur (S) or nitrogen (N). Heteroaryls may be monocyclic or polycyclic rings wherein at least one ring in the polycyclic ring system is aromatic and at least one ring (not necessarily the same ring contains a heteroatom. Examples include but are not limited to dithiadiazinyl, furanyl, isooxazolyl, isothiazolyl, imidazolyl, oxadiazolyl, oxazolyl, pyrazinyl, pyridazinyl, pyrimidinyl, pyridyl, pyrazolyl, pyrrolyl, thiatriazolyl, tetrazolyl, thiadiazolyl, triazolyl, thiazolyl, thienyl, tetrazinyl, thiadiazinyl, triazinyl, thiazinyl, furoisoxazolyl, imidazothiazolyl, thienoisothiazolyl, thienothiazolyl, imidazopyrazolyl, pyrrolopyrrolyl, thienothienyl, thiadiazolopyrimidinyl, thiazolothiazinyl, thiazolopyrimidinyl, thiazolopyridinyl, oxazolopyrimidinyl, oxazolopyridyl, benzoxazolyl, benzisothiazolyl, benzothiazolyl, benzodioxolyl, dihydrobenzodioxinyl, benzothiadiazolyl, thienofuranyl, imidazopyrazinyl, purinyl, pyrazolopyrimidinyl, imidazopyridinyl, benzimidazolyl, indazolyl, benzoxathiolyl, benzodioxolyl, benzodithiolyl, indolizinyl, indolinyl, isoindolinyl, furopyrimidinyl, furopyridyl, benzofuranyl, isobenzofuranyl, thienopyrimidinyl, thienopyridyl, benzothienyl, benzoxazinyl, benzothiazinyl, quinazolinyl, naphthyridinyl, quinolinyl, isoquinolinyl, benzopyranyl,
BOST 1803930.1 90 pyridopyridazinyl, chromen, benzodiazinyl. Where indicated the heteroaryl groups can be optionally substituted one or more times by, for example, halogen, -ORA, - NRARB, -C(=0)ORa, -C(0)N RARB, -C(=0)OH , -C(=0)RA, -C(=NORC)RA, -C(=NRC)NRARB, - NRDC(=0)NRARB, - NRBC(=0)RA, -NRDC(=N RC)NRARB, - NRBC(=0)ORA, -OC(=0)NRARB, - OC(=0)RA, -OC(=0)ORA, hydroxyl, nitro, azido, cyano, -S(0)o-3RA, -S02NRARB, - NRbS02RA, -NRbS02NRARB, or - P(=0)ORAORB, C1 -12 alkyl, C2.12 alkenyl, C2.12 alkynyl, C6.12 aryl, C7.16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, wherein RA, RB, RC, and RD are each independently H , CM2 alkyl, C2_i2 alkenyl, C2_i2 alkynyl, C6-i2 aryl, C7. 10 16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl. It is to be understood that terms such as "thienothienyl" encompasses all connectivites, including but not limited to, thieno[3,2-b]thiophene.
The term "heteroaralkyl" represents an optionally substituted heteroaryl group attached to the adjacent atom by an alkyl, alkenyl or alkynyl group. Where indicated the heteroaralkyl groups can be optionally substituted one or more times by, for example, halogen, -ORA, -NRARB, -C(=0)ORA, -C(0)NRARB, -C(=0)OH, -C(=0)RA, -C(=NORC)RA, -C(=N RC)NRARB, -NRDC(=0)NRARB, - NRBC(=0)RA, -N RDC(=NRC)NRARB, -
20 NRBC(=0)ORA, -OC(=0)NRARB, -OC(=0)RA, -OC(=0)ORA, hydroxyl, nitro, azido, cyano, - S(0)o-3RA, -S02NRARB, - NRbS02RA, -N RbS02NRARB, or - P(=0)ORAORB, C1 - 12 alkyl, C2-i2 alkenyl, C2.12 alkynyl, C6-i2 aryl, C7.16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, wherein RA, RB, RC, and RD are each independently H, d.12 alkyl, C2-i2 alkenyl, C2_i2 alkynyl, C6-i2 aryl, C7_i6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl. It is understood that in, for example, a 6-18 member heteroaralkyl moiety, the 6-18 member represents the total of the ring atoms present in the heterocycle moiety and the carbon atoms in the alkyl, alkenyl or
30 alkynyl groups. For example, the following groups are encompassed by a 7 member heteroaralkyl (* represents the attachment point):
Figure imgf000092_0001
BOST 1803930.1 91 "Halogen atom or halo" is specifically a fluorine atom, chlorine atom, bromine atom or iodine atom.
The term "oxo" represents =0.
A dash ("-") that is not between two letters or symbols is used to indicate a point of attachement for a substitutent. For example, -CONRdRe is attached through the carbon of the amide.
10
A dash line (" ") is used to indicate the point of attachment for the group. For example, A is attached through the carbon at position 1 and 4 in the following representation:
Figure imgf000093_0001
When there is a sulfur atom present, the sulfur atom can be at different oxidation levels, i.e., S, SO, or S02. All such oxidation levels are within the scope of the present invention.
20
The term "independently" means that a substituent can be the same or a different definition for each item.
In general, the term "substituted," whether preceded by the term "optionally" or not, refers to the replacement of hydrogen radicals on a carbon or nitrogen atom in a given structure with the radical of a specified substituent. Specific substituents are described above in the definitions and below in the description of compounds and examples thereof. Unless otherwise indicated, an optionally substituted group can have a substituent at each substitutable position of the group, and when more than one 30 position in any given structure can be substituted with more than one substituent selected from a specified group, the substituent can be either the same or different at every position. For example, the language, "which is unsubstituted or substituted one or more times by R10" means that when the group is substituted with more than one R10 group, the R10 groups can be different from each other. A ring substituent, such as a
BOST 1803930.1 92 heterocycle, can be bound to another ring, such as a cycloalkyl, to form a spiro-bicyclic ring system, e.g., both rings share one common atom.
As one of ordinary skill in the art will recognize, combinations of substituents envisioned by this invention are those combinations that result in the formation of stable or chemically feasible compounds. The term "stable", as used herein, refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and preferably their recovery, purification, and use for one or more of the purposes disclosed herein. In some embodiments, a stable compound or 10 chemically feasible compound is one that is not substantially altered when kept at a temperature of 40°C or less, in the absence of moisture or other chemically reactive conditions, for at least a week. When two alkoxy groups are bound to the same atom or adjacent atoms, the two alkoxy groups can form a ring together with the atom(s) to which they are bound.
In certain embodiment, a compound represented by:
Figure imgf000094_0001
also includes where the R group replaces the H on the nitrogen atom.
20
Additionally, unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds of this invention, wherein one or more hydrogen atoms are replaced deuterium or tritium, or one or more carbon atoms are replaced by a 13C- or 14C-enriched carbon are within the scope of this invention. Such compounds are useful, for example, as analytical tools, probes in biological assays, or antiviral compounds with improved therapeutic profile.
30 The terms "host" or "patient" mean human male or female, for example child, adolescent or adult.
BOST 1803930.1 93 It will be appreciated that the amount of a compound of the invention required for use in treatment will vary not only with the particular compound selected but also with the route of administration, the nature of the condition for which treatment is required and the age and condition of the patient and will be ultimately at the discretion of the attendant physician or veterinarian. In general however a suitable dose will be in the range of from about 0.1 to about 750 mg/kg of body weight per day, for example, in the range of 0.5 to 60 mg/kg/day, or, for example, in the range of 1 to 20 mg/kg/day.
The desired dose may conveniently be presented in a single dose or as divided 10 dose administered at appropriate intervals, for example as two, three, four or more doses per day.
The compound is conveniently administered in unit dosage form; for example containing 10 to 1500 mg, conveniently 20 to 1000 mg, most conveniently 50 to 700 mg of active ingredient per unit dosage form.
Ideally the active ingredient should be administered to achieve peak plasma concentrations of the active compound of from about 1 to about 75μΜ, about 2 to 50 μΜ, about 3 to about 30 μΜ. This may be achieved, for example, by the intravenous injection 20 of a 0.1 to 5% solution of the active ingredient, optionally in saline, or orally administered as a bolus containing about 1 to about 500 mg of the active ingredient. Desirable blood levels may be maintained by a continuous infusion to provide about 0.01 to about 5.0 mg/kg/hour or by intermittent infusions containing about 0.4 to about 15 mg/kg of the active ingredient.
When the compounds of the present invention or a pharmaceutically acceptable salts thereof is used in combination with a second therapeutic agent active against the same virus the dose of each compound may be either the same as or differ from that when the compound is used alone. Appropriate doses will be readily appreciated by 30 those skilled in the art.
While it is possible that, for use in therapy, a compound of the invention may be administered as the raw chemical it is preferable to present the active ingredient as a pharmaceutical composition. The invention thus further provides a pharmaceutical composition comprising compounds of the present invention or a pharmaceutically acceptable derivative thereof together with one or more pharmaceutically acceptable
BOST 1803930.1 94 carriers therefore and, optionally, other therapeutic and/or prophylactic ingredients. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
Pharmaceutical compositions include those suitable for oral, rectal, nasal, topical (including buccal and sub-lingual), transdermal, vaginal or parenteral (including intramuscular, sub-cutaneous and intravenous) administration or in a form suitable for administration by inhalation or insufflation. The formulations may, where appropriate, be conveniently presented in discrete dosage units and may be prepared by any of the 10 methods well known in the art of pharmacy. All methods include the step of bringing into association the active compound with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.
Pharmaceutical compositions suitable for oral administration may conveniently be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution, a suspension or as an emulsion. The active ingredient may also be presented as a bolus, electuary or paste. Tablets and capsules for oral administration may contain conventional excipients such as binding agents, fillers, lubricants, disintegrants, or 20 wetting agents. The tablets may be coated according to methods well known in the art.
Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, nonaqueous vehicles (which may include edible oils), or preservatives.
The compounds according to the invention may also be formulated for parenteral administration (e.g. by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume 30 infusion or in multi-dose containers with an added preservative. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution, for constitution with a suitable vehicle, e.g. sterile, pyrogen -free water, before use.
BOST 1803930.1 95 For topical administration to the epidermis, the compounds according to the invention may be formulated as ointments, creams or lotions, or as a transdermal patch. Such transdermal patches may contain penetration enhancers such as linalool, carvacrol, thymol, citral, menthol and t-anethole. Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, or colouring agents.
10 Compositions suitable for topical administration in the mouth include lozenges comprising active ingredient in a flavoured base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerin or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
Pharmaceutical compositions suitable for rectal administration wherein the carrier is a solid are for example presented as unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art, and the suppositories may be conveniently formed by admixture of the active compound with the softened or 20 melted carrier(s) followed by chilling and shaping in moulds.
Compositions suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
For intra-nasal administration the compounds of the invention may be used as a liquid spray or dispersible powder or in the form of drops. Drops may be formulated with an aqueous or non-aqueous base also comprising one more dispersing agents, solubilizing agents or suspending agents. Liquid sprays are conveniently delivered from pressurized 30 packs.
For administration by inhalation the compounds according to the invention are conveniently delivered from an insufflator, nebulizer or a pressurized pack or other convenient means of delivering an aerosol spray. Pressurized packs may comprise a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a
BOST 1803930.1 96 pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount.
Alternatively, for administration by inhalation or insufflation, the compounds according to the invention may take the form of a dry powder composition, for example a powder mix of the compound and a suitable powder base such as lactose or starch. The powder composition may be presented in unit dosage form in, for example, capsules or cartridges or e.g. gelatin or blister packs from which the powder may be administered with the aid of an inhalator or insufflator.
When desired the above described formulations adapted to give sustained release of the active ingredient may be employed.
The following general schemes and examples are provided to illustrate various embodiments of the present invention and shall not be considered as limiting in scope. It will be appreciated by those of skill in the art that other compounds of the present invention can be obtained by substituting the generically or specifically described reactants and/or operating conditions used in the following examples.
In the foregoing and in the following examples, all temperatures are set forth uncorrected in degrees Celsius; and, unless otherwise indicated, all parts and percentages are by weight.
The following abbreviations may be used as follows:
aq aqueous
cone concentrate
DCM methylene chloride
DIPEA Diisopropylethylamine
DMF dimethylformamide
DMSO Dimethylsulfoxide
EtOAc Ethyl acetate
HATU 0-(7-Azabenzotriazol-1 -yl)-N,N,N',N'-tetramethylu
hexafluorophosphate
M molar
MeOH Methanol
BOST 1803930.1 97 MTBE methyl ter-butyl ether
n-BuLi n-butyl lithium
PdCl2dppf (1 ,1 '-Bis-(diphenylphosphino)-ferrocene)palladium (II) dichloride
Pd(PPh3)2Cl2 trans-dichlorobis(triphenyl phosphine) Palladium (II)
RT room temperature
TEA Triethylamine
THF Tetrahydrofuran
The compounds of this invention may be prepared in light of the specification 10 using steps generally known to those of ordinary skill in the art. Those compounds may be analyzed by known methods, including but not limited to LCMS (liquid chromatography mass spectrometry) HPLC (high performance liquid chromatography) and NMR (nuclear magnetic resonance). It should be understood that the specific conditions shown below are only examples, and are not meant to limit the scope of the conditions that can be used for making compounds of this invention. Instead, this invention also includes conditions that would be apparent to those skilled in that art in light of this specification for making the compounds of this invention. Unless otherwise indicated, all variables in the following schemes are as defined herein. General Schemes:
Mass spec, samples were analyzed on a MicroMass Quattro Micro of MicroMass LCZ 20 mass spectrometer operated in single MS mode with electrospray ionization. Samples were introduced into the mass spectrometer using chromatography. Mobile phase for all mass spec, analyses consisted of 10mM pH 7 ammonium acetate and a 1 :1 acetonitrile- methanol mixture. Method A: Column gradient conditions were 5%-100% acetonitrile- methanol over 3.5 mins gradient time and 4.8 mins run time on an ACE5C8 3.0 x 75mm column. Flow rate was 1.2 ml/min. Method B: Column gradient were 5%-100%
acetonitrile-methanol over 10 mins gradient time and 12 mins run time on a ACE5C8 4.6 x 150 mm column. Flow rate was 1.5 mL/min. As used herein, the term "Rt(min)" refers to the LCMS retention time, in minutes, associated with the compound. Unless otherwise indicated, the LCMS method utilized to obtain the reported retention time is as detailed 30 above. If the Rt(min) is < 5 min method A was used, if the Rt(min) is >5 min then method B was used.
1 H-NMR spectra were recorded at 400 MHz using a Bruker DPX 400 or Varian instrument.
Purification by reverse phase HPLC is carried out under standard conditions using a Phenomenex Gemini C18 column, 21.2 mmID x 250 mm, 5 μιη, 1 1 θΑ. Elution is
BOST 1803930.1 98 performed using a linear gradient 20 to 90 % (CH3CN in water or CH3CN in water with 0.02%HCl) with a flow rate of 5.0 mL/minute.
General procedure 1 :
Figure imgf000100_0001
hal is halogen
The diethynyl intermediate is prepared in 2 steps from the commercially available bis-halogenated aryl or heterocycle. A Sonogashira coupling with bis(trimethylsilyl)acetylene using Cul and palladium catalysts in solvent such as DMF in presence of base such as TEA or DIPEA give the bis-trimethyl ethynyl silane intermediate. 10 The silyl groups are hydrolyzed in presence of a base such as K2C03 in MeOH to give the expected diethynyl intermediate.
The Sonogashira coupling reaction is a well established method for producing acetylene containing compounds. Conditions for such coupling are well known in the art and can be found for example in the examples of the present application, in Yamagushi et al. (Synlett 1999, No.5, 549-550), or in Tykwinski et al. Angew. Chem.. Inte. Ed. 2003, 42, 1566-1568.
General procedure 2:
Figure imgf000100_0002
hal is halogen
The compound is formed from the diethynyl intermediate and the iodo or bromo imidazole intermediate by a Sonogoshira coupling using Cul and palladium catalysts in solvents such as DMF in presence of base such as TEA or DIPEA.
BOST 1803930.1 99 In one embodiment, the halogen is iodo or bromo. In one embodiment, the halogen is iodo.
General procedure 3:
Figure imgf000101_0001
Reduction of the triple bond is done under standard hydrogenation procedure as known by those of ordinary skill in the art. The compound having triple bonds is dissolved in a suitable solvent such as methanol and a catalytic amount of a 1M solution 10 of HCl is added followed by a catalytic amount of 10% Pd/C. The reaction mixture is stirred at RT under 1 atmosphere of hydrogen until completion of the reaction, filtered and the filtrate concentrated to dryness to afford the alkyl derivatives.
General procedure 4:
Figure imgf000101_0002
Reduction of the triple bonds to double bonds could be done under standard hydrogenation procedure as known in the art. Such conditions are described for example in the following references:
Tri H. V. Huynh et al. Organic Letters, 2009, vol. 11 , 999-1002.
Sellarajah, Shan et al. J.Med. Chem. 2004, 47 (22) 5515
Chandrasehkar, S et al. Tetrahedron Letters 2004, 45, 2421 -2423.
General procedure 5:
BOST 1803930.1 100
Figure imgf000102_0001
hal is halogen
PG is a protecting group
Figure imgf000102_0002
Alternatively, the compound is formed from the diethynyl intermediate and the protected iodo or bromo imidazole intermediate by a Sonogoshira coupling using Cul and palladium catalysts in solvents such as DMF in presence of base such as TEA or DIPEA. Removal of the protecting group optionally followed by coupling with the complimentary functionalized X-R5' or Y-R5 group can be accomplished under standard reactioj conditions known in the art.
In one embodiment, the halogen is iodo or bromo.
10
In one embodiment, the halogen is iodo.
In one embodiment, the protecting group is tert-butoxycarbonyl.
Mass spec, samples were analyzed on a Micromass Platform LCZ mass spectrometer operated in single MS mode with electrospray ionization. Samples were introduced into the mass spectrometer using chromatography. Mobile phase for all mass spec, analyses consisted of H2O+0.01%TFA and CH3CN+0.01%TFA. Method: Column gradient conditions were 5%-85%CH3CN+0.01%TFA in 20 minutes gradient time on a 20 SymmetryShield RP18 3.5um, 2.1x50mm column. Flow rate was 0.5mL/minute. As used herein, the term "Rt(minute)" refers to the LCMS retention time, in minutes, associated with the compound. Unless otherwise indicated, the LCMS method utilized to obtain the reported retention time is detailed above.
BOST 1803930.1 101 Intermediate 1
(2S)-2-(methoxycarbon lamino)-3-methyl-butanoic acid
Figure imgf000103_0001
L- Valine (140 g, 1.195 mol) is added to a stirred solution of 1 M sodium hydroxide (1.183 L, 1.183 mol). After complete dissolution, sodium carbonate (65.8 g, 621.4 mmol) is added followed by methyl chloroformate (122g, 99.75 mL, 1.291 mol) at 0°C over 40 minutes. The reaction mixture is stirred at RT for 3.5 hours, then washed with diethyl ether (3x 200ml). The aqueous layer is cooled to 0°C, and acidified to pH 1 -2. The white solid formed is filtered on a Buchner, washed with cold water and dried to afford the title compound (2S)-2-(methoxycarbonylamino)-3-methyl-butanoic acid (140g, 67%).
Intermediate 2
(2S)-2-[Methoxycarbonyl(methyl)amino]-3-methyl-butanoic acid
Figure imgf000103_0002
(2S)-3-Methyl-2-methylamino-butanoic acid (5 g, 38.12 mmol) is added to a stirring solution of sodium hydroxide (76.2 mL of 1 M, 76.24 mmol). After complete dissolution, disodium carbonate (2.1 g, 19.82 mmol) is added followed by methyl chloroformate (3.18 mL, 41.17 mmol) at 0°C over 40 minutes. The reaction mixture is stirred at RT for 4 20 hours, then washed with diethyl ether (2x 75 ml). The aqueous layer is cooled to 0°C, acidified to pH 1 -2 and extracted with CH2Cl2. The organic phase is dried over MgS04, filtered and concentrated to dryness to give the title compound (2S)-2- [methoxycarbonyl(methyl)amino]-3-methyl-butanoic acid (5.12g, 71%) as a clear oil.
BOST 1803930.1 102 Intermediate 3
Methyl N-[(1S)-1-[(2S)-2-(5-iodo-1 H-imidazol-2-yl)pyrrolidine-1-carbonyl]-2-methyl- propyl]carbamate
Figure imgf000104_0001
Step I:
tert-Butyl(2S)-2-(1 H-imidazol-2-yl)pyrrolidine-1 -carboxylate
10 To a stirred solution of commercially available tert-butyl (2S)-2-formylpyrrolidine-1 - carboxylate (15 g, 75.3 mmol) in a 1 /1 mixture MeOH (30ml_) / NH4OH (30ml_) is added oxaldehyde (3.4 mL, 75.3 mmol) over 10 minutes. The reaction is stirred at RT for 72 hours and evaporated to dryness. The residue is purified by flash column chromatography on silica gel (EtOAc/Hexanes 50% to 75%) to give tert-butyl(2S)-2-(1 H- imidazol-2-yl)pyrrolidine-1 -carboxylate (5.2g, 29%).
Step II:
tert-Butyl(2S)-2-(4,5-diiodo-1 H-imidazol-2-yl)pyrrolidine-1 -carboxylate
20 To a stirred solution of tert-butyl (2S)-2-(1 H-imidazol-2-yl)pyrrolidine-1 -carboxylate (5g, 21 mmol) in CH2Cl2 (120 mL) is added 1 -iodopyrrolidine-2,5-dione (10.4 g, 46.3 mmol) at 0°C over 15 minutes. The reaction mixture is stirred 2 hours at 0°C, concentrated to dryness, and the residue is purified by flash column chromatography on silica gel (25% EtOAc in Hexanes) to give tert-butyl(2S)-2-(4,5 diiodo-1 H-imidazol-2-yl)pyrrolidine-1 - carboxylate(8.6g, 83%).
Step III:
BOST 1803930.1 103 tert-Butyl(2S)-2-(5-iodo-1 H-imidazol-2-yl)pyrrolidine-1 -carboxylate
To a cooled (-78°C) solution of tert-butyl (2S)-2-(4,5-diiodo-1 H-imidazol-2-yl)pyrrolidine- 1 -carboxylate (6.5g, 13.29 mmol) in THF (65 mL) is added dropwise 1.5M n-BuLi in hexanes (22.15 mL, 33.22 mmol) over 30 minutes. The reaction mixture is stirred 30 minutes and an additional 1.5 eq of 1.5 M n-BuLi in hexanes is added over 30 minutes. After addition of 20 mL 1 N HCl the reaction mixture is allowed to stir at RT. The reaction mixture is extracted by EtOAc, washed with H20, dried over Na2S04, filtered, concentrated to dryness, and purified by flash column chromatography on silica gel (0 to 10 50% EtOAc in Hexanes) to give tert-butyl (2S)-2-(5-iodo-1 H-imidazol-2-yl)pyrrolidine-1 - carboxylate (2.93g, 60%).
Step IV:
5-lodo-2-[(2S)-pyrrolidin-2-yl]-1 H-imidazole (HCl salt)
To tert-butyl (2S)-2-(5-iodo-1 H-imidazol-2-yl)pyrrolidine-1 -carboxylate (2.9g, 7.9 mmol) is added a 4 M solution of HCl in dioxane (29 mL, 795.4 mmol) at 0°C. The reaction mixture is stirred for 4 hours at RT, evaporated to dryness to afford 5-iodo-2-[(2S)- pyrrolidin-2-yl]-1 H-imidazole (HCl salt) (2.4g, 100%) as a white solid.
Step V:
Methyl N-[(1 S)-1 -[(2S)-2-(5-iodo-1 H-imidazol-2-yl)pyrrolidine-1 -carbonyl]-2-methyl-
20 propyljcarbamate
To a chilled solution (0°C) of (2S)-2-(methoxycarbonylamino)-3-methyl-butanoic acid (2.2 g, 12.7 mmol) and HATU (5.4 g, 14.3 mmol) in DMF (48 mL) is added DIPEA (10.3 g, 13.9 mL, 79.8 mmol) followed by 5-iodo-2-[(2S)-pyrrolidin-2-yl]-1 H-imidazole HCL salt (2.4 g, 7.9 mmol). The reaction mixture is stirred overnight at RT, diluted with H20 and EtOAc. The organic phase is separated, dried over Na2S04, filtered and concentrated to dryness. The residue is purified by flash column chromatography on silica gel (0 to 100% EtOAc in Hexanes) to give Methyl N-[(1 S)-1 -[(2S)-2-(5-iodo-1 H-imidazol-2-yl)pyrrolidine-1 - carbonyl]-2-methyl-propyl]carbamate (1.3g, 35%).
BOST 1803930.1 104 Intermediate 4
Methyl N-[(1S)-1-[(2S,4S)-2-(5-iodo-1 H-imidazol-2-yl)-4-methyl-pyrrolidine-1- carbonyl]-2-methyl-propyl]carbamate
Figure imgf000106_0001
Step I:
(2S)-1 -tert-Butoxycarbonyl-4-methyl-pyrrolidine-2-carboxylic acid
A solution of (2S)-1 -tert-butoxycarbonyl-4-methylene-pyrrolidine-2-carboxylic acid (25g, 110 mmol) in methanol or ethanol (250 mL) is purged 3 times under N2(g) before the addition of Pt02 (2.5g, 11 mmol). The solution is purged again with vacuum and H2(g)j and 10 this purge is repeated three times. Then the reaction mixture is stirred for 20 hours under one atmosphere of hydrogen. The reaction mixture is filtered on celite to remove the catalyst, and the filtrate is concentrated to dryness to give (2S)-1 -tert- butoxycarbonyl-4-methyl-pyrrolidine-2-carboxylic acid (24.9g, 98.7%) as a white solid (mixture of cis/trans approx. 80/20 ratio).
Step II:
tert-Butyl (2S)-2-(hydroxymethyl)-4-methyl-pyrrolidine-1 -carboxylate
To a solution of (2S)-1 -tert-butoxycarbonyl-4-methyl-pyrrolidine-2-carboxylic acid (26.6 g, 116.0 mmol) in THF (160 mL) is added 1 M Borane in THF ( 243.6 mL, 243.6 mmol) at 20 0°C. The reaction mixture is stirred at RT overnight. Then 50 mL of a saturated aqueous solution of NH4Cl is carefully added (dropwise) at 4°C, followed by 100 mL of H20. The
BOST 1803930.1 105 mixture is extracted with EtOAc and the organic phase is washed with H20, dried over Na2S04, filtered and concentrated to dryness. The residue is purified by flash column chromatography on silica gel (0 to 20% EtOAc in Hexanes) to give tert-butyl (2S)-2- (hydroxymethyl)-4-methyl-pyrrolidine-1 -carboxylate (23.5g, 94%).
Step III:
tert-Butyl (2S)-2-formyl-4-methyl-pyrrolidine-1 -carboxylate
To a solution of oxalyl chloride (319.4 mL of 2 M, 638.8 mmol) in CH2Cl2 (460 mL) is added DMSO (90.69 mL, 1.28 mol) over 30 minutes, keeping the internal temperature 10 around -60 C. tert-Butyl (2S)-2-(hydroxymethyl)-4-methyl-pyrrolidine-1 -carboxylate (55g, 255.5 mmol) in CH2Cl2 (460 mL) is then added over 50 minutes at -78°C. The reaction mixture is stirred for 20 minutes before dropwise addition of DIPEA (445 mL, 2.55 mol). The reaction mixture is stirred at -78°C for 2 hours and is allowed to warm to RT over 2 hours. To this mixture is added slowly 800 mL of 1 N HCl. After stirring, the organic phase is separated, dried over Na2S04, filtered and concentrated to dryness. The residue is purified by flash column chromatography on silica gel (0 to 20% EtOAc in Hexanes) to give tert-butyl (2S)-2-formyl-4-methyl-pyrrolidine-1 -carboxylate (48.5 g, 227.4 mmol, 85%) as a brown oil (mixture cis/trans 77/23).
20 Step IV:
tert-Butyl (2S)-2-(1 H-imidazol-2-yl)-4-methyl-pyrrolidine-1 -carboxylate
To a stirred solution of tert-butyl (2S)-2-formyl-4-methyl-pyrrolidine-1 -carboxylate (45 g, 211 mmol) in MeOH (90 mL) is added NH4OH (90 mL). Oxaldehyde (85.6g, 67.7 mL of 40 %w/v, 466.7 mmol) is added by portions (exothermic reaction). The reaction mixture is stirred at RT overnight, diluted with H20 (300 ml) and is extracted with CH2Cl2 (2 x 300ml). The aqueous phase is extracted a second time with CH2Cl2 and the combined organic layers are washed with H20, dried over Na2S04, filtered and evaporated to dryness. The residue is purified by recrystallization in EtOAc, to give 24 g of the title compound. The filtrate is evaporated to dryness and the residue is purified by flash 30 column chromatography on silica gel (25 to 100% EtOAc in Hexanes) to give 9.67 g of title compound. The two isolated solids are combined to give tert-butyl (2S)-2-(1 H-imidazol- 2-yl)-4-methyl-pyrrolidine-1 -carboxylate (33.67 g, 63.5%).
1H NMR (400 MHz, dmso, mixture of Cis and Trans isomers and its rotamers) δ 11.71 (s, 1 H), 6.85 (s, 2 H), 4.86 - 4.58 (m, 2 H), 3.75-3.5 (m, 2 H), 3.03 - 2.82 (m, 2 H), 2.36 - 2.25 (m, 1 H), 2.25 - 2.11 (m, 1 H), 1.6-1.45 (m, 1 H), 1.39 (s, minor rotamer of minor isomer), 1.37 (s, minor rotamer of major isomer), 1.15 (s, major rotamer of minor
BOST 1803930.1 106 isomer), 1.09 (s, major rotamer of major isomer) 1.005 (d, minor isomer) 0.99 (d, major isomer).
Step V:
tert-Butyl (2S,4S)-2-(4,5-diiodo-1 H-imidazol-2-yl)-4-methyl-pyrrolidine-1 -carboxylate To a stirred solution of tert-butyl (2S)-2-(1 H-imidazol-2-yl)-4-methyl-pyrrolidine-1 - carboxylate (36.6 g, 145.6 mmol) in CH2Cl2 (366.0 mL) at 5°C is added 1 -iodopyrrolidine- 2,5-dione (68.80 g, 305.8 mmol) over 15 minutes. After 1 hour, a 10% sodium thiosulfate solution (800ml) is added. After stirring for 10 minutes, the organic phase is separated, 10 washed with water, dried over Na2S04, filtered and evaporated to dryness. The crude is purified by flash column chromatography on silica gel (0 to 50% EtOAc in Hexanes) to give tert-butyl (2S,4S)-2-(4,5-diiodo-1 H-imidazol-2-yl)-4-methyl-pyrrolidine-1 -carboxylate (52.3 g, 65.7%).
1H NMR (400 MHz, dmso, 2.5:1 mixture of rotamers), peaks for the major rotamer δ 12.70 (s, 1 H), 4.57 (dd, 1 H), 3.62 - 3.52 (m, 1 H), 2.95 (t, 1 H), 2.35 - 2.0 (m, 2 H), 1.50 (dd, 1 H), 1.10 (s, 9 H), 1.01 (d, 3 H).
tert-Butyl (2S,4R)-2-(4,5-diiodo-1 H-imidazol-2-yl)-4-methyl-pyrrolidine-1 -carboxylate (10.5 g, 13%) is also isolated.
1H NMR (400 MHz, DMSO, 1.2:1 mixture of rotamers), peaks for the major rotamer, δ 20 12.65 (br s, 1 H), 4.69 (dd,1 H), 3.69 - 3.50 (m, 1 H), 2.82 (t, 1 H), 2.45-2.3 (m, 1 H), 1.91 - 1.68 (m, 2 H), 1.15 (s, 9 H), 0.97 (d, J = 6.6 Hz, 3 H). Selected peaks for the minor rotamer: 4.77 (d), 1.38 (s).
Step VI:
tert-Butyl (2S,4S)-2-(5-iodo-1 H-imidazol-2-yl)-4-methyl-pyrrolidine-1 -carboxylate
A solution of LiCl in THF (3.9 mL of a 0.5 M solution, 1.99 mmol) is added to tert-butyl (2S,4S)-2-(4,5-diiodo-1 H-imidazol-2-yl)-4-methyl-pyrrolidine-1 -carboxylate (1 g, 1.99 mmol). After stirring for 5 minutes at RT the reaction mixture is cooled down to -20° C and a solution of methyl magnesium chloride in THF (946.7 μΙ_ of 2.1 M, 1.99 mmol) is 30 added dropwise. After stirring for 20 minutes at -20° C, a solution of isopropyl magnesium chloride in THF (3.2 mL of 1.24 M, 3.97 mmol) is added dropwise. The reaction mixture is slowly warmed up to RT and stirred for 2 hours. The reaction mixture is cooled down to 0°C and a saturated aqueous NH4Cl solution is slowly added followed by water. This mixture is then extracted with EtOAc (3 x 20 mL), and the combined organic layers are washed with brine, dried over Na2S04, filtered and concentrated to dryness. The residue is purified by flash column chromatography on silica gel (0 to 25%
BOST 1803930.1 107 EtOAC/Hexane) to afford tert-butyl (2S,4S)-2-(5-iodo-1 H-imidazol-2-yl)-4-methyl- pyrrolidine-1 -carboxylate (636 mg, 83%) as a white solid.
1H NMR (400 MHz, dmso, 2:1 mixture of rotamers), peaks for the major rotamer, δ 12.15 (s, 1 H), 7.19 (s, 1 H), 4.65 - 4.57 (m, 1 H), 3.65 - 3.55 (m, 1 H), 2.95 (t, 1 H), 2.4-2.1 (m, 2 H), 1.52 (dd, 1 H), 1.10 (s, 9 H), 1.00 (d, 3 H). Selected peaks for minor rotamer, 12.09 (s), 7.15 (s), 1.36 (s).
Step VII:
5-lodo-2-[(2S,4S)-4-methylpyrrolidin-2-yl]-1 H-imidazole as a HCl salt
10 To a solution of tert-butyl (2S,4S)-2-(5-iodo-1 H-imidazol-2-yl)-4-methyl-pyrrolidine-1 - carboxylate (1.6g, 4.242 mmol) in MeOH (16ml_) is added a 4M HCl in dioxane solution (16 ml) at 0°C. The reaction mixture is stirred at RT overnight and evaporated to dryness to afford 5-iodo-2-[(2S,4S)-4-methylpyrrolidin-2-yl]-1 H-imidazole (1.37g, 92.5%) as a yellow solid.
1H NMR (400 MHz, dmso) δ 9.98 (br s, 1 H), 9.17 (br s, 1 H), 7.46 (s, 1 H), 4.8-4.6 (m, 1 H), 3.45-3.35 (m, 1 H), 2.9-2.75 (m, 1 H), 2.5-2.3 (m, 2 H), 1.88-1.78 (m, 1 H), 1.09 (d, 3 H).
Step VIII:
20 Methyl N-[(1 S)-1 -[(2S,4S)-2-(5-iodo-1 H-imidazol-2-yl)-4-methyl-pyrrolidine-1 -carbonyl]-2- methyl-propyljcarbamate
To a solution of (2S)-2-(methoxycarbonylamino)-3-methyl-butanoic acid (644.5 mg, 3.68 mmol) in DMF (25 mL) at 0°C is added HATU (1.4 g, 3.68 mmol), DIPEA ( 2.5ml_, 14.57 mmol) followed by 5-iodo-2-[(2S,4S)-4-methylpyrrolidin-2-yl]-1 H-imidazole as HCl salt (1.28 g, 3.64 mmol). The reaction mixture is stirred at RT for 20 hours, diluted with EtOAc and H20. The organic phase is separated, washed with H20, dried over Na2S04, filtered and concentrated to dryness. The residue is purified by flash column chromatography on silica gel (0 to 100% EtOAC/Hexane) to afford methyl N-[(1 S)-1 - [(2S,4S)-2-(5-iodo-1 H-imidazol-2-yl)-4-methyl-pyrrolidine-1 -carbonyl]-2-methyl- 30 propyl]carbamate(1.3g, 87.3%) as a white solid.
1H NMR (400 MHz, dmso) δ 12.03 (s, 1 H), 7.19 (d, 1 H), 7.18 (s, 1 H), 4.83 (dd, 1 H), 4.16 - 3.91 (m, 2 H), 3.52 (s, 3 H), 3.16 (t, 1 H), 2.38-2.08 (m, 2 H), 1.9-1.72 (m, 1 H), 1.72-1.61 (m, 1 H), 1.06 (d, 3 H), 0.76 (d, 3 H), 0.755 (m, 3 H).
BOST 1803930.1 108 Intermediate 5
Methyl (S)-1-((2S,4R)-2-(4-iodo-1 H-imidaz
1 -oxobutan-2-ylcarbamate
Figure imgf000110_0001
Step I:
(2S,4R)-tert-Butyl 2-(4-iodo-1 H-imidazol-2-yl)-4-methylpyrrolidine-1 -carboxylate
A solution of LiCl in THF (2.000 mL of 0.5 M, 1.000 mmol) is added to tert-butyl (2S,4R)-
2-(4,5-diiodo-1 H-imidazol-2-yl)-4-methyl-pyrrolidine-1 -carboxylate (503.12 mg, 1.000
10 mmol) in 25 mL flask. The mixture is stirred at RT for 5 minutes, cooled to -20° C, and a solution of 3 M methyl magnesium chloride in THF (333.3 μΙ_, 1.000 mmol) is added drop wise. The reaction mixture is stirred at -20° C for 20 minutes, and a solution of isopropyl magnesium chloride in THF (846.2 μΙ_ of 1.3 M, 1.100 mmol) is added drop wise. The reaction mixture is slowly warmed up to RT over 1 hour, and left overnight. An additional amount of isopropyl magnesium chloride in THF (423.1 μΙ_ of 1.3 M, 0.5500 mmol) is added at RT, and the mixture is stirred for 1 hour. Another additional amount of isopropyl magnesium chloride in THF (423.1 μΙ_ of 1.3 M, 0.5500 mmol) is added, and the mixture is stirred at RT for 2 hours. An additional amount of isopropyl magnesium chloride in THF (423.1 μΙ_ of 1.3 M, 0.5500 mmol) is added, and the mixture is stirred for
20 30 minutes. The reaction mixture is poured into cold saturated aq. NH4Cl solution, extracted with EtOAc (3 x 20 mL), and the combined extracts are washed with brine, dried over Na2S04, filtered and concentrated to dryness. The residue is purified by flash column chromatography on silica gel (0 to 20% EtOAC/CH2Cl2) to afford (2S,4R)-tert-butyl 2-(4-iodo-1 H-imidazol-2-yl)-4-methylpyrrolidine-1 -carboxylate (240 mg, 0.6133 mmol, 61.34%) as white solid.
Rf = 0.5 (EA:Hex, 1 :1 ).
BOST 1803930.1 109 1H NMR (400 MHz, CDCl3) δ 10.59 (s, 1 H), 7.02 (s, 1 H), 4.90 (d, J = 8.1 Hz, 1 H), 3.55 - 3.39 (m, 1 H), 3.05 - 2.82 (m, 2H), 2.6-2.45 (m, 1 H), 1.80 - 1.65 (m, 1 H), 1.46 (s, 9H), 1.06 (dd, J = 6.7 Hz, 3H).
Step II:
4-lodo-2-((2S,4R)-4-methylpyrrolidinium-2-yl)-1 H-imidazol-3-ium chloride
To a stirred solution of tert-butyl (2S,4R)-2-(4-iodo-1 H-imidazol-2-yl)-4-methyl- pyrrolidine-1 -carboxylate (229 mg, 0.6071 mmol) in MeOH (1 mL) is added HCl in dioxane (1.518 mL of 4 M, 6.071 mmol). The resulting solution is stirred at RT and a thick 10 precipitate is formed within 20 min The precipitate is diluted with diethyl ether, filtered, and dried under high vacuum to afford 4-iodo-2-((2S,4R)-4-methylpyrrolidinium- 2-yl)-1 H-imidazol-3-ium chloride (185 mg, 0.5250 mmol, 86.48%) as a white solid.
1H NMR (400 MHz, DMSO-d6) δ 10.30 (br s, 1 H), 9.24 (br s, 1 H), 7.46 (s, 1 H), 4.85-4.7 (m, 1 H), 3.5-3.35 (m, 1 H), 2.85-2.72 (m, 1 H), 2.61 - 2.5 (m, 1 H), 2.38 - 2.24 (m, 1 H), 1.98 - 1.85 (m, 1 H), 1.05 (d, J = 6.8 Hz, 3H).
Step III:
Methyl (S)-1 -((2S,4R)-2-(4-iodo-1 H-imidazol-2-yl)-4-methylpyrrolidin-1 -yl)-3-methyl-1 - oxobutan-2-ylcarbamate
20 To a cold (0-4 °C) stirred solution of (2S)-2-(methoxycarbonylamino)-3-methyl-butanoic acid (50.10 mg, 0.2860 mmol), 4-iodo-2-((2S,4R)-4-methyl- pyrrolidinium-2-yl)-1 H-imidazol-3-ium chloride (96 mg, 0.2724 mmol) and HATU (108.7 mg, 0.2860 mmol) in DMF (1.918 mL) is added DIPEA (140.9 mg, 189.9 μΙ_, 1.090 mmol). The reaction mixture is slowly warmed up to RT, stirred overnight, diluted with water (5 mL), and extracted with ethyl acetate (3 x 10 mL). The combined extracts are washed with a saturated aqueous sodium bicarbonate solution, brine, dried over Na2S04, and concentrated to dryness. The residue is purified by flash column chromatography on silica gel (50% to 100% EtOAC/hexanes) to afford methyl (S)-1 -((2S,4R)-2-(4-iodo-1 H- imidazol-2-yl)-4-methylpyrrolidin-1 -yl)-3-methyl-1 -oxobutan-2-ylcarbamate (119 mg, 30 0.2595 mmol, 95.26%) as white solid.
Rf = 0.47 (EtOAc).
1H NMR (400 MHz, CD3OD) δ 7.06 (s, 1 H), 5.13 (dd, J = 8.4, 3.7 Hz, 1 H), 4.14 (d, J = 7.5 Hz, 1 H), 3.92 (dd, J = 9.7, 7.1 Hz, 1 H), 3.62 (s, 3H), 3.43 (dd, J = 9.6, 8.0 Hz, 1 H), 2.71 - 2.6 (m, 1 H), 2.30-1.81 (m, 3H), 1.09 (d, J = 6.7 Hz, 3H), 0.88 (d, J = 6.7 Hz, 3H), 0.861 (d, J = 6.7 Hz, 3H).
LC/MS : m/z 434.9 (M + H+).
BOST 1803930.1 110 Intermediate 6
Methyl N-[(1S)-1-[(2S,4S)-2-(4-iodo-1 H-imidazol-2-yl)-4-methyl-pyrrolidine-1^ carbonyl]-2-methyl-propyl]-N-methyl-carbamate
Figure imgf000112_0001
To a stiring solution of 4-iodo-2-[(2S,4S)-4-methylpyrrolidin-2-yl]-1 H-imidazole (250 mg, 0.90 mmol), (2S)-2-[methoxycarbonyl(methyl)amino]-3-methyl-butanoic acid (179.2 mg, 0.94 mmol) and 2,4,6-collidine (357.7 μΙ_, 2.7 mmol) in DMF (4 mL) is added HATU (581.2 mg, 0.94 mmol) at 0°C. The reaction mixture is stirred at RT overnight and diluted with 10 EtOAc. The organic layer is washed with H20, brine, dried over Na2S04, filtered and concentrated to dryness. The residue is purified by flash column chromatography on silica gel (10 to 100% EtOAc/Hexane) to afford Methyl N-[(1 S)-1 -[(2S,4S)-2-(4-iodo-1 H- imidazol-2-yl)-4-methyl-pyrrolidine-1 -carbonyl]-2-methyl-propyl]-N-methyl-carbamate (180mg, 44.5%).
1H NMR (400 MHz, CD3OD): δ [ppm] 7.04 (s, 1 H), 4.89(m, 1 H), 4.48(d, 1 H), 4.33(d, 0.5H), 4.19 (m, 1 H), 4.9 (m, 0.5H), 3.7 (s, 3H), 2.79 (s, 3H), 2.4 (m, 1 H), 2.25-2.2 (m, 1 H), 2.11 -2.05(m, 1 H), 1.79-1.7 (m, 1 H), 1.12 (s, 3H), 0.8 (dd, 3H), 0.76 (dd, 3H).
LC/MS: m/z = 448.95(M+H+).
20 Intermediate 7
Methyl N-[( 1 S)- 1 -[(2S)-2-(4-ethynyl- 1 H-imidazol-2-yl)pyrrolidine- 1 -carbonyl]-2- meth l-propyl]carbamate
Figure imgf000112_0002
Step I
Methyl N-[(1 S)-2-methyl-1 -[(2S)-2-[4-(2-trimethylsilylethynyl)-1 H-imidazol-2- yl]pyrrolidine-1 -carbonyl]propyl]carbamate
Ethynyl(trimethyl)silane (91.1 mg, 131.1 μΙ_, 0.93 mmol), methyl N-[(1 S)-1 -[(2S)-2-(4- iodo-1 H-imidazol-2-yl)pyrrolidine-1 -carbonyl]-2-methyl-propyl]carbamate (130 mg, 0.31 mmol), Pd(dppf)Cl2-DCM (25.2 mg, 0.031 mmol), TEA (62.60 mg, 86.2 μΙ_, 0.62 mmol),
BOST 1803930.1 111 and Cul (11.78 mg, 0.062 mmol) are dissolved in 10 mL of DMF. The system is purged with nitrogen and the mixture is heated to 70° C overnight under nitrogen. After evaporation of the solvent under vacuum, the residue is purified by flash column chromatography on silica gel (0 to 5% methanol/CH2Cl2) to afford methyl N-[(1 S)-2- methyl-1 -[(2S)-2-[4-(2-trimethylsilylethynyl)-1 H-imidazol-2-yl]pyrrolidine-1 - carbonyl]propyl]carbamate (100 mg).
1H NMR (400 MHz, CDCl3): δ [ppm] 10.35 (s, 1 H), 6.93 (s, 1 H), 5.50 (d, 1 H), 4.95 (m, 1 H), 4.07 (m, 1 H), 3.37-3.69 (m, 5H), 1.69-2.10 (m, 5H), 0.60-0.83 (m, 6H), 0.00 (m, 9H). LC/MS : m/z 391.00 (M + H+).
10
Step II:
Methyl N-[(1 S)-1 -[(2S)-2-(4-ethynyl-1 H-imidazol-2-yl)pyrrolidine-1 -carbonyl]-2-methyl- propyljcarbamate
To a solution of methyl N-[(1 S)-2-methyl-1 -[(2S)-2-[4-(2-trimethylsilylethynyl)-1 H- imidazol-2-yl]pyrrolidine-1 -carbonyl]propyl]carbamate (100 mg, 0.256 mmol) in 3 mL of THF is added 1M TBAF/THF (384 L, 0.38 mmol). The mixture is stirred at RT for 20 minutes and the solvent is removed under reduced pressure. The residue is purified by flash column chromatography on silica gel (0 to 5% methanol/CH2Cl2) to afford methyl N- [(1 S)-1 -[(2S)-2-(4-ethynyl-1 H-imidazol-2-yl)pyrrolidine-1 -carbonyl]-2-methyl- 20 propyljcarbamate (56 mg).
Intermediate 8
Methyl (2S,3R)-1-((2S,4S)-2-(4-iodo-1H-imidazol-2-yl)-4-methylpyrrolidin-1-yl)-3- methoxy- 1 -oxobutan-2-ylcarbamate
Figure imgf000113_0001
Step I:
(2S,3R)-3-methoxy-2-(methoxycarbonylamino)butanoic acid
To a solution of (2S,3R)-2-amino-3-methoxy-butanoic acid (2 g, 15.02 mmol) in aq. NaOH (14.87 mL of 1 M, 14.87 mmol) is added Na2C03 (827.8 mg, 7.810 mmol). The reaction 30 mixture is stirred for few minutes until solution become clear, and cooled to ice-bath temperature. Methyl chloroformate (1.533 g, 1.253 mL, 16.22 mmol) is added drop wise over a period of 10 minutes and the reaction mixture is stirred for 4.5 hours at RT. The
BOST 1803930.1 1 1 9 aqueous solution is washed with diethyl ether (3 x 30 mL), cooled to ice-bath temperature, acidified with HClconc, extracted with CH2Cl2 (3 x 30 mL). The combined organic extracts are washed with brine, dried over Na2S04, filtered, and concentrated to afford (2S,3R)-3-methoxy-2-(methoxycarbonylamino)butanoic acid (1.96 g, 10.25 mmol, 68.25%) as white solid.
1H NMR (400 MHz, CD3OD) δ 4.92 (br s, 1 H), 4.18 (d, 1 H), 3.93 (td, 1 H), 3.65 (s, 3 H), 3.29 (s, 3H), 1.16 (d, 3 H).
Step II:
10 Methyl (2S,3R)-1 -((2S,4S)-2-(4-iodo-1 H-imidazol-2-yl)-4-methylpyrrolidin-1 -yl)-3-methoxy- 1 -oxobutan-2-ylcarbamate
To a cold (0-4°C) stirred solution of 5-iodo-2-[(2S,4S)-4-methylpyrrolidin-1 -ium-2-yl]-1 H- imidazole hydrochloride (90 mg, 0.2564 mmol) and (2S,3R)-3-methoxy-2- (methoxycarbonylamino)butanoic acid (51.47 mg, 0.2692 mmol) in DMF (1.800 mL) is sequentially added HATU (102.4 mg, 0.2692 mmol) and DIPEA (132.6 mg, 178.7 μΙ_, 1.026 mmol). The reaction mixture is slowly warmed up to RT, stirred overnight, diluted with water (5 mL), and extracted with EtOAc (3 x 10 mL). The combined extracts are washed with saturated aqueous sodium bicarbonate solution, brine, dried over Na2S04, and concentrated to dryness. The residue is purified by flash column chromatography on 20 silica gel (50 to 100% EtOAc / hexanes). The residue is dissolved in toluene and concentrated to dryness to remove azeotropically trace amounts of DMF to afford methyl (2S,3R)-1 -((2S,4S)-2-(4-iodo-1 H-imidazol-2-yl)-4-methylpyrrolidin-1 -yl)-3-methoxy-1 - oxobutan-2-ylcarbamate (107 mg, 0.2376 mmol, 92.72%) as solid.
Rf = 0.15 (EtOAc-Hexanes, 7:3).
1H NMR (400 MHz, CDCl3) δ 10.48 (s, 1 H), 6.99 (s, 1 H), 5.63 (d, 1 H), 5.15 (t, 1 H), 4.51 (br s, 1 H), 3.94 - 3.84 (m, 1 H), 3.68 (s, 3 H), 3.6-3.5 (m, 1 H), 3.15 (s, 3 H), 3.07 (t, 1 H), 2.47 (t, 2 H), 2.35-2.2 (m, 1 H), 1.7-1.55 (m, 1 H), 1.13 (d, 3 H), 1.08 (d, 3 H).
BOST 1803930.1 113 Intermediate 9
Methyl N-[(1S)-1-[(2S,4S)-2-(5-iodo-1 H-imidazol-2-yl)-4-methyl-pyrrolidine-1- carbonyl]-2-methyl-propyl]carbamate
Figure imgf000115_0001
tert-Butyl (2S)-4-methyl-2-(4-methyl-1 H-imidazol-2-yl)pyrrolidine-1 -carboxylate
A stirred solution of tert-butyl (2S)-2-formyl-4-methyl-pyrrolidine-1 -carboxylate (282 mg, 10 1.322 mmol) in MeOH (5,6 mL) is cooled to -20° C and gaseous ammonia is bubbled for 10 minutes. 2-Oxopropanal (35% w/w in water, 1.905 g, 9.254 mmol) is added and the reaction mixture is warmed to room temperature over one hour. The mixture is then heated to 65° C for 1 hour, concentrated and 5ml_ of water is added to the residue. The aqueous layer is extracted with CH2Cl2 (3 x 10ml_). The combined organic layers are dried over Na2S04, filtered, and evaporated to dryness. The residue is purified by flash column chromatography on silica gel (0 to 20% MeOH in CH2Cl2) to afford tert-Butyl (2S)- 4-methyl-2-(4-methyl-1 H-imidazol-2-yl)pyrrolidine-1 -carbo-xylate 307 mg (88%).
Step II
20 tert-butyl (2S,4S)-2-(5-iodo-4-methyl-1 H-imidazol-2-yl)-4-methyl-pyrrolidine-1 - carboxylate
To a stirred solution of tert-butyl (2S)-4-methyl-2-(4-methyl-1 H-imidazol-2-yl)pyrrolidine- 1 -carboxylate (307 mg, 1.013 mmol) in CH2Cl2 (15 mL) is added N-iodosuccinimide (240 mg, 1.013 mmol) at 5°C. The reaction mixture is stirred for one hour and 2 mL of water is added. The organic layer is separated, dried over Na2S04, and evaporated to dryness. The residue is purified by flash column chromatography on silica gel (12 to 100% EtOAc in
BOST 1803930.1 114 Hexanes) to give tert-butyl (2S,4S)-2-(5-iodo-4-methyl-1 H-imidazol-2-yl)-4-methyl- pyrrolidine-1 -carboxylate (246 mg, 62%).
Step III:
4- lodo-5-methyl-2-[(2S,4S)-4-methylpyrrolidin-2-yl]-1 H-imidazole hydrochloride tert-Butyl (2S,4S)-2-(5-iodo-4-methyl-1 H-imidazol-2-yl)-4-methyl-pyrrolidine-1 - carboxylate (125 mg, 0.320 mmol) is stirred with HCl (4M in dioxane, 2ml_) overnight. The reaction mixture is then concentrated to afford 5-iodo-4-methyl-2-[(2S,4S)-4- methylpyrrolidin-2-yl]-1 H-imidazole hydrochloride used as is for the next step.
10
Step IV:
Methyl N-[(1 S)-1 -[(2S,4S)-2-(5-iodo-4-methyl-1 H-imidazol-2-yl)-4-methyl-pyrrolidine-1 - carbonyl]-2-methyl-propyl]carbamate
5- iodo-4-methyl-2-[(2S,4S)-4-methylpyrrolidin-2-yl]-1 H-imidazole hydrochloride (0.320 mmol) and (2S)-2-(methoxycarbonylamino)-3-methyl-butanoic acid (56 mg, 0.320 mmol) are dissolved in DMF (2 mL) and the mixture is cooled in an ice bath. DIPEA (167 μΙ_, 0.960 mmol) is added followed by HATU (134 g, 0.352 mmol). The reaction mixture is warmed to room temperature, stirred for 20 hours, diluted with 5 mL of saturated NaHC03 (aq.) and extracted with EtOAc. The combined organic layers are washed with
20 water, dried over Na2S04, and evaporated to dryness. The residue is purified by flash column chromatography on silica gel (0 to 20% MeOH/CH2Cl2) to afford methyl N-[(1 S)-1 - [(2S,4S)-2-(5-iodo-4-methyl-1 H-imidazol-2-yl)-4-methyl-pyrrolidine-1 -carbonyl]-2-methyl- propyljcarbamate (125 mg, 88% for the last two steps).
BOST 1803930.1 115 Intermediate 10
Methyl N-[(1S)-1-[(2S)-2-(5-iodo-4-methyl-1 H-imid^
2-meth l-propyl]carbamate
Figure imgf000117_0001
Step I:
tert-butyl (2S)-2-(4-methyl-1 H-imidazol-2-yl)pyrrolidine-1 -carboxylate
A stirred solution of tert-butyl (2S)-2-formyl-pyrrolidine-1 -carboxylate (540 mg, 2.710 mmol) in MeOH (10,8 mL) is cooled to -20° C and gaseous ammonia is bubbled for 10 minutes. 2-oxopropanal (35% w/w in water, 3.9 g, 19.0 mmol) is then added and the 10 reaction mixture is warmed to RT over one hour. The mixture is then heated to 65° C for 1 hour. The solvent is evaporated and 5mL of water is added to the residue. The product is then extracted with EtOAc (3 x 10 mL). The combined organic layers are dried over Na2S04, filtered, and evaporated to dryness. The residue is purified by flash column chromatography on silica gel (20 to 100% EtOAc in hexanes) to give tert-butyl (2S)-2-(4- methyl-1 H-imidazol-2-yl)pyrrolidine-1 -carboxylate (644 mg, 88%).
Step II:
tert-Butyl (2S)-2-(5-iodo-4-methyl-1 H-imidazol-2-yl)-pyrrolidine-1 -carboxylate
To a stirred solution of tert-butyl (2S)-2-(4-methyl-1 H-imidazol-2-yl)pyrrolidine-1 - 20 carboxylate (625 mg, 2.178 mmol) in CH2Cl2 (5.5 mL) at 5°C is added N-iodosuccinimide (516 mg, 2.178 mmol). The reaction is stirred for one hour and 5 mL of water is added. The organic layer is separated, dried over Na2S04, and evaporated to dryness. The residue is purified by flash column chromatography on silica gel (0 to 20% MeOH in CH2Cl2) to give tert-butyl (2S)-2-(5-iodo-4-methyl-1 H-imidazol-2-yl)-pyrrolidine-1 - carboxylate.
BOST 1803930.1 116 Step III:
5-iodo-4-methyl-2-[(2S)-pyrrolidin-2-yl]-1 H-imidazole hydrochloride
tert-butyl (2S)-2-(5-iodo-4-methyl-1 H-imidazol-2-yl)-pyrrolidine-1 -carboxylate
(2.178 mmol from previous step) is stirred with HCl (4M in dioxane, 5.4 mL) for one hour. Diethyl ether is added (5 ml) and a precipitate is formed. The precipitate is collected by filtration and dried under vacuum to afford 5-iodo-4-methyl-2-[(2S)- pyrrolidin-2-yl]-1 H-imidazole hydrochloride (505mg, 74% for the last two steps).
10 Step IV:
Methyl N-[(1 S)-1 -[(2S)-2-(5-iodo-4-methyl-1 H-imidazol-2-yl)-pyrrolidine-1 -carbonyl]-2- methyl-propyljcarbamate
5-iodo-4-methyl-2-[(2S,4S)-pyrrolidin-2-yl]-1 H-imidazole hydrochloride (492 mg, 1.569 mmol) and (2S)-2-(methoxycarbonylamino)-3-methyl-butanoic acid (275 mg, 1.569 mmol) are dissolved in DMF (4.9 mL) and the mixture is cooled in an ice bath. DIPEA (820 μΙ_, 4.707 mmol) is added followed by HATU (656 g, 1.726 mmol). The reaction mixture is warmed to room temperature and stirred for 20 hours. The reaction mixture is then diluted with 10 mL of saturated NaHC03 (aq.) and extracted with EtOAc. The combined organic layers are dried over Na2S04, filtered, and evaporated to dryness. The residue is 20 diluted in 5 mL of xylene and evaporated again. The residue is purified by flash column chromatography on silica gel (0 to 20% MeOH/CH2Cl2) to afford methyl N-[(1 S)-1 -[(2S)-2- (5-iodo-4-methyl-1 H-imidazol-2-yl)-pyrrolidine-1 -carbonyl]-2-methyl-propyl]carbamate (507 mg, 74%).
Intermediate 1 1
4, 7-diethyny I- 1 , 3-benzodioxole
Figure imgf000118_0001
Step I:
Trimethyl-[2-[7-(2-trimethylsilylethynyl)-1 ,3-benzodioxol-4-yl]ethynyl]silane
30 To a stirred solution of 4, 7-diiodo-1 , 3-benzodioxole (500 mg, 1.3 mmol), Pd(PPh3)2Cl2 (93.8 mg, 0.13 mmol), Cul (50.9 mg, 0.26 mmol) in DMF (5mL) is added ethynyl(trimethyl)silane (472 μί, 3.3 mmol) and TEA (931 μί, 6.6 mmol). The reaction mixture is stirred at 80°C for 16 hours, diluted with EtOAc, H20, and filtered on celite. The organic phase is separated, dried over Na2S04, filtered and concentrated to dryness.
BOST 1803930.1 117 The residue is purified by flash column chromatography on silica gel (0 to 10% EtOAc in Hexanes) to give trimethyl-[2-[7-(2-trimethylsilylethynyl)-1 ,3-benzodioxol-4- yl]ethynyl]silane (344mg, 81%).
Step II:
4,7-diethynyl-1 ,3-benzodioxole
To a solution of trimethyl-[2-[7-(2-trimethylsilyl-ethynyl)-1 ,3-benzodioxol-4- yl]ethynyl]silane (340 mg, 1.08 mmol) in MeOH (6.8 mL) is added K2C03 (328.7 mg, 2.37 mmol). The reaction mixture is stirred at RT for 2 hours and evaporated to dryness. The 10 residue is diluted with EtOAc and H20. The organic phase is separated, dried over Na2S04, filtered and concentrated to give 4, 7-diethynyl-1 ,3-benzodioxole (180mg, 98%) as a brown solid.
Intermediate 12
2, 6-Diethynylnaphthalene
Figure imgf000119_0001
Step I:
2,6-Bis((trimethylsilyl)ethynyl)naphthalene
20
To a suspension of 2,6-dibromonaphthalene (500 mg, 1.748 mmol), Cul (66.58 mg, 0.3496 mmol) and Pd(dppf)Cl2-DCM (214.1 mg, 0.2622 mmol) in DMF (8 mL) is sequentially added TEA (707.5 mg, 974.5 μΐ, 6.992 mmol) and cold ethynyl(trimethyl)silane (377.7 mg, 543.5 il, 3.846 mmol) under nitrogen atmosphere. The reaction mixture is heated at 80° C for 7.5 hrs in a sealed tube and a precipitate is formed in the reaction tube after few hours of heating. The reaction mixture is cooled to RT, and filtered off. The white precipitate is washed with DMF (3.0 mL), dried under high vacuum to afford 2,6- bis((trimethylsilyl)ethynyl)naphthalene (620 mg) as white solid.
1 H NMR spectra showed 2.6:1 mixture of the desired compound and triethyl ammonium 30 bromide, this mixture is used as such in the next step without further purification.
1H NMR (400 MHz, CDCl3) δ 7.91 (s, 2 H), 7.67 (d, 2 H), 7.47 (d, 2 H), 0.27 (s, 18 H).
Step II:
2, 6-Diethynylnaphthalene
BOST 1803930.1 118 To a stirred suspension of trimethyl-[2-[6-(2-trimethylsilylethynyl)-2- naphthyl]ethynyl]silane (590 mg, 1.472 mmol) in MeOH (10 mL) is added K2C03 (447.5 mg, 3.238 mmol) in one portion, and the heterogeneous mixture is stirred at RT for 2.5 hours. To this reaction mixture is added CH2Cl2 (3.0 mL) and the mixture is stirred for an additional 30 minutes, concentrated, diluted with water (6 mL), and extracted with CH2Cl2 (3 x 10 mL). The combined organic extracts are washed with brine, dried over Na2S04> filtered, and concentrated to dryness. The residue is purified by flash column chromatography on silica gel (0 to 5% EtOAc in Hexanes) to give 2,6-diethynylnaphthalene (157 mg, 0.8901 mmol, 60.46%) as white solid.
10 Rf = 0.37 (EA: hex, 1 :20).
1H NMR (400 MHz, CDCl3) δ 8.00-7.95 (m, 2 H), 7.73 (d, 2 H), 7.53 (dd, 2 H), 3.17 (s, 2 H).
Intermediate 13
1 ,4-Diethynyl-2,5-dimethyl-benzene
Figure imgf000120_0001
Step I:
1 ,4-Dimethyl-2,5-bis-trimethylsilyl)ethynyl-benzene
1 ,4-Dimethyl-2,5-bis-trimethylsilyl)ethynyl-benzene is prepared from 1 ,4-dibromo-2,5- 20 dimethyl-benzene according to the procedure reported for 2,6- bis((trimethylsilyl)ethynyl)naphthalene.
Step II:
1 ,4-Diethynyl-2,5-dimethyl-benzene
To a stirred suspension of 1 ,4-dimethyl-2,5-bis-trimethylsilyl)ethynyl-benzene
(700 mg, 2.345 mmol) in MeOH (14.70 mL) is added dipotassium carbonate (713.0 mg, 5.159 mmol) in one portion and the heterogeneous mixture is stirred at RT for 2.5 hours. To this mixture is added CH2Cl2 (3.0 mL), and the mixture is stirred for an additional 30 minutes, concentrated, diluted with water (6 mL), and extracted with CH2Cl2 (3 x 15 30 mL). The combined organic extracts are washed with brine, dried over Na2S04, filtered and concentrated to dryness. The residue is purified by flash column chromatography on silica gel (0 to 5% MeOH in CH2Cl2) to give 1 ,4-diethynyl-2,5-dimethyl-benzene (248 mg, 1.608 mmol, 68.58%) as light yellow solid.
BOST 1803930.1 119 Rf = 0.43 (Hexanes).
1H NMR (400 MHz, CDCl3) δ 7.29 (s, 2 H), 3.31 (s, 2 H), 2.37 (s, 6 H).
Intermediate 14
1 ,4-Diethynyl-2-methyl-benzene
Figure imgf000121_0001
The title compound is synthesized from 1 ,4-dibromo-2-methyl benzene as described in Intermediate 13.
10 Intermediate 15
-Diethynyl-thieno[3,2-b]thiophene
Figure imgf000121_0002
The title compound is synthesized from 2,5-Dibromo-thieno[3,2-b]thiopheneas described in Intermediate 13.
Intermediate 16
-Diethynyl-thieno[3,2-b]thiophene
Figure imgf000121_0003
The title compound is synthesized from 2,5-Dibromo-thieno[3,2-b]thiopheneas described 20 in Intermediate 13.
BOST 1803930.1 120 Intermediate 17
(2S, 4S)-4-methyl-N-(t-butoxycarbonyl)prolinol
Figure imgf000122_0001
Step I:
Ethyl-(2S)-pyroglutamate
To a solution of L-pyroglutamic acid (445 g, 3.45 mol) in ethanol (3.6 L) was added 98% sulfuric acid (18 mL). The resulting reaction mixture was stirred at room temperature 10 overnight. Sodium carbonate (140 g) was added and the stirring was continued for an additional 1.5 hr. The suspension was filtered and the filtrate was evaporated under reduced pressure. The residue was azeotroped with dichloromethane to afford 541 g (100%) of ethyl-(2S)-pyroglutamate as a viscous oil. This material was used in the next step without any further purification.
Step II:
Ethyl-(2S)-N-(t-butoxycarbonyl)pyroglutamate
To a solution of ethyl L-pyroglutamate (542 g, 3.45 mol), dimethylaminopyridine (42.14 g, 3.79 mol), and triethylamine (577 mL, 4.139 mol) in dichloromethane (4 L) was added 20 in portions BOC anhydride (827.8 g, 3.79 mol). The resulting mixture was stirred at room temperature overnight. The reaction mixture was washed with saturated aqueous ammonium chloride solution. The dichloromethane layer was separated, dried with magnesium sulfate, filtered, and evaporated in vacuo to afford 887.4 g (100%) of (ethyl- (2S)-N-(t-butoxycarbonyl)pyroglutamate as a light red oil that solidified upon standing.
BOST 1803930.1 121 The crude product contained traces of dimethylaminopyridine and dichloromethane but was clean enough to use in the next step without further purification.
Step III:
Ethyl-(2S)-4-(N,N-dimethylaminomethylidene-N-(t-butoxylcarbonyl)pyroglutamate To a solution of ethyl-(2S)-N-(t-butoxycarbonyl)pyroglutamate (150 g, 583 mmol) in 1 ,2- dimethoxylethane (1.5 L) was added 1 -t-butoxy-N,N,N',N'-tetramethylmethanediamine (162 g, 932.8 mmol). The reaction was heated to reflux overnight, cooled, and evaporated in vacuo. The residue was triturated with hexanes and filtered to afford 170 10 g (93%) of ethyl-(2S)-4-(N,N-dimethylaminomethylidene-N-(t- butoxycarbonyl)pyroglutamate as a red solid.
Step IVA:
Ethyl-(2S)-4-methylene-N-(t-butoxycarbonyl)pyroglutamate
To a solution of ethyl-(2S)-4-(N,N-dimethylaminomethylidene-N-(t- butoxycarbonyl)pyroglutamate (23.6 g, 75.4 mmol) in tetrahydrofuran (120 mL) was added 1 N HCl (70 mL). The reaction stirred at room temperature for two hours. The layers were separated and the aqueous layer was extracted with an additional 50 mL of tetrahydrofuran. The tetrahydrofuran layers were combined and potassium carbonate 20 (14.9 g, 107.5 mmol) and 37% formaldehyde in water 60 mL) were added. The mixture was stirred for 45 minutes. The layers were separated and the tetrahydrofuran layer was dried with magnesium sulfate. The solvent was evaporated in vacuo and the oil that remained was dissolved in dichloromethane and filtered over a plug of silica gel. The plug was eluted with 25% ethyl acetate/dichloromethane and the filtrate was evaporated in vacuo to afford 16.4 g (81%) of ethyl-(2S)-4-methylene-N-(t- butoxycarbonyl)pyroglutamate was a yellow solid.
Step IVB:
Ethyl-(2S, 4S)-4-methyl-N-(t-butoxycarbonyl)pyroglutamate
30 To a solution of ethyl-(2S)-4-methylene-N-(t-butoxycarbonyl)pyroglutamate (9.6 g, 35.7 mmol) in methanol (96 mL) was platinum (IV) oxide (404 mg, 1.782 mmol). The reaction degassed and stirred under an atmosphere of hydrogen overnight. The reaction was filtered through Celite and the filtercake was rinsed with methanol. The filtrate was evaporated in vacuo to afford 8.6 g (89%) of ethyl-(2S, 4S)-4-methyl-N-(t- butoxycarbonyl)pyroglutamate as a clear, colorless oil.
BOST 1803930.1 122 Step V:
Ethyl-(2S, 4S)-4-methyl-N-(t-butoxycarbonyl)pyroglutamate
A Parr vessel was charged with a solution of ethyl-(2S)-4-(N,N- dimethylaminomethylidene-N-(t-butoxylcarbonyl)pyroglutamate (30 g, 96.04 mmol) in ethanol (300 mL) and 10.22 g (9.60 mmol) of 10% wet, Degussa-type Pd/C. The atmosphere above the solution was evacuated and replaced with hydrogen at 50 psi. The reaction shaken for a day replacing the pressure of hydrogen as necessary. The filtrate was filtered over Celite and the filterbed was washed with ethyl acetate. The combined filtrates were evaporated in vacuo to afford an oil. The oil was purified on a silica gel 10 column using 10-30% ethyl acetate/ hexanes to afford 18.6 g (71%) of ethyl-(2S, 4S)-4- methyl-N-(t-butoxycarbonyl)pyroglutamate as a clear, viscous oil.
Step VI:
(2S, 4S)-4-methyl-N-(t-butoxycarbonyl)prolinol
To a solution of ethyl-(2S, 4S)-4-methyl-N-(t-butoxycarbonyl)pyroglutamate (11 g, 40.5 mmol) in tetrahydrofuran (66 mL) cooled to 0°C was added sodium borohydride (3.84 g, 101.4 mmol). The reaction stirred for 15 minutes and boron trifluoride etherate (14.39 g, 101.4 mmol) was added dropwise. The reaction was stirred at 0°C for three hours and then warmed to ambient temperature and stirred for twelve hours. The reaction was 20 poured into ice cold water, stirred for thirty minutes, and evaporated in vacuo. The residue was dissolved in ethyl acetate and washed successively with 1 N hydrochloric acid, water and brine. The organic solution was dried with sodium sulfate, filtered, and evaporated in vacuo. The crude product was purified through column chromatography on a silica gel column using 10-40% ethyl acetate in hexanes to afford 8.73 g (69%) of (2S, 4S)-4-methyl-N-(t-butoxycarbonyl)prolinol as a clear, colorless oil.
BOST 1803930.1 123 Intermediate 18 : method A
(3S,5S)-tert-butyl 5-(5-iodo-1 H-imidazol-2-yl)-3-methyl-2-oxopyrrolidine-1- carboxylate
Figure imgf000125_0001
Step I :
(2S,4S)-tert-butyl 2-formyl-4-methylpyrrolidine-1 -carboxylate
4-Methyl-N-(t-butoxycarbonyl)-(2S)-prolinol is oxidized to (2S,4S)-tert-butyl 2-formyl-4- methylpyrrolidine-1 -carboxylate under standard oxidizing conditions known in the art for oxidizing an alcohol to an aldehyde (e.g. TEMPO/bleach).
Step I I :
(2S,4S)-tert-butyl 2-(1 H-imidazol-2-yl)-4-methylpyrrolidine-1 -carboxylate
The (2S,4S)-tert-butyl 2-formyl-4-methylpyrrolidine-1 -carboxylate is converted to the (2S,4S)-tert-butyl 2-(1 H -imidazol-2-yl)-4-methylpyrrolidine-1 -carboxylate using ammonium hydroxide and glyoxal in methanol (see Intermediate 3, Step I ).
Step I I I :
(2S,4S)-tert-butyl 2-(4,5-diiodo-1 H-imidazol-2-yl)-4-methylpyrrolidine-1 -carboxylate The (2S,4S)-tert-butyl 2-(1 H -imidazol-2-yl)-4-methylpyrrolidine-1 -carboxylate is reacted with N-iodosuccinimide to afford the bis-iodoimidazole (2S,4S)-tert-butyl 2-(4,5-diiodo- 1 H-imidazol-2-yl)-4-methylpyrrolidine-1 -carboxylate (see Intermediate 3, Step I I ).
Step IV:
(2S,4S)-tert-butyl 2-(5-iodo-1 H-imidazol-2-yl)-4-methylpyrrolidine-1 -carboxylate
BOST 1803930.1 124 The 4-iodo substituent of (2S,4S)-tert-butyl 2-(4,5-diiodo-1 H-imidazol-2-yl)-4- methylpyrrolidine-1 -carboxylate is selectively removed by metallation, preferably with isopropyl magnesium chloride, followed by a quench with a proton source such as water to afforde the mono-iodoimidazole (2S,4S)-tert-butyl 2-(5-iodo-1 H-imidazol-2-yl)-4- methylpyrrolidine-1 -carboxylate (see Intermediate 3, Step III).
Intermediate 18: method B
Methyl N-[(1S)-1-[(2S,4S)-2-(5-iodo-1 H-imidazol-2-yl)-4-methyl-pyrrolidine-1- carbonyl]-2-methyl-propyl]carbamate
Figure imgf000126_0001
Step I:
In a 2L Parr flask under nitrogen, a solution of (2S)-1 -tert-butoxycarbonyl-4-methylene- pyrrolidine-2-carboxylic acid (175 g, 770.1 mmol) in ethanol (700 mL) is added Pt02 (5.250 g, 23.12 mmol). The suspension is purged 3 times, (vacuum/hydrogen) and stirred at rt on a Parr apparatus under 30-40 psi of hydrogen. The Initial H2 consumption is rapid and then the reaction is completed after 60 minutes. The catalyst is decanted and the supernatant is cannulated in 1 L Erlenmeyer, then filtered through Celite and washed with ethanol. The mother liquor is put aside. The reaction is repeated 7 times using a total of 8.8 g of Pt02. The reaction mixtures of the 7 runs are combined (ratio of
20 cisl trans 3.6/1 ) and evaporated to a volume of 3 L. Isopropyl acetate (1 .5 L) is added and 2 L of the solution is evaporated. Isopropyl acetate (1 .5 L) is added and 1 L of the solution is evaporated. The compound is started to crystallize in the solution, heptane (1 .5 liters) and isopropyl acetate (1 L) are added and the suspension is stirred at rt for 1 hour and then at 0° C for 2 hours. The mixture is filtered and washed with a cold solution of 2:1 heptane/isopropyl acetate (1 L). The cake is dried for 2 hours, then put in the
BOST 1803930.1 125 vacuum oven yielding (2S)-1 -tert-butoxycarbonyl-4-methyl-pyrrolidine-2-carboxylic acid; 883.44 g (71 % yield) as a pale gray crystalline powder, 9: 1 (S:R).
The crude product (850 g) is recrystallized in isopropyl acetate (2 volume) and heptane (1 volume). The recrystallization process is repeated 2 times to reach a ratio of 23/1 (S:R).
Step II:
In a 22 L, 3 neck round bottom flask under nitrogen equipped with a thermocouple, an addition funnel and a mechanical stirrer (2S,4S)-1 -tert-butoxycarbonyl-4-methyl- pyrrolidine-2-carboxylic acid (672 g, 2.931 mol) and THF (4 L) are added and cooled in an
10 ice bath until the internal temperature is about 3° C. The Borane/THF solution (5.527 kg, 6.155 L of 1 M, 6.155 mol) is added dropwise over 3.5 hours using the addition funnel. An exotherm of 10° C and a very strong gas formation are occurred during the addition of the first 1800 mL. The reaction mixture is stirred overnight at room temp. TLC: (25% EtOAC/Hexane) shows no starting material. Then 1 L of a saturated aqueous solution of NH4Cl is carefully added (dropwise) at 4° C. An exotherm of 20° C and a very strong gas formation are observed. H20 (5000 mL) is added and the mixture is extracted with EtOAc (2 L), the phases are separated and the aqueous phase is re-extracted with EtOAc (2L). The organic phases are merged and the solvent is evaporated. To the residual mixture is added EtOAc (3 L) and the phases are separated and dried over Na2S04, filtered and
20 concentrated to a small volume. The residual solution contains water and a white solid.
The mixture is transferred to a 5L extraction funnel and added EtOAc (1 L) and water (500 mL). The organic phase is dried over sodium sulfate and the mixture is stirred for 30 minutes, filtered and evaporated to dryness. The residue is purified by a plug of silica gel using 0 to 30% EtOAc/Hexanes as eluant to give tert-butyl (2S,4S)-2-(hydroxymethyl)- 4-methyl-pyrrolidine-1 -carboxylate (604 g, 2.806 mol, 95% yield).
Step III:
In a 12L of three-neck RBF under nitrogen equipped with a mechanical stirrer, a thermocouple and a 2L addition funnel, oxalyl chloride (2.2 kg, 1 .52 L of 2 M, 3.05 mol) 30 and CH2Cl2 (2.1 L) are added. The solution is cooled to -78° C in an acetone/dry ice bath while stirring. The DMSO (476.6 g, 432.9 mL, 6.1 mol) is added dropwise using the addition funnel, while keeping the internal temp around -67±5° C. A solution of tert-butyl (2S,4S)-2-(hydroxymethyl)-4-methyl-pyrrolidine-1 -carboxylate (262.65 g, 1 .22 mol) in CH2Cl2 (1 .8 L) is added and the mixture is stirred for 20 minutes at -75±5° C. Finally DIPEA
BOST 1803930.1 126 (1.57 kg, 2.13 L, 12.2 mol) is added over 90 minutes keeping the internal temp at -73 ± 2°C. The reaction mixture is stirred for 2 hours at -76±2°C and then the temperature is raised to room temp over 2 hours. A solution of HCl 1 N (3400 ml) is slowly added using an addition funnel, an exotherm of 6°C is observed, the phases are separated (aqueous pH=8) and the HCl washing procedure is repeated until the pH of the aqueous phase is below 2. The organic phase is dried using Na2S04, filtered and concentrated to give a yellow oil (300 g). The Swern reaction was repeated on the same scale and the two crude reactions are combined and purified together. The residue is purified by a plug of silica gel using 0 to 15% EtOAc in Hexanes as eluant to give tert-butyl (2S,4S)-2-formyl-4- 10 methyl-pyrrolidine-1 -carboxylate (480 g, 2.25 mol, 92.2%) as a golden oil.
Step IV:
In a 5L 3 neck RBF under nitrogen equipped with a thermocouple, a refrigerant and an addition funnel, tert-butyl (2S,4S)-2-formyl-4-methyl-pyrrolidine-1 -carboxylate (480 g, 2.25 mol) and MeOH (960 ml) are added while stirring an exotherm of +20° C is observed. NH4OH (960.0 mL) is added, an exotherm of 12°C is noted. Oxaldehyde (913.7 g, 722.3 mL of 40 %w/v, 4.98 mol) is added over 39 minutes using the addition funnel. A very big exotherm up to 70° C is observed. The reaction mixture is stirred overnight at room temperature. In the morning the reaction mixture is all solidified with no apparent liquid. Water (1.5 L) is added and stirred for 1 hour. The suspension is filtered on a
20 Buchner funnel and washed with water (~2L) until the mother liquor is pale brown. The wet solid is transferred in a 12L RBF, then water (3L) is added and the suspension is stirred for 2 hours, filtered and washed with water (1.5 L) and heptane (1.5 L) and then dried for 2 days in a vacuum oven at 45° C. The crude gray solid contains 8% of 2-(1 H- imidazol-2-yl)-1 H-imidazole as a side product impurity. The solid is transferred into a 12L 5 neck RBF, ethyl acetate (4L) is added and the mixture is refluxed. The water is azeotroped with ethyl acetate (1.5 L). The hot solution is filtered to remove the insoluble 2-(1 H-imidazol-2-yl)-1 H-imidazole. The remaining solution is evaporated to 1 L and then the suspension is stirred in an ice/bath, filtered and washed with cold ethyl acetate to give tert-butyl (2S,4S)-2-(1 H-imidazol-2-yl)-4-methyl-pyrrolidine-1 -carboxylate
30 (330g, 1.31 mol, 58% yield) as a pale gray solid, 99.4 % pure.
Step V:
In a 12L 4 neck RBF under nitrogen equipped with mechanical stirrer, a thermocouple a refrigerant and an addition funnel, tert-butyl (2S,4S)-2-(1 H-imidazol-2-yl)-4-methyl- pyrrolidine-1 -carboxylate (334.4 g, 1.331 mol) and CH2Cl2 (3.344 L) are added while stirring. The solution is cooled to below 5°C using an ice bath. NIS (628.8 g, 2.795 mol) is
BOST 1803930.1 127 added in 6 batches of 104.8 g each over 30 minutes while keeping the internal temperature below 5°C. The reaction mixture is stirred for 2.5 hours and then HPLC shows the completion of the reaction. A solution of 10% sodium thiosulfate solution (4 L) is added and the reaction mixture is stirred for 15 minutes and the phases are separated. The organic phase is transferred back in the 12L reactor, water (2 L) and CH2Cl2 (1 L) are added, the mixture is stirred for 15 minutes. The organic phase is dried over sodium sulfate, filtered and evaporated to dryness to afford tert-butyl (2S,4S)-2-(4,5-diiodo-1 H- imidazol-2-yl)-4-methyl-pyrrolidine-1 -carboxylate, (646.3g, 93% yield, 96% purity). 1H NMR (400 MHz, dmso, 2.5:1 mixture of rotamers), peaks for the major rotamer: δ 12.70 10 (s, 1 H), 4.57 (dd, 1 H), 3.62 - 3.52 (m, 1 H), 2.95 (t, 1 H), 2.35 - 2.0 (m, 2 H), 1.50 (dd, 1 H), 1.10 (s, 9 H), 1.01 (d, 3 H).
Step VI:
In a 5L 3 neck round bottom flask under nitrogen equipped with a mechanical stirrer, LiCl (54.09 g, 1.276 mol) and THF (2.504 L) are added and stirred at rt overnight. In a 12L 3 neck round bottom flask under nitrogen equipped with a temperature reader, a mechanical stirrer and an 1 L addition funnel, tert-butyl (2S,4S)-2-(4,5-diiodo-1 H- imidazol-2-yl)-4-methyl-pyrrolidine-1 -carboxylate (642 g, 1.276 mol) and LiCl solution in THF are added while stirring. The reaction mixture is cooled down to -20 C. To the beige suspension is added dropwise a solution of methyl magnesium chloride in THF (425.3 mL
20 of 3 M, 1.276 mol) over 60 minutes keeping the internal temperature between -17 and - 20° C. The reaction mixture is stirred at the same temperature for 20 minutes. A solution of isopropyl magnesium chloride in THF (1.276 L of 2 M, 2.552 mol) is added dropwise over 70 minutes while keeping the internal temperature between -17 and -23 C, then the mixture is slowly warmed up to rt. TLC 50% ETOAC/Hexane shows that the reaction is completed. The reaction mixture is cooled down in an ice/water bath to -10° C and a 10% aq. NH4Cl solution (2 L) is added dropwise. An exotherm of 35° C and gas formation are observed. Water (1 L) and ethyl acetate (2L) are added and the mixture is stirred for 30 minutes. The phases are separated and the aqueous phase is re-extracted with EtOAc (2L). The organic phases are combined and 2L of water is added, the mixture is stirred
30 for 10 minutes. The phases are separated and the organic phase is dried over Na2S04and filtered. The solvent is concentrated to a small volume and heptane (1000 mL) is added and evaporated slowly. The suspension is stirred for 30 minutes at rt and then in an ice bath for 1 hour, filtered and washed with cold heptane/ethyl acetate (95/5). The solid is dried in the vacuum oven at 35° C to afford tert-butyl (2S,4S)-2-(5-iodo-1 H-imidazol-2- yl)-4-methyl-pyrrolidine-1 -carboxylate (420.24 g; 91% pure, 87.3% yield)) as a beige solid, used as it is for the next step.
BOST 1803930.1 128 Intermediate 19
Trimethyl-[2-[5- 2-trimethylsilylethynyl)-2-pyridyl]ethynyl]silane
Figure imgf000130_0001
A stirred suspension of 2,5-dibromopyridine (1.5 g, 6.332 mmol), copper Iodide (120.6 mg, 0.6332 mmol) and PdCl2(dppf)-CH2Cl2 (517.1 mg, 0.6332 mmol) in DMF (24.00 mL) is degassed and added triethyl amine (2.563 g, 3.530 mL, 25.33 mmol). Then ethynyl(trimethyl)silane (1.368 g, 1.968 mL, 13.93 mmol) is added under nitrogen atmosphere and the resultant reaction mixture is heated at 80°C for 8 hours in a sealed 10 tube. The reaction mixture is concentrated, passed through a small plug of silica and eluted with 10% ethyl acetate-hexanes. The solvents are concentrated and the residue is purified by silica gel column chromatography using EtOAc-Hexanes (0:100 to 1 :90) as eluent to obtain trimethyl-[2-[6-(2-trimethylsilylethynyl)-3-pyridyl]ethynyl]silane (780 mg, 2.811 mmol, 43.43%) as light brown solid. Rf = 0.61 (10% EtOAc-Hexanes). 1H NMR (400 MHz, CDCl3): δ 8.61 (dd, 1 H), 7.67 (dd, 1 H), 7.37 (dd, 1 H), 0.254 (s, 9 H), 0.246 (s, 9 H).
LC/MS: m/z = 271.86 (M+H+). Rt = 18.7 minutes.
Intermediate 20
20 tert-Butyl (1S,3S,5S)-3-(4-iodo-1 H-imidazol-2-yl)-4-azabicyclo[3.1.0]hexane-4- carboxylate
Figure imgf000130_0002
The title compound is prepared from (1 S,3S,5S)-2-tert-butoxycarbonyl-2- azabicyclo[3.1.0]hexane-3-carboxylic using the same sequence of reactions (Step II to VI) as described for intermediate 4.
LC/MS: m/z = 375.78 (M+H+). Rt = 6.33 minutes.
BOST 1803930.1 129 Intermediate 21
tert-But l 2 4 -2- 4-iodo-1 H-imidazol-2- l -4-methoxy-pyrrolidine-1-carboxylate
Figure imgf000131_0001
Title compound is prepared using the same sequence of reactions (step II to VI) as described for intermediate 4 starting from tert-butyl (2S,4S)-2-(hydroxymethyl)-4- methoxy-pyrrolidine-1 -carboxylate. Rf = 0.18 (70% EtOAc-Hexanes).
1H NMR (400 MHz, CDCl3, peaks for the major rotamer): δ 9.85 (s, 1 H), 6.99 (s, 1 H), 4.96 (br s, 1 H), 4.1 - 3.3 (m, 3 H), 3.35 (s, 3 H), 2.4 - 2.2 (m, 2 H), 1.28 (s, 9 H).
LC/MS: m/z = 393.78 (M+H+). Rt = 8.46 minutes.
10 HPLC (Rt) = 22.55 minutes, Method: 0-40% acetonitrile-water in 40 min, Gemini C18 3μιη, 4.6 mmx250 mm. Intermediate 22:
4,4,5,5-Tetramethyl-2-[6-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-2-naphthyl]- 1 ,3,2-dioxaborolane
Figure imgf000131_0002
To a stirred suspension of 2,6-dibromonaphthalene (1 g, 3.497 mmol), 4,4,5,5- tetramethyl-2-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 ,3,2-dioxaborolane (2.131 g, 8.393 mmol) and KOAc (2.059 g, 20.98 mmol) in dioxnae (30.00 mL) is added Pd(dppf)Cl2-CH2Cl2 (571.2 mg, 0.6994 mmol) in one portion, degassed and filled with nitrogen. The flask is sealed, heated at 100°C overnight (crude LC-MS shows the desired 20 compound) and cooled to rt. The reaction mixture is filtered through celite, washed with CH2Cl2 and concentrated. The residue is purified on a small plug of silica gel using CH2Cl2. The organic layer is diluted with heptanes (20 mL), concentrated on rotary evaporator until CH2Cl2 is removed. The resultant product is collected by filtration, washed with heptanes, dried under high vacuum to afford 4,4,5,5-tetramethyl-2-[6- (4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-2-naphthyl]-1 ,3,2-dioxaborolane (760 mg, 1.990 mmol, 56.90%) as light brown solid. Rf = 0.39 (1 :9 EtOAc-Hexanes).
LC/MS, m/z = 381 (M+H+); Rt : 18.94 minutes.
1H NMR (400 MHz, CDCl3): δ 8.357 (s, 2H), 7.86 (d, 2 H), 7.827 (d, 2 H), 1.39 (s, 24 H).
BOST 1803930.1 130 Intermediate 23
4,4,5,5-Tetramethyl-2-[5-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)thieno[3,2- b]thiophen-2-yl]- 1 , 3, 2-dioxaborolane
Figure imgf000132_0001
To a solution of thieno[3,2-b]thiophene (1.5 g, 10.70 mmol) in THF (25.5 mL) at -78°C under N2 is added dropwise a solution of BuLi in hexanes (8.988 mL of 2.5 M, 22.47 mmol), stirred for 20 minutes, cooling bath is replaced with ice bath and stirred for 50 minutes. The resultant thick suspension is quenched with 2-isopropoxy-4, 4,5,5- tetramethyl-1 ,3,2-dioxaborolane (4.181 g, 4.584 mL, 22.47 mmol). The reaction mixture 10 is kept overnight and then quenched with saturated aq. NH4Cl solution. After extraction with CH2Cl2 (2 x 100 mL), the combined extracts are washed with brine and dried (Na2S04). Organic solution is diluted with -20 mL of ethyl acetate, concentrated slowly on rotary evaporator until CH2Cl2 is removed. The resultant white fine crystals are collected by filtration. The solid is washed with heptanes and dried under high vacuum to afford 4,4,5,5-tetramethyl-2-[5-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)thieno[3,2- b]thiophen-2-yl]-1 ,3,2-dioxaborolane (2.57 g, 6.554 mmol, 61.25%) as half-white solid. 1H NMR (400 MHz, CDCl3): δ 7.75 (s, 4H), 1.343 (s, 24H).
Example 1
Figure imgf000132_0002
The above compound was prepared according to the procedures disclosed herein.
BOST 1803930.1 131 Example 2
((S)-1-{(S)-2-[5-(7-{2-[(S)-1-((S)-2-(methoxycarbonylamino)-3-methyl- butanoyl]pyrrolidin-2-yl]-3H-imidazol-4-ylethynyl}-benzo[1,3]dioxol-4-ylethynyl)1 H- 1 H-imidazol-2-yl]pyrrolidine- 1 -carbonyl}-2-methyl-propyl]-carbamic acid methyl ester
Figure imgf000133_0001
To a solution of 4,7-diethynyl-1 ,3-benzodioxole (40.50 mg, 0.24 mmol), methyl N-[(1 S)-1 - [(2S)-2-(5-iodo-1 H-imidazol-2-yl)pyrrolidine-1 -carbonyl]-2-methyl-propyl]carbamate (200 10 mg, 0.47 mmol), Pd(PPh3)2Cl2 (16.7 mg, 0.024 mmol), Cul (4.53 mg, 0.024mmol) in DMF is added TEA (165.8 μΙ_, 1.19 mmol). The reaction mixture is stirred at 80° C for 16 hours, diluted with EtOAc and H20, and filtered on celite. The organic phase is dried over Na2S04, filtered and concentrated to dryness. The residue is purified by reverse phase flash column chromatography on silica gel (25 to 50% CH3CN in H20) and repurified by reverse phase HPLC using a gradient of CH3CN/water to give ((S)-1 -{(S)-2-[5-(7-{2-[(S)-1 - ((S)-2-(methoxycarbonylamino)-3-methyl-butanoyl]pyrrolidin-2-yl]-3H-imidazol-4- ylethynyl}-benzo[1 ,3]dioxol-4-ylethynyl)1 H-1 H-imidazol-2-yl]pyrrolidine-1 -carbonyl}-2- methyl-propylj-carbamic acid methyl ester (19 mg, 9.4%) as a white solid.
LC/MS: m/z = 755.5 (M + H+).
20
Example 3
Methyl N-[(1S)-1-[(2S)-2-[4-[2-[5-[2-[2-[(2S)-1-[2-(Methoxycarbonylamino)-3-methyl- butanoyl]pyrrolidin-2-yl]- 1 H-imidazol-4-yl]ethynyl]-2-thienyl]ethynyl]- 1 H-imidazol-2- yl]pyrrolidine- 1 -carbonyl]-2-methyl-propyl]carbamate
Figure imgf000133_0002
BOST 1803930.1 132 The title compound is synthesized from 2,5-diethynyl-thiophene and methyl N-[(1 S)-1 - [(2S)-2-(5-iodo-1 H-imidazol-2-yl)pyrrolidine-1 -carbonyl] -2-methyl-propyl]carbamate as described in Example 1 3.
Example 4A
((S)- 1 -{(2S,4S)-2-[5-(4-{2-[(2S,4S)- 1 -((S)-2-Methoxycarbonylamino-3-methyl-butyryl)- 4-methyl-pyrrolidin-2-yl]-3H-imidazol-4-ylethynyl}-phenylethynyl)- 1 H-imidazol-2-yl]- 4-methyl-pyrrolidine- 1 -carbonyl}-2-methylpropyl -carbamic acid methyl ester
Figure imgf000134_0001
10 To a stirring solution of 1 ,4-diethynylbenzene (145.3 mg, 1 .1 52 mmol), methyl N- [(1 S)-1 - [(2S,4S)-2-(5-iodo-1 H-imidazol-2-yl)-4-methyl-pyrrolidine-1 -carbonyl] -2-methyl- propyl]carbamate (1000 mg, 2.303 mmol), Pd(dppf)Cl2-DCM (47.04 mg, 0.05760 mmol), and Cul (21 .94 mg, 0.1 152 mmol) in DMF (8 mL, degassed) is added triethylamine (582.9 mg, 802.9 μΙ_, 5.760 mmol). The reaction mixture is stirred at 80° C for 16 hours, diluted with 100 ml of EtOAc and 20 ml of H20, and is filtrated on celite. The organic phase is separated, dried over Na2S04, filtered and concentrated to dryness to give 900 mg of brown solid. The residue is purified by flash column chromatography on silica gel (0 to 10% MeOH/Toluene) to afford 400 mg of the title compound with a purity of 85%. The solid is purified by recrystallization in MeOH to afford ((S)-1 -{(2S,4S)-2- [5-(4-{2- [(2S,4S)-
20 1 -((S)-2-methoxycarbonylamino-3-methyl-butyryl)-4-methyl-pyrrolidin-2-yl] -3H-imidazol- 4-ylethynyl}-phenylethynyl)-1 H -imidazol-2-yl] -4-methyl-pyrrolidine-1 -carbonyl}-2- methylpropyl)-carbamic acid methyl ester (240 mg, 28%) as a white solid.
1 H NMR (400 MHz, cdcl3> mixture of rotamers), peaks for the major rotamer, δ 10.70 (s, 2 H), 7.45 - 7.35 (m, 6 H), 7.21 5 (d, 2 H), 5.45-5.4 (m, 2 H), 5.18 - 5.07 (m, 2 H), 4.39 - 4.29 (m, 2 H), 4.05-3.9 (m, 2 H), 3.68 (s, 6 H ) , 3.1 -3.0 (m, 2 H ), 2.75-2.2 (m, 4 H), 1 .95- 1 .8 (m, 2 H), 1 .16 (d, 6 H), 0.87 - 0.8 (doublets, 12 H).
BOST 1803930.1 133 Example 4B
((S)-1-{(2S,4S)-2-[5-(4-{2-[(2S,4S)-1-((S)-2-Methoxycarbonylamino-3-methyl-butyryl)- 4-methyl-pyrrolidin-2-yl]-3H-imidazol-4-ylethynyl}-phenylethynyl)-1H-imidazol-2-^ 4-meth l-pyrrolidine-1-carbonyl}-2-methylpropyl)-carbamic acid methyl ester
Figure imgf000135_0001
Step I:
tert-Butyl (2S,4S)-2-[4-[2-[4-[2-[2-[(2S,4S)-1 -tert-butoxycarbonyl-4-methyl-pyrrolidin-2- yl] - 1 H-imidazol-4-yl]ethynyl]phenyl]ethynyl]-1 H-imidazol-2-yl]-4-methyl-pyrrolidine-1 - 10 carboxylate
To a stirred suspension of tert-butyl (2S,4S)-2-(5-iodo-1 H-imidazol-2-yl)-4-methyl- pyrrolidine-1 -carboxylate (1 g, 2.556 mmol), copper Iodide (46.4 mg, 0.24 mmol) and Pd(dppf)Cl2-DCM (198.8 mg, 0.24 mmol) in DMF (11 mL) is sequentially added TEA (739.2 mg, 1.018 mL, 7.31 mmol) and 1 ,4-diethynylbenzene (153.5 mg, 1.217 mmol) under nitrogen atmosphere. The reaction mixture is heated at 80 0 C for 2 hours, cooled to RT, and diluted with water (10 mL). The reaction mixture is stirred at RT for 30 minutes, and cooled at 0°C for 15 min. The reaction mixture is filtered to collect a precipitate. The precipitate is purified by flash column chromatography on silica gel (10% MeOH/Toluene) to afford tert-butyl (2S,4S)-2-[4-[2-[4-[2-[2-[(2S,4S)-1 -tert- 20 butoxycarbonyl-4-methyl-pyrrolidin-2-yl]-1 H-imidazol-4-yl]ethynyl]phenyl]ethynyl]-1 H- imidazol-2-yl]-4-methyl-pyrrolidine-1 -carboxylate (260 mg, 31.5%, purity, 92%) as solid. LC/MS, m/z: 625.45 (M+H+).
BOST 1803930.1 134 Step II:
(S,S)-4,4'-(1 ,4-phenylenebis(ethyne-2,1 -diyl))bis(2-((2S,4S)-4-methylpyrrolidinium-2-yl)- 1 H-imidazol-3-ium) chloride
To a stirred mixture of tert-butyl (2S,4S)-2-[4-[2-[4-[2-[2-[(2S,4S)-1 -tert-butoxycarbonyl- 4-methyl-pyrrolidin-2-yl]-1 H-imidazol-4-yl]ethynyl]phenyl]ethynyl]-1 H-imidazol-2-yl]-4- methyl-pyrrolidine-1 -carboxylate (260 mg, 0.4162 mmol) in MeOH (1.3 mL) at 0°C (using water/ice bath) is added HCl in dioxane (1.457 mL of 4 M, 5.827 mmol) over 2 minutes. The reaction mixture is warmed up to RT and stirred for 19 hours. The reaction mixture is filtered and washed with MTBE to give (S,S)-4,4'-(1 ,4-phenylenebis(ethyne-2,1 - 10 diyl))bis(2-((2S,4S)-4-methylpyrrolidinium-2-yl)-1 H-imidazol-3-ium) chloride (192 mg, 95%) as pale brownish powder.
LC/MS, m/z: 425 (M+H+).
Step III:
Methyl N-[(1 S)-1 -[(2S,4S)-2-[5-[2-[4-[2-[2-[(2S,4S)-1 -[(2S)-2-(methoxycarbonylamino)-3- methyl-butanoyl]-4-methyl-pyrrolidin-2-yl]-1 H-imidazol-5-yl]ethynyl]phenyl]ethynyl]-1 H- imidazol-2-yl]-4-methyl-pyrrolidine-1 -carbonyl]-2-methyl-propyl]carbamate
(2S)-2-(methoxycarbonylamino)-3-methyl-butanoic acid (113.3 mg, 0.6470 mmol), (S,S)- 4,4'-(1 ,4-phenylenebis(ethyne-2,1 -diyl))bis(2-((2S,4S)-4-methylpyrrolidinium-2-yl)-1 H- 20 imidazol-3-ium) chloride (180 mg, 0.32 mmol), HATU (240 mg, 0.63 mmol), DIPEA (326.3 mg, 439.8 pL, 2.525 mmol) are dissolved in DMF (3.6 mL) at 0°C. The reaction mixture is warmed to RT and stirred overnight. The reaction mixture is diluted with water, stirred for 30 minutes, and filtered to collect a precipitate. The precipitate is purified by flash column chromatography on silica gel (0 to 10% MeOH in toluene) to afford methyl N-[(1 S)- 1 -[(2S,4S)-2-[5-[2-[4-[2-[2-[(2S,4S)-1 -[(2S)-2-(methoxycarbonylamino)-3-methyl- butanoyl]-4-methyl-pyrrolidin-2-yl]-1 H-imidazol-5-yl]ethynyl]phenyl]ethynyl]-1 H- imidazol-2-yl]-4-methyl-pyrrolidine-1 -carbonyl]-2-methyl-propyl]carbamate (129 mg, 0.1549 mmol, 49.1%) as a beige solid. LC/MS, m/z: 739.3 (M+H+).
BOST 1803930.1 135 Example 4C:
((S)-1-{(2S,4S)-2-[5-(4-{2-[(2S,4S)-1-((S)-2-Methoxycarbonylamino-3-methyl-butyryl)- 4-methyl-pyrrolidin-2-yl]-3H-imidazol-4-ylethynyl}-phenylethynyl)-1H-imidazol-2-^ 4-methyl-pyrrolidine-1-carbonyl}-2-methylpropyl)-carbamic acid methyl ester
Figure imgf000137_0001
Step I:
In a 3 neck, 5 L RBF equipped with a thermocouple and a stirring bar, tert-butyl (2S,4S)- 2-(5-iodo-1 H-imidazol-2-yl)-4-methyl-pyrrolidine-1 -carboxylate (400 g, 996.8 mmol), the trimethyl-[2-[4-(2-trimethylsilylethynyl)phenyl]ethynyl]silane (137.5 g, 498.2 mmol), the
10 PdCl2(dppf)2-CH2Cl2 (20.34 g, 24.91 mmol) and copper Iodide (4.744 g, 24.91 mmol) are added under nitrogen atmosphere. DMF (2 L) is added and the suspension is stirred and then degassed twice (vacuum 5 minutes followed by bubbled stream of nitrogen gas for 5 minutes). DBU (834.3 g, 819.5 ml_, 5.480 mol) is added over 1 minute. The solution is degassed twice (vacuum 5 minutes followed by bubbled stream of nitrogen gas for 5 minutes) and degassed water (13.46 g, 13.46 ml_, 747.3 mmol) is added. The stirring is switched from magnetic to mechanical under N2 atmosphere. The reaction mixture is heated to 60 C and then degassed water (13.46 g, 13.46 ml_, 747.3 mmol) is added. The reaction is followed by HPLC. After 4 hours the reaction mixture is transferred in a 22 L reactor with stirring and water (18 L) is added over 60 minutes (exotherm of 10°C is
20 observed). The reaction mixture is cooled to below 5°C in an ice bath and stirred for 30 minutes. The solid is filtered and washed with water (5 L) and heptane (4 L). The solid is dried in a vacuum oven at 35° C overnight. The wet solid is dissolved in CH2Cl2/MeOH ( 3L; 90/10) and stirred for 20 minutes. The phases are separated and the aqueous phase is re-extracted with CH2Cl2/MeOH (500 ml; 90/10). The phases are separated, the organic phases are merged and silica gel (800 mL) is added to the solution and then it is evaporated to dryness. The residue is purified by a plug of silica gel using 1 to 10%
BOST 1803930.1 136 MeOH/CH2Cl2 as eluant. The selected fractions are concentrated to a thick paste and stirred in an ice bath for 30 minutes and then filtered to afford tert-butyl (2S,4S)-2-[4-[2- [4-[2-[2-[(2S,4S)-1 -tert-butoxycarbonyl-4-methyl-pyrrolidin-2-yl]-1 H-imidazol-4- yl]ethynyl]phenyl]ethynyl]-1 H-imidazol-2-yl]-4-methyl-pyrrolidine-1 -carboxylate (234 g, 366.6 mmol, 73.57% yield) as a pale yellow solid; 97.8% pure.
Step II:
In a 3 neck, 5 L RBF equipped with a mechanical stirrer, a temperature controller J-Kem model 260 and a heating mantel, tert-butyl (2S,4S)-2-[5-[2-[4-[2-[2-[(2S,4S)-1 -tert- butoxycarbonyl-4-methyl-pyrrolidin-2-yl]-1 H-imidazol-5-yl]ethynyl]phenyl]ethynyl]-1 H-
10 imidazol-2-yl]-4-methyl-pyrrolidine-1 -carboxylate (234.5 g, 367.1 mmol) and methanol (1.834 L) are added while stirring. Charcoal (233.7 g, 19.46 mol) is added and the suspension is heated at reflux for 1.5 hours. Celite (100 g) is added and the mixture is stirred for 5 minutes and filtered through celite and washed with methanol. The solution is evaporated to 1 L and transferred in a 3 neck, 5 L RBF equipped with a mechanical stirrer, the solution is cooled in an ice bath. HCl in Dioxane (1.285 L of 4 M, 5.139 mol) is added over 35 minutes while keeping the internal temperature below 15 °C. At the end of the addition, an off white solid is started to form and it becomes thicker, the reaction is slowly warmed to rt and followed by HPLC. After 5.5 hours, the suspension becomes very thick. MTBE (917.2 mL) is added and the mixture is stirred for 1 hour at rt, filtered
20 and washed with MTBE. The solid is dried in a vacuum oven at 35° C for 2 days to afford (S,S)-4,4'-(1 ,4-phenylenebis(ethyne-2,1 -diyl))bis(2-((2S,4S)-4-methylpyrrolidinium-2-yl)- 1 H-imidazol-3-ium) chloride (206.9 g, 360.9 mmol, 98.31%) 99.5% pure as a yellow powder.
Step III:
In a 12L 4 neck RBF under nitrogen equipped with mechanical stirrer, a thermocouple and an addition funnel, (S,S)-4,4'-(1 ,4-phenylenebis(ethyne-2,1 -diyl))bis(2-((2S,4S)-4- methylpyrrolidinium-2-yl)-1 H-imidazol-3-ium) chloride (196.27 g, 342.4 mmol), the (2S)- 2-(methoxycarbonylamino)-3-methyl-butanoic acid (120.0 g, 684.8 mmol) and HATU (260.4 g, 684.8 mmol) are added. The powder is stirred under nitrogen and DMF (1.953 L) 30 is added, the solution is then cooled to 3 C using an ice/water bath. N,N- diisopropylethylamine (354.0 g, 477.1 mL, 2.739 mol) is added dropwise over 80 minutes while keeping the internal temperature at 4±2°C. The reaction mixture is stirred for 1.5 hours and followed by HPLC/MS that shows that the reaction is completed. Cold water (5.859 L) is added dropwise over 90 minutes while keeping the internal temperature below 8.5°C. The suspension is stirred for 1 hour in an ice bath, filtered and washed with
BOST 1803930.1 137 cold water (600 ml) and then with cold heptane (400 ml). The crude product is dried overnight at 45 C in vacuum oven. The crude powder (253 g) is transferred in a 12 L 5 neck RBF equipped with a mechanical stirrer, a condenser, a temperature controller J- Kem model 260 and a heating mantel. Methanol (6L) is added and the mixture is heated at reflux until the compound is dissolved. The hot solution is filtered and washed with methanol (500 ml_). The solution is transferred in a 12 L 5 neck RBF equipped with a mechanical stirrer, a temperature controller J-Kem model 260, a heating mantel and a distillation head. Methanol (4 L) is distilled off while stirring. The heating is turned off and the solution is slowly brought back to room temperature and slowly crystallized out overnight. The suspension is cooled for 30 minutes in an ice bath, filtered on a large Buchner and washed with cold methanol (200 ml_). The cake is dried in a vacuum oven at 35°C for 3 days to give methyl N-[(1 S)-1 -[(2S,4S)-2-[5-[2-[4-[2-[2-[(2S,4S)-1 -[(2S)-2- (methoxycarbonylamino)-3-methyl-butanoyl]-4-methyl-pyrrolidin-2-yl]-1 H-imidazol-5- yl]ethynyl]phenyl]ethynyl]-1 H-imidazol-2-yl]-4-methyl-pyrrolidine-1 -carbonyl]-2-methyl- propyl]carbamate (172 g, 228.5 mmol, 66.73% yield) as an off white powder 98.16% pure by HPLC.
Example 5
Methyl N-[(1S)-2-methyl-1-[(2S,4S)-4-methyl-2-[4-[2-[2,3,5,6-tetradeuterio-4-[2-[2- [(2S,4S)-1-[(2S)-2-(methoxycarbonylamino)-3-methyl-butanoyl]-4-methyl-pyrrolidin- 2-yl]- 1 H-imidazol-4-yl]ethynyl]phenyl]ethynyl]- 1 H-imidazol-2-yl]pyrrolidine- 1 - carbonyl]-2-methyl-propyl]carbamate
Figure imgf000139_0001
Step I
To a solution of 1 ,4-dibromo-2,3,5,6-tetradeuterio-benzene (500 mg, 2.084 mmol) in DMF (10 mL) are added PdCl2(dppf)-CH2Cl2 (85.09 mg, 0.1042 mmol) and Cul (19.84 mg, 0.1042 mmol). After degassing, DIPEA (1.077 g, 1.451 mL, 8.336 mmol) and ethynyl- trimethyl-silane (614.1 mg, 883.6 pL, 6.252 mmol) are added to the reaction mixture. Then the solution is heated at 45°C under nitrogen overnight. After removal of the solvent under reduced pressure, the residue is purified by silica gel column chromatography using hexane to provide trimethyl-[2-[2,3,5,6-tetradeuterio-4-(2- trimethylsilylethynyl)phenyl]ethynyl]silane (360 mg, 1.311 mmol, 62.93%) as yellow solid. 10 1H NMR (CD3OD, 400 MHz): 0.00 (m, 9H).
Step II
To a solution of tert-butyl (2S,4S)-2-(4-iodo-1 H-imidazol-2-yl)-4-methyl-pyrrolidine-1 - carboxylate (288.5 mg, 0.7648 mmol) in DMF (3 mL) are added trimethyl-[2-[2, 3,5,6- tetradeuterio-4-(2-trimethylsilylethynyl)phenyl]ethynyl]silane (100 mg, 0.3642 mmol), PdCl2(dppf)-CH2Cl2 (14.87 mg, 0.01821 mmol), Cul (3.468 mg, 0.01821 mmol) and DBU (665.3 mg, 653.5 pL, 4.370 mmol). After degassing, water (19.69 mg, 19.69 pL, 1.093 mmol) is added to the reaction mixture. Then the solution is heated at 60°C under nitrogen overnight. After removal of the solvent under reduced pressure, the residue is purified by silica gel column chromatography using MeOH (0-5%) in CH2Cl2 to provide tert- 20 butyl (2S,4S)-2-[4-[2-[4-[2-[2-[(2S,4S)-1 -tert-butoxycarbonyl-4-methyl-pyrrolidin-2-yl]-1 H- imidazol-4-yl]ethynyl]-2,3,5,6-tetradeuterio-phenyl]ethynyl]-1 H-imidazol-2-yl]-4-methyl- pyrrolidine-1 -carboxylate (141 mg, 0.2242 mmol, 61.57%) as a off-white solid. LC/MS: m/z = 629.20 (M+H+).
Step III
To a solution of tert-butyl (2S,4S)-2-[4-[2-[4-[2-[2-[(2S,4S)-1 -tert-butoxycarbonyl-4- methyl-pyrrolidin-2-yl]-1 H-imidazol-4-yl]ethynyl] -2,3,5, 6-tetradeuterio-phenyl]ethynyl]- 1 H-imidazol-2-yl]-4-methyl-pyrrolidine-1 -carboxylate (196 mg, 0.3117 mmol) in 3 mL of methanol is added HCl/dioxane (779.2 pL of 4 M, 3.117 mmol) . The mixture is stirred at rt for 1 hour and then concentrated to dryness. The residue is used in the next step 30 without any further purification.
Step IV
To a solution of 2-[(2S,4S)-4-methylpyrrolidin-2-yl]-4-[2-[2,3,5,6-tetradeuterio-4-[2-[2- [(2S,4S)-4-methylpyrrolidin-2-yl]-1 H-imidazol-4-yl]ethynyl]phenyl]ethynyl]-1 H-imidazole (hydrochloric acid (4)) (179 mg, 0.3116 mmol) HCl salt in DMF (5 mL) are added (2S)-2- (methoxycarbonylamino)-3-methyl-butanoic acid (136.5 mg, 0.7790 mmol), HATU (296.2 mg, 0.7790 mmol) and DIPEA (402.7 mg, 542.7 pL, 3.116 mmol). The mixture is stirred at
BOST 1803930.1 139 rt overnight. After removal of the solvent under reduced pressure, the residue is purified twice by silica gel column chromatography using MeOH (0-6%) in CH2Cl2 to provide methyl N-[(1 S)-2-methyl-1 -[(2S,4S)-4-methyl-2-[4-[2-[2,3,5,6-tetradeuterio-4-[2-[2-[(2S,4S)-1 - [(2S)-2-(methoxycarbonylamino)-3-methyl-butanoyl]-4-methyl-pyrrolidin-2-yl]-1 H- imidazol-4-yl]ethynyl]phenyl]ethynyl]-1 H-imidazol-2-yl]pyrrolidine-1 -carbonyl]-2-methyl- propyl]carbamate (184 mg, 0.2353 mmol, 75.51%) as an off-white solid. LC/MS: m/z = 743.58 (M+H+). 1H NMR (CD3OD, 400 MHz): δ 7.15-7.24 (d, 2H), 4.95(m, 2H), 4.20 (m, 4H), 3.62 (s, 6H), 2.46 (m, 4H), 1.96 (m, 4H), 1.15-1.30 (m, 8H), 0.84(m, 12H).
Example 6:
10 Methyl N-[(1S)-1-[(2S,4S)-2-[4-[2-[6-[2-[2-[(2S,4S)-1-[(2S)-2-
(methoxycarbonylamino)-3-methyl-butanoyl]-4-methyl-pyrrolidin-2-yl]-1 H-imidazol- 3-ium-4-yl]ethynyl]-2-naphthyl]ethynyl]-1 H-imidazol-3-ium-2-yl]-4-methyl- rrolidine-1-carbonyl]-2-methyl-propyl]carbamate as HCI salt
Figure imgf000141_0001
To a stirred suspension of methyl N-[(1 S)-1 -[(2S,4S)-2-(5-iodo-1 H-imidazol-2-yl)-4-methyl- pyrrolidine-1 -carbonyl]-2-methyl-propyl]carbamate, Cul and Pd(dppf)Cl2-DCM in DMF is sequentially added TEA and 2,6-diethynylnaphthalene under nitrogen atmosphere. The reaction mixture is heated at 70° C for 3 hours in a sealed tube, and is concentrated to dryness. The residue is purified by flash column chromatography on silica gel (0 to 15% 20 MeOH in EtOAc) to give a mixture of diastereomers. The mixture is purified by reverse phase HPLC using a gradient of CH3CN/water to afford the title compound as HCI salt. 1H NMR (400 MHz, CD3OD) δ 8.11 (s, 2 H), 7.925 (d, 2 H), 7.67 (s, 2 H), 7.61 (d, 2 H), 5.09 (dd, 2 H), 4.29 (t, 2 H), 4.18 (d, 2 H), 3.64 (s, 6 H), 3.4-3.25 (m, 2 H), 2.65-2.4 (m, 4 H), 2.05-1.75 (m, 4 H), 1.208 (d, 6 H), 0.88 (d, 6 H), 0.86 (d, 6 H).
LC/MS: m/z = 789.61 (M+H+).
Example 7:
Dimethyl (2S,2'S,3R,3,R)-1 , 1 ,-((3S,3,S,5S,5,S)-5,5,-(4,4,-(1,4-phenylenebis(ethyne-2,1- diyl))bis(1 H-imidazole-4,2-diyl))bis(3-methylpyrrolidine-5, 1-diyl))bis(3-methoxy-1- 30 oxobutane-2, 1 -diyl)dicarbamate
BOST 1803930.1 140
Figure imgf000142_0001
To a stirred suspension of methyl N-[(1 S,2R)-1 -[(2S,4S)-2-(4-iodo-1 H-imidazol-2-yl)-4- methyl-pyrrolidine-1 -carbonyl]-2-methoxy-propyl]carbamate (99.96 mg, 0.2220 mmol), Cul (4.228 mg, 0.02220 mmol) and Pd(dppf)Cl2-DCM (18.13 mg, 0.02220 mmol) in DMF (1.5 mL) is sequentially added TEA (67.39 mg, 92.82 μΙ_, 0.6660 mmol) and 1 ,4- diethynylbenzene (14 mg, 0.1110 mmol) under nitrogen atmosphere. The reaction mixture is heated at 70°C for 3 hours, diluted with water (10 mL) and extracted with CH2Cl2 (3 x 10 mL). The combined extracts are washed with water, brine, dried over Na2S04, filtered, and concentrated to dryness. The residue is purified by flash column 10 chromatography on silica gel (5 to 25% MeOH in toluene) and is repurified by reverse phase HPLC using a gradient of CH3CN/water to afford dimethyl (2S,2'S,3R,3'R)-1 ,1 '- ((3S,3'S,5S,5'S)-5,5,-(4,4,-(1 ,4-phenylenebis(ethyne-2,1 -diyl))bis(1 H-imidazole-4,2- diyl))bis(3-methylpyrrolidine-5,1 -diyl))bis(3-methoxy-1 -oxobutane-2,1 -diyl)dicarbamate (11.4 mg, 0.01321 mmol, 11.90%) as HCl salt.
Rf = 0.42 (MeOH -Toluene, 1 :4),
1H NMR (400 MHz, CD3OD) δ 7.64 (s, 2 H), 7.50 (s, 4 H), 5.03 (dd, 2 H), 4.35 (d, 2 H), 4.26 - 4.1 (m, 2 H), 3.6-3.4 (m, 2 H), 3.56 (s, 6 H), 3.3-3.1 (m, 1 H), 3.2 (s, 6 H), 2.6-2.3 (m, 4 H), 1.75-1.55 (m, 2 H), 1.11 (d, 6 H), 0.99 (d, 6 H).
LC/MS: m/z = 771.58 (M+H+).
20
Example 8:
Dimethyl (2S,2,S)-1 , 1 ,-((3S,3,S,5S,5'S)-5,5,-(4,4,-(2,5-dimethyl-1 ,4- phenylene)bis(ethyne-2, 1-diyl)bis(1 H-imidazole-4,2-diyl))bis(3-methylpyrrolidine- 5, 1 -diyl))bis(3-methyl-1 -oxobutane-2, 1 -diyl)dicarbamate
BOST 1803930.1 141
Figure imgf000143_0001
Figure imgf000143_0002
To a stirred suspension of methyl N-[(1 S)-1 -[(2S,4S)-2-(5-iodo-1 H-imidazol-2-yl)-4-methyl- pyrrolidine-1 -carbonyl]-2-methyl-propyl]carbamate (73.22 mg, 0.1686 mmol) , Cul (3.211 mg, 0.01686 mmol) and Pd(dppf)Cl2-DCM (13.77 mg, 0.01686 mmol) in DMF (1.144 mL) is sequentially added TEA (70.50 μΙ_, 0.5058 mmol) and 1 ,4-diethynyl-2,5-dimethyl-benzene (13 mg, 0.08430 mmol) under nitrogen atmosphere. The reaction mixture is heated at 50° C overnight, diluted with water (10 mL), and a precipitate is formed. The precipitate is filtered, washed with water, and dried under high vacuum to afford the title compound (65 mg) which is converted into HCl salt using 4N HCl in dioxane. The mixture 10 is freeze dried and purified by reverse phase HPLC using a gradient of CH3CN/water to afford dimethyl (2S,2'S)-1 ,1 ,-((3S,3'S,5S,5,S)-5,5,-(4,4,-(2,5-dimethyl-1 ,4- phenylene)bis(ethyne-2,1 -diyl)bis(1 H-imidazole-4,2-diyl))bis(3-methylpyrrolidine-5,1 - diyl))bis(3-methyl-1 -oxobutane-2,1 -diyl)dicarbamate as HCl salt (3.9 mg, 0.004276 mmol, 5.072%) as light yellow solid.
Rf = 0.29 (MeOH -Toluene, 1 :9).
1H NMR (400 MHz, CD3OD) δ 7.79 (s, 2 H), 7.44 (s, 2 H), 5.10 (dd, 2 H), 4.30 (t, 2 H), 4.17 (d, 2 H), 3.63 (s, 6 H), 3.39 - 3.31 (m, 2 H), 2.45 (s, 6 H), 2.65-2.45 (m, 4 H), 2.04 - 1.90 (m, 2 H), 1.8-1.7 (m, 2 H), 1.20 (d, 6 H), 0.87 (d, 6 H), 0.85 (d, 6 H).
LC/MS: m/z = 767.59 (M+H+).
20
Example 9:
Dimethyl (2S,2,S)-1 , 1 ,-((3R,3'R,5S,5,S)-5,5,-(4,4,-(1 ,4-phenylenebis-
BOST 1803930.1 142 (ethyne-2,1-diyl))bis(1H-imidazole-4,2-diyl))bis(3-methylpyrrolidine-5, 1-diyl))bis(3 methyl- 1 -oxobutane-2, 1 -diyl)dicarbamate
Figure imgf000144_0001
To a stirred suspension of methyl (S)-1 -((2S,4R)-2-(4-iodo-1 H-imidazol-2-yl)-4- methylpyrrolidin-1 -yl)-3-methyl-1 -oxobutan-2-ylcarbamate (96.41 mg, 0.21 mmol), Cul (4.23 mg, 0.022 mmol) and Pd(dppf)Cl2-DCM (18.13 mg, 0.022 mmol) in DMF (1.5 mL) is sequentially added TEA (92.82 μΙ_, 0.67 mmol) and 1 ,4-diethynylbenzene (14 mg, 0.11 mmol) under nitrogen atmosphere. The reaction mixture is heated at 70° C for 3 hours, diluted with water (6 mL), and a precipitate is filtered off. The precipitate is dissolved 10 in CH2Cl2, filtered through a pad of celite, and concentrated to dryness. The residue is purified by flash column chromatography on silica gel (5 to 10% MeOH in toluene) to afford the title compound (43 mg) which is converted into its HCl salt and purified by reverse phase HPLC using a gradient of CH3CN/water to afford dimethyl (2S,2'S)-1 ,1'- ((3R,3'R,5S,5'S)-5,5,-(4,4,-(1 ,4-phenylenebis-ethyne-2,1 -diyl))bis(1 H-imidazole-4,2- diyl))bis(3-methylpyrrolidine-5,1 -diyl))bis(3-methyl-1 -oxobutane-2, 1 -diyl)dicarbamate as HCl salt (17.1 mg, 0.0199 mmol, 17.93%) as white solid.
1H NMR (400 MHz, CD3OD) δ 7.76 (s, 2 H), 7.60 (s, 4 H), 5.25 (dd, 2 H), 4.17 (d, 2 H), 4.02 - 3.86 (m, 2 H), 3.64 (s, 6 H), 3.61 - 3.48 (m, 2 H), 2.7-2.58 (m, 2 H), 2.28-1.99 (m, 6 H), 1.14 (d, 6 H), 0.91 (d, 6 H), 0.89 (d, 6 H).
20 LC/MS: m/z = 739.5 (M + H+).
BOST 1803930.1 143 Example 10:
Methyl N-[(1S)-1-[(2S,4S)-2-[5-[2-[5-[2-[2-[(2S,4S)-1-[(2S)-2-(methoxycar- bonylamino)-3-methyl-butanoyl]-4-methyl-pyrrolidin-2-yl]-1 H-imidazol-5
yl]ethynyl]thieno[3,2-b]thiophen-2-yl]ethynyl]-1 H-imidazol-2-yl]-4-methyl- pyrrolidine- 1 -carbonyl]-2-methyl-propyl]carbamate
Figure imgf000145_0001
The title compound is synthesized from 2,5-Diethynyl-thieno[3,2-b]thiophene and methyl N-[(1 S)-1 -[(2S,4S)-2-(5-iodo-1 H-imidazol-2-yl)-4-methyl-pyrrolidine-1 -carbonyl]-2-methyl- propyl]carbamate as described in Example 4A.
10 LC/MS: m/z = 801.5 (M+H+).
Example 1 1 :
Methyl N-[(1S)-1-[(2S,4S)-2-[4-[2-[4-[2-[2-[(2S,4S)-1-[(2S)-2- [methoxycarbonyl(methyl)amino]-3-methyl-butanoyl]-4-methyl-pyrrolidin-2-yl]-1 H- imidazol-4-yl]ethynyl]phenyl]ethynyl]- 1 H-imidazol-2-yl]-4-methyl-pyrrolidine- 1 - carbonyl]-2-methyl-propyl]-N-methyl-carbamate
Figure imgf000145_0002
To a stirred suspension of methyl N-[(1 S)-1 -[(2S,4S)-2-(5-iodo-1 H-imidazol-2-yl)-4- methyl-pyrrolidine-1 -carbonyl]-2-methyl-propyl]-N-methyl-carbamate (75mg, 0.17 20 mmol), Cul(3.18 mg, 0.017 mmol) and Pd(dppf)Cl2-DCM (13.6 mg, 0.017mmol) in DMF (1.2 mL) is sequentially added TEA (70 μΙ_, 0.50 mmol) and 1 ,4-diethynylbenzene (10.55 mg, 0.083 mmol) under nitrogen atmosphere. The reaction mixture is heated at 70° C for 1 hour, diluted with water and extracted with CH2Cl2. The organic phase is washed with water, brine, dried over Na2S04, filtered and concentrated to dryness. The residue is purified by flash column chromatography on silica gel (1 to 30% MeOH in CH2Cl2) and purified by reverse phase HPLC using a gradient of CH3CN/water to give methyl N-[(1 S)- 1 -[(2S,4S)-2-[4-[2-[4-[2-[2-[(2S,4S)-1 -[(2S)-2-[methoxycarbonyl(methyl)amino]-3-
BOST 1803930.1 144 methyl-butanoyl]-4-methyl-pyrrolidin-2-yl]-1 H-imidazol-4-yl]ethynyl]phenyl]ethynyl]- 1 H-imidazol-2-yl]-4-methyl-pyrrolidine-1 -carbonyl]-2-methyl-propyl] -N-methyl- carbamate.
1H NMR (400 MHz, CD3OD) δ 7.65 (m, 2H), 7.47 (s, 4H), 4.95 (m, 2H),4.43 (d, 2H), 4.29 (m,1 H), 4.19-4.14(m, 2H), 4.0-3.8(m, 1 H), 3.64 (s, 6H), 2.74 (s, 6H), 2.57-2.46 (m, 2H), 2.33-2.27 (m, 2H), 2.07-2.01 (m, 2H), 1.70 -1.62 (m, 2H), 1.08 (d, 6H), 0.84 (dd, 6H), 0.70(dd, 6H).
LC/MS: m/z = 767.46(M+H+). 10 Example 12:
Methyl N-[(1S)-1-[(2S,4S)-2-[4-[2-[4-[2-[2-[(2S,4S)-1-[(2S)-2- (methoxycarbonylamino)-3-methyl-butanoyl]-4-methyl-pyrrolidin-2-yl]-1 H-imidazol- 4-yl]ethynyl]phenyl]ethynyl]- 1 H-imidazol-2-yl]-4-methyl-pyrrolidine- 1 -carbonyl]-2- meth l-propyl]-N-methyl-carbamate
Figure imgf000146_0001
To a stirred suspension of methyl N-[(1 S)-1 -[(2S,4S)-2-(5-iodo-1 H-imidazol-2-yl)-4-methyl- pyrrolidine-1 -carbonyl]-2-methyl-propyl]carbamate (100 mg, 0.23mmol), methyl N-[(1 S)- 1 -[(2S,4S)-2-(5-iodo-1 H-imidazol-2-yl)-4-methyl-pyrrolidine-1 -carbonyl]-2-methyl-propyl]- 20 N-methyl-carbamate (103.2 mg, 0.23mmol), Cul (8.7mg, 0.04 mmol) and Pd(dppf)Cl2-DCM (37.6 mg, 0.04 mmol) in DMF (3 mL) is sequentially added TEA (192.6 μΙ_, 1.38 mmol) and 1 ,4-diethynylbenzene (29mg, 0.23 mmol) under nitrogen atmosphere. The reaction mixture is heated at 70° C for 1 hour, diluted with water and extracted with CH2Cl2. The organic phase is washed with water, brine, dried over Na2S04, filtered and concentrated to dryness. The residue is purified by flash column chromatography on silica gel (1 to 30% MeOH in CH2Cl2) and purified by reverse phase HPLC using a gradient of CH3CN/water to give methyl N-[(1 S)-1 -[(2S,4S)-2-[4-[2-[4-[2-[2-[(2S,4S)-1 -[(2S)-2-
(methoxycarbonylamino)-3-methyl-butanoyl]-4-methyl-pyrrolidin-2-yl]-1 H-imidazol-4-
BOST 1803930.1 145 yl]ethynyl]phenyl]ethynyl]-1 H-imidazol-2-yl]-4-methyl-pyrrolidine-1 -carbonyl]-2-methyl- propyl]-N-methyl-carbamate as a white powder.
1H NMR (400 MHz, CD3OD) δ 7.55 (m, 2H), 7.47 (s, 4H), 5.00-4.92 (m, 2H), 4.42 (d, 1 H), 4.41 -4.14(m, 2H), 4.22 (m, 1 H), 4.08 (d, 1 H), 3.99 (m, 1 H), 3.64 (s, 3H), 3.54 (s, 3H), 2.74 (s, 3H), 2.55-2.44 (m, 2H), 2.34 (m, 2H), 2.03 (m, 1 H), 1.87 (m, 1 H), 1.67 (m, 2H), 1.10-1.04 (m, 6H), 0.79-0.69 (m, 12H).
LC/MS: m/z = 753.4(M+H+).
Example 13:
10 Methyl N-[(1S)-1-[(2S)-2-[4-[2-[4-[2-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3- methyl-butanoyl]pyrrolidin-2-yl]- 1 H-imidazol-4-yl]ethynyl]- 1 , 3-benzoxazol-7- l]ethynyl]-1 H-imidazol-2-yl]pyrrolidine-1-carbonyl]-2-methyl-propyl]carbamate
Figure imgf000147_0001
4,7-Dibromo-1 ,3-benzoxazole (19 mg, 0.07 mmol), methyl N-[(1 S)-1 -[(2S)-2-(4-ethynyl- 1 H-imidazol-2-yl)pyrrolidine-1 -carbonyl]-2-methyl-propyl]carbamate (56 mg, 0.17 mmol), Pd(dppf)Cl2-DCM (5.7 mg, 0.007 mmol), TEA (19.6 uL,0.14 mmol) and Cul (2.6 mg, 0.014 mmol) are dissolved in 3 mL of DMF. The system is flushed with nitrogen and the mixture is heated at 70° C overnight. After evaporation of the solvent under vacuum, the residue 20 is purified by flash column chromatography on silica gel (0 to 7% MeOH in CH2Cl2) and is further purified by reverse phase HPLC using a gradient of CH3CN/water to give methyl N-[(1 S)-1 -[(2S)-2-[4-[2-[4-[2-[2-[(2S)-1 -[(2S)-2-(methoxycarbonylamino)-3-methyl- butanoyl]pyrrolidin-2-yl]-1 H-imidazol-4-yl]ethynyl]-1 ,3-benzoxazol-7-yl]ethynyl]-1 H- imidazol-2-yl]pyrrolidine-1 -carbonyl]-2-methyl-propyl]carbamate (10.4 mg).
1H NMR (400 MHz, CD3OD): δ [ppm] 8.58 (s, 1 H), 7.38-7.50 (m, 4H), 5.08 (m, 2H), 4.18 (d, 2H), 3.80-3.94 (m, 4H), 3.55 (s, 6H), 1.99-2.26 (m, 10H), 0.86-0.97 (m, 12H).
LC/MS : m/z 752.58 (M+H+).
1 H NMR (400 MHz, CD3OD) δ 7.29 (m, 2H), 7.12 (m, 4H), 5.05(m, 2H), 4.17(d, 2H), 3.98- 30 3.92 (m, 2H), 3.82-3.78 (m, 2H), 3.62 (s, 6H), 2.24 (m, 4H), 2.12 (m, 2H), 2.03-1.97 (m, 4H), 1.3-1.27 (m, 6H), 0.95-0.85 (m, 12H).
LC/MS: m/z = 717.5(M+H+).
BOST 1803930.1 146 Examples 14 and 15:
methyl N-[(1S)-1-[(2S)-2-[4-[2-[2-[2-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3- methyl-butanoyl]pyrrolidin-2-yl]-1H-imidazol-4-yl]ethynyl]thieno[3,2-b]thiophen-5- yl]ethynyl]-1H-imidazol-2-yl]pyrrolidine-1-carbonyl]-2-methyl-propyl]carbamate (14) and
methyl N-[(1S)-1-[(2S)-2-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methyl- butanoyl]pyrrolidin-2-yl]- 1 H-imidazol-4-yl]buta- 1 , 3-diynyl]- 1 H-imidazol-2- l]pyrrolidine-1-carbonyl]-2-methyl-propyl]carbamate (15)
Figure imgf000148_0001
10
2,5-Dibromothieno[3,2-b]thiophene (26 mg, 0.088 mmol), methyl N-[(1S)-1-[(2S)-2-(4- ethynyl-1 H-imidazol-2-yl)pyrrolidine-1 -carbonyl]-2-methyl-propyl]carbamate (70 mg, 0.22 mmol), Pd(dppf)Cl2-DCM (57.1 mg, 0.008 mmol), TEA (24.5 uL,0.17 mmol) and Cul (3.3 mg, 0.017 mmol) are dissolved in 3 mL of DMF. The system is flushed with nitrogen and the reaction mixture is heated at 70° C overnight. After evaporation of the solvent under vacuum, the residue is purified by flash column chromatography on silica gel (0 to 7% MeOH in CH2Cl2) and is further purified by reverse phase HPLC using a gradient of CH3CN/water to give methyl N-[(1S)-1-[(2S)-2-[4-[2-[2-[2-[2-[(2S)-1-[(2S)-2- (methoxycarbonylamino)-3-methyl-butanoyl]pyrrolidin-2-yl]-1 H-imidazol-4- 20 yl]ethynyl]thieno[3,2-b]thiophen-5-yl]ethynyl]-1 H-imidazol-2-yl]pyrrolidine-1 -carbonyl]- 2-methyl-propyl]carbamate (16 mg)
1H NMR (400 MHz, CD3OD): δ [ppm] 7.41 (s, 2H), 7.25 (s, 2H), 5.08 (m, 2H), 4.18 (d, 2H), 3.80-3.94 (m, 4H), 3.56 (s, 6H), 1.97-2.27 (m, 10H), 0.82-0.96 (m, 12H).
LC/MS : m/z 773.53 (M+H+).
Methyl N-[(1S)-1-[(2S)-2-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methyl- butanoyl]pyrrolidin-2-yl]-1 H-imidazol-4-yl]buta-1 , 3-diynyl] -1 H-imidazol-2-yl]pyrrolidine- 1 -carbonyl]-2-methyl-propyl]carbamate (5 mg) is also isolated.
1H NMR (400 MHz, CD3OD): δ [ppm] 7.33 (s, 2H), 5.08 (m, 2H), 4.18 (d, 2H), 3.77-3.91 (m, 4H), 3.56 (s, 6H), 1.92-2.22 (m, 10H), 0.86-0.96 (m, 12H).
30 LC/MS : m/z 635.48 (M+H+).
BOST 1803930.1 147 Example 16:
Methyl N-[(1S)-1-[(2S,4S)-2-[4-[2-[4-[2-[2-[(2S,4S)-1-[(2S)-2- (methoxycarbonylamino)-3-methyl-butanoyl]-4-methyl-pyrrolidin-2-yl]-1 H-imidazol- 4-yl]ethynyl]-2-methyl-phenyl]ethynyl]- 1 H-imidazol-2-yl]-4-methyl-pyrrolidine- 1 - carbonyl]-2-methyl-propyl]carbamate
Figure imgf000149_0001
Methyl N-[(1 S)-1 -[(2S,4S)-2-(4-iodo-1 H-imidazol-2-yl)-4-methyl-pyrrolidine-1 -carbonyl]-2- 10 methyl-propyljcarbamate (60 mg, 0.14 mmol), 1 ,4-diethynyl-2-methyl-benzene (8.8 mg, 0.06 mmol), Pd(dppf)Cl2-DCM (5.1 mg, 0.006 mmol), TEA (22 uL, 0.16 mmol) and Cul (2.4 mg, 0.012 mmol) are dissolved in 2 mL of DMF. The mixture is heated to 50° C under N2 overnight. After evaporation of the solvent under vacuum, the residue is purified by flash column chromatography on silica gel (0 to 7% MeOH in CH2Cl2) and is further purified by reverse phase HPLC using a gradient of CH3CN/water to give methyl N-[(1 S)-1 - [(2S,4S)-2-[4-[2-[4-[2-[2-[(2S,4S)-1 -[(2S)-2-(methoxycarbonylamino)-3-methyl-butanoyl]- 4-methyl-pyrrolidin-2-yl]-1 H-imidazol-4-yl]ethynyl]-2-methyl-phenyl]ethynyl]-1 H- imidazol-2-yl]-4-methyl-pyrrolidine-1 -carbonyl]-2-methyl-propyl]carbamate (10 mg) as a white solid.
20 1H NMR (400 MHz, CD3OD): δ [ppm] 7.42-7.82 (m, 5H), 5.10 (m, 2H), 4.30 (m, 2H), 4.18 (d, 2H), 3.63 (s, 6H), 2.45-2.65 (m, 9H), 1.70-1.96 (m, 4H), 1.19 (m, 6H).0.86 (m, 12H). LC/MS : m/z 753.56 (M+H+).
Example 17:
Methyl N-[(1S)-1-[(2S,4S)-2-[4-[2-[4-[2-[2-[(2S,4S)-1-[(2S)-2-(methoxy- carbonylamino)-3-methyl-butanoyl]-4-methyl-pyrrolidin-2-yl]-1 H-imidazol-4- yl]ethyl]phenyl]ethyl]-1 H-imidazol-2-yl]-4-methyl-pyrrolidine-1-carbonyl]-2-methyl- ropyl]carbamate
Figure imgf000149_0002
BOST 1803930.1 148 To a solution of methyl N-[(1 S)-1 -[(2S,4S)-2-[4-[2-[4-[2-[2-[(2S,4S)-1 -[(2S)-2- (methoxycarbonylamino)-3-methyl-butanoyl]-4-methyl-pyrrolidin-2-yl]-1 H-imidazol-4- yl]ethynyl]phenyl]ethynyl]-1 H-imidazol-2-yl]-4-methyl-pyrrolidine-1 -carbonyl]-2-methyl- propyl]carbamate (9.3 mg, 0.012 mmol) in 2 mL of methanol are added one drop of 1M HCl and a catalytic amount of 10% Pd/C. The reaction mixture is stirred at RT overnight under 1 atmosphere of hydrogen. The mixture is filtered and the filtrate is concentrated to dryness. The residue is purified by reverse phase HPLC using a gradient of CH3CN/water to give methyl N-[(1 S)-1 -[(2S,4S)-2-[4-[2-[4-[2-[2-[(2S,4S)-1 -[(2S)-2- (methoxy-carbonylamino)-3-methyl-butanoyl]-4-methyl-pyrrolidin-2-yl]-1 H-imidazol-4- 10 yl]ethyl]phenyl]ethyl]-1 H-imidazol-2-yl]-4-methyl-pyrrolidine-1 -carbonyl]-2-methyl- propyljcarbamate (2.8 mg).
1H NMR (400 MHz, CD3OD): [ppm] 7.07 (m, 6H), 5.06 (m, 2H), 4.16-4.27 (m, 4H), 3.60 (s, 6H), 2.89 (m, 6H), 2.45-2.60 (m, 4H), 1.70-1.96 (m, 4H), 1.19 (m, 10H).0.86 (m, 12H). LC/MS : m/z 747.56 (M+H+).
Example 18:
Methyl N-[(1S)-1-[(2S,4S)-2-[5-[2-[4-[2-[2-[(2S,4S)-1-[(2S)-2- (methoxycarbonylamino)-3-methyl-butanoyl]-4-methyl-pyrrolidin-2-yl]-4-methyl-1 H- imidazol-5-yl]ethynyl]phenyl]ethynyl]-4-methyl-1 H-imidazol-2-yl]-4-methyl- 20 rrolidine- 1-carbonyl]-2-methyl-propyl] carbamate
Figure imgf000150_0001
To a solution of methyl N-[(1 S)-1 -[(2S,4S)-2-(5-iodo-1 H-imidazol-2-yl)-4-methyl- pyrrolidine-1 -carbonyl]-2-methyl-propyl]carbamate (125 mg, 0.28 mmol), 1 ,4- diethynylbenzene (17.59 mg, 0.14 mmol), Pd(dppf)Cl2-DCM (11.38 mg, 0.014 mmol), and Cul (5.31 mg, 0.028 mmol) in DMF (2.50 mL) is added TEA (70.53 mg, 97.15 μΙ_, 0.70 mmol) and the reaction mixture is heated at 80° C for 18 hours. The reaction mixture is diluted with water (10 mL) and is extracted with of EtOAc (5 x 10 mL). The combined organic layers are washed with water, dried over Na2S04, and evaporated to dryness. The residue is purified by flash column chromatography on silica gel (0 to 15% MeOH in 30 CH2Cl2) and is further purified by reverse phase HPLC using a gradient of CH3CN/water to give methyl N-[(1 R)-1 -[(2S,4S)-2-[5-[2-[4-[2-[2-[(2S,4S)-1 -[(2S)-2-
BOST 1803930.1 149 (methoxycarbonylamino)-3-methyl-butanoyl]-4-methyl^yrrolidin-2-yl]-4-methy H- imidazol-5-yl]ethynyl]phenyl]ethynyl]-4-methyl-1 H-imidazol-2-yl]-4-methyl-pyrrolidine-1 - carbonyl]-2-methyl-propyl] carbamate (10.7 mg, 9%).
LC/MS : m/z 767.58 (M+H+).
Example 19:
Methyl N-[(1S)-1-[(2S)-2-[5-[2-[4-[2-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3- methyl-butanoyl]-pyrrolidin-2-yl]-4-methyl-1 H-imidazol-5- yl]ethynyl]phenyl]ethynyl]-4-methyl-1 H-imidazol-2-yl]-pyrrolidine-1-carbonyl]-2- 10 methyl-propyl] carbamate
Figure imgf000151_0001
To a solution of methyl N-[(1 S)-1 -[(2S)-2-(5-iodo-1 H-imidazol-2-yl)-pyrrolidine-1 - carbonyl]-2-methyl-propyl]carbamate (129 mg, 0.296 mmol) , 1 ,4-diethynylbenzene (18.7 mg, 0.148 mmol) , Pd(dppf) (12.1 mg, 0.0148 mmol) , and Cul (5.6 mg, 0.0296 mmol) in DMF (2.6 mL) is added TEA (103 μΙ_, 0.740 mmol) and the mixture is heated at 80° C for 18 hours. The reaction mixture is diluted with water (10 mL) and is extracted with of EtOAc (5 x 10 mL). The combined organic layers are washed with water, dried over Na2S04, and evaporated to dryness. The residue is purified by flash column chromatography on silica gel (0 to 15% MeOH in CH2Cl2) and is further purified by reverse phase HPLC using a 20 gradient of CH3CN/water to give Methyl N-[(1 R)-1 -[(2S,4S)-2-[5-[2-[4-[2-[2-[(2S,4S)-1 - [(2S)-2-(methoxycarbonylamino)-3-methyl-butanoyl]-pyrrolidin-2-yl]-4-methyl-1 H- imidazol-5-yl]ethynyl]phenyl]ethynyl]-4-methyl-1 H-imidazol-2-yl]-pyrrolidine-1 - carbonyl]-2-methyl-propyl] carbamate (46 mg, 42%).
1H NMR (400 MHz, DMSO-d6) δ 12.00 (m, 2H), 7.44 (m, 4H), 7.25 (m, 2H), 4.92 (m, 2H), 3.98 (m, 2H), 3.74 (m, 2H), 3.50 (s, 6H), 2.22 (m, 6H), 2.12 (m, 6H), 1.91 (m, 6H), 0.82 (m, 12H).
BOST 1803930.1 150 Examples 20 and 21
Methyl N-[(1S)-1-[(2S,4S)-2-[4-iodo-5-[2-[4-[2-[4-iodo-2-[(2S,4S)-1-[(2S)-2- (methoxycarbonylamino)-3-methyl-butanoyl]-4-methyl-pyrrolidin-2-yl]-1 H-imidazol- 5-yl]ethynyl]phenyl]ethynyl]- 1 H-imidazol-2-yl]-4-methyl-pyrrolidine- 1 -carbonyl]-2- methyl-propyl]carbamate (21 )
Figure imgf000152_0001
To a stirred suspension of Methyl N-[(1 S)-1 -[(2S,4S)-2-[5-[2-[4-[2-[2-[(2S,4S)-1 -[(2S)-2- (methoxycarbonylamino)-3-methyl-butanoyl]-4-methyl-pyrrolidin-2-yl]-1 H-imidazol-5- yl]ethynyl]phenyl]ethynyl]-1 H-imidazol-2-yl]-4-methyl-pyrrolidine-1 -carbonyl]-2-methyl- propyl]carbamate (0.127 g, 0.172 mmol) in CH2Cl2 (1.3 mL) at 0°C is added N- iodosuccinimide (0.085 g, 0.378 mmol) under nitrogen atmosphere. The reaction mixture is stirred 1 hour at 0°C and 1 hour at RT. The reaction mixture is concentrated and purified by reverse phase HPLC using a gradient of CH3CN/water to afford methyl N-[(1 S)- 1 -[(2S,4S)-2-[4-iodo-5-[2-[4-[2-[4-iodo-2-[(2S,4S)-1 -[(2S)-2-(methoxycarbonylamino)-3- methyl-butanoyl]-4-methyl-pyrrolidin-2-yl]-1 H-imidazol-5-yl]ethynyl]phenyl]ethynyl]-1 H- imidazol-2-yl]-4-methyl-pyrrolidine-1 -carbonyl]-2-methyl-propyl]carbamate (32 mg, 0.03114 mmol, 18.11%, purity, 96.4%)
LC/MS, m/z: 991.01 (M+H+)
and methyl N-[(2S)-1 -[(2S,4S)-2-(5-{2-[4-(2-{4-iodo-2-[(2S,4S)-1 -[(2S)-2-
[(methoxycarbonyl)amino]-3-methylbutanoyl]-4-methylpyrrolidin-2-yl]-1 H-imidazol-5- yl}ethynyl)phenyl]ethynyl}-1 H-imidazol-2-yl)-4-methylpyrrolidin-1 -yl]-3-methyl-1 - oxobutan-2-yl]carbamate (7.5 mg, 0.0087 mmol 4.4%, purity, 95.9%)
LC/MS, m/z: 865.33 (M+H+).
BOST 1803930.1 151 Example 22
Methyl N-[1-[(2S,4S)-2-[4-[2-[4-[2-[2-[(2S,4S)-1-[2-(methoxycarbonylamino)-3- methyl-butanoyl]-4-methyl-pyrrolidin-2-yl]-1 H-imidazol-4-yl]ethynyl]-2- (trifluoromethyl)phenyl]ethynyl]-1 H-imidazol-2-yl]-4-methyl-pyrrolidine-1-carbonyl]- 2-meth l-propyl]carbamate
Figure imgf000153_0001
To a stirred solution of methyl N-[1 -[(2S,4S)-2-(4-iodo-1 H-imidazol-2-yl)-4-methyl- pyrrolidine-1 -carbonyl]-2-methyl-propyl]carbamate (59.02 mg, 0.1359 mmol) in DMF (2
10 mL) are added trimethyl-[2-[2-(trifluoromethyl)-4-(2- trimethylsilylethynyl)phenyl]ethynyl]silane (20 mg, 0.05908 mmol), PdCl2(dppf)-CH2Cl2 (4.825 mg, 0.005908 mmol), Cul (2.251 mg, 0.01182 mmol), H20 (5.322 mg, 5.322 μΙ_, 0.2954 mmol) and DBU (89.94 mg, 88.35 μΙ_, 0.5908 mmol). The mixture is degassed and heated to 75°C under nitrogen overnight. After removal of the solvent under reduced pressure, the residue is suspended in water, extracted with CH2Cl2 (3x10 mL). The combined organic extracts are washed with brine, dried over Na2S04, concentrated, purified by silica gel column chromatography using MeOH/CH2Cl2 (0-6%), and the major fraction is further purified using reverse-phase prep-HPLC to provide methyl N-[1 - [(2S,4S)-2-[4-[2-[4-[2-[2-[(2S,4S)-1 -[2-(methoxycarbonylamino)-3-methyl-butanoyl]-4-
20 methyl-pyrrolidin-2-yl]-1 H-imidazol-4-yl]ethynyl]-2-(trifluoromethyl)phenyl]ethynyl]-1 H- imidazol-2-yl]-4-methyl-pyrrolidine-1 -carbonyl]-2-methyl-propyl]carbamate (6.9 mg, 0.008466 mmol, 14.33%) as a white solid . LC/MS: m/z = 807.44 (M+H+). 1H NMR (CD3OD, 400 MHz): δ 7.20-7.7.80 (m, 5H), 4.98(m, 2H), 4.20 (m, 4H), 3.62 (s, 6H), 2.46 (m, 4H), 1.96 (m, 4H), 1.15-1.30 (m, 8H), 0.84(m, 12H).
BOST 1803930.1 152 Examples 23 and 24
Figure imgf000154_0001
Figure imgf000154_0003
The above compoun s were prepare accor ng to t e proce ures sc ose erein.
Example 25:
Methyl N-[(1S)-1-[(2S)-2-[4-[2-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methyl- butanoyl]pyrrolidin-2-yl]-1 H-imidazol-4-yl]thieno[3,2-b]thiophen-5-yl]-1 H-imidazol- 2- l]pyrrolidine- 1 -carbonyl]-2-methyl-propyl]carbamate
Figure imgf000154_0002
To a solution of methyl N-[(1 S)-1 -[(2S)-2-(4-iodo-1 H-imidazol-2-yl)pyrrolidine-1 -carbonyl]- 10 2-methyl-propyl]carbamate (116.6 mg, 0.2775 mmol) and 4,4,5, 5-tetramethyl-2-[5- (4,4,5, 5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)thieno[3,2-b]thiophen-2-yl]-1 ,3,2- dioxaborolane (47 mg, 0.08629 mmol) in acetonitrile (2.5 mL) in a microwave vial (10 mL) under nitrogen atmosphere are sequentially added Pd(dppf)Cl2-CH2Cl2 (14.78 mg, 0.01810 mmol) and aq. sodium bicarbonate (603.3 μί of 1 M, 0.6033 mmol). The resultant suspension is heated in microwave at 150°C for 10 minutes and concentrated. The residue is dissolved in 10% MeOH-CH2Cl2, filtered off salts and concentrated. The residue is purified by silica gel column chromatography using methanol-ethyl acetate (0:100 to 15:85) as eluent to afford a yellow compound (29 mg) which is repurified by reverse phase HPLC to afford methyl N-[(1 S)-1 -[(2S)-2-[4-[2-[2-[(2S)-1 -[(2S)-2- 20 (methoxycarbonylamino)-3-methyl-butanoyl]pyrrolidin-2-yl]-1 H-imidazol-4-yl]thieno[3,2- b]thiophen-5-yl]-1 H-imidazol-2-yl]pyrrolidine-1 -carbonyl]-2-methyl-propyl]carbamate (6.90 mg, 0.009014 mmol, 9.893%) as a light yellow solid. Rf = 0.29 (MeOH:EtOAc, 1 :4). LC/MS, m/z = 725.5 (M+H+); Rt : 7.55 minutes.
HPLC (Rt) = 18.1 minutes, Method: 10%-50% AcCN-water (0.01% TFA) for 40 min, Gemini C18 3μιη, 4.6 mm x 250 mm.
BOST 1803930.1 Example 26:
Methyl N-[(1S)-1-[(2S,4S)-2-[4-[5-[2-[(2S,4S)-1-[(2S)-2-(methoxycarbonylamino)-3- methyl-butanoyl]-4-methyl-pyrrolidin-2-yl]-1 H-imidazol-4-yl]thieno[3,2-b]thiophen- 2- l]- 1 H-imidazol-2-yl]-4-methyl-pyrrolidine- 1 -carbonyl]-2-methyl-propyl]carbamate
Figure imgf000155_0001
The title compound is prepared from methyl N-[(1 S)-1 -[(2S,4S)-2-(4-iodo-1 H-imidazol-2- yl)-4-methyl-pyrrolidine-1 -carbonyl]-2-methyl-propyl]carbamate as described for Example 25.
LC/MS, m/z = 753.15 (M+H+); Rt : 7.01 minutes.
10 HPLC (Rt) = 9.9 minutes, Method: 20%-60% AcCN-water (0.01% TFA) for 40 min, Gemini C18 3μιη, 4.6 mm x 250 mm.
Exampl
Figure imgf000155_0002
BOST 1803930.1 154
Figure imgf000156_0001
BOST 1803930.1 155
Figure imgf000157_0001
BOST 1803930.1 156
Figure imgf000158_0001
The above compounds were prepared according to the procedures disclosed herein.
BOST 1803930.1 157 Example 46:
Methyl N-[(1S)-1-[(2S,4S)-2-[5-[2-[4-[2-[2-[(2S,4S)-1-[(2S)-2-[[(2S)-2- (methoxycarbonylamino)-3-methyl-butanoyl]amino]-3-methyl-butanoyl]-4-methyl- pyrrolidin-2-yl]- 1 H-imidazol-5-yl]ethynyl]phenyl]ethynyl]- 1 H-imidazol-2-yl]-4- meth l-pyrrolidine- 1 -carbonyl]
Figure imgf000159_0001
The same procedures are followed as mentioned for Example 4B.
LC/MS: m/z = 838.56 (M+H+). HPLC (Rt) = 43.34 minutes; Method: Phenomenex Gemini C18 3 urn, 25% CH3CN-H20 (isocratic).
Example 47:
Methyl N-[(1S)-1-[(2S,4S)-2-[4-[5-[2-[(2S,4S)-1-[(2S)-2-(methoxycarbonylamino)-3- methyl-butanoyl]-4-methyl-pyrrolidin-2-yl]-5-methyl-1 H-imidazol-4-yl]thieno[3,2- b]thiophen-2-yl]-5-methyl-1H-imidazol-2-yl]-4-methyl-pyrrolidine-1-carbonyl]-2- meth l-propyl]carbamate
Figure imgf000159_0002
To a degassed (vacuum/nitrogen flush) mixture of methyl N-[(1 S)-1 -[(2S,4S)-2-(5-iodo-1 H- 20 benzimidazol-2-yl)-4-methyl-pyrrolidine-1 -carbonyl]-2-methyl-propyl]carbamate (92.65 mg, 0.1913 mmol), methyl N-[(1 S)-1 -[(2S,4S)-2-(5-iodo-4-methyl-1 H-imidazol-2-yl)-4- methyl-pyrrolidine-1 -carbonyl]-2-methyl-propyl]carbamate (85.76 mg, 0.1913 mmol),
BOST 1803930.1 158 4,4,5,5-tetramethyl-2-[5-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)thieno[3,2- b]thiophen-2-yl]-1 ,3,2-dioxaborolane (75 mg, 0.1913 mmol) and K2C03 (132.2 mg, 0.9565 mmol) in degassed IPA (2.250 mL) and H20 (750.0 μΐ) are added [3-(2- dicyclohexylphosphanylphenyl)-2,4-dimethoxy-phenyl]sulfonyloxysodium (15.69 mg, 0.03061 mmol) and Pd(OAc)2 (1.718 mg, 0.007652 mmol). The reaction mixture is degassed twice and slowly heated at 90°C for 16 hours, diluted with ethyl acetate (30 mL) and then the aqueous solution is discarded. The organic layer is washed with brine, dried (Na2S04) and concentrated. The residue is purified by silica gel column chromatography using ethyl acetate to 10% MeOH-EtOAc as eluent to afford a mixture of
10 products (110 mg) as yellow solid. LC-MS shows the presence of a mixture of methyl N- [(1 S)-1 -[(2S,4S)-2-[4-[5-[2-[(2S,4S)-1 -[(2S)-2-(methoxycarbonylamino)-3-methyl- butanoyl]-4-methyl-pyrrolidin-2-yl]-5-methyl-1 H-imidazol-4-yl]thieno[3,2-b]thiophen-2- yl]-5-methyl-1 H-imidazol-2-yl]-4-methyl-pyrrolidine-1 -carbonyl]-2-methyl- propyl]carbamate (HPLC Rt 8.42 minutes, M.Wt. 781 ), methyl N-[(1 S)-1 -[(2S,4S)-2-[4-[5- [2-[(2S,4S)-1 -[(2S)-2-(methoxycarbonylamino)-3-methyl-butanoyl]-4-methyl-pyrrolidin-2- yl] - 1 H-benzimidazol-5-yl]thieno[3,2-b]thiophen-2-yl]-5-methyl-1 H-imidazol-2-yl]-4- methyl-pyrrolidine-1 -carbonyl]-2-methyl-propyl]carbamate (HPLC Rt, 13.6 minutes, M.Wt. 817) and methyl N-[(1 S)-1 -[(2S,4S)-2-[5-[5-[2-[(2S,4S)-1 -[(2S)-2- (methoxycarbonylamino)-3-methyl-butanoyl]-4-methyl-pyrrolidin-2-yl]-1 H-benzimidazol-
20 5-yl]thieno[3,2-b]thiophen-2-yl]-1 H-benzimidazol-2-yl]-4-methyl-pyrrolidine-1 -carbonyl]- 2-methyl-propyl]carbamate (HPLC Rt. 19.3 minutes, M.Wt. 853.06). Reverse phase HPLC purification of the mixture gives the title compound (18.3 mg, 0.02160 mmol, 45.17%) as a light yellow solid.
LC/MS, m/z = 781.17 (M+H+); Rt : 6.92 minutes.
HPLC (Rt) = 8.26 minutes, Method: 20%-60% AcCN-water (0.01% TFA) for 40 min, Gemini C18 3μιη, 4.6 mm x 250 mm.
Example 48
Figure imgf000160_0001
30 The above compound was prepared according to the procedures disclosed herein.
BOST 1803930.1 159 Example 49:
Methyl N-[(1S)-1-[(2S,4S)-2-[4-[6-[2-[(2S,4S)-1-[(2S)-2-(methoxycarbonylamino)-3- methyl-butanoyl]-4-methyl-pyrrolidin-2-yl]- 1 H-imidazol-4-yl]-2-naphthyl]- 1 H- imidazol-2- l]-4-methyl-pyrrolidine-1-carbonyl]-2-methyl-propyl]carbamate
Figure imgf000161_0001
The title compound is prepared from methyl N-[(1 S)-1 -[(2S,4S)-2-(4-iodo-1 H-imidazol-2- yl)-4-methyl-pyrrolidine-1 -carbonyl]-2-methyl-propyl]carbamate, methyl N-[(1 S)-1 - [(2S,4S)-2-(5-iodo-1 H-benzimidazol-2-yl)-4-methyl-pyrrolidine-1 -carbonyl]-2-methyl- 10 propyl]carbamate and 4,4,5,5-tetramethyl-2-[6-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan- 2-yl)-2-naphthyl]-1 ,3,2-dioxaborolane as described for Example 47.
LC/MS, m/z = 741.42 (M+H+); Rt : 6.46 minutes.
HPLC (Rt) = 6.72 minutes, Method: 20%-60% AcCN-water (0.01% TFA) for 40 min, Gemini C18 3μιη, 4.6 mm x 250 mm.
Examples 50 a
Figure imgf000161_0002
The above compoun s were prepare accor ng to t e proce ures sclosed herein.
BOST 1803930.1 160 Example 52
Methyl N-[(1S)-1-[(2R,4S)-2-[4-[2-[4-[2-[2-[(2S,4S)-1-[(2S)-2- (methoxycarbonylamino)-3-methyl-butanoyl]-4-methyl-pyrrolidin-2-yl]-1 H-imidazol- 4-yl]ethynyl]phenyl]ethynyl]- 1 H-imidazol-2-yl]-4-methyl-pyrrolidine- 1 -carbonyl]-2- meth l-propyl]carbamate
Figure imgf000162_0001
To a stirred solution of methyl N-[(1 S)-2-methyl-1 -[(2S,4S)-4-methyl-2-[4-[2-[4-(2- trimethylsilylethynyl)phenyl]ethynyl]-1 H-imidazol-2-yl]pyrrolidine-1 - carbonyl]propyl]carbamate (63.89 mg, 0.1266 mmol) in DMF (2 mL) are added methyl N-
10 [(1 S)-1 -[(2R,4S)-2-(4-iodo-1 H-imidazol-2-yl)-4-methyl-pyrrolidine-1 -carbonyl]-2-methyl- propyl]carbamate (50 mg, 0.1151 mmol), PdCl2(dppf)-CH2Cl2 (9.400 mg, 0.01151 mmol), Cul (2.192 mg, 0.01151 mmol), DBU (140.2 mg, 137.7 μΙ_, 0.9208 mmol) and water (10.37 mg, 10.37 μΙ_, 0.5755 mmol). The mixture is degassed and heated at 75°C under nitrogen overnight. After removal of the solvent under reduced pressured, the residue is suspended in water, extracted with CH2Cl2 (3x10 mL). The combined organic extracts are washed with brine, dried over Na2S04, concentrated, purified by silica gel column chromatography using MeOH (0-6%) in CH2Cl2 and the major fraction is further purified using reverse-phase prep-HPLC to provide methyl N-[(1 S)-1 -[(2R,4S)-2-[4-[2-[4-[2-[2- [(2S,4S)-1 -[(2S)-2-(methoxycarbonylamino)-3-methyl-butanoyl]-4-methyl-pyrrolidin-2-yl]-
20 1 H-imidazol-4-yl]ethynyl]phenyl]ethynyl]-1 H-imidazol-2-yl]-4-methyl-pyrrolidine-1 - carbonyl]-2-methyl-propyl]carbamate (3.9 mg, 0.005199 mmol, 4.517%) as a white solid. LC/MS: m/z = 739.43 (M+H+). 1H NMR (CD3OD, 400 MHz): δ 7.55-7.65 (m, 6H), 5.25(m, 1 H), 5.10(m, 1 H), 4.20 (m, 4H), 3.62 (2xs, 6H), 2.50 (m, 4H), 2.00 (m, 4H), 1.15 (m, 8H), 0.84(m, 12H).
BOST 1803930.1 161 Example 53
Methyl N-[(1S)-1-[(2S,4S)-2-[4-[4-[2-[(2S,4S)-1-[(2S)-2-(methoxycarbonylamino)-3- methyl-butanoyl]-4-methyl-pyrrolidin-2-yl]- 1 H-imidazol-4-yl]buta- 1 , 3-diynyl]- 1 H- imidazol-2-yl]-4-methyl-pyrrolidine-1-carbonyl]-2-methyl-propyl]carbamate
Figure imgf000163_0001
LC/MS, m/z = 663.44 (M+H+); Rt : 7.61 minutes.
HPLC RT = 14.47 minutes; Method: 20%-60% AcCN-water (0.01% TFA) for 40 min, Gemini C18 3μιη, 4.6 mm x 250 mm.
10 Example 54
Figure imgf000163_0003
The above compound was prepared according to the procedures disclosed herein.
Example 55
Methyl N-[(1S)-1-[(2S,4S)-2-[4-[2-[2-[2-[2-[(2S,4S)-1-[(2S)-2- (methoxycarbonylamino)-3-methyl-butanoyl]-4-methyl-pyrrolidin-2-yl]-1 H-imidazol- 4-yl]ethynyl]-6-quinolyl]ethynyl]- 1 H-imidazol-2-yl]-4-methyl-pyrrolidine- 1 -carbonyl]- -methyl-propyl]carbamate
Figure imgf000163_0002
20 The title compound is synthesized from methyl N-[(1 S)-1 -[(2S,4S)-2-(4-iodo-1 H-imidazol- 2-yl)-4-methyl-pyrrolidine-1 -carbonyl]-2-methyl-propyl]carbamate and 2,6- diethynylquinoline as described in Example 6.
BOST 1803930.1 ] < ο 1H NMR (400 MHz, CD3OD): δ 8.30 (d, 1 H), 8.03 (s, 1 H), 7.92 (d, 1 H), 7.79 (d, 1 H), 7.63(d, 1 H), 7.45 (s, 1 H), 7.32 (s, 1 H), 5.01 (m, 2H), 4.19 (m, 2H), 4.17 (m, 2H), 3.62 (s, 6H), 2.46 (m, 2H), 2.34 (m, 2H), 1.99-1.86 (m, 4H), 1.36-1.27 (m, 2H), 1.17 (d, 6H), 0.89-0.82 (m, 12H).
LC/MS: m/z = 790.3 (M + H+).
2,6-Diethynylquinoline is prepared from 2,6-dibromoquinoline according to the procedure reported for intermediate 12.
Example 56
10 Methyl N-[(1S)-1-[(2S,4S)-2-[4-[2-[5-[2-[2-[(2S,4S)-1-[(2S)-2- (methoxycarbonylamino)-3-methyl-butanoyl]-4-methyl-pyrrolidin-2-yl]-1 H-imidazol- 4-yl]ethynyl]-2-pyridyl]ethynyl]- 1 H-imidazol-2-yl]-4-methyl-pyrrolidine- 1 -carbonyl]- 2-meth l-propyl]carbamate
Figure imgf000164_0001
To a mixture of methyl N-[(1 S)-1 -[(2S,4S)-2-(4-iodo-1 H-imidazol-2-yl)-4-methyl- pyrrolidine-1 -carbonyl]-2-methyl-propyl]carbamate (102.4 mg, 0.2234 mmol), trimethyl- [2-[6-(2-trimethylsilylethynyl)-3-pyridyl]ethynyl]silane (31 mg, 0.1117 mmol), PdCl2(dppf)-CH2Cl2 (13.69 mg, 0.01676 mmol) and copper Iodide (3.192 mg, 0.01676 mmol) is added DMF (1 mL) under nitrogen atmosphere. The reaction mixture is degassed 20 thrice (vacuum and nitrogen gas) and DBU (204.0 mg, 200.4 μΙ_, 1.340 mmol) is added.
The reaction mixture is degassed three times, degassed water (6.037 mg, 6.037 μΙ_, 0.3351 mmol) is added and heated at 60°C for 8 hours. The reaction mixture is diluted with water (6 mL), extracted with methanol-CH2Cl2, and the combined extracts are washed with brine. The organic layer is dried (Na2S04), concentrated and purified by silica gel column chromatography using methanol-CH2Cl2 (0 to 10%) as eluent to afford a crude product (43 mg) which is repurified by HPLC to afford methyl N-[(1 S)-1 -[(2S,4S)-2- [4-[2-[5-[2-[2-[(2S,4S)-1 -[(2S)-2-(methoxycarbonylamino)-3-methyl-butanoyl]-4-methyl- pyrrolidin-2-yl]-1 H-imidazol-4-yl]ethynyl]-2-pyridyl]ethynyl]-1 H-imidazol-2-yl]-4-methyl- pyrrolidine-1 -carbonyl]-2-methyl-propyl]carbamate (22.7 mg, 0.02985 mmol, 26.73%).
BOST 1803930.1 163 1H NMR (400 MHz, CD3OD): δ 8.49 (s, 1 H), 7.78 (d, 1 H), 7.46 (d, 1 H), 7.3 (s, 1 H), 7.25 (s, 1 H), 4.95 - 4.86 (m, 2 H), 4.15 - 4.05 (m, 4 H), 3.54 (s, 6 H), 3.3 - 3.5 (m, 2 H), 2.44 - 2.16 (m, 4 H), 1.94 - 1 .66 (m, 4 H), 1 .08 (d, 6 H), 0.77 (d, 6 H), 0.74 (d, 6 H).
LC/MS: m/z = 740.45 (M+H+). Rt = 7.75 minutes.
HPLC (Rt) = 13.4 minutes, Method: 20%-60% AcCN-water (0.01 % TFA) for 40 minutes, Gemini C18 3μιη, 4.6 mm x 250 mm.
Example 57
Methyl 2,5-bis[2-[2-[(2S,4S)-1-[(2S)-2-(methoxycarbonylamino)-3-methyl-butanoyl]-4- 10 meth l-pyrrolidin-2-yl]- 1 H-imidazol-4-yl]ethynyl]benzoate
Figure imgf000165_0001
The title compound is synthesized from tert-butyl (2S,4S)-2-(4-iodo-1 H-imidazol-2-yl)-4- methyl-pyrrolidine-1 -carboxylate and methyl 2,5-diethynylbenzoate as described in Example 4B.
1 H NMR (400 MHz, CD3OD): δ 7.97 (s, 1 H), 7.58 (m, 2H), 7.29 (m, 2H), 4.98 (m, 2H),4.21 - 4.15 (m, 4H), 3.92 (s, 3H), 3.62 (s, 6H), 2.48-2.42 (m, 2H), 2.36-2.31 (m, 2H), 1 .97- 1 .85(m, 4H), 1 .16 (s, 6H), 0.81 -0.88 (m, 12H).
LC/MS: m/z = 797.4 (M + H+).
Methyl 2,5-diethynylbenzoate is prepared from methyl 2,5-diiodobenzoate according to 20 the procedure reported for intermediate 12.
Examples 58 and 59
Figure imgf000165_0002
BOST 1803930.1 164
Figure imgf000166_0001
The above compounds were prepared according to the procedures disclosed herein.
Example 60
Methyl N-[(1S)-1-[(2S,4S)-2-[4-[2-[5-[2-[2-[(2S,4S)-1-[(2S)-2- (methoxycarbonylamino)-3-methyl-butanoyl]-4-methyl-pyrrolidin-2-yl]-1 H-imidazol- 4-yl]ethynyl]-2-thienyl]ethynyl]- 1 H-imidazol-2-yl]-4-methyl-pyrrolidine- 1 -carbonyl]- 2-meth l-propyl]carbamate
Figure imgf000166_0002
10 The title compound is synthesized from methyl N-[(1 S)-1 -[(2S)-2-(4-ethynyl-1 Himidazol-2- yl)pyrrolidine-1 -carbonyl]-2-methyl-propyl]carbamate and 2,5-dibromothiophene as described in Example 13.
1H NMR (400 MHz, CD3OD): δ 7.27 (m, 2H), 7.12 (m, 2H), 4.95 (m, 2H), 4.2-4.07(m, 4H), 3.62 (s, 6H), 2.47-2.41 (m, 2H), 2.35-2.32 (m, 2H), 1.96-1.89 (m, 2H), 1.91 -1.83 (m, 2H), 1.27 (m, 2H),1.15(d, 6H), 0.91 -0.82 (m, 12H).
LC/MS: m/z = 745.3 (M + H+).
BOST 1803930.1 165 Example 61
Methyl N-[(1S)-1-[(2S,4S)-2-[4-[2-[2-[2-[2-[(2S,4S)-1-[(2S)-2- (methoxycarbonylamino)-3-methyl-butanoyl]-4-methyl-pyrrolidin-2-yl]-1 H-imidazol- 4-yl]ethynyl]benzothiophen-5-yl]ethynyl]-1 H-imidazol-2-yl]-4-methyl-pyrrolidine-1- carbonyl]-2-methyl-propyl]carbamate
Figure imgf000167_0001
To a solution of 2-[(2S,4S)-4-methylpyrrolidin-2-yl]-4-[2-[2-[2-[2-[(2S,4S)-4- methylpyrrolidin-2-yl]-1 H-imidazol-4-yl]ethynyl]benzothiophen-5-yl]ethynyl]-1 H-
10 imidazole (Hydrochloric Acid (4)) (30 mg, 0.04789 mmol) HCl salt in DMF (2 mL) are added (2S)-2-(methoxycarbonylamino)-3-methyl-butanoic acid (20.97 mg, 0.1197 mmol), HATU (45.51 mg, 0.1197 mmol) and DIPEA (61.89 mg, 83.41 μΙ_, 0.4789 mmol). The mixture is stirred at rt overnight. After removal of the solvent under reduced pressure, the residue is purified by silica gel column chromatography using MeOH (0-6%) in CH2Cl2, and the major fraction is further purified using reverse-phase prep-HPLC to provide methyl N-[(1 S)-1 -[(2S,4S)-2-[4-[2-[2-[2-[2-[(2S,4S)-1 -[(2S)-2-(methoxycarbonylamino)-3- methyl-butanoyl]-4-methyl-pyrrolidin-2-yl]-1 H-imidazol-4-yl]ethynyl]benzothiophen-5- yl]ethynyl]-1 H-imidazol-2-yl]-4-methyl-pyrrolidine-1 -carbonyl]-2-methyl- propyljcarbamate (23 mg, 0.02841 mmol, 59.33%) as a white solid. LC/MS: m/z = 795.40
20 (M+H+). 1H NMR (CD3OD, 400 MHz): δ 7.24-7.95 (m, 6H), 4.95(m, 2H), 4.20 (m, 4H), 3.62 (s, 6H), 2.46 (m, 4H), 1.96 (m, 4H), 1.15 (m, 6H), 0.84(m, 14H).
BOST 1803930.1 166 Example 62
Methyl N-[(1S)-1-[(2S,4S)-2-[4-[2-[2-cyano-4-[2-[2-[(2S,4S)-1-[(2S)-2- (methoxycarbonylamino)-3-methyl-butanoyl]-4-methyl-pyrrolidin-2-yl]-1 H-imidazol- 4-yl]ethynyl]phenyl]ethynyl]- 1 H-imidazol-2-yl]-4-methyl-pyrrolidine- 1 -carbonyl]-2- methyl-propyl]carbamate
Figure imgf000168_0001
The title compound is synthesized from tert-butyl (2S,4S)-2-(4-iodo-1 H-imidazol-2-yl)-4- methyl-pyrrolidine-1 -carboxylate and 2,5-diethynylbenzonitrile as described in Example 4B.
10 1H NMR (400 MHz, CD3OD): δ 7.83 (s, 1 H), 7.69 (d, 1 H), 7.62 (d, 1 H), 7.39 (s, 1 H), 7.32(s, 1 H), 4.99-4.95 (m, 2H), 4.21 -4.15 (m, 4H), 3.62 (s, 6H), 2.47-2.42 (m, 2H), 2.34 (m, 2H), 1.96-1.88 (m, 4H),1.27(m, 2H), 1.16 (d, 6H), 0.88-0.81 (m, 12H).
LC/MS: m/z = 764.4 (M + H+).
2,5-Diethynylbenzonitrile is prepared from 2,5-diiodobenzonitrile according to the procedure reported for intermediate 12.
Example 63
Dimethyl (2S,2'S)-1, 1 ,-((3S,3,S,5S,5,S)-5,5,-(4,4,-(2-chloro-1 ,4-phenylene)bis(ethyne- 2, 1-diyl)bis(1 H-imidazole-4,2-diyl))bis(3-methylpyrrolidine-5, 1-diyl))bis(3-methyl-1- 20 oxobutane-2, 1 -di l)dicarbamate
Figure imgf000168_0002
The same procedures are followed as mentioned for Example 4B.
LC/MS: m/z = 659.30 (M+H+); RT= 9.95 minutes.
BOST 1803930.1 167 Example 64
((S)-1-{(2S,4S)-4-Hydroxymethyl-2-[4-(4-{2-[(2S,4S)-1-((S)-2-methoxycarbonylamino- 3-methyl-butyryl)-4-methyl-pyrrolidin-2-yl]-1H-imidazol-4-ylethynyl}-phenylethynyl)- 1 H-imidazol-2-yl]-pyrrolidine- 1 -carbonyl}-2-methyl-propyl)-carbamic acid methyl ester
Figure imgf000169_0001
The starting material, (2S)-di-tert-butyl 4- (hydroxymethyl)pyrrolidine-l ,2-dicarboxylate is obtained according to published literature procedures (Durand X., Hudhomme P., Khan J.A., Young D.W.; J. Chem. Soc, Perkin Trans. 1 , 1996, 11 , 1131 ).
10 Step I
A suspension of (2S)-di-tert-butyl 4-(hydroxymethyl)pyrrolidine-1 ,2-dicarboxylate (3990 mg, 13.24 mmol) in HCl (4M in dioxane, 26.47 mL of 4 M, 105.9 mmol) is stirred for 90 minutes and evaporated to dryness. The sample is used as it is for the next step.
Step II
To a solution of (2S)-2-carboxy-4-(hydroxymethyl)pyrrolidin-1 -ium chloride (13.24 mmol) (from step I) in THF (20 mL) and water (6.6 mL) are sequentially added NaOH (7.408 mL of 2.5 M, 18.52 mmol) and tert-butoxycarbonyl tert-butyl carbonate (2.761 g, 2.906 mL, 12.65 mmol). The reaction mixture is stirred at room temperature overnight. NaOH (aqueous 2.5 M, 1.25 mL) is then added to bring the pH to 10-11. THF is evaporated and 20 the residue is washed with ether (2 x 2 mL) and the residue is then acidified with 1M HCl to bring the pH to 1. The mixture is extracted by EtOAc (5 x 20 mL) and the combined
BOST 1803930.1 168 organic layers are dried over Na2S04, filtered and concentrated to dryness to give (2S)-1 - (tert-butoxycarbonyl)-4-(hydroxymethyl)pyrrolidine-2-carboxylic acid (1.848 g, 84 %). Step III
To a solution of (2S)-1 -(tert-butoxycarbonyl)-4-(hydroxymethyl)pyrrolidine-2-carboxylic acid (1775 mg, 7.237 mmol) in DMF (17.75 mL) are sequentially added imidazole (1.084 g, 15.92 mmol) followed by TBDMSCl (2.291 g, 2.828 mL, 15.20 mmol). The mixture is stirred overnight at room temperature. The reaction mixture is extracted by EtOAc (5 x 70 mL) and the combined organic layers are washed with H20 (3 x 35 mL), dried over Na2S04, filtered and concentrated to dryness. The residue is purified by flash column 10 chromatography on silica gel (0 to 20% methanol in CH2Cl2) to give a mixture of mono and bis-silylated product. The product is dissolved in 5:1 methanol (10 mL) water and stirred for 1 h. The mixture is concentrated to dryness and the residue is purified by flash column chromatography on silica gel (0 to 20% methanol in CH2Cl2) to give (2S)-1 -(tert- butoxycarbonyl)-4-(((tert-butyldimethylsilyl)oxy)methyl)pyrrolidine-2-carboxylic acid (1.239 g, 88 %).
Step IV
To a solution of (2S)-1 -(tert-butoxycarbonyl)-4-(((tert- butyldimethylsilyl)oxy)methyl)pyrrolidine-2-carboxylic acid ( 1.080 g, 3.004 mmol) in THF (10.8 mL) is added Borane/THF (5.665 g, 6.308 mL of 1 M, 6.308 mmol) over 10 minutes 20 in an ice bath. The mixture is stirred for 1 hour, warmed to room temperature and stirred for another 2 hours. The mixture is then cooled in an ice bath and diluted with 10% aqueous NH4Cl (5 mL) followed by 10 mL of water. The reaction mixture is extracted by EtOAc (3 x 20 mL) and the combined organic layers are washed with H20 (2 x 5 mL), dried over Na2S04, filtered and concentrated to dryness. The residue is purified by flash column chromatography on silica gel (6 to 50 % EtOAc in hexane) to give (2S)-tert-butyl 4-(((tert-butyldimethylsilyl)oxy)methyl)-2-(hydroxymethyl)pyrrolidine-1 -carboxylate (775 mg, 75 %).
Step V
To a solution of oxalyl chloride in CH2Cl2 (1.567 mL of 2 M, 3.134 mmol) in CH2Cl2 (3.6 30 mL) at -78°C is added DMSO (489.7 mg, 444.8 μΐ, 6.267 mmol) and the mixture is stirred for 10 minutes. A solution of (2S)-4-[[tert-butyl(dimethyl)silyl]oxymethyl]-2- (hydroxymethyl)pyrrolidine-l -carboxylate (722 mg, 2.089 mmol) in CH2Cl2 (8 mL) is then added and the mixture is stirred for another 30 minutes. DIPEA (1.619 g, 2.182 mL, 12.53 mmol) is added and the mixture is stirred for 30 minutes, warmed to room temperature, stirred again for 1 hour and diluted with 1M aqueous HCl (30 mL). The layers are separated and the aqueous layer is extracted by CH2Cl2 (2 x 20 mL). The
BOST 1803930.1 169 combined organic layers are dried over Na2S04, filtered, and concentrated to dryness. The residue is purified by flash column chromatography on silica gel (6 to 40 % EtOAc in hexane) to give (2S)-tert-butyl 4-(((tert-butyldimethylsilyl)oxy)methyl)-2- formylpyrrolidine-1 -carboxylate ( 647 mg, 90 %).
Step VI
Ammonia gas is bubbled in a solution of (2S)-4-[[tert-butyl(dimethyl)silyl]oxymethyl]-2- formyl-pyrrolidine-1 -carboxylate (581 mg, 1 .691 mmol) in methanol (20 mL) at -20°C for 15 minutes and glyoxal (aqueous) (1 .718 g, 1 .358 mL of 40 % (w/w), 1 1 .84 mmol) is added. The mixture is warmed gently to avoid strong bubbling and refluxed for 2 hours. 10 The reaction mixture is then cooled to room temperature, methanol is evaporated and the residue is diluted with water (10 mL). The reaction mixture is extracted by CH2Cl2 (2 x 15 mL) and the combined organic layers are dried over Na2S04, filtered and concentrated to dryness. The residue is purified by flash column chromatography on silica gel (0 to 15 % methanol in CH2Cl2) to give (2S)-tert-butyl 4-(((tert- butyldimethylsilyl)oxy)methyl)-2-(1 H-imidazol-2-yl)pyrrolidine-1 -carboxylate (454 mg, 70 %).
Step VII
To a solution of (2S)-tert-butyl 4-(((tert-butyldimethylsilyl)oxy)methyl)-2-(1 H-imidazol-2- yl)pyrrolidine-1 -carboxylate (450 mg, 1 .179 mmol in CH2Cl2 (4.6 mL) is added N- 20 iodosuccinimide (557.1 mg, 2.476 mmol). The reaction mixture is stirred at room temperature for 3 hours and diluted with water (5 mL). The layers are separated and aqueous portion is extracted by CH2Cl2 (2 x 5 mL) and the combined organic layers are dried over Na2S04, filtered and concentrated to dryness. The residue is purified by flash column chromatography on silica gel (6 to 50 % EtOAc in hexane) to give (2S,4S)-tert- butyl-4-(((tert-butyldimethylsilyl)oxy)methyl)-2-(4,5-diiodo-1 H-imidazol-2-yl)pyrrolidine- 1 -carboxylate (230 mg, 31 %) as a pure c/s compound.
Step VIII
To a solution of (2S,4S)-tert-butyl-4-(((tert-butyldimethylsilyl)oxy)methyl)-2-(4,5-diiodo- 1 H-imidazol-2-yl)pyrrolidine-1 -carboxylate (225 mg, 0.355 mmol) and 0.5 M LiCl (710 μί) 30 in THF at -20°C is added iPrMgCl (177.6 il of 2 M in THF, 0.3552 mmol) and the mixture is stirred for 15 minutes. Another portion of iPrMgCl (355.2 μί of 2 M in THF, 0.7104 mmol) is added and the mixture is warmed to room temperature and the mixture is stirred for another 2 hours. Another portion of iPrMgCl (150 μί of 2 M in THF) is added to complete the reaction and the mixture is stirred for another 30 minutes. The reaction mixture is diluted with 10% aqueous NH4Cl (2 mL) and water (2 mL). The reaction mixture is extracted by AcOEt (3 x 10 mL), and the combined organic layers are dried
BOST 1803930.1 170 over Na2S04, filtered and concentrated to dryness. The residue is purified by flash column chromatography on silica gel (6 to 50 % AcOEt in hexane) to give (2S,4S)-tert- butyl 4-(((tert-butyldimethylsilyl)oxy)methyl)-2-(4-iodo-1 H-imidazol-2-yl)pyrrolidine-1 - carbox late (118 mg, 65 %).
Figure imgf000172_0001
Figure imgf000172_0002
Figure imgf000172_0003
Step IX
To a solution of tert-butyl (2S,4S)-4-[[tert-butyl(dimethyl)silyl]oxymethyl]-2-(4-iodo-1 H- imidazol-2-yl)pyrrolidine-1 -carboxylate (66 mg, 0.1301 mmol), tert-butyl (2S,4S)-4- methyl-2-[4-[2-[4-(2-trimethylsilylethynyl)phenyl]ethynyl]-1 H-imidazol-2-yl]pyrrolidine-1 - 10 carboxylate (58.24 mg, 0.1301 mmol), PdCl2(dppf)-CH2Cl2 (5.312 mg, 0.006505 mmol) and Cul (1.239 mg, 0.006505 mmol) in DMF (2 mL) is added DBU (198.1 mg, 194.6 μΙ_, 1.301
BOST 1803930.1 171 mmol) followed by one portion of water (1.2 μΙ_, 0.5 eq.). The mixture is then warmed up to 60°C and stirred at that temperature for 30 minutes before another portion of water is added (1.2 μΙ_, 0.5 eq.) followed by another portion (1.2 μΙ_, 0.5 eq.) after 30 minutes. The mixture is then stirred overnight at that temperature. The reaction is warmed to 100°C and PdCl2(dppf)-CH2Cl2 (4.6 mg, 0.0065 mmol) is added followed by Cul (1.2 mg, 0.0065 mmol). The mixture is stirred for another 3 hours at that temperature. The mixture is then cooled to room temperature and DMF is evaporated to dryness and the residue is purified by flash column chromatography on silica gel (0 to 15 % methanol in CH2Cl2) to give (2S,4S)-tert-butyl 2-(4-((4-((2-((2S,4S)-1 -(tert-butoxycarbonyl)-4- 10 (((tert-butyldimethylsilyl)oxy)methyl)pyrrolidin-2-yl)-1 H-imidazol-4- yl)ethynyl)phenyl)ethynyl)-1 H-imidazol-2-yl)-4-methylpyrrolidine-1 -carboxylate (26 mg, 26 %).
Step XI
A solution tert-butyl (2S,4S)-2-[4-[2-[4-[2-[2-[(2S,4S)-1 -tert-butoxycarbonyl-4-[[tert- butyl(dimethyl)silyl]oxymethyl]pyrrolidin-2-yl]-1 H-imidazol-4-yl]ethynyl]phenyl]ethynyl]- 1 H-imidazol-2-yl]-4-methyl-pyrrolidine-1 -carboxylate (25 mg, 0.03311 mmol) in HCl (2 ml_ of 4 M in dioxane, 8.000 mmol) is stirred for 1 hour and evaporated to dryness. The sample is used as it is for the next step.
Step XII
20 To a solution of [(3S,5S)-5-[4-[2-[4-[2-[2-[(2S,4S)-4-methylpyrrolidin-2-yl]-1 H-imidazol-4- yl]ethynyl]phenyl]ethynyl]-1 H-imidazol-2-yl]pyrrolidin-3-yl]methanol (Hydrochloric Acid (2)) (17 mg, 0.03311 mmol) and (2S)-2-(methoxycarbonylamino)-3-methyl-butanoic acid (11.60 mg, 0.06622 mmol) in DMF (2 mL) is cooled in an ice bath and are sequentially added HATU (26.44 mg, 0.06953 mmol) and DIPEA (25.68 mg, 34.61 μΙ_, 0.1987 mmol) under nitrogen atmosphere. The reaction mixture is stirred at that temperature for 1.5 hours and evaporated to dryness. The residue is purified successively by flash column chromatography on silica gel (0 to 15 % methanol in CH2Cl2) followed by reverse phase preparative HPLC to afford ((S)-1 -{(2S,4S)-4-hydroxymethyl-2-[4-(4-{2-[(2S,4S)-1 -((S)-2- methoxycarbonylamino-3-methyl-butyryl)-4-methyl-pyrrolidin-2-yl]-1 H-imidazol-4-
30 ylethynyl}-phenylethynyl)-1 H-imidazol-2-yl]-pyrrolidine-1 -carbonyl}-2-methyl-propyl)- carbamic acid methyl ester (6.2 mg, 26 %).
1H NMR (400 MHz, DMSO-d6): δ 12.09 (broad s, 2H), 7.43 (m, 4H), 7.21 (m, 2H), 4.83 (m, 2H), 4.05 (m, 4H), 3.50 (s, 6H), 3.45 (m, 2H), 3.31 (s, 1 H), 3.15 (m, 2H), 2.23 (m, 4H), 1.86 (m, 4H), 1.21 (m, 3H), 1.06 (m, 2H), 0.75 (m, 6H). LC/MS: m/z = 755.51 (M+H+).
BOST 1803930.1 172 Examples 65 and 66
Figure imgf000174_0002
The above compounds were prepared according to the procedures disclosed herein.
Example 67
Methyl N-[(1S)-1-[(2S,4S)-2-[4-[2-[2-[2-[2-[(2S,4S)-1-[(2S)-2- (methoxycarbonylamino)-3-methyl-butanoyl]-4-methyl-pyrrolidin-2-yl]-1 H-imidazol- 4-yl]ethynyl]benzothiophen-6-yl]ethynyl]-1 H-imidazol-2-yl]-4-methyl-pyrrolidine-1- carbon l]-2-methyl-propyl]carbamate
Figure imgf000174_0001
To a solution of 2-[(2S,4S)-4-methylpyrrolidin-2-yl]-4-[2-[2-[2-[2-[(2S,4S)-4- methylpyrrolidin-2-yl]-1 H-imidazol-4-yl]ethynyl]benzothiophen-6-yl]ethynyl]-1 H-
BOST 1803930.1 173 imidazole (59.3 mg, 0.12 mmol) in DMF (2 mL) are added (2S)-2-(methoxycarbonylamino)- 3-methyl-butanoic acid (47.5 mg, 0.27 mmol), HATU (112.6 mg, 0.29 mmol) and DIPEA (159.5 mg, 215.0 μΙ_, 1.234 mmol). The mixture is stirred at rt overnight. After removal of the solvent under reduced pressure, the residue is purified by silica gel column chromatography using methanol (0-6%) in CH2Cl2, and the major fraction is further purified using revers-phase prep-HPLC to obtain methyl N-[(1 S)-1 -[(2S,4S)-2-[4-[2-[2-[2- [2-[(2S,4S)-1 -[(2S)-2-(methoxycarbonylamino)-3-methyl-butanoyl]-4-methyl-pyrrolidin-2- yl] - 1 H-imidazol-4-yl]ethynyl]benzothiophen-6-yl]ethynyl]-1 H-imidazol-2-yl]-4-methyl- pyrrolidine-1 -carbonyl]-2-methyl-propyl]carbamate (46 mg, 0.05699 mmol, 46.18%) as an 10 off-white solid. LC/MS: m/z = 795.40 (M+H+). 1H NMR (CD3OD, 400 MHz): δ 7.24-7.95 (m, 6H), 4.95(m, 2H), 4.20 (m, 4H), 3.62 (s, 6H), 2.46 (m, 4H), 1.96 (m, 4H), 1.15 (m, 6H), 0.84(m, 14H).
Example 68
Methyl N-[(1S)-1-[(2S,4S)-4-methoxy-2-[4-[2-[4-[2-[2-[(2S,4S)-4-methoxy-1-[(2S)-2- (methoxy-carbonylamino)-3-methyl-butanoyl]pyrrolidin-2-yl]-1 H-imidazol-4- yl]ethynyl]phenyl]ethynyl]- 1 H-imidazol-2-yl]pyrrolidine- 1 -carbonyl]-2-methyl- propyl]carbamate
Figure imgf000175_0001
The title compound is prepared from tert-butyl (2S,4S)-2-(4-iodo-1 H-imidazol-2-yl)-4- methoxy-pyrrolidine-1 -carboxylate using the reactions described below.
Step I:
BOST 1803930.1 174 To a mixture of tert-butyl (2S,4S)-2-(4-iodo-1 H-imidazol-2-yl)-4-methoxy-pyrrolidine-1 - carboxylate, trimethyl-[2-[4-(2-trimethylsilylethynyl)phenyl]ethynyl]-silane, PdCl2(dppf)- CH2Cl2 and copper Iodide is added DMF under nitrogen atmosphere. The reaction mixture is degassed thrice (vacuum and nitrogen gas) and then DBU and water are added and heated at 60°C for 8 hours. The reaction mixture is cooled to 0°C, diluted with water and filtered.
Step II:
To a solution of the product from step I in dry MeOH (400 μΙ_) is added HCl in Dioxane. The reaction mixture is stirred at rt for 2 hours and concentrated to afford the 10 corresponding amine as the HCl salt. This material is used as such in the next step.
Step III:
To a cold (-10 to -5°C) stirred solution of the product from step II and HATU in DMF is added DIPEA dropwise. The resultant reaction mixture is slowly warmed up to rt and stirred overnight. The reaction mixture is diluted with water, the resultant white precipitate is collected by filtration and the filtrate is refiltered. The combined precipitates are washed with water and heptanes, dried under high vacuum and purified by reverse phase HPLC to afford the title compound.
1H NMR (400 MHz, CD3OD, Peaks for the major rotamer): δ 7.44 (s, 4 H), 7.23 (s, 2 H), 5.2 - 5.1 (m, 2 H), 4.2 - 3.0 (m, 8 H), 3.63 (s, 6 H), 3.34 (s, 6 H), 2.6 -1.9 (m, 6 H), 0.92 - 20 0.86 (doublets, 12 H).
LC/MS, m/z = 771.59 (M+H+); Rt : 7.25 minutes.
HPLC (RT) = 11.70 minutes, Method: 20%-60% AcCN-water (0.01% TFA) for 40 min, Gemini C18 3μιη, 4.6 mm x 250 mm.
Example 69
Figure imgf000176_0001
The above compound was prepared according to the procedures disclosed herein.
BOST 1803930.1 175 Example 70
Activity determination using the ELISA and the sub-genomic replicon 1a cell line
The cell line W11.8 containing the sub-genomic HCV replicon of genotype 1 a is used to determine the potency of the drugs. The RNA replication in presence of different drug concentrations is indirectly measured in this cell line by the level of NS5A protein content upon drug treatment for four days. It is shown that the level of the NS5A protein correlates well with the level of HCV RNA in the replicon cell line. Cells are split twice a
10 week in order to keep the confluence state below 85% of the culture flask surface area.
The culture media used for cell passaging consists of DMEM-10% foetal bovine serum with 100 UI/mL penicillin, 100 μg/mL streptomycin, 2 mM glutamine, 1 mM sodium pyruvate, non-essential amino acids (1x) and 600 μg/mL of G418 final concentrations. Monolayer of the W11.8 cells is trypsinized and cells are counted. Cells are diluted at 50,000 cells/mL with complete DMEM without G418, then approximately 5,000 viable cells (100 μΙ_) are plated per well in a white opaque 96-well microtiter plate. After an incubation period of 2 - 4 hours at 37 °C in a 5% C02 incubator, compounds are added at various concentrations. Drugs are resuspended in DMSO at a stock concentration of 10 mM. Then, drugs are serially diluted at twice the final concentration in the same medium.
20 One volume (100 μΙ_) of each drug dilution is then added to each well that contains cells.
A control compound is used as an internal standard for each plate assay. Sixteen wells are used as control (0% inhibition) without drug. Eight wells are used as background control (100% inhibition) containing 2 μΜ (final concentration) of the control drug that was shown to inhibit the NS5A expression at = 100% and is nontoxic to the cells. Values from 100% inhibited wells were averaged and used as the background value. Cells are further incubated for four days at 37° C in a 5% C02 incubator. Following the incubation time of four days, the media is removed and wells are washed once with 150 μΙ_ of PBS at room temperature for five minutes. Cells are then fixed for five minutes using 150 μΙ_ per well of cold (-20 °C) fixative solution (50% methanol / 50% acetone mix). Cells are then
30 washed twice with 150 μΙ_ of PBS (phosphate buffered saline) per well, following the addition of 150 μΙ_ of blocking solution, cells are incubated for one hour at 37 °C to block non-specific sites. The blocking solution is removed and cells are washed twice with 150 μΙ_ of PBS per well and once with 150 μΙ_ of PBSTS solution (PBS / 0.1% Triton X-100 / 0.02% SDS) per well. Then, 50 μΙ_ of mouse monoclonal anti-NS5A antibody (Santa Cruz, Cat. No. sc-52417) is added in each well, diluted 1 /1 ,000 in the blocking solution and incubated at 4 °C overnight. Next day, media is removed and plates are washed five
BOST 1803930.1 176 times with 150 μΙ_ of PBS per well with five-minute incubations at room temperature. Then 50 μΙ_ per well of peroxidase-conjugated donkey anti-mouse antibody (Jackson Immunoresearch, Cat. No. 715-036-150) diluted 1 /10,000 in the blocking solution is added and incubated at room temperature for three hours on a shaker (500 rpm). Plates are washed four times with 150 μΙ_ of PBSTS solution per well and once with 150 μΙ_ of PBS. Then, substrate solution (100 μΐ, SuperSignal ELISA Pico Chemiluminescent Substrate, Fisher Cat. No.37069) is added in each well and plates are incubated 60 minutes at room temperature prior to reading the luminescence (relative light units) on the Analyst HT plate reader. The percentage of inhibition at each drug concentration 10 tested (in duplicate) is calculated. The concentration required to reduce viral replication by 50% (IC50) is then determined from dose response curves using nonlinear regression analysis with the GraphPad Prism software, version 2.0 (GraphPad Software Inc., San Diego, CA, USA).
Example 71
Cell-Based Luciferase Reporter HCV (lb) RNA Replication Assay Cell Culture
Replicon cell lines Huh-5.2 are derived from the Huh-7 hepatocarcinoma cell line are 20 maintained in culture as generally described in Krieger, N; Lohmann, V; Bartenschlager, R. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J. Virol. 2001 , 75, 4614-4624 . The Huh-5.2 cells contain the highly cell culture- adapted replicon l389luc-ubi-neo/NS3-375.1 construct that carries, in addition to the neomycin gene, an integrated copy to the firefly luciferase gene (Krieger, N; Lohmann, V; Bartenschlager, R. Enhancement of hepatitis C virus RNA replication by cell culture- adaptive mutations. J. Virol. 2001 , 75, 4614-4624). This cell line allows measurement of HCV RNA replication and translation by measuring luciferase activity. It has been previously shown that the luciferase activity tightly follows the replicon RNA level in these cells (Krieger, N; Lohmann, V; Bartenschlager, R. Enhancement of hepatitis C 30 virus RNA replication by cell culture-adaptive mutations. J. Virol. 2001 , 75, 4614-4624).
The Huh- ET cell line has the same features as those mentioned for Huh-5.2 cell line, except that ET cells are more robust and contain an adaptative mutation in the HCV NS4B gene instead of NS5A. Both cell lines are maintained in cultures at a sub-confluent level (<85%) as the level of replicon RNA is highest in actively proliferating cells. The culture media used for cell passaging consist of DMEM (Gibco BRL Laboratories, Mississauga, ON, Canada) supplemented with 10% foetal bovine serum with 1 %
BOST 1803930.1 177 penicilin/streptomycin, 1 % glutamine, 1 % sodium pyruvate, 1 % non-essential amino acids, and 180 μg/ml of G418 final concentration. Cells are incubated at 37°C, in an atmosphere of 5% C02 and passaged twice a week to maintain sub-confluence.
Approximately 3000 viable Huh- ET cells (100 μΐ) are plated per well in a white opaque 96-well microtiter plate. The cell culture media used for the assay is the same as described above except that it contains no G418 and no phenol red. After an incubation period of 3-4 hours at 37° C in a 5% C02 incubator, compounds (100 μΐ) are added at various concentrations. Cells are then further incubated for 4 days at 37° C in a 5% C02 10 incubator. Thereafter, the culture media is removed and cells are lysed by the addition of 95 μΙ_ of the luciferase buffer (luciferin substrate in buffered detergent). Cell lysates are incubated at room temperature and protected from direct light for at least 10 minutes. Plates are read for luciferase counts using a luminometer (Wallac MicroBeta Trilux, Perkin Elmer™, MA, USA).
The 50% inhibitory concentrations (IC50s) for inhibitory effect are determined from dose response curves using eleven concentrations per compound in duplicate. Curves are fitted to data points using nonlinear regression analysis, and IC50s are interpolated from the resulting curve using GraphPad Prism software, version 2.0 (GraphPad Software Inc. , 20 San Diego, CA, USA).
Table 1 C shows comparative data for exemplary compounds of formula (I) (entries 1 -3) and formula (IA) (entries 4-5). As is shown in the table, the compounds having a substituent at the 4-position of the pyrrolidine ring (i.e. compounds of the invention where R4 and R4> are methyl). Data shows IC50 values against the sub-genomic replicon 1 a cell line.
Table 1 C
Figure imgf000179_0001
BOST 1803930.1 178
Figure imgf000180_0001
Table 1 D shows compounds representative of the present invention and the EC50 values against the HCV 1 b genotype. EC50 ranges are presented in micromolar as follows: μΜ +++ <= 0.005 < ++<= 5.0 < +.
BOST 1803930.1 179 Table 1 D
Figure imgf000181_0001
BOST 1803930.1 180 Retention
M + 1 time IC50 (μΜ)
Compound (observed) (minutes) 1H-NMR
Hz, 6H).
24 425 5.08 ++
25 725.5 7.55 +++
26 753.45 7.14 +++
27 739.57 9.06 ++
28 767.53 8.1 1 +++
29 803.55 8.73 +++
30 795.6 8.47 +++
31 785.27 8.31 +++
32 739.49 8.39 ++
33 739.53 8.17 +++
34 625.41 8.91
35 424.99 4.94
36 757.4 17.58 +++
37 817.63 8.57 +++
38 739.47 8.32 +++
39 582.42 6.49 ++
40 797.53 8.7 +++
41 767.6 9.06 +++
42 739.4 9.49 +++
43 767.5 8.93 +++
44 747.49 8.05 +++
45 819.65 10.3 +++
46 838.4 8.49 +++
47 781 .17 6.92 +++
48 875.45 16.08 +++
49 741 .42 6.46 +++
50
51 743.4 2.79
52 739.43 8.62 ++
53 663.44 7.61 +++
54 682 8.55 +++
55 790.3 8.64 +++
BOST 1803930.1 181 Retention
M + 1 time IC50 (μΜ)
Compound (observed) (minutes) 1H-NMR
56 740.45 7.75 +++
57 797.4 8.57 +++
58 829.84 2 +++
59 799.51 7.24 ++
60 745.3 8.74 +++
61 795.4 9.48 +++
62 764.45 9.01 +++
63 773.6 18.6 +++
64 755.51 7.45 +++
65 659.59 1 .76 ++
66 829.55 16.6 +++
67 795.57 9.21 +++
68 771 .59 7.25 +++
69 829.37 1 .75 +++
The preceding examples can be repeated with similar success by substituting the generically or specifically described reactants and /or operating conditions of this invention for those used in the preceding examples.
From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention and, without departing from the spirit and scope 10 thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.
BOST 1803930.1 182

Claims

AttorneyWO 2011/079327 PCT/US2010/062168
Claims
1 . A compound of Formula (I II ):
Figure imgf000184_0001
wherein
A is C6-14 aryl, 4-12 membered heterocycle, C3.10 cycloalkyl, 5-12 membered heteroaryl, or a bond;
10 B and B' are each independently Ci-6 alkyl, C2-6 alkenyl, or C2.6 alkynyl;
Ri is H, halogen, -ORa, -NRaRb, -C(=0)ORa, -C(0)NRaRb, -C(=0)OH, -C(=0)Ra, -C(=NORc)Ra, - C(=NRc)NRaRb, -NRdC(=0)NRaRb, -NRbC(=0)Ra, -NRdC(=NRc)NRaRb, -NRbC(=0)ORa, - OC(=0)NRaRb, -OC(=0)Ra, -OC(=0)ORa, hydroxyl, nitro, azido, cyano, -S(O)0. Ra, -S02NRaRb, -NRbS02Ra, -NRbS02NRaRb, -P(=0)ORaORb, C1 -6 alkyl, C2.6 alkenyl, C2.6 alkynyl, or C1 -6 halogenated alkyl, or any two occurrences of can be taken together with the atoms to which they are attached to form a 5-7 cycloalkyl which is unsubstituted or substituted one or more times by R10 or a 5-7 membered heterocycle which is unsubstituted or substituted one or more times by R12, wherein Ra, Rb, Rc, and Rd are each independently H, C-i-12 alkyl, C2-i2 alkenyl, C2-i2 alkynyl, C6. aryl, C7.16 aralkyl, 5-12 membered 20 heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
R2 and R2' are each independently H, halogen, Ci-6 alkyl, -(CH2)i-3OH, -ORa, -C(=0)ORa, - C(0)NRaRb, -C(=0)OH, C6-12 aryl, or 5-12 membered heteroaryl, wherein Ra, Rb, Rc, and Rd are each independently H, d.12 alkyl, C2.12 alkenyl, C2.12 alkynyl, C6.n aryl, C7.16 aralkyl, 5- 12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
R3 and R ' are each independently H, Ci-6 alkyl, C2.6 alkenyl, or C2.6 alkynyl;
R4 and R4' are each independently halogen, Ci-6 alkyl, hydroxyl, C6-14 aryl, or Ci.4 alkoxy;
X and Y are each independently
BOST 1803930.1 183 Attorney,
WO 2011/079327 PCT/US2010/062168 or a bond;
Figure imgf000185_0001
wherein the bond marked with an asterisk (*) indicates the attachment to the nitrogen of ring C or C;
R5 and R5' are each independently H, d-12 alkyl which is unsubstituted or substituted one or more times by R10, C2-12 alkenyl which is unsubstituted or substituted one or more times by R10, C2-12 alkynyl which is unsubstituted or substituted one or more times by R10, C6-i4 aryl which is unsubstituted or substituted one or more times by R11 , C7.16 aralkyl which is unsubstituted or substituted one or more times by R11 , 5- 1 2 membered heteroaryl which is unsubstituted or substituted one or more times by R11 , 6- 1 8 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11 , 3- 1 2 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-1 8 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by
12.
R
R6 is H, C1-6 alkyl, or halogenated Ci_6 alkyl, or can be merged with R6 or R6' to form a 3- 1 2 membered heterocycle;
p is 0, 1 , 2, 3 or 4;
R10 is halogen, -ORa, oxo, -NRaRb, =NO-Rc , -C(=0)ORa, -C(0)NRaRb, -C(=0)OH, -C(=0)Ra, - C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=0)NRaRb, -NRbC(=0)Ra, -NRdC(=NRc)NRaRb, - NRbC(=0)ORa, -OC(=0)NRaRb, -OC(=0)Ra, -OC(=0)ORa, hydroxyl, nitro, azido, cyano, -S(O)0- 3Ra, -S02NRaRb, -NRbS02Ra, -NRbS02NRaRb, or -P(=0)ORaORb, wherein Ra, Rb, Rc, and Rd are each independently H, Ci-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7_i6 aralkyl, 5- 1 2 membered heteroaryl, 6- 1 8 membered heteroaralkyl, 3- 1 2 membered heterocycle, or 4- 1 8 membered heterocycle-alkyl;
R11 is halogen, -ORa, -NRaRb, -C(=0)ORa, -C(0)NRaRb, -C(=0)OH, -C(=0)Ra, -C(=NORc)Ra, - C(=NRc)NRaRb, -NRdC(=0)NRaRb, -NRbC(=0)Ra, -NRdC(=NRc)NRaRb, -NRbC(=0)ORa, - OC(=0)NRaRb, -OC(=0)Ra, -OC(=0)ORa, hydroxyl, nitro, azido, cyano, -S(0)o-3Ra, -S02NRaRb, -NRbS02Ra, -NRbS02NRaRb, or -P(=0)ORaORb, C1 -12 alkyl, C2-i2 alkenyl, C2-12 alkynyl, C6.12 aryl, C7.16 aralkyl, 5- 1 2 membered heteroaryl, 6- 1 8 membered heteroaralkyl, 3- 1 2 membered heterocycle, or 4- 1 8 membered heterocycle-alkyl, wherein Ra, Rb, Rc, and Rd are each independently H , CM2 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7_i6 aralkyl, 5- 1 2 membered heteroaryl, 6- 1 8 membered heteroaralkyl, 3- 1 2 membered heterocycle, or 4- 1 8 membered heterocycle-alkyl;
R12 is halogen, -ORa, oxo, -NRaRb, =NO-Rc , -C(=0)ORa, -C(0)NRaRb, -C(=0)OH, -C(=0)Ra, - C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=0)NRaRb, -NRbC(=0)Ra, -NRdC(=NRc)NRaRb, - 03930.1 184 Attorney,
WO 2011/079327 PCT/US2010/062168
NRbC(=0)0Ra, -0C(=0)NRaRb, -0C(=0)Ra, -0C(=0)0Ra, hydroxyl, nitro, azido, cyano, -S(O)0. 3Ra, -S02NRaRb, -NRbS02Ra, -NRbS02NRaRb, or -P(=0)ORaORb, d.12 alkyl, C2.12 alkenyl, C2.12 alkynyl, C6-i2 aryl, C7.i6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, wherein Ra, Rb, Rc, and Rd are each independently H, d-12 alkyl, C2_i2 alkenyl, C2_i2 alkynyl, C6-i2 aryl, C7.16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
wherein as valency allows in B, B' , Ra, Rb, Rc, and Rd, R1 ; R2, R2', R3, R3', R4, R4 ', R10, R11 and R12 each of alkyl, alkenyl, alkynyl, alkoxy, aryl, aralkyl, heteroaryl, heteroaralkyl, 10 heterocycle, or heterocycle-alkyl is independently unsubstituted or substituted one or more times by halogen, -ORa., oxo, -NRa.Rb., =NO-Rc., -C(=0)ORa., -C(0)NRa.Rb., -C(=0)OH , -C(=0)Ra., -C(=NORc.)Ra., -C(=NRc.)NRa.Rb., -NRd.C(=0)NRa.Rb., -NRb.C(=0)Ra., - NRd.C(=NRc.)NRa.Rb., -NRb.C(=0)ORa., -OC(=0)NRa.Rb., -OC(=0)Ra., -OC(=0)ORa., hydroxyl, nitro, azido, cyano, -S(O)0-3 Ra' , -S02NRa'Rb>, or -NRb>S02Ra>; wherein Ra°-Rd> are each independently H or Ci -12 alkyl; or
a pharmaceutically acceptable salt thereof.
2. A compound according to claim 1 , wherein R4 and R4' are each independently halogen, d-6 alkyl or d.4 alkoxy.
20
A compound according to claim 1 , wherein R4 and R4' are d-6 alkyl.
A compound according to any one of claims 1 to 3, wherein A is phenyl, thiophene, pyridine, pyrimidine, triazole, naphthalene, thienothiene, benzothiadiazole, quinoline, or benzothiophene.
A compound according to any one of claims 1 to 3, wherein A is phenyl, thiophene, pyridine, pyrimidine, or triazole.
A compound according to claim 5, wherein A is phenyl, or thiophene. A compound according to claim 5, wherein A is
Figure imgf000186_0001
BOST 1803930.1 185
8. A compound according to any one of claims 1 to 7, wherein B and B' are independently
C2-6 alkynyl or d.6 alkyl.
9. A compound according to any one of claims 1 to 7, wherein B and B' are independently - (C≡C)- or -(CH2)2-.
10. A compound according to any one of claims 1 to 7, wherein B and B' are-(C≡C)-.
1 1 . A compound according to any one of claims 1 to 10, wherein p is 2.
10
12. A compound according to any one of claims 1 to 10, wherein p is 1 .
1 3. A compound according to any one of claims 1 to 12, wherein X and Y are
Figure imgf000187_0001
14. A compound according to any one of claims 1 or 4 to 1 3, wherein R4 and R4' are each independently halogen, methyl, ethyl, isopropyl, di-fluoromethyl, di-fluoroethyl, trifluoromethyl, tri-fluoroethyl, -CH2OH, or hydroxyl, or t-butoxy.
20 1 5. A compound according to any one of claims 1 or 4 to 14, wherein R4 and R4' are each independently halogen, methyl, ethyl, t-butoxy-, or hydroxyl.
16. A compound according to claim 2, wherein R4 and R4' are methoxy.
17. A compound according to claim 1 5, wherein R4 and R4' are fluoro.
18. A compound according to claim 1 5, wherein R4 and R4' are methyl.
19. A compound according to any one of claims 1 to 18, wherein R3 and R3' are H.
30
20. A compound according to any one of claims 1 to 18, wherein R3 and R3' are methyl.
21 . A compound according to any one of claims 1 to 20, wherein is halogen, d. alkyl, hydroxyl, cyano, d. alkoxy, or methoxycarbonyl.
BOST 1803930.1 186 AttorneyWO 2011/079327 PCT/US2010/062168
22. A compound according to any one of claims 1 to 20, wherein is halogen, d.3 alkyl, hydroxyl, cyano, or Ci_3 alkoxy.
23. A compound according to claim 22, wherein is chloro, fluoro, methyl, hydroxyl, cyano, or methoxy.
24. A compound according to any one of claims 1 to 19, wherein is H.
10 25. A compound according to any one of claims 1 to 24, wherein R2 and R2' are methyl.
26. A compound according to any one of claims 1 to 24, wherein R2 and R2' are H.
27. A compound according to any one of claims 1 to 24, wherein R2 and R2' are H, iodo, methyl, hydroxy methyl, trifluoromethyl, or thienothienyl.
28. A compound according to any one of claims 1 to 27, wherein R5 and R5' are each independently, Ci-8 alkyl which is unsubstituted or substituted one or more times by R10, C2-8 alkenyl which is unsubstituted or substituted one or more times by R10, C2s alkynyl
20 which is unsubstituted or substituted one or more times by R10, phenyl which is unsubstituted or substituted one or more times by R11 , C7.8 aralkyl which is unsubstituted or substituted one or more times by R11 , 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R11 , 6-8 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11 , 3-6 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-8 membered heterocycle- alkyl which is unsubstituted or substituted one or more times by R12.
29. A compound according to claim 28, wherein R5 and R5' are each independently, d.6 alkyl which is unsubstituted or substituted one or more times by R10, C2-6 alkenyl which is
30 unsubstituted or substituted one or more times by R10, C2-6 alkynyl which is unsubstituted or substituted one or more times by R10, phenyl which is unsubstituted or substituted one or more times by R11 , benzyl which is unsubstituted or substituted one or more times by R11 , 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R11 , 6-7 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11 , 5-6 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 6-7 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12.
BOST 1803930.1 187
30. A compound according to claim 28, wherein R5 and R5' are each independently, d-6 alkyl which is unsubstituted or substituted one or more times by R10, C2-6 alkenyl which is unsubstituted or substituted one or more times by R10, C2.6 alkynyl which is unsubstituted or substituted one or more times by R10.
31 . A compound according to claim 28, wherein R5 and R5' are each independently methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, 2-methylbutane, 3- methylbutane, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cyclohexyl(CH2)-, which are unsubstituted or substituted one or more times by R10.
10
32. A compound according to claim 28, wherein R5 and R5' are each independently phenyl which is unsubstituted or substituted one or more times by R11.
33. A compound according to claim 28, wherein R5 and R5' are each independently benzyl which is unsubstituted or substituted one or more times by R11.
34. A compound according to any one of claims 1 to 32, wherein R10 is halogen, -ORa, oxo, - NRaRb, =NO-Rc , -C(=0)ORa, -C(0)NRaRb, -C(=0)OH, -C(=0)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=0)NRaRb, -NRbC(=0)Ra, -NRdC(=NRc)NRaRb, -NRbC(=0)ORa, -OC(=0)NRaRb, -OC(=0)Ra,
20 -OC(=0)ORa, hydroxyl, nitro, azido, cyano, -S(0)o-3Ra, -S02NRaRb, -NRbS02Ra, or -
NRbS02NRaRb, wherein Ra -Rd are each independently H, d-12 alkyl, C2.12 alkenyl, C2.12 alkynyl, C6-i2 aryl, C7.16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
35. A compound according to claim 34, wherein R10 is -NRaRb, -NRdC(=0)NRaRb, -NRbC(=0)Ra, - NRdC(=NRc)NRaRb, -NRbC(=0)ORa, -NRbS02Ra, or -NRbS02NRaRb, wherein Ra, Rb, Rc, and Rd are each independently H, d.12 alkyl, C2.12 alkenyl, C2.12 alkynyl, C6-i2 aryl, C7.16 aralkyl, 5- 12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
30
36. A compound according to claim 34, wherein R10 is -NRaRb, -NRdC(=0)NRaRb, -NRbC(=0)Ra, - NRbC(=0)ORa> or -NRbS02Ra, wherein Ra,Rb, and Rd are each independently H, d.12 alkyl, C2.12 alkenyl, C2.12 alkynyl, C6-i2 aryl, C7.16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle- alkyl.
37. A compound according to claim 34, wherein R10 is halogen, -ORa, oxo, -C(=0)ORa, - C(0)NRaRb, -C(=0)OH, -C(=0)Ra, -OC(=0)NRaRb, -OC(=0)Ra, -OC(=0)ORa, hydroxyl, cyano,
BOST 1803930.1 188 wherein Ra-Rb are each independently H, Ci-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, Cb.n aryl,
C7.16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
38. A compound according to any one of claims 1 to 29, 32 or 33, wherein R11 is halogen, - ORa, -NRaRb, -C(=0)ORa, -C(0)NRaRb, -C(=0)OH, -C(=0)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, - NRdC(=0)NRaRb, -NRbC(=0)Ra, -NRdC(=NRc)NRaRb, -NRbC(=0)ORa, -OC(=0)NRaRb, -OC(=0)Ra, -OC(=0)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -S02NRaRb, -NRbS02Ra, or - NRbS02NRaRb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7.i6 aralkyl, 5-12 membered
10 heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, wherein Ra, Rb, Rc, and Rd are each independently H, d-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, Cb.n aryl, C7.16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle- alkyl.
39. A compound according to claim 38, wherein R11 is halogen, -ORa, -NRaRb, -C(=0)ORa, - C(0)NRaRb, -C(=0)OH , -C(=0)Ra, -NRdC(=0)NRaRb, -NRbC(=0)Ra, -NRbC(=0)ORa, - OC(=0)NRaRb, -OC(=0)Ra, -OC(=0)ORa, hydroxyl, cyano, -S02NRaRb, -NRbS02Ra, C1 -6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7.8 aralkyl, 5-6 membered heteroaryl, 6-8 membered
20 heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl, wherein
Ra, Rb, and Rd are each independently are each independently H, C1 12 alkyl, C2-12 alkenyl, C2-12 alkynyl, Cb.n aryl, C7.16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
40. A compound according to claim 38, wherein R11 is halogen, -ORa, -NRaRb, -C(0)NRaRb, - C(=0)OH, -C(=0)Ra, -NRdC(=0)NRaRb, -NRbC(=0)Ra, -NRbC(=0)ORa, -OC(=0)NRaRb, hydroxyl, cyano, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7.8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle- alkyl, wherein Ra,Rb, and Rd are each independently H, C^.n alkyl, C2-12 alkenyl, C2-12
30 alkynyl, Cb.n aryl, C7.16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
41 . A compound according to claim 38, wherein R11 is halogen, -ORa, -NRaRb, hydroxyl, cyano, d-6 alkyl, wherein Ra-Rb are each independently H, alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7.16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
BOST 1803930.1 189
42. A compound according to any one of claims 1 to 29, wherein R12 is halogen, -ORa, oxo, - NRaRb, =NO-Rc , -C(=0)ORa, -C(0)NRaRb, -C(=0)OH, -C(=0)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=0)NRaRb, -NRbC(=0)Ra, -NRdC(=NRc)NRaRb, -NRbC(=0)ORa, -OC(=0)NRaRb, -OC(=0)Ra, -OC(=0)ORa, hydroxyl, nitro, azido, cyano, -S(0)o-3Ra, -S02NRaRb, -NRbS02Ra, - NRbS02NRaRb, Ci_i2 alkyl, d-12 alkenyl, C2_i2 alkynyl, C6-i2 aryl, C7.i6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, wherein Ra, Rb, Rc, and Rd are each independently H, d-12 alkyl, C2.12 alkenyl, C2.12 alkynyl, C6-i2 aryl, C7.16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-
10 alkyl.
43. A compound according to claim 42, wherein R12 is halogen, -ORa, oxo, -NRaRb, -C(=0)ORa, -C(0)NRaRb, -C(=0)OH , -C(=0)Ra, -NRdC(=0)NRaRb, -NRbC(=0)Ra, -NRbC(=0)ORa, - OC(=0)NRaRb, -OC(=0)Ra, -OC(=0)ORa, hydroxyl, cyano, -S02NRaRb, -NRbS02Ra, d-6 alkyl, C2-6 alkenyl, C2.6 alkynyl, phenyl, C7.8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl, wherein Ra, Rb, and Rd are each independently H, d-12 alkyl, C2.12 alkenyl, C2.12 alkynyl, d-12 aryl, C7.16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
20
44. A compound according to claim 42 wherein R12 is halogen, -ORa, oxo, -NRaRb, -C(0)NRaRb, -C(=0)OH, -C(=0)Ra, -NRdC(=0)NRaRb, -NRbC(=0)Ra, -NRbC(=0)ORa, -OC(=0)NRaRb, hydroxyl, cyano, d-6 alkyl, C2.6 alkenyl, C2.6 alkynyl, phenyl, C7.8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl, wherein Ra,Rb, and Rd are each independently H, d-12 alkyl, d-12 alkenyl, d-12 alkynyl, C6-i2 aryl, -16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
45. A compound according to claim 42, wherein R12 is halogen, -ORa, oxo, -NRaRb, hydroxyl, 30 cyano, d-6 alkyl, wherein Ra-Rb are are each independently H, d-12 alkyl, C2.12 alkenyl, C2.
12 alkynyl, C6-i2 aryl, -16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
46. A compound according to any one of claim 1 to 45, wherein Ra, Rb, Rc, and Rd are each independently H, d.6 alkyl, C2.6 alkenyl, C2.6 alkynyl, phenyl, C7.8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
BOST 1803930.1 190 AttorneyWO 2011/079327 PCT/US2010/062168
47. A compound according to claim 46, wherein Ra and Rc are each independently H, d.6 alkyl, C2-6 alkenyl, C2.6 alkynyl, phenyl, C7.8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle- alkyl, and Rb, and Rd.are each independently H or C1 3 alkyl.
48. A compound according to claim 46, wherein Ra, Rb, Rc, and Rd are each independently H or d-3 alkyl.
10 49. A compound according to any one of claims 1 to 27, wherein wherein said compound is of formula (IV):
Figure imgf000192_0001
or a pharmaceutically acceptable salt thereof; wherein
R7 and R7' are each independently d.8 alkyl which is unsubstituted or substituted one or more 20 times by R10, C2.8 alkenyl which is unsubstituted or substituted one or more times by R10,
C2-8 alkynyl which is unsubstituted or substituted one or more times by R10, phenyl which is unsubstituted or substituted one or more times by R11, benzyl which is unsubstituted or substituted one or more times by R11, 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-7 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 3-6 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-7 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12; and
R8 and R8' are each independently -NRaRb, -NRdC(=0)NRaRb, -NRbC(=0)Ra, -NRdC(=NRc)NRaRb, - 30 NRbC(=0)ORa, -NRbS02Ra, -NRbS02NRaRb, wherein Ra, Rb, Rc, and Rd are each independently
BOST 1803930.1 191 Attorney,
WO 2011/079327 PCT/US2010/062168
H, Ci-12 alkyl, C2-12 alkenyl, C2-i2 alkynyl, C6-i2 aryl, C7.16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
50. A compound according to claim 49, wherein R8 and R8' are each independently -NRaRb, - NRbC(=0)Ra, -NRbC(=0)ORa> wherein Ra, Rb, Rc, and Rd are each independently H, d.6 alkyl, phenyl, benzyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
10 51. A compound according to claim 49, wherein R8 and R8' in formulas (IV), are each independently -NRbC(=0)ORa> wherein Ra-Rb are each independently H, d.6 alkyl, phenyl, tetrahydrofuran, or benzyl.
52. A compound according to any one of claims 49 to 51 , wherein R7 and R7' are each independently phenyl.
53. A compound according to any one of claims 49to 51 , wherein R7 and R7' are each independently, Ci_6 alkyl.
20 54. A compound according to claim 53 wherein R7 and R7' are each independently methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, 2-methylbutane, 3- methylbutane, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
. A compound according to any one of claims 49 to 54, wherein wherein said compound of formula (V):
Figure imgf000193_0001
or a pharmaceutically acceptable salt thereof.
30
BOST 1803930.1 192
56. A compound according to any one of claims 1 to 55, wherein as the formula and valency allows in B, B', Ra, Rb, Rc, and Rd, R1; R2, R2', R3, R3', R4, R4 ', R10, R11 and R12 each of alkyl, alkenyl, alkynyl, alkoxy, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocycle, or heterocycle-alkyl is independently unsubstituted or substituted one or more times by halogen, -ORa. -NRa.Rb., C(=0)ORa., -C(0)NRa.Rb., -C(=0)OH, hydroxyl, nitro, azido, cyano; and wherein Ra°-Rd> are each independently H, d.12 alkyl.
57. A compound according to claim 56, wherein as the formula and valency allows in B, B', Ra, Rb, Rc, and Rd, R1; R2, R2', R3, R3', R4, R4 ', R10, R11 and R12 each of alkyl, alkenyl, 10 alkynyl, alkoxy, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocycle, or heterocycle-alkyl is independently unsubstituted or substituted one time by halogen.
58. A compound according to claim 57, wherein as the formula and valency allows in B, B', Ra, Rb, Rc, and Rd, R1; R2, R2', R3, R3', R4, R4 ', R10, R11 and R12 each of alkyl, alkenyl, alkynyl, alkoxy, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocycle, or heterocycle-alkyl is independently unsubstituted or substituted one time by fluoro.
59. A compound of formula (IIIA):
Figure imgf000194_0001
or a pharmaceutically acceptable salt thereof, wherein each A is independently C6-i4 aryl, 4-12 membered heterocycle, C .10 cycloalkyl, or 5-12 membered heteroaryl;
B and B' are each independently absent, d.6 alkyl, C2.6 alkenyl, or C2.6 alkynyl; wherein when q is 1 then at least one of B and B' is absent;
30 R† is halogen, -ORa, -NRaRb, -C(=0)ORa, -C(0)NRaRb, -C(=0)OH, -C(=0)Ra, -C(=NORc)Ra, -
C(=NRc)NRaRb, -NRdC(=0)NRaRb, -NRbC(=0)Ra, -NRdC(=NRc)NRaRb, -NRbC(=0)ORa, - OC(=0)NRaRb, -OC(=0)Ra, -OC(=0)ORa, hydroxyl, nitro, azido, cyano, -S(O)0.
BOST 1803930.1 193 3Ra, -S02NRaRb, -NRbS02Ra, -NRbS02NRaRb, -P(=0)0Ra0Rb, C1-6 alkyl which is unsubstituted or substituted one or more times by R10, C2.6 alkenyl which is unsubstituted or substituted one or more times by R10, C2.6 alkynyl which is unsubstituted or substituted one or more times by R10, or any two occurrences of can be taken together with the atoms to which they are attached to form a 5-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 5-7 membered heterocycle which is unsubstituted or substituted one or more times by
10 Ra, Rb, Rc, and Rd are each independently H, Ci_12 alkyl, d-12 alkenyl, d-12 alkynyl, C6-i2 aryl, C7.16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
R2. and R2 are independently H, halogen, d-10 alkyl, d-6 halogenated alkyl, -(CH2)1.
6OH, -NRbC(=0)Ra C6-i2 aryl, or 5-12 membered heteroaryl;
R3 and R3' are each independently H, d.6 alkyl, -(CH2)1.6OH, C2.6 alkenyl, or C2.6 alkynyl; and R4' are each independently -NRaRb, -C(0)NRaRb, -(CH2)1.6OH, d-6 alkyl, d-6 halogenated alkyl, C6-14 aryl, or d-6 alkoxy; wherein two occurrence of R4 can be taken together with the atoms to which they are attached to form a d-6 alkenyl which is unsubstituted or substituted one or more times by R10, a 4-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R12 ; wherein two occurrence of R4' can be taken together with the atoms to which they are attached to form a d-6 alkenyl which is unsubstituted or substituted one or more times by R10, a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R12 ; wherein Ra-Rb are each independently H, d_12 alkyl, d-12 alkenyl, d-12 alkynyl, C6-i2 aryl, -16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
X and Y are each independently — , or a bond;
Figure imgf000195_0001
wherein the asterisk (*) indicates the point of attachment to the nitrogen of ring C or C;
BOST 1803930.1 194 AttorneyWO 2011/079327 PCT/US2010/062168
R5 and R5' are each independently H, d-18 alkyl which is unsubstituted or substituted one or more times by R10, C2-12 alkenyl which is unsubstituted or substituted one or more times by R10, C2-12 alkynyl which is unsubstituted or substituted one or more times by R10, C6-14 aryl which is unsubstituted or substituted one or more times by R11 , C7.i 6 aralkyl which is unsubstituted or substituted one or more times by R11 , 5-12 membered heteroaryl which is unsubstituted or substituted one or more times by R11 , 6-18 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11 , 3-12 membered heterocycle which is unsubstituted or substituted one 10 or more times by R12, or 4-18 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12;
R6 is H, d-6 alkyl, or halogenated .b alkyl; m and n are a positive integer and when combined are 1 , 2, 3, or 4, provided that each of m and n are not 3 or 4; p is 0, 1 , 2, 3 or 4; 20 q is 1 or 2; u is 0 or 1 ; s is 0 or 1 ;
R10 is halogen, -ORa, oxo, -NRaRb, =NO-Rc , -C(=0)ORa, -C(0)NRaRb, C(=0)OH, -C(=0)Ra, - C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=0)NRaRb, -NRbC(=0)Ra, -NRdC(=NRc)NRaRb, - NRbC(=0)ORa, -OC(=0)NRaRb, -OC(=0)Ra, -OC(=0)ORa, hydroxyl, nitro, azido, cyano, - S(O)0-3Ra, -S02NRaRb, -NRbS02Ra, -NRbS02NRaRb, or -P(=0)ORaORb,;
30
R11 is halogen, -ORa, -NRaRb, -C(=0)ORa, -C(0)NRaRb, -C(=0)OH , -C(=0)Ra, -C(=NORc)Ra, - C(=NRc)NRaRb, -NRdC(=0)NRaRb, -NRbC(=0)Ra, -NRdC(=NRc)NRaRb, -NRbC(=0)ORa, - OC(=0)NRaRb, -OC(=0)Ra, -OC(=0)ORa, hydroxyl, nitro, azido, cyano, -S(O)0.3Ra, - S02NRaRb, -NRbS02Ra, -NRbS02NRaRb, or -P(=0)ORaORb, C1 -12 alkyl, C2-i2 alkenyl, C2-12 alkynyl, C6-12 aryl, C7_i6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl; and
BOST 1803930.1 195 AttorneyWO 2011/079327 PCT/US2010/062168
R12 is halogen, -ORa, oxo, -NRaRb, =NO-Rc , -C(=0)ORa, -C(0)NRaRb, -C(=0)OH , -C(=0)Ra, - C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=0)NRaRb, -NRbC(=0)Ra, -NRdC(=NRc)NRaRb, - NRbC(=0)ORa, -OC(=0)NRaRb, -OC(=0)Ra, -OC(=0)ORa, hydroxyl, nitro, azido, cyano, - S(0)o-3Ra, -S02NRaRb, -NRbS02Ra, -NRbS02NRaRb, or -P(=0)ORaORb, C1-12 alkyl, C2-n alkenyl, C2-12 alkynyl, C6-i2 aryl, C7.i6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
60. A compound according to claim 59, wherein R4 and R4' are each
10 independently -NRaRb, -C(0)NRaRb, -(CH2)i-60H, .6 alkyl, Ci_6 halogenated alkyl, C6-i4 aryl, or d-6 alkoxy.
61 . A compound according to claim 59, wherein R4 and R4' are d.6 alkyl.
62. A compound of formula (NIB):
Figure imgf000197_0001
or a pharmaceutically acceptable salt thereof, wherein
20
each A is independently C6-i4 aryl, 4-12 membered heterocycle, C3.10 cycloalkyl, or 5-12 membered heteroaryl wherein when q is 2 then both A rings are not phenyl;
B and B' are each independently absent, d.6 alkyl, C2-6 alkenyl, or C2-6 alkynyl; wherein q is 1 then at least one of B and B' is absent; is halogen, -ORa, -NRaRb, -C(=0)ORa, -C(0)NRaRb, -C(=0)OH, -C(=0)Ra, -C(=NORc)Ra, - C(=NRc)NRaRb, -NRdC(=0)NRaRb, -NRbC(=0)Ra, -NRdC(=NRc)NRaRb, -NRbC(=0)ORa, - OC(=0)NRaRb, -OC(=0)Ra, -OC(=0)ORa, hydroxyl, nitro, azido, cyano, -S(O)0.
30 3Ra, -S02NRaRb, -NRbS02Ra, -NRbS02NRaRb, -P(=0)ORaORb, Ci-6 alkyl which is unsubstituted or substituted one or more times by R10, C2-6 alkenyl which is unsubstituted or substituted one or more times by R10, C2-6 alkynyl which is
BOST 1803930.1 196 unsubstituted or substituted one or more times by R10, or any two occurrences of can be taken together with the atoms to which they are attached to form a 5-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 5-7 membered heterocycle which is unsubstituted or substituted one or more times by
Ra, Rb, Ro and Rd are each independently H, d-12 alkyl, C2.12 alkenyl, C2.12 alkynyl, C6-i2 aryl, C7.16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
10
R2> and R2 are independently H, halogen, d-10 alkyl, d-6 halogenated alkyl, -(CH2)1.
6OH, -NRbC(=0)Ra C6-i2 aryl, or 5-12 membered heteroaryl;
R3 and R3' are each independently H, d-6 alkyl, -(CH2)1.6OH, C2.6 alkenyl, or C2.6 alkynyl;
R4 and R4' are each independently halogen, -NRaRb, -C(0)NRaRbj -(CH2)1.6OH, d-6 alkyl, d-6 halogenated alkyl, hydroxyl, or d-6 alkoxy; wherein two occurrence of R4 can be taken together with the atoms to which they are attached to form a d-6 alkenyl which is unsubstituted or substituted one or more times by R10, a 3-7 cycloalkyl 20 which is unsubstituted or substituted one or more times by R11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R12 ; wherein two occurrence of R4' can be taken together with the atoms to which they are attached to form a d-6 alkenyl which is unsubstituted or substituted one or more times by R10, a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R12 ; wherein Ra-Rb are each independently H, d-12 alkyl, d-12 alkenyl, C2.12 alkynyl, C6-i2 aryl, d_16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
30
X and Y are each independently --- , or a bond;
Figure imgf000198_0001
wherein the asterisk (*) indicates the point of attachment to the nitrogen of ring C or C;
R5 and R5' are each independently H, -ie alkyl which is unsubstituted or substituted one or more times by R10, C2.12 alkenyl which is unsubstituted or substituted one or more
BOST 1803930.1 197 times by R10, C2-12 alkynyl which is unsubstituted or substituted one or more times by R10, C6-14 aryl which is unsubstituted or substituted one or more times by R11 , C7.16 aralkyl which is unsubstituted or substituted one or more times by R11 , 5-12 membered heteroaryl which is unsubstituted or substituted one or more times by R11 , 6-18 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11 , 3-12 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-18 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12;
R6 is H, Ci-6 alkyl, or halogenated C1 6 alkyl; m and n are a positive integer and when combined are 1 , 2, 3, or 4, provided that each of m and n are not 3 or 4; p is 0, 1 , 2, 3 or 4; q is 1 or 2; u is 0 or 1 ; s is 0 or 1 ;
R10 is halogen, -ORa, oxo, -NRaRb, =NO-Rc , -C(=0)ORa, -C(0)NRaRb, -C(=0)OH, -C(=0)Ra, - C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=0)NRaRb, -NRbC(=0)Ra, -NRdC(=NRc)NRaRb, - NRbC(=0)ORa, -OC(=0)NRaRb, -OC(=0)Ra, -OC(=0)ORa, hydroxyl, nitro, azido, cyano, - S(0)o-3Ra, -S02NRaRb, -NRbS02Ra, -NRbS02NRaRb, or -P(=0)ORaORb,;
R11 is halogen, -ORa, -NRaRb, -C(=0)ORa, -C(0)NRaRb, -C(=0)OH, -C(=0)Ra, -C(=NORc)Ra, - C(=NRc)NRaRb, -NRdC(=0)NRaRb, -NRbC(=0)Ra, -NRdC(=NRc)NRaRb, -NRbC(=0)ORa, - OC(=0)NRaRb, -OC(=0)Ra, -OC(=0)ORa, hydroxyl, nitro, azido, cyano, -S(0)o-3Ra, - S02NRaRb, -NRbS02Ra, -NRbS02NRaRb, or -P(=0)ORaORb, C1-12 alkyl, Q2-n alkenyl, Q2-n alkynyl, C6-i2 aryl, C7.16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl; and
R12 is halogen, -ORa, oxo, -NRaRb, =NO-Rc , -C(=0)ORa, -C(0)NRaRb, -C(=0)OH, -C(=0)Ra, - C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=0)NRaRb, -NRbC(=0)Ra, -NRdC(=NRc)NRaRb, - NRbC(=0)ORa -OC(=0)NRaRb, -OC(=0)Ra -OC(=0)ORa, hydroxyl, nitro, azido, cyano, -
BOST 1803930.1 198 Attorney,
WO 2011/079327 PCT/US2010/062168
S(0)o-3Ra, -S02NRaRb, -NRbS02Ra, -NRbS02NRaRb, or -P(=0)0Ra0Rb, d.12 alkyl, C2.12 alkenyl, C2.12 alkynyl, C6-i2 aryl, C7.16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
63. The compound according to any one of claims 1 to 3, 18 or 59 to 62, wherein each A is independently cyclopropyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, piperazinyl, piperadinyl, phenyl, naphthalenyl, thienyl, furanyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, oxazolyl, oxadiazolyl, pyridyl, 10 pyrimidyl, pyrazinyl, pyridazinyl, indolyl, indazolyl, benzimidazolyl, benzoxazolyl, benzodioxolyl, benzothiazolyl, benzothiadiazolyl, dihydrobenzodioxine, thienofuranyl, thienothienyl, thienopyrrolyl, quinolinyl, quinoxalinyl, quinazolinyl, cinnolinyl, or triazolyl; and wherein each A is independently substituted with (Ri )p.
64. The compound according to claim 63, wherein each A is independently cyclopropyl, cyclohexyl, phenyl, or naphthalenyl, wherein each A is independently substituted with
65. The compound according to claim 64, wherein each A is independently selected from the
20 group consisting of:
Figure imgf000200_0001
Figure imgf000200_0002
t1 + t2 = p.
66. The compound according to claim 65, wherein A is:
BOST 1803930.1 199 AttorneyWO 2011/079327 PCT/US2010/062168
Figure imgf000201_0001
67. The compound according to claim 66, wherein each A is independently piperazinyl, piperadinyl, thienyl, furanyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, thiadiazolyl, pyrrolidinyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzoxazolyl, benzodioxolyl, benzothiazolyl, benzothiadiazolyl, dihydrobenzodioxinyl, thienofuranyl, thienothienyl, quinolinyl, or triazolyl.
10 68. The compound according to claim 67, wherein each A is independently selected from the group consisting of:
BOST 1803930.1 200
Figure imgf000202_0001
AttorneyWO 2011/079327 PCT/US2010/062168
Figure imgf000203_0001
and
t1 + t2 = p.
69. The compound according to any one of claims 1 to 3, 18 or 57 to 60, wherein each A is independently a 5-12 membered heteroaryl wherein the heteroatom(s) are selected from the group consisting of oxygen and sulphur; wherein each A is independently substituted with (Ri )p.
10 70. The compound according to any one of claims 59 to 69, wherein B and B' are independently absent, Ci-6 alkyl or C2-6 alkynyl.
BOST 1803930.1 202
71 . The compound according to claim 70, wherein B and B' are independently absent, -(CH2)2- or -(C≡C)-.
72. The compound according to claim 71 , wherein B and B' are independently absent or -(C≡C)-.
The compound according claim 1 ,
Figure imgf000204_0001
BOST 1803930.1 203 Attomeywo 2οιι/θ79327! PCT/US2010/062168
74. ccording to any one of claims 59 to 66, wherein
Figure imgf000205_0001
is selected from the group consisting of:
Figure imgf000205_0002
(Ri )P · (Ri )P ' and (R^p
Figure imgf000205_0003
BOST 1803930.1 204 AttorneyWO 2011/079327 PCT/US2010/062168
Figure imgf000206_0001
BOST 1803930.1 205 AttorneyWO 2011/079327 PCT/US2010/062168
Figure imgf000207_0001
BOST 1803930.1 206 AttorneyWO 2011/079327 PCT/US2010/062168
Figure imgf000208_0001
and t1 + t2 = p.
10
76. The compound according to claim 75, wherein
Figure imgf000208_0002
is selected from the group consisting of:
BOST 1803930.1 207 AttorneyWO 2011/079327 PCT/US2010/062168
Figure imgf000209_0001
BOST 1803930.1 208 AttorneyWO 2011/079327 PCT/US2010/062168
78. The compound according to claim 76, wherein
Figure imgf000210_0001
is:
Figure imgf000210_0002
t1 + t2 = p.
79. The compound according to is:
Figure imgf000210_0003
t1 + t2 = p.
10 80.
The compound according to claim 76, wherein
Figure imgf000210_0004
is:
Figure imgf000210_0005
t1 + t2 = p.
The compound according to claim 76, wherein
BOST 1803930.1 209 AttorneyWO 2011/079327 PCT/US2010/062168
Figure imgf000211_0001
t1 + t2 = p.
82. The compound according to any one of claims 59 to 78, wherein is halogen, Ci-4 alkyl which is unsubstituted or substituted one or more times by R10, -C(=0)ORa, -C(0)NRaRb, hydroxyl, cyano, or Ci- alkoxy.
83. The compound according to claim 82, wherein is chloro, fluoro, bromo, methyl, ethyl, 10 propyl, butyl, -CH2OH, difluoromethyl, trifluoromethyl, -C(=0)ORa, hydroxyl, cyano, or methoxy.
84. The compound according to any one of claims 59 to 83, wherein R2 and R2' are each independently H, methyl, trifluoromethyl, iodo, CH2OH, NHC(0)CH3, or thienothienyl.
85. The compound according to any one of claims 59 to 83, wherein R2' is independently methyl, trifluoromethyl, iodo, CH2OH, or NHC(0)CH3.
20 86. The compound according to claim 85, wherein u is 0.
87. The compound according to any one of claims 59 to 83, wherein each R2 is independently methyl, trifluoromethyl, iodo, CH2OH, or NHC(0)CH3.
88. The compound according to claim 87, wherein s is 0.
89. The compound according to any one of claims 59 to 88, wherein R3 and R3' are H or methyl.
30
BOST 1803930.1 210
90. The compound according to claim 62, wherein R4 and R4' are each independently halogen, methyl, ethyl, isopropyl, di-fluoromethyl, di-fluoroethyl, trifluoromethyl, tri- fluoroethyl, -CH2OH, -NRaNb, ί-butoxy-, or hydroxyl; or two R4 ogether with the
atoms to which they are attached form spiro cyclopropyl or
Figure imgf000212_0001
, two ' groups
together with the atoms to which they are attached form spiro cyclopropyl or
Figure imgf000212_0002
The compound according to any one of claims 59 to 61 , wherein R4 and R4' are each independently methyl, ethyl, isopropyl, di-fluoromethyl, di-fluoroethyl, trifluoromethyl, tri-fluoroethyl, -CH2OH, -NRaNb or t-butoxy-; or two R4 groups together
10 with the atoms to which they are attached for , or two R4' groups together
with the atoms to which they are attached form
Figure imgf000212_0003
The compound according to any one of claims 59 erein two R4 groups
together with the atoms to which they are attached for , and two R4' groups
together with the atoms to which they are attached form
Figure imgf000212_0004
93. The compound according claim 62, wherein R4 and R4' are each independently methyl, ethyl, methoxy, di-fluoromethyl, trifluoromethyl, or two R4 groups together with the atoms to which they are attached form spiro cyclopropyl or two R4' groups together with
20 the atoms to which they are attached form spiro cyclopropyl.
94. The compound according to any one of claims 59 to 62, wherein R4 and R4' are each independently methyl, ethyl, methoxy, di-fluoromethyl, trifluoromethyl.
The compound according to claim 93, wherein R4 and R4' are methyl or ethyl.
96. The compound according to claim 94, wherein R4 and R4' are methyl.
BOST 1803930.1 211 Attomeywo 2οιι/θ79327! PCT/US2010/062168
97. The compound according to anyone of claims 59 to 95, wherein m and n are independently 1 or 2.
98. The compound according to claim 96, wherein m and n are 1 .
99. The compound according to any one of claims 59 to 97, wherein X and Y are
O O
■ U Q" ' , n orr a a h bnonndd.
The compound according to claim 98, wherein X and Y are
O
10
101 . The compound according to any one of claims 59 to 99, wherein R5 and R5' are each independently, Ci-8 alkyl which is unsubstituted or substituted one or more times by R10, C2-8 alkenyl which is unsubstituted or substituted one or more times by R10, C2.8 alkynyl which is unsubstituted or substituted one or more times by R10, phenyl which is unsubstituted or substituted one or more times by R11 , C7.8 aralkyl which is unsubstituted or substituted one or more times by R11 , 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R11 , 6-8 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11 , 3-6 membered heterocycle which
20 is unsubstituted or substituted one or more times by R12, or 4-8 membered heterocycle- alkyl which is unsubstituted or substituted one or more times by R12.
102. The compound according to claim 100, wherein R5 and R5' are each independently, d.6 alkyl which is unsubstituted or substituted one or more times by R10, C2-6 alkenyl which is unsubstituted or substituted one or more times by R10, C2.6 alkynyl which is unsubstituted or substituted one or more times by R10, phenyl which is unsubstituted or substituted one or more times by R11 , benzyl which is unsubstituted or substituted one or more times by R11 , 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R11 , 6-7 membered heteroaralkyl which is unsubstituted
30 or substituted one or more times by R11 , 5-6 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 6-7 membered heterocycle- alkyl which is unsubstituted or substituted one or more times by R12.
103. The compound according to claims 101 , wherein R5 and R5' are each independently, Ci_6 alkyl which is unsubstituted or substituted one or more times by R10,
BOST 1803930.1 212 C2-6 alkenyl which is unsubstituted or substituted one or more times by R10, C2-6 alkynyl which is unsubstituted or substituted one or more times by R10.
104. The compound according to claim 102, wherein R5 and R5' are each independently methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, 2-methylbutane, 3- methylbutane, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cyclohexyl(CH2)-, which are unsubstituted or substituted one or more times by R10.
105. The compound according to claim 103, wherein R5 and R5' are each independently 10 phenyl which is unsubstituted or substituted one or more times by R11 .
106. The compound according to claim 104, wherein R5 and R5' are each independently benzyl which is unsubstituted or substituted one or more times by R11 .
107. The compound according to any one of claims 59 to 105, wherein R10 is halogen, - ORA, oxo, - NRARB, =NO-RC , -C(=0)ORA, -C(0)NRARB, -C(=0)OH, -C(=0)RA, -C(=NORC)RA, - C(=NRC)N RARB, -NRDC(=0)NRARB, - NRBC(=0)RA, -NRDC(=NRC)NRARB, -N RBC(=0)ORA, - OC(=0)N RARB, -OC(=0)RA, -OC(=0)ORA, hydroxyl, nitro, azido, cyano, -S(0)o-3RA, -S02NRARB, - NRbS02RA, or -N RbS02NRARB, wherein RA -RD are each independently H , CM2 alkyl, C2-12
20 alkenyl, C2-12 alkynyl, C6-i2 aryl, C7Ab aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
108. The compound according to claim 106, wherein R10 is -NRARB, - NRDC(=0)NRARB, - NRBC(=0)RA, - NRDC(=NRC)NRARB, -N RBC(=0)ORA, - NRbS02RA, or - NRbS02NRARB.
109. The compound according to claim 107, wherein R10 is -NRARB, - NRDC(=0)NRARB, - NRBC(=0)RA, - NRBC(=0)ORA, or -N RbS02RA.
30 1 10. The compound according to any one of claims 59 to 108, wherein RA, RB, RC, and RD are each independently H, Ci-6 alkyl, C2-6 alkenyl, C2.6 alkynyl, phenyl, C7.8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
1 1 1 . The compound according to claim 109, wherein RA and RC are each independently H, C1-6 alkyl, C2.6 alkenyl, C2.6 alkynyl, phenyl, C7.8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle- alkyl, and RB, and Rd.are each independently H or d.3 alkyl.
BOST 1803930.1 213 ATTORNEYWO 2011/079327 PCT/US2010/062168
1 1 2. The compound according to claim 1 1 0, wherein Ra, Rb, Rc, and Rd are each independently H or C1 3 alkyl.
1 1 3. The compound according to any one of claims 59 to 61 , 63 to 72, 74 to 89 or 91 to 1 1 1 , wherein said compound is of formula (IVA):
Figure imgf000215_0001
and R7' are each independently d-8 alkyl which is unsubstituted or substituted one or more times by R10, C2.8 alkenyl which is unsubstituted or substituted one or more times by R10, C2.8 alkynyl which is unsubstituted or substituted one or more times by R10, phenyl which is unsubstituted or substituted one or more times by R11 , benzyl which is unsubstituted or substituted one or more times by R11 , 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R11 , 6-7 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11 , 3-6 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-7 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12;
R8 and R8' are each independently -NRaRb, -NRdC(=0)NRaRb, -NRbC(=0)Ra, -NRdC(=NRc)NRaRb, -NRbC(=0)ORa, -NRbS02Ra, or -NRbS02NRaRb, wherein Ra, Rb, Rc, and Rd are each independently H , CM2 alkyl, C2_i2 alkenyl, C2_i2 alkynyl, C6-i2 aryl, C7_i6 aralkyl, 5- 1 2 membered heteroaryl, 6- 1 8 membered heteroaralkyl, 3- 1 2 membered heterocycle, or 4- 1 8 membered heterocycle-alkyl; and
m and n are a positive integer and when combined are 1 , 2, 3 or 4, provided that each of m and n are not 3 or 4.
30
BOST 1803930.1 214
114. The compound according to claim 113, wherein R8 and R8' are each independently
-NRaRb, -NRbC(=0)Ra, -NRbC(=0)ORa, wherein Ra-Rb are each independently H, d.6 alkyl, phenyl, benzyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
115. The compound according to claim 113, wherein R8 and R8' in formulas (IV), are each independently -NRbC(=0)ORa> wherein Ra, Rb, Rc, and Rd are each independently H, d-6 alkyl, phenyl, tetrahydrofuran, or benzyl.
116. The compound according to any one of claims 113 to 114, wherein R7 and R7' are each independently phenyl which is unsubstituted or substituted one or more times by R11.
117. The compound according to any one of claims 113 to 114, wherein R7 and R7' are each independently, Ci_6 alkyl which is unsubstituted or substituted one or more times by R10.
118. The compound according to claim 116 wherein R7 and R7' are each independently methyl, ethyl, propyl, isopropyl, methoxyisopropyl, butyl, sec-butyl, tert-butyl, pentyl, 2-methylbutane, 3-methylbutane, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
119. The compound according to any one of claims 113 to 114, wherein R7 and R8 or R7. and R8. together with the carbon to which they are attached are each independently:
Figure imgf000216_0001
120. The compound according to any one of claims 113 to 118, wherein said compound is of formula (VA):
BOST 1803930.1 215 ATTORNEYWO 2011/079327 PCT/US2010/062168
Figure imgf000217_0001
or a pharmaceutically acceptable salt thereof.
The compound selected from Table 1A or Table IB, or a pharmaceutically acceptable salt thereof.
A compound of formula:
Figure imgf000217_0002
10 or a pharmaceutically acceptable salt thereof.
A compound of formula:
Figure imgf000217_0003
or a pharmaceutically acceptable salt thereof.
A compound of formula:
BOST 1803930.1 216 AttorneyWO 2011/079327 PCT/US2010/062168
Figure imgf000218_0001
or a pharmaceutically acceptable salt thereof.
125. A compound of formula:
Figure imgf000218_0002
or a pharmaceutically acceptable salt thereof.
A compound of formula:
Figure imgf000218_0003
10 or a pharmaceutically acceptable salt thereof.
127. The compound according to any one of claims 1 to 125, for treating or preventing a Hepatitis C viral infection in a human.
128. A pharmaceutical composition comprising at least one compound according to any one of claims 1 to 126and at least one pharmaceutically acceptable carrier or excipient.
BOST 1803930.1 217
129. A pharmaceutical combination comprising at least one compound according to any one of claims 1 to 126and at least one additional agent and at least one pharmaceutically acceptable carrier or excipient.
130. The pharmaceutical combination according to claim 128, wherein said at least one additional agent is selected from viral serine protease inhibitors, viral polymerase inhibitors, viral helicase inhibitors, immunomudulating agents, antioxidant agents, antibacterial agents, therapeutic vaccines, hepatoprotectant agents, antisense agents, inhibitors of HCV NS2/3 protease and inhibitors of internal ribosome entry site (IRES).
10
131 . The pharmaceutical combination according to claim 126, wherein said at least one additional agent is selected from ribavirin and interferon-a.
132. The pharmaceutical combination according to any one of claim 129 to 130, wherein said compound and said additional agent are in dosage unit forms suitable for sequential administration.
133. The pharmaceutical combination according to any one of claim 127 to 128, wherein said compound and said additional agent are in dosage unit forms suitable for
20 simultaneous administration.
134. The use of a compound according to any one of claims 1 to 125 for treating a Hepatitis C viral infection in a human.
135. The use according to claim 133, further comprising administering at least one additional agent.
136. The use according to claim 134, wherein said at least one additional agent is selected from viral serine protease inhibitors, viral polymerase inhibitors, viral helicase
30 inhibitors, immunomudulating agents, antioxidant agents, antibacterial agents, therapeutic vaccines, hepatoprotectant agents, antisense agents, inhibitors of HCV NS2/3 protease and inhibitors of internal ribosome entry site (IRES).
137. The use according to claim 134, wherein said at least one additional agent is selected from ribavirin and interferon-a.
BOST 1803930.1 218 AttorneyWO 2011/079327 PCT/US2010/062168
138. The use of a compound according to any one of claims 1 to 125 for the manufacture of a medicament.
139. A pharmaceutical formulation comprising at least one compound as defined in any one of claims 1 to 125 and at least one pharmaceutically acceptable carrier or excipient.
140. A method for preparing a compound of formula (IV) according to claim 49:
Figure imgf000220_0001
or a pharmaceutically acceptable salt thereof, wherein each of A, B, B', R1, p, R2, R2>, R3, 10 R3', R4, R4', R7, R7', R8, and R8>, are as defined in claim 49,
wherein said method comprises the steps of:
a) contacting a compound of formula XXX):
Figure imgf000220_0002
under coupling conditions with a compound of formula (XXXI) and a compound of formula (XXXII); and
Figure imgf000220_0003
(XXXII)
b) optionally hydrogenating the alkyne groups to provide a compound of formula (IV).
141. A method according to claim 139, wherein the coupling conditions comprise 20 bis(triphenylphosphine)palladiumchloride, copper iodide, and triethylamine.
A method for preparing a compound of formula (XXXII):
BOST 1803930.1 219 AttorneyWO 2011/079327 PCT/US2010/062168
Figure imgf000221_0001
wherein each of R2, R3, R4, R7, and R8, are as defined in claim 47,
wherein said method comprises the steps of:
a) reducing a compound of formula (XXVI) to provide a compound of formula (XXVII), where each R is each independently an alkyl group:
Figure imgf000221_0002
(XXVII)
g) oxidizing a compound of formula (XXVII) to provide a compound of formula (XVI):
Figure imgf000221_0003
h) contacting a compound of formula (XVI) with a compound of formula (XVII) and optionally 10 a compound of formula R3-LG, where LG is a leaving group, under reaction conditions sufficient to provide a compound of formula (XV):
Figure imgf000221_0004
e) halogenating a compound of formula (XV) under reaction conditions sufficient to provide a compound of formula (XIII):
Figure imgf000221_0005
f) reacting a compound of formula (XIII) under deprotection conditions to provide a compound of formula (XI); and:
BOST 1803930.1 220 AttorneyWO 2011/079327 PCT/US2010/062168
Figure imgf000222_0001
g) contacting a compound of formula (XI) under coupling conditions with a compound of formula (XII) to provide a compound of formula (XXXII):
to provide a compound of formula (XXXII).
143. A method according to claim 141 , wherein the oxidizing of step g) comprises 2,2,6,6-tetramethyl-piperidin-1 -oxyl (TEMPO).
A method for preparing a compound of formula (XXVI):
Figure imgf000222_0002
wherein R4 is as defined in claim 47, and each R is each independently an alkyl group, wherein said method comprises the steps of:
a) contacting a compound of formula (XXI) under reaction conditions sufficient to provide a compound of formula (XXII):
Figure imgf000222_0003
b) contacting a compound of formula (XXII) under reaction conditions sufficient to provide a compound of formula (XXIII), and:
Figure imgf000222_0004
(XXIII)
c) contacting a compound of formula (XXIII) under reaction conditions sufficient to provide
20 a compound of formula (XXVI):
Figure imgf000222_0005
to provide a compound of formula (XXVI).
BOST 1803930.1 221 AttorneyWO 2011/079327 PCT/US2010/062168
145. A method for preparing ((S)-1 -{(2S,4S)-2-[5-(4-{2-[(2S,4S)-1 -((S)-2- Methoxycarbonylamino-3-methyl-butyryl)-4-methyl-pyrrolidin-2-yl]-3H-imidazol-4- ylethynyl}-phenylethynyl)-1 H-imidazol-2-yl]-4-methyl-pyrrolidine-1 -carbonyl}-2- methylpropyl)-carbamic acid methyl ester:
Figure imgf000223_0001
wherein said method comprises:
contacting a compound of formula (X) under coupling conditions with a compound of formula
Figure imgf000223_0002
to provide ((S)-1 -{(2S,4S)-2-[5-(4-{2-[(2S,4S)-1 -((S)-2-Methoxycarbonylamino-3-methyl- butyryl)-4-methyl-pyrrolidin-2-yl]-3H-imidazol-4-ylethynyl}-phenylethynyl)-1 H-imidazol-2-yl]- 4-methyl-pyrrolidine-1 -carbonyl}-2-methylpropyl)-carbamic acid methyl ester.
146. A method according to claim 144, wherein the coupling conditions comprise bis(triphenylphosphine)palladiumchloride, copper iodide, and triethylamine.
A method for preparing a compound of formula (X):
Figure imgf000223_0003
wherein said method comprises
a) reacting a compound of formula (XIII) under deprotection conditions to provide compound of formula (XI); and:
BOST 1803930.1 222 AttorneyWO 2011/079327 PCT/US2010/062168
Figure imgf000224_0001
b) contacting a compound of formula (XI) under coupling conditions with a compound formula (XII):
Figure imgf000224_0002
to provide a compound of formula (X).
148. A method according to claim 146, wherein the coupling conditions of step b) comprise first contacting a compound of formula (XII) with 0-(7-azabenzotriazol-1 -yl)- Ν,Ν,Ν',Ν'-tetramethyluronium hexafluorophosphate (HATU) and diisopropypyethylamine 10 (DIPEA).
149. A method according to claim 146, wherein the deprotection conditions of step a) comprise a mineral acid.
A method for preparing a compound of formula (XIII):
Figure imgf000224_0003
wherein said method comprises reacting a compound of formula (XIV):
Figure imgf000224_0004
(XIV)
under reaction conditions sufficient to provide a compound of formula (XIII).
20
151. A method according to claim 149, wherein the reaction conditions comprise methyl magnesium bromide.
BOST 1803930.1 223 AttorneyWO 2011/079327 PCT/US2010/062168
152. A method for preparing a compound of formula (XIV) having a (2! configuration:
Figure imgf000225_0001
(XIV)
wherein said method comprises the steps of:
a) hydrogenating a compound of formula (XX) to provide a compound of formula (XIX):
Figure imgf000225_0002
(XIX)
b) reducing a compound of formula (XIX) to provide a compound of formula (XIII):
Figure imgf000225_0003
(XIII)
10 c) oxidizing a compound of formula (XIII) to provide a compound of formula (XVI):
Figure imgf000225_0004
d) contacting a compound of formula (XVI) with a compound of formula (XVII) under reaction conditions sufficient to provide a compound of formula (XV):
Figure imgf000225_0005
(XV)
e) halogenating a compound of formula (XV) under reaction conditions sufficient to provide a compound of formula (XV), and:
BOST 1803930.1 224 AttorneyWO 2011/079327 PCT/US2010/062168
Figure imgf000226_0001
f) separating the mixture of (2S,4S) and (2S,4R) diastereomers to provide a compound of formula (XIV) having a (2S,4S) configuration.
153. A method according to claim 149, wherein the separating of step f) comprises silica gel chromatography.
154. A method according to claim 149, wherein the reaction conditions of step e) comprise 1 -iodopyrrolidine-2,5-dione.
155. A method according to claim 149, wherein the oxidizing of step c) comprises 2,2,6,6-tetramethyl-piperidin-1 -oxyl (TEMPO).
156. A method according to claim 149, wherein the reducing of step b) comprises borane.
157. A method according to claim 149, wherein the hydrogenating of step a) comprises platinum oxide and hydrogen gas.
158. A method for preparing a compound of formula (XIV) having a (2S,4S) configuration:
Figure imgf000226_0002
wherein said method comprises the steps of:
a) contacting a compound of formula (XXI) under reaction conditions sufficient to provide a compound of formula (XXII):
BOST 1803930.1 225 Attomeywo 2οιι/θ79327! PCT/US2010/062168
Figure imgf000227_0001
b) contacting a compound of formula (XXII) under reaction conditions sufficient to provide a compound of formula (XXIII):
Figure imgf000227_0002
(XXIII)
c) contacting a compound of formula (XXIII) with 1 -t-butoxy-N,N,N',N'- tetramethylmethanediamine under reaction conditions sufficient to provide a compound of formula (XXIV):
Figure imgf000227_0003
d) reacting a compound of formula (XXIV) under reaction conditions sufficient to provide a 10 compound of formula (XXVI):
Figure imgf000227_0004
e) reducing a compound of formula ide a compound of formula (XXVII):
Figure imgf000227_0005
(XXVII)
f) oxidizing a compound of formula (XXVII) to provide a compound of formula (XVI):
BOST 1803930.1 226 Attomeywo 2οιι/θ79327! PCT/US2010/062168
Figure imgf000228_0001
g) contacting a compound of formula (XVI) with a compound of formula (XVII) reaction conditions sufficient to provide a compound of formula (XV); and:
Figure imgf000228_0002
h) halogenating a compound of formula (XV) under reaction conditions sufficient to provide a compound of formula (XIV) having a (2S,4S) configuration.
159. The method of claim 157, wherein the reaction conditions of step d) comprise the steps of:
10 a) reacting a compound of formula (XXIV) under reaction conditions sufficient to provide a compound of formula (XXV); and:
Figure imgf000228_0003
r (xXxXmIV) (XXV)
b) hydrogenating a compound of formula (XXV) to provide a compound of formula (XXVI):
Figure imgf000228_0004
160. A method for preparing a compound of formula (III)
BOST 1803930.1 227 AttorneyWO 2011/079327 PCT/US2010/062168
Figure imgf000229_0001
or a pharmaceutically acceptable salt thereof, wherein each of A, B, B', R1, p, R2, R2>, R , R >, R4, R4>, R7, R7>, R8, and R8., are as defined herein,
wherein said method comprises the steps of:
a) contacting the compound of formula (XXXIV) with a compound of formula R -X-OH and/or R -Y-OH:
Figure imgf000229_0002
(XXXIV)
under reaction conditions to provide a compound of formula (III). 10 161. A method for preparing a compound of formula (XXXIV)
Figure imgf000229_0003
(XXXIV)
wherein each of A, B, B', R1, p, R2, R2., R3, R3., R4, R4., R7, R7., R8, and R8., are as defined herein and each of B and B', R2 and R2., R3 and R3., R4 and R4., R7 and R7., and R8, and R8. are the same respectively,
wherein said method comprises the steps of:
a) contacting a compound of formula (XXX) with a compound of formula (XIII) where R is an alkyl group:
Figure imgf000229_0004
20 under coupling conditions to provide a compound of formula (XXXIII):
BOST 1803930.1 AttorneyWO 2011/079327 PCT/US2010/062168
Figure imgf000230_0001
(XXXIII)
b) contacting the compound of formula (XXXIII) under conditions to provide a compound of formula (XXXIV).
162. The method of claim 156, wherein the coupling conditions comprise bis(triphenylphosphine)palladiumchloride, copper iodide, and triethylamine.
163. A method for preparing ((S)-1 -{(2S,4S)-2-[5-(4-{2-[(2S,4S)-1 -((S)-2- Methoxycarbonylamino-3-methyl-butyryl)-4-methyl-pyrrolidin-2-yl]-3H-imidazol-4-
10 ylethynyl}-phenylethynyl)-1 H-imidazol-2-yl]-4-methyl-pyrrolidine-1 -carbonyl}-2- methylpropyl)-carbamic acid methyl ester:
Figure imgf000230_0002
wherein said method comprises the steps of:
a) contacting a compound of formula (X) under coupling conditions with a compound formula (XXX):
Figure imgf000230_0003
to provide a compound of formula (XXXV):
Figure imgf000230_0004
BOST 1803930.1 229 Attorney,
WO 2011/079327 PCT/US2010/062168 b) contacting the compound of formula (XXXV) under conditions to provide a compound of formula (XXXVI); and
Figure imgf000231_0001
c) contacting the compound of formula (XXXVI) with N-methoxycarbonyl valine under reaction conditions to provide ((S)-1 -{(2S,4S)-2-[5-(4-{2-[(2S,4S)-1 -((S)-2- Methoxycarbonylamino-3-methyl-butyryl)-4-methyl-pyrrolidin-2-yl]-3H-imidazol-4-ylethynyl}- phenylethynyl)-1 H-imidazol-2-yl]-4-methyl-pyrrolidine-1 -carbonyl}-2-methylpropyl)-carbamic acid methyl ester.
10 164. The method of claim 158, wherein the coupling conditions of step a) comprise bis(triphenylphosphine)palladiumchloride, copper iodide, and triethylamine.
BOST 1803930.1 230
PCT/US2010/062168 2009-12-24 2010-12-27 Analogues for the treatment or prevention of flavivirus infections WO2011079327A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
SG2012042610A SG181614A1 (en) 2009-12-24 2010-12-27 Analogues for the treatment or prevention of flavivirus infections
MX2012007420A MX2012007420A (en) 2009-12-24 2010-12-27 Analogues for the treatment or prevention of flavivirus infections.
US13/518,059 US20130072523A1 (en) 2009-12-24 2010-12-27 Analogues for the treatment or prevention of flavivirus infections
JP2012546254A JP2013515746A (en) 2009-12-24 2010-12-27 Analogs for the treatment or prevention of flavivirus infections
CA2784036A CA2784036A1 (en) 2009-12-24 2010-12-27 Analogues for the treatment or prevention of flavivirus infections
CN2010800642874A CN102883718A (en) 2009-12-24 2010-12-27 Analogues for the treatment or prevention of flavivirus infections
EP10801348A EP2515902A1 (en) 2009-12-24 2010-12-27 Analogues for the treatment or prevention of flavivirus infections
AU2010336355A AU2010336355A1 (en) 2009-12-24 2010-12-27 Analogues for the treatment or prevention of flavivirus infections
KR1020127019619A KR20120130173A (en) 2009-12-24 2010-12-27 Analogues for treatment or prevention of flavivirus infections
IL220215A IL220215A0 (en) 2009-12-24 2012-06-06 Analogues for the tretment or prevention of flavivirus infections
ZA2012/04625A ZA201204625B (en) 2009-12-24 2012-06-21 Analogues for the treatment or prevention of flavivirus infections

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29003009P 2009-12-24 2009-12-24
US61/290,030 2009-12-24
US31699810P 2010-03-24 2010-03-24
US61/316,998 2010-03-24

Publications (1)

Publication Number Publication Date
WO2011079327A1 true WO2011079327A1 (en) 2011-06-30

Family

ID=43530715

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/062168 WO2011079327A1 (en) 2009-12-24 2010-12-27 Analogues for the treatment or prevention of flavivirus infections

Country Status (12)

Country Link
US (1) US20130072523A1 (en)
EP (1) EP2515902A1 (en)
JP (1) JP2013515746A (en)
KR (1) KR20120130173A (en)
CN (1) CN102883718A (en)
AU (1) AU2010336355A1 (en)
CA (1) CA2784036A1 (en)
IL (1) IL220215A0 (en)
MX (1) MX2012007420A (en)
SG (1) SG181614A1 (en)
WO (1) WO2011079327A1 (en)
ZA (1) ZA201204625B (en)

Cited By (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088368B2 (en) 2009-05-13 2012-01-03 Gilead Sciences, Inc. Antiviral compounds
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8143301B2 (en) 2009-04-09 2012-03-27 Bristol Myers Squibb Company Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2012135581A1 (en) * 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
CN102863428A (en) * 2011-07-09 2013-01-09 广东东阳光药业有限公司 Spiro-compounds taken as hepatitis c virus (HCV) inhibitor
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8394968B2 (en) 2009-02-17 2013-03-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20130102629A1 (en) * 2010-03-24 2013-04-25 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
US8541424B2 (en) 2008-12-23 2013-09-24 Abbott Laboratories Anti-viral compounds
US8546405B2 (en) 2008-12-23 2013-10-01 Abbott Laboratories Anti-viral compounds
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2651923A1 (en) * 2010-12-15 2013-10-23 Abbvie Inc. Anti-viral compounds
CN103420991A (en) * 2012-05-17 2013-12-04 广东东阳光药业有限公司 Pyrrolidine derivative used as hepatitis c inhibitor and application thereof in medicine
US8618153B2 (en) 2009-11-12 2013-12-31 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8686026B2 (en) 2010-06-10 2014-04-01 Abbvie Inc. Solid compositions
US8691938B2 (en) 2009-06-11 2014-04-08 Abbvie Inc. Anti-viral compounds
CN103709151A (en) * 2012-09-28 2014-04-09 广东东阳光药业有限公司 Spiro compounds adopted as hepatitis C inhibitor, and applications of spiro compounds in preparation of drugs
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
WO2014082379A1 (en) * 2012-11-29 2014-06-05 Sunshine Lake Pharma Co.,Ltd. Spiro ring compound as hepatitis c virus (hcv) inhibitor and uses thereof field of the invention
WO2014082381A1 (en) * 2012-11-29 2014-06-05 Sunshine Lake Pharma Co., Ltd. Spiro ring compounds as hepatitis c virus inhibitors, pharmaceutical compositions and uses thereof
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US9006455B2 (en) 2009-11-11 2015-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
JP2015517528A (en) * 2012-05-16 2015-06-22 ギリアード サイエンシーズ， インコーポレイテッド Antiviral compounds having an imidazole-biphenyl-imidazole core
US9073942B2 (en) 2012-02-10 2015-07-07 Lupin Limited Antiviral compounds with a heterotricycle moiety
WO2015120127A3 (en) * 2014-02-06 2015-11-12 Georgetown University Treating flavivirus infections with amodiaquine and derivatives thereof
US9187496B2 (en) 2009-12-18 2015-11-17 Idenix Pharmaceuticals Llc 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
US9206159B2 (en) 2012-04-25 2015-12-08 Theravance Biopharma R&D Ip, Llc Piperazine-piperidine compounds as hepatitis C virus inhibitors
WO2015184644A1 (en) * 2014-06-06 2015-12-10 爱博新药研发(上海)有限公司 Compounds and pharmaceutical compositions for inhibiting hepatitis c virus, and uses thereof
US9212168B2 (en) 2011-11-03 2015-12-15 Theravance Biopharma R&D Ip, Llc Hepatitis C virus inhibitors
US9278922B2 (en) 2009-04-15 2016-03-08 Abbvie Inc. Anti-viral compounds
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9333204B2 (en) 2014-01-03 2016-05-10 Abbvie Inc. Solid antiviral dosage forms
US9393256B2 (en) 2011-09-16 2016-07-19 Gilead Pharmasset Llc Methods for treating HCV
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US9738629B2 (en) 2014-01-23 2017-08-22 Sunshine Lake Pharma Co., Ltd. Bridged ring compounds as Hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof
US9770439B2 (en) 2013-07-02 2017-09-26 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9775831B2 (en) 2013-07-17 2017-10-03 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of HCV
US9776981B2 (en) 2009-11-11 2017-10-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9802949B2 (en) 2012-11-29 2017-10-31 Sunshine Lake Pharma Co., Ltd. Fused ring compounds as hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof
US10039779B2 (en) 2013-01-31 2018-08-07 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US10086011B2 (en) 2013-08-27 2018-10-02 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US10201541B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US12037340B2 (en) 2021-05-21 2024-07-16 Gilead Sciences, Inc. Pentacyclic derivatives as Zika virus inhibitors

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2794145A1 (en) * 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
TWI610916B (en) 2012-08-03 2018-01-11 廣東東陽光藥業有限公司 Bridged ring compounds as hepatitis c virus (hcv) inhibitors and pharmaceuticals applications thereof
KR102168562B1 (en) * 2012-11-19 2020-10-22 발리오팜 아게 Recombinant bispecific antibody binding to cd20 and cd95
CN111116563B (en) * 2013-06-06 2023-07-04 上海爱博医药科技有限公司 Compound for inhibiting hepatitis C virus, pharmaceutical composition and application thereof
CN104860931A (en) 2014-02-21 2015-08-26 常州寅盛药业有限公司 Hepatitis C virus inhibitors and pharmaceutical uses thereof
CN104860935A (en) * 2014-02-21 2015-08-26 常州寅盛药业有限公司 Thiophene adopted as hepatitis C virus inhibitor or variant derivative thereof, and pharmaceutical uses thereof
CN111051280B (en) * 2017-08-02 2023-12-22 弗特克斯药品有限公司 Process for preparing pyrrolidine compounds
CN108096562B (en) * 2017-12-25 2021-05-11 武汉百药联科科技有限公司 Application of 20S proteasome inhibitor in preparation of medicine for treating Japanese encephalitis virus infection
AU2022296214A1 (en) * 2021-06-25 2024-01-25 Albius Sciences Alpha Private Limited Heterocycloalkyl-substituted polyheteroazole derivative as medical drug for treatment and/or prevention of rs virus infectious disease

Citations (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998017679A1 (en) 1996-10-18 1998-04-30 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
WO1999007733A2 (en) 1997-08-11 1999-02-18 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptides
WO1999007734A2 (en) 1997-08-11 1999-02-18 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptide analogues
WO2000006529A1 (en) 1998-07-27 2000-02-10 Istituto Di Ricerche Di Biologia Molecolare P Angeletti S.P.A. Diketoacid-derivatives as inhibitors of polymerases
WO2000009543A2 (en) 1998-08-10 2000-02-24 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
WO2000009558A1 (en) 1998-08-10 2000-02-24 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptides
WO2000059929A1 (en) 1999-04-06 2000-10-12 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis c virus
WO2001047883A1 (en) 1999-12-27 2001-07-05 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
WO2001085172A1 (en) 2000-05-10 2001-11-15 Smithkline Beecham Corporation Novel anti-infectives
WO2001090121A2 (en) 2000-05-23 2001-11-29 Idenix (Cayman) Limited Methods and compositions for treating hepatitis c virus
WO2002006246A1 (en) 2000-07-19 2002-01-24 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Dihydroxypyrimidine carboxylic acids as viral polymerase inhibitors
WO2002018369A2 (en) 2000-08-31 2002-03-07 Eli Lilly And Company Peptidomimetic protease inhibitors
WO2002057425A2 (en) 2001-01-22 2002-07-25 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2002060926A2 (en) 2000-11-20 2002-08-08 Bristol-Myers Squibb Company Hepatitis c tripeptide inhibitors
WO2002069903A2 (en) 2001-03-06 2002-09-12 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
EP1256628A2 (en) 2001-05-10 2002-11-13 Agouron Pharmaceuticals, Inc. Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof
WO2002098424A1 (en) 2001-06-07 2002-12-12 Smithkline Beecham Corporation Novel anti-infectives
WO2002100851A2 (en) 2001-06-11 2002-12-19 Shire Biochem Inc. Thiophene derivatives as antiviral agents for flavivirus infection
WO2002100846A1 (en) 2001-06-11 2002-12-19 Shire Biochem Inc. Compounds and methods for the treatment or prevention of flavivirus infections
WO2003000254A1 (en) 2001-06-26 2003-01-03 Japan Tobacco Inc. Fused cyclic compounds and medicinal use thereof
WO2003010140A2 (en) 2001-07-25 2003-02-06 Boehringer Ingelheim (Canada) Ltd. Hepatitis c virus polymerase inhibitors with heterobicyclic structure
WO2003026587A2 (en) 2001-09-26 2003-04-03 Bristol-Myers Squibb Company Compounds useful for treating hepatitus c virus
WO2003035060A1 (en) 2001-10-24 2003-05-01 Vertex Pharmaceuticals Incorporated Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4a protease, incorporating a fused ring system
WO2003087092A2 (en) 2002-04-11 2003-10-23 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease
WO2004092161A1 (en) 2003-04-11 2004-10-28 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2004092162A1 (en) 2003-04-11 2004-10-28 Vertex Pharmaceuticals, Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2005007681A2 (en) 2003-07-18 2005-01-27 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2005028502A1 (en) 2003-09-18 2005-03-31 Vertex Pharmaceuticals, Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2005035525A2 (en) 2003-09-05 2005-04-21 Vertex Pharmaceuticals Incorporated 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2005077969A2 (en) 2004-02-04 2005-08-25 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2006019831A1 (en) 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis c
WO2006039488A2 (en) 2004-10-01 2006-04-13 Vertex Pharmaceuticals Incorporated Hcv ns3-ns4a protease inhibition
WO2006133326A1 (en) * 2005-06-06 2006-12-14 Bristol-Myers Squibb Company Inhibitors of hcv replication
WO2008021928A2 (en) * 2006-08-11 2008-02-21 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2008021927A2 (en) * 2006-08-11 2008-02-21 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US20090068140A1 (en) * 2006-08-11 2009-03-12 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2010132601A1 (en) * 2009-05-13 2010-11-18 Gilead Sciences, Inc. Antiviral compounds
WO2010138791A1 (en) * 2009-05-29 2010-12-02 Schering Corporation Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010065668A1 (en) * 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
US20110269956A1 (en) * 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8377980B2 (en) * 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors

Patent Citations (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998017679A1 (en) 1996-10-18 1998-04-30 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
WO1999007733A2 (en) 1997-08-11 1999-02-18 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptides
WO1999007734A2 (en) 1997-08-11 1999-02-18 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptide analogues
WO2000006529A1 (en) 1998-07-27 2000-02-10 Istituto Di Ricerche Di Biologia Molecolare P Angeletti S.P.A. Diketoacid-derivatives as inhibitors of polymerases
WO2000009543A2 (en) 1998-08-10 2000-02-24 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
WO2000009558A1 (en) 1998-08-10 2000-02-24 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptides
WO2000059929A1 (en) 1999-04-06 2000-10-12 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis c virus
WO2001047883A1 (en) 1999-12-27 2001-07-05 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
WO2001085172A1 (en) 2000-05-10 2001-11-15 Smithkline Beecham Corporation Novel anti-infectives
WO2001090121A2 (en) 2000-05-23 2001-11-29 Idenix (Cayman) Limited Methods and compositions for treating hepatitis c virus
WO2002006246A1 (en) 2000-07-19 2002-01-24 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Dihydroxypyrimidine carboxylic acids as viral polymerase inhibitors
WO2002018369A2 (en) 2000-08-31 2002-03-07 Eli Lilly And Company Peptidomimetic protease inhibitors
WO2002060926A2 (en) 2000-11-20 2002-08-08 Bristol-Myers Squibb Company Hepatitis c tripeptide inhibitors
WO2002057425A2 (en) 2001-01-22 2002-07-25 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2002057287A2 (en) 2001-01-22 2002-07-25 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2002069903A2 (en) 2001-03-06 2002-09-12 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
EP1256628A2 (en) 2001-05-10 2002-11-13 Agouron Pharmaceuticals, Inc. Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof
WO2002098424A1 (en) 2001-06-07 2002-12-12 Smithkline Beecham Corporation Novel anti-infectives
WO2002100851A2 (en) 2001-06-11 2002-12-19 Shire Biochem Inc. Thiophene derivatives as antiviral agents for flavivirus infection
WO2002100846A1 (en) 2001-06-11 2002-12-19 Shire Biochem Inc. Compounds and methods for the treatment or prevention of flavivirus infections
WO2003000254A1 (en) 2001-06-26 2003-01-03 Japan Tobacco Inc. Fused cyclic compounds and medicinal use thereof
WO2003010140A2 (en) 2001-07-25 2003-02-06 Boehringer Ingelheim (Canada) Ltd. Hepatitis c virus polymerase inhibitors with heterobicyclic structure
WO2003026587A2 (en) 2001-09-26 2003-04-03 Bristol-Myers Squibb Company Compounds useful for treating hepatitus c virus
WO2003035060A1 (en) 2001-10-24 2003-05-01 Vertex Pharmaceuticals Incorporated Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4a protease, incorporating a fused ring system
WO2003087092A2 (en) 2002-04-11 2003-10-23 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease
WO2004092161A1 (en) 2003-04-11 2004-10-28 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2004092162A1 (en) 2003-04-11 2004-10-28 Vertex Pharmaceuticals, Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2005007681A2 (en) 2003-07-18 2005-01-27 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2005035525A2 (en) 2003-09-05 2005-04-21 Vertex Pharmaceuticals Incorporated 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2005028502A1 (en) 2003-09-18 2005-03-31 Vertex Pharmaceuticals, Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2005077969A2 (en) 2004-02-04 2005-08-25 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2006019831A1 (en) 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis c
WO2006039488A2 (en) 2004-10-01 2006-04-13 Vertex Pharmaceuticals Incorporated Hcv ns3-ns4a protease inhibition
WO2006133326A1 (en) * 2005-06-06 2006-12-14 Bristol-Myers Squibb Company Inhibitors of hcv replication
WO2008021928A2 (en) * 2006-08-11 2008-02-21 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2008021927A2 (en) * 2006-08-11 2008-02-21 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US20090068140A1 (en) * 2006-08-11 2009-03-12 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2010132601A1 (en) * 2009-05-13 2010-11-18 Gilead Sciences, Inc. Antiviral compounds
WO2010138791A1 (en) * 2009-05-29 2010-12-02 Schering Corporation Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
"Handbook of Chemistry and Physics"
"March's Advanced Organic Chemistry", 2001, JOHN WILEY & SONS
BERGE ET AL., PHARMACEUTICAL SALTS, J. OF PHAR. SCI., vol. 66, no. 1, January 1977 (1977-01-01), pages 1 - 19
CHANDRASEHKAR, S ET AL., TETRAHEDRON LETTERS, vol. 45, 2004, pages 2421 - 2423
DURAND X.; HUDHOMME P.; KHAN J.A.; YOUNG D.W., J. CHEM. SOC., PERKIN TRANS. 1, vol. 11, 1996, pages 1131
KRIEGER, N; LOHMANN, V; BARTENSCHLAGER, R.: "Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations", J. VIROL., vol. 75, 2001, pages 4614 - 4624
See also references of EP2515902A1
SELLARAJAH, SHAN ET AL., J.MED. CHEM., vol. 47, no. 22, 2004, pages 5515
THOMAS SORRELL: "Organic Chemistry", 1999, UNIVERSITY SCIENCE BOOKS
TRI H. V. HUYNH ET AL., ORGANIC LETTERS, vol. 11, 2009, pages 999 - 1002
TYKWINSKI ET AL., ANGEW. CHEM.. INTE. ED., vol. 42, 2003, pages 1566 - 1568
YAMAGUSHI ET AL., SYNLETT, vol. 5, 1999, pages 549 - 550

Cited By (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546405B2 (en) 2008-12-23 2013-10-01 Abbott Laboratories Anti-viral compounds
US8541424B2 (en) 2008-12-23 2013-09-24 Abbott Laboratories Anti-viral compounds
US9249138B2 (en) 2008-12-23 2016-02-02 Abbvie Inc. Anti-viral compounds
US9163017B2 (en) 2008-12-23 2015-10-20 Abbvie Inc. Anti-viral compounds
US8394968B2 (en) 2009-02-17 2013-03-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8143301B2 (en) 2009-04-09 2012-03-27 Bristol Myers Squibb Company Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9278922B2 (en) 2009-04-15 2016-03-08 Abbvie Inc. Anti-viral compounds
US8822430B2 (en) 2009-05-13 2014-09-02 Gilead Pharmasset Llc Antiviral compounds
US9981955B2 (en) 2009-05-13 2018-05-29 Gilead Pharmasset Llc Antiviral compounds
US8669234B2 (en) 2009-05-13 2014-03-11 Gilead Sciences, Inc. Antiviral compounds
US20120264711A1 (en) * 2009-05-13 2012-10-18 Gilead Sciences, Inc. Antiviral compounds
US8841278B2 (en) 2009-05-13 2014-09-23 Gilead Pharmasset Llc Antiviral compounds
US8273341B2 (en) 2009-05-13 2012-09-25 Gilead Sciences, Inc. Antiviral compounds
US8088368B2 (en) 2009-05-13 2012-01-03 Gilead Sciences, Inc. Antiviral compounds
US9511056B2 (en) 2009-05-13 2016-12-06 Gilead Pharmasset Llc Antiviral compounds
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US9586978B2 (en) 2009-06-11 2017-03-07 Abbvie Inc. Anti-viral compounds
US8691938B2 (en) 2009-06-11 2014-04-08 Abbvie Inc. Anti-viral compounds
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8921514B2 (en) 2009-06-11 2014-12-30 Abbvie Inc. Anti-viral compounds
US10039754B2 (en) 2009-06-11 2018-08-07 Abbvie Inc. Anti-viral compounds
US10028937B2 (en) 2009-06-11 2018-07-24 Abbvie Inc. Anti-viral compounds
US9776981B2 (en) 2009-11-11 2017-10-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9006455B2 (en) 2009-11-11 2015-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8618153B2 (en) 2009-11-12 2013-12-31 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9187496B2 (en) 2009-12-18 2015-11-17 Idenix Pharmaceuticals Llc 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8735398B2 (en) 2009-12-30 2014-05-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20130102629A1 (en) * 2010-03-24 2013-04-25 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
US8686026B2 (en) 2010-06-10 2014-04-01 Abbvie Inc. Solid compositions
EP2651923A4 (en) * 2010-12-15 2014-06-18 Abbvie Inc Anti-viral compounds
EP2651923A1 (en) * 2010-12-15 2013-10-23 Abbvie Inc. Anti-viral compounds
US9340520B2 (en) 2011-02-07 2016-05-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2012135581A1 (en) * 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US10201541B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
WO2013007106A1 (en) * 2011-07-09 2013-01-17 广东东阳光药业有限公司 Spiro compounds as hepatitis c virus inhibitors
US9303061B2 (en) 2011-07-09 2016-04-05 Sunshine Luke Pharma Co., Ltd. Spiro compounds as Hepatitis C virus inhibitors
TWI482766B (en) * 2011-07-09 2015-05-01 Sunshine Lake Pharma Co Ltd As a spiro compound for hepatitis C virus inhibitors
CN102863428A (en) * 2011-07-09 2013-01-09 广东东阳光药业有限公司 Spiro-compounds taken as hepatitis c virus (HCV) inhibitor
JP2014520822A (en) * 2011-07-09 2014-08-25 スンシネ ルアケ プハルマ カンパニー リミテッド Spiro compounds as hepatitis C virus inhibitors
AU2012283609B2 (en) * 2011-07-09 2016-09-29 Sunshine Lake Pharma Co., Ltd. Spiro compounds as hepatitis C virus inhibitors
US9393256B2 (en) 2011-09-16 2016-07-19 Gilead Pharmasset Llc Methods for treating HCV
US10456414B2 (en) 2011-09-16 2019-10-29 Gilead Pharmasset Llc Methods for treating HCV
US9669027B2 (en) 2011-11-03 2017-06-06 Theravance Biopharma R&D Ip, Llc Hepatitis C virus inhibitors
US9212168B2 (en) 2011-11-03 2015-12-15 Theravance Biopharma R&D Ip, Llc Hepatitis C virus inhibitors
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9073942B2 (en) 2012-02-10 2015-07-07 Lupin Limited Antiviral compounds with a heterotricycle moiety
US9073943B2 (en) 2012-02-10 2015-07-07 Lupin Limited Antiviral compounds with a dibenzooxaheterocycle moiety
US9206159B2 (en) 2012-04-25 2015-12-08 Theravance Biopharma R&D Ip, Llc Piperazine-piperidine compounds as hepatitis C virus inhibitors
JP2015517528A (en) * 2012-05-16 2015-06-22 ギリアード サイエンシーズ， インコーポレイテッド Antiviral compounds having an imidazole-biphenyl-imidazole core
CN103420991A (en) * 2012-05-17 2013-12-04 广东东阳光药业有限公司 Pyrrolidine derivative used as hepatitis c inhibitor and application thereof in medicine
CN103420991B (en) * 2012-05-17 2017-07-07 乳源东阳光药业有限公司 Application as the pyrrolidin derivatives of hepatitis c inhibitor and its in medicine
CN103709151A (en) * 2012-09-28 2014-04-09 广东东阳光药业有限公司 Spiro compounds adopted as hepatitis C inhibitor, and applications of spiro compounds in preparation of drugs
US9416139B2 (en) 2012-11-29 2016-08-16 Sunshine Lake Pharma Co., Ltd. Spiro ring compound as hepatitis C virus (HCV) inhibitor and uses thereof
CN103848819A (en) * 2012-11-29 2014-06-11 广东东阳光药业有限公司 Spiro compound serving as hepatitis C inhibitor, drug composition and applications of spiro compound and drug composition in drugs
CN103848819B (en) * 2012-11-29 2017-04-12 广东东阳光药业有限公司 Spiro compound serving as hepatitis C inhibitor, drug composition and applications of spiro compound and drug composition in drugs
CN103848821A (en) * 2012-11-29 2014-06-11 广东东阳光药业有限公司 Spiro compound serving as hepatitis C inhibitor, drug composition and applications of spiro compound and drug composition
TWI585082B (en) * 2012-11-29 2017-06-01 廣東東陽光藥業有限公司 Spiro ring compound as hepatitis c virus (hcv) inhibitor and uses thereof
CN103848821B (en) * 2012-11-29 2016-10-12 广东东阳光药业有限公司 Spiro-compound, pharmaceutical composition and their purposes as hepatitis c inhibitor
WO2014082381A1 (en) * 2012-11-29 2014-06-05 Sunshine Lake Pharma Co., Ltd. Spiro ring compounds as hepatitis c virus inhibitors, pharmaceutical compositions and uses thereof
WO2014082379A1 (en) * 2012-11-29 2014-06-05 Sunshine Lake Pharma Co.,Ltd. Spiro ring compound as hepatitis c virus (hcv) inhibitor and uses thereof field of the invention
US9802949B2 (en) 2012-11-29 2017-10-31 Sunshine Lake Pharma Co., Ltd. Fused ring compounds as hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof
US10039779B2 (en) 2013-01-31 2018-08-07 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US9770439B2 (en) 2013-07-02 2017-09-26 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9775831B2 (en) 2013-07-17 2017-10-03 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of HCV
US10086011B2 (en) 2013-08-27 2018-10-02 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US11116783B2 (en) 2013-08-27 2021-09-14 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US11707479B2 (en) 2013-08-27 2023-07-25 Gilead Sciences, Inc. Combination formulation of two antiviral compounds
US10105365B2 (en) 2014-01-03 2018-10-23 Abbvie Inc. Solid antiviral dosage forms
US9744170B2 (en) 2014-01-03 2017-08-29 Abbvie Inc. Solid antiviral dosage forms
US9333204B2 (en) 2014-01-03 2016-05-10 Abbvie Inc. Solid antiviral dosage forms
US9738629B2 (en) 2014-01-23 2017-08-22 Sunshine Lake Pharma Co., Ltd. Bridged ring compounds as Hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof
WO2015120127A3 (en) * 2014-02-06 2015-11-12 Georgetown University Treating flavivirus infections with amodiaquine and derivatives thereof
WO2015184644A1 (en) * 2014-06-06 2015-12-10 爱博新药研发(上海)有限公司 Compounds and pharmaceutical compositions for inhibiting hepatitis c virus, and uses thereof
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US12037340B2 (en) 2021-05-21 2024-07-16 Gilead Sciences, Inc. Pentacyclic derivatives as Zika virus inhibitors

Also Published As

Publication number Publication date
AU2010336355A1 (en) 2012-07-05
IL220215A0 (en) 2012-07-31
KR20120130173A (en) 2012-11-29
ZA201204625B (en) 2014-06-25
CA2784036A1 (en) 2011-06-30
EP2515902A1 (en) 2012-10-31
CN102883718A (en) 2013-01-16
JP2013515746A (en) 2013-05-09
US20130072523A1 (en) 2013-03-21
MX2012007420A (en) 2012-07-23
SG181614A1 (en) 2012-07-30

Similar Documents

Publication Publication Date Title
EP2515902A1 (en) Analogues for the treatment or prevention of flavivirus infections
US8779156B2 (en) Analogues for the treatment or prevention of flavivirus infections
US8354419B2 (en) Benzimidazole analogues for the treatment or prevention of flavivirus infections
EP2550278A1 (en) Analogues for the treatment or prevention of flavivirus infections
US20130102629A1 (en) Analogues for the treatment or prevention of flavivirus infections
US20130085150A1 (en) Analogues for the treatment or prevention of flavivirus infections
TWI475019B (en) Hepatitis c virus inhibitors
TWI501957B (en) Hepatitis c virus inhibitors
KR20110124774A (en) Hepatitis c virus inhibitors
JP2014514296A (en) Method for treating drug-resistant hepatitis C virus infection using 5,5-condensed arylene or 5,5-condensed heteroarylene, a C-type infectious virus inhibitor
KR101857689B1 (en) 9,9,10,10-tetrafluoro-9,10-dihydrophenanthrene hepatitis c virus inhibitor and application thereof
TW201238961A (en) Analogues for the treatment or prevention of flavivirus infections

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080064287.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10801348

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 220215

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2010336355

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2784036

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2012546254

Country of ref document: JP

Ref document number: MX/A/2012/007420

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 5868/DELNP/2012

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2010336355

Country of ref document: AU

Date of ref document: 20101227

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010801348

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20127019619

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2012131295

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 13518059

Country of ref document: US